Carbapenem compounds

ABSTRACT

This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

FIELD

Described herein are carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections. Also described herein are the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

BACKGROUND

Antimicrobial resistance is the most important crisis in the antibacterial therapy. One of the mechanisms of resistance development is due to enzymes, which deactivate certain class of antibiotics by hydrolysis, e.g. β-lactam ring of β-lactam antibiotics. In the mid 1980's, it was found that the enzymes which are responsible for the deactivation of the β-lactams are β-lactamases, particularly Extended Spectrum β-Lactamase (ESBL). ESBL is produced mainly by Enterobacteriaceae group (Chaudhary et al., Indian Journal of Medical Microbiology, 2004, 22(2), 75-80, Extended Spectrum β-Lactamases (ESBL)—An Emerging Threat to Clinical Therapeutics).

The risk factors involved in the expression of ESBL are increased length of hospitalization or ICU stay, increased severity of illness, use of a central venous or arterial catheter or urinary catheter, ventilatory support, hemodialysis, emergency abdominal surgery, gastrostomy or jejunostomy, gut colonization, prior administration of antibiotics, particularly of oxyimino-β-lactams (Falagas et al., Journal of Antimicrobial Chemotherapy, 2007, 60, 1124-1130, Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case—control study).

The antibiotics which are used as a last resort because of their broad spectrum of antimicrobial activity are carbapenems. Carbapenems such as Imipenem (U.S. Pat. No. 4,194,047 A), Meropenem (European Pat. No. EP0126587 B1), Ertapenem (European Pat No. EP0579826 B1) and Doripenem (European Pat. No. EP0528678 B1) are ultrabroad spectrum injectable antibiotics. These antibiotics give rise to cell death by binding to penicillin-binding proteins (PBPs) and inhibiting cell wall biosynthesis. The emergence of carbapenemases belonging to class A and class D β-lactamases threatens their clinical utility.

It has been reported that the presence of a hydroxyethyl side chain in carbapenems provides stability to these compounds. (Sumita, Y et al., Journal of Antibiotics, 1995, 48(2), 188-190).

Sunagawa M et al., Journal of Antibiotics, 1997, 50(7), 621-627, discloses carbapenem compounds having antimicrobial activity.

Carbapenem compounds with potency against carbapenem-resistant gram negative bacteria have not been reported. Therefore, the development of a novel carbapenem compound with broad antibacterial spectrum, preferably a compound possessing potent activity against resistant bacteria which produce β-lactamase is desirable.

Still there remains a huge unmet medical need for new antimicrobial agents due to the emerging bacterial resistance over the current therapies.

Objective

The objective of the present invention is to provide carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof.

Yet another objective of the present invention is to provide processes for the preparation of Carbapenem compounds and pharmaceutical compositions containing these compounds.

A further objective of the present invention is to provide a method for preventing or treating bacterial infection and to provide carbapenem compounds as broad spectrum antibacterial agents.

SUMMARY

The present invention relates to novel carbapenems. In particular, the present invention relates to a compound of formula ((I), (Ia) or (Ib), or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof. The compounds of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof can be useful in the treatment of bacterial infections. The present invention relates to compounds of formula (I)

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof: wherein:

A represents —NR⁰R or —OR^(z);

Z represents —H or —CH₃;

X represents —S— or —CH₂—;

R^(z) represents isoxazolyl;

R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy;

R is:

-   -   1) —(CH₂)_(n)C(═O)R²,     -   2) —(CH₂)_(n)C(═S)R²,     -   3) —(CH₂)_(n)SO₂R²,     -   4) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or     -   5) —CH(═NH), or

R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

n is an integer selected from 0, 1, 2, 3, 4, 5 and 6;

R¹ is:

-   -   1) —(CH₂)₀₋₆-AryC,     -   2) —(CH₂)₀₋₆-HetC,     -   3) —(CH₂)₁₋₆NH(C═NH)NH₂, or     -   4) C₂₋₆aminoalkyl optionally substituted with         -   a) —C(═O)C₁₋₆alkoxy,     -   b) —C(═O)-pyrrolidinyl substituted with —NR^(x)R^(y),     -   c) —CR^(x)═NR^(x), or     -   d) —COO-phenyl;         -   R² is:     -   1) H,     -   2) C₁₋₆alkyl optionally substituted with 1, 2 or 3 substitutents         independently selected from halogen, —OH, —CN, —C₃₋₈cycloalkyl,         —(CH₂)₀₋₁C(═O)NR^(x)R^(y), —NR^(a)R^(b), C₁₋₆alkoxy,         —OC(═O)C₁₋₆alkyl, —P(═O)(C₁₋₆alkoxy)₂, —COOH, —COOC₁₋₆alkyl,         —SO₂C₁₋₆alkyl, —S(═O)C₁₋₆haloalkyl, —SCHF₂, Het A, AryA,         —S-AryA, azetidine and azetidinone optionally substituted with         C₁₋₆hydroxyalkyl,     -   3) C₃₋₈cycloalkyl substituted with C₁₋₆haloalkyl or         —NR^(x)R^(y),     -   4) —(CH₂)₀₋₃—CR^(k)NOC₁₋₆alkyl optionally substituted with         —COOR^(x),     -   5) —C(═O)NR^(x)R^(y),     -   6) —C(═O)C₁₋₆alkoxy,     -   7) —NR^(x)R^(y),     -   8) —OH,     -   9) —COOH,     -   10) C₁₋₆alkoxy,     -   11) C₁₋₆haloalkyl,     -   12) C₁₋₆haloalkoxy,     -   13) AryA, or     -   14) HetA;

R⁴ is —COO⁻ or —COOR⁵;

R⁵ is hydrogen, a carboxylic acid protecting group or an ester prodrug moiety;

AryA is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, or

-   -   2) a substituted or unsubstituted 9- or 10-membered bicyclic         aromatic ring with 1, 2, 3, 4, 5 or 6 heteroatom ring atoms         independently selected from N; O and S;

HetA is a substituted or unsubstituted 5- to 10-membered saturated ring with 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, wherein any S atom in the ring is optionally oxidized;

AryC is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms independently selected from N, O and S, wherein the N atom is optionally quaternized with —CH₃, or

2) a substituted or unsubstituted 7- to 10-membered bicyclic aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms selected from N, S, and O;

HetC is a substituted or unsubstituted 4- to 8-membered saturated ring with 1 or 2 heteroatom ring atoms selected from N, O or S;

R^(a) is hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, —CR^(x)(═NR^(x)), —C(═NR^(x))N(R^(x))₂, —CH₂C(═O)N(R^(x))₂, —(CH₂)₁₋₆ OR^(x) or —SO₂C₁₋₆alkyl;

R^(b) is hydrogen or C₁₋₃alkyl;

R^(c) is

-   -   1) H,     -   2) —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j), —CN or         —OH     -   3) —(CH₂)₁₋₃C(═O)NR^(x)R^(y),     -   4) —(CH₂)₁₋₃C(═O)NHCH₂CH₂OH,     -   5) —(CH₂)₁₋₃C(═O)NHOCH₃,     -   6) —(CH₂)₁₋₃C(═O)NHOBn,     -   7) —C₁₋₆alkoxy,     -   8) pyridinyl,     -   9) —(CH₂)₁₋₃-pyrrolidinyl optionally substituted with         —C(═O)NR^(x)R^(y),     -   10) tetrahydro-2H-pyran-4-yl,     -   11) —(CH₂)₁₋₃C(═O)-diazepanyl,     -   12) —(CH₂)₁₋₃C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y),     -   13) —C(═NH)-pyrrolidin-1-yl optionally substituted with         NR^(x)R^(y),     -   14) —(CH₂)₁₋₃-pyranyl optionally-substituted with 1 or 2         substituents selected from oxo and methoxy,     -   15) —(CH₂)₁₋₃-pyridinyl optionally substituted with one or more         groups selected from —CH₃, —OH, and oxo,     -   16) -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y)     -   17) -phenyl-C(═O)-piperazinyl; or     -   18) -phenyl-(CH₂)₁₋₃—NR^(x)R^(y);

R^(d) is hydrogen, C₁₋₃alkyl, —C₁₋₃hydroxyalkyl or C₁₋₃cyanoalkyl, or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form a substituted or unsubstituted 4- to 12-membered heterocyclic ring or ring system with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S, wherein the rings in the heterocyclic ring system can be bridged; fused, spiro-linked or any combination of two thereof; wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; and wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from

-   -   1) —(CH₂)₀₋₃halogen,     -   2) oxo,     -   3)═NH,     -   4) —(CH₂)₀₋₃OH,     -   5) —C₁₋₆alkyl optionally substituted with halogen, —CN and —OH,     -   6) —OC₁₋₆alkyl,     -   7) —CH₂CH(OH)CH₂NH₂,     -   8) —CH₂CH(F)CH₂NH₂,     -   9) —C(═O)OH,     -   10) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with 1 or 2 of         —CH₃. —NH₂ or halogen,     -   11) —NHCH₂CN,     -   12) —NHCH═NH,     -   13) —NHC(═O)R^(i),     -   14) —NH C(═O)CH₂NHC(═NH)NH₂,     -   15) —C(═NH)NH₂,     -   16) —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH,     -   17) —(CH₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j) optionally substituted         with —NH₂ or —OH,     -   18) —(CH₂)₀₋₂ C(═O)CH(NH₂)(CH₂)₀₋₂OH,     -   19) —C(═O)NH(CH₂)₁₋₃NH₂ optionally substituted with —OH,     -   20) —C(═O)(CH₂)₁₋₃NH₂ optionally substituted with —NH₂,     -   21) —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂,     -   22) —(CH₂)₀₋₁ NHCH₂CH₂NR^(h)R^(j),     -   23) —(CH₂)₀₋₃NHC(═NH)NH₂,     -   24) —(CH₂)₀₋₁NH(CH₂)₀₋₁C(═O)(CH₂)₀₋₁NR^(h)R^(j),     -   25) —(CH₂)₀₋₁NHSO₂(CH₂)₀₋₂NR^(h)R^(j),     -   26) —(CH₂)₂NHSO₂CH₃,     -   27) —ONH₂,     -   28) —ONHC(═O)CH₂NHCH₃,     -   29) —C(═O)NH-pyridinyl,     -   30) —C(═O)-diazepinyl optionally substituted with —C(═N)NH₂,     -   31) —C(═O)-piperazinyl,     -   32) —(CH₂)₀₋₁C(═O)-pyrrolidinyl optionally substituted with         —NH₂,     -   33) —NHCH₂-pyridinyl optionally substituted with one or more         groups selected from —CH₃, —OH, and oxo,     -   34) —NH-pyrimidinyl,     -   35) —(CH₂)₀₋₁-phenyl,     -   36) —(CH₂)₀₋₂-piperazinyl,     -   37) —(CH₂)₀₋₂azetidinyl optionally substituted with —NH₂,         —CH₂NH₂, or —OH,     -   38) —(CH₂)₀₋₂pyrrolidinyl optionally substituted with —NH₂,     -   39) —(CH₂)₀₋₂triazolyl optionally substituted with —CH₂NH₂, and     -   40) —(CH₂)₀₋₂tetrazolyl;

R^(f) is H, —C(═O)N(C₁₋₆alkyl)₂, —SO₂C₁₋₆alkyl, —SO₂N(R^(x))₂, —C(═O)-cyclopentyl-N(R^(x))₂, —C(═O)-pyridinyl optionally substituted with one or more groups selected from oxo, —C₁₋₃alkyl and —OH, —C(═O)-pyrrolidinyl substituted with —NR^(a)R^(b) or halogen, —C(═O)-thiazolidinyl, —SO₂-piperazine, or —SO₂-pyrrolidinyl-N(R^(x))₂;

R^(g) is hydrogen or C₁₋₃alkyl, or

R^(f) and R^(g) are taken together, with the N to which they are attached, to form morpholinyl; piperazinyl; pyrrolidinyl optionally substituted with —CH₃; piperidinyl or thiomorpholinyl optionally substituted with —C₁₋₆alkyl or —N(R^(x))₂; or triazolyl substituted with —CH₂NH₂;

R^(h) and R^(j) is independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl;

R^(i) is —C₁₋₅ amino alkyl, —OC₁₋₆alkyl, —C₁₋₃cyanoalkyl, or —C₁₋₆haloalkyl optionally substituted with —NR^(x)R^(y);

R^(k) is C₁₋₆alkyl, or thiazole substituted with —NH₂;

each R^(x) and R^(y) is independently hydrogen or C₁₋₃alkyl; and

wherein when HetA, AryA, AryC, HetC, or the rings formed by combining R and R⁰ are substituted, the substituents are 1 to 4 members selected from

-   -   1) halogen,     -   2) —OH,     -   3) oxo,     -   4) —COOH,     -   5) —COOC₁₋₆alkyl,     -   6) C₁₋₄alkyl,     -   7) C₁₋₄alkoxy,     -   8) —(CH₂)₀₋₃O—C₁₋₃alkyl,     -   9) C₁₋₆haloalkyl,     -   10) C₁₋₆hydroxyalkyl,     -   11) C₃-C₈cycloalkyl,     -   12) —C(═O)C₁₋₆alkyl,     -   13) —C(═O)C₁₋₆aminoalkyl,     -   14) —C(═O)NR^(c)R^(d)     -   15) —(CH₂)₀₋₁NR^(x)R^(y),     -   16) —(CH₂)₀₋₃NR^(f)R^(e),     -   17) —(CH₂)₁₋₃—C(═O)NR^(x)R^(y),     -   18) —NHCH₂CN,     -   19) —NHC(═O)R^(i),     -   20) —(CH₂)₀₋₁NHSO₂NR^(x)R^(y),     -   21) —SO₂NR^(c)R^(d),     -   22) —CH═NH,     -   23) —(CH₂)₀₋₃C(═NH)NH₂,     -   24) —(CH₂)₀₋₃NHC(═NH)NH₂,     -   25) —(CH₂)₀₋₂-thienyl,     -   26) —(CH₂)₀₋₂-tetrazolyl,     -   27) —(CH₂)₀₋₂-thiazolyl,     -   28) —(CH₂)₀₋₂-pyridinyl optionally substituted with —CH₃ or         quaternized with —CH₃ or CH₂CONH₂,     -   29) —(CH₂)₀₋₂-triazolyl,     -   30) —(CH₂)₀₋₂-piperidinyl optionally substituted with —CH₃ or         quaternized with —CH₃ or —(CH₂)₀₋₃NH₂,     -   31) —(CH₂)₀₋₂-pyrazolyl optionally substituted with one or more         of —(CH₂)₀₋₃NH₂ and further optionally quaternized with —CH₃,     -   32) —(CH₂)₁₋₃—C(═O)-pyrolidinyl optionally substituted with         —NR^(x)R^(y),     -   33) —(CH₂)₀₋₂-pyrolidinyl optionally substituted with         —NR^(x)R^(y),     -   34) —C(═NH)-pyrolidinyl optionally substituted with         —NR^(x)R^(y), and     -   35) 4,5-dihydrothiazol-2-yl.

The present invention also relates to compounds of formula (Ib)

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof: wherein:

A represents —NR⁰R or —OR^(z);

R^(z) represents isoxazolyl;

R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy;

R is:

-   -   —(CH₂)_(n)C(═O)R²;     -   —(CH₂)_(n)C(═S)R²;     -   —(CH₂)_(n)SO₂R²;     -   —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl; or     -   —CH(═NH); or

R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

n is an integer-selected from 0, 1, 2, 3, 4, 5 and 6;

R¹ is:

-   -   1) —CH₂)₀₋₆-AryC;     -   2) —(CH₂)₀₋₆-HetC; or     -   3) C₂₋₆aminoalkyl optionally substituted with         -   a) —C(═O)C₁₋₆alkoxy,         -   b) —C(═O)-pyrrolidinyl substituted with —NR^(x)R^(y),         -   c) —CR^(x)═NR^(x), or         -   d) —COO-phenyl;

R² is:

-   -   H;     -   C₁₋₆alkyl optionally substituted with 1; 2 or 3 substitutents         independently selected from halogen, —OH, —CN,         -   C₃₋₈cycloalkyl, —(CH₂)₀₋₁C(═O)NR^(x)R^(y), —NR^(a)R^(b),             C₁₋₆alkoxy, —OC(═O)C₁₋₆alkyl, —P(═O)(C₁₋₆alkoxy)₂, —COOH,             —COOC₁₋₆alkyl, —SO₂C₁₋₆alkyl, —S(═O)C₁₋₆haloalkyl, AryA,             —S-AryA and azetidinone optionally substituted with             C₁₋₆hydroxyalkyl;     -   C₃₋₈cycloalkyl substituted with C₁₋₄haloalkyl or —NR^(x)R^(y);     -   —CR^(k)═NOC₁₋₆alkyl optionally substituted with —COOR^(x);     -   —C(═O)NR^(x)R^(y);     -   —C(═O)C₁₋₆alkoxy;     -   —NR^(x)R^(y);     -   —OH;     -   —COOH;     -   C₁₋₆alkoxy;     -   C₁₋₆haloalkyl;     -   C₁₋₆haloalkoxy;     -   AryA; or     -   HetA;

R⁴ is —COO⁻ or —COOR⁵;

R⁵ is hydrogen, a carboxylic acid protecting group or an ester prodrug moiety;

AryA is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, or

-   -   2) a substituted or unsubstituted 9- or 10-membered bicyclic         aromatic ring with 1, 2, 3, 4, 5 or 6 heteroatom ring atoms         independently selected from N, O and S;

HetA is a substituted or unsubstituted 5- to 10-membered saturated ring with 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, wherein any S atom in the ring is optionally oxidized;

AryC is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 1, 2 or 3 heteroatom ring atoms independently selected from N, O and S, or

-   -   2) a substituted or unsubstituted 7- to 10-membered bicyclic         aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms selected         from N, S, and O;

HetC is a substituted or unsubstituted 4- to 6-membered saturated ring with 1 or 2 heteroatom ring atoms selected from N, O or S;

R^(a) is hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, —CR^(x)(═NR^(x)), —C(NR^(x))N(R^(x))₂, —CH₂C(═O)N(R^(x))₂, or —SO₂C₁₋₆alkyl;

R^(b) is hydrogen or C₁₋₃alkyl;

R^(c) is H; —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j), —CN or —OH; —(CH₂)₁₋₃C(═O)NR^(x)R^(y); —(CH₂)₁₋₃C(═O)NHCH₂CH₂OH; —(CH₂)₁₋₃C(═O)NHOCH₃; —(CH₂)₁₋₃C(═O)NHOBn; —C₁₋₆alkoxy; pyridinyl; pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y); tetrahydro-2H-pyran-4-yl; —(CH₂)₁₋₃ C(═O)-diazepanyl; —(CH₂)₁₋₃C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y); —(CH₂)₁₋₃-pyranyl optionally substituted with 1 or 2 substituents selected from oxo and methoxy; —(CH₂)₁₋₃-pyridinyl optionally substituted with one or more groups selected from —CH₃, —OH, and oxo; or

-phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y);

R^(d) is hydrogen, C₁₋₃alkyl, C₁₋₃hydroxyalkyl or C₁₋₃cyanoalkyl; or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form a substituted or unsubstituted 4- to 12-membered heterocyclic ring or ring system with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S, wherein the rings in the heterocyclic ring system can be bridged, fused, spiro-linked or any combination of two thereof; wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; and wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from.

-   -   halogen;     -   oxo;     -   —OH;     -   —C₁₋₆alkyl optionally substituted with —OH, halogen, or cyano;     -   —CH₂CH(OH)CH₂NH₂;     -   —C(═O)OH     -   —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or         halogen;     -   —NHCH₂CN;     -   —NHCH═NH;     -   —NHC(═O)R^(i);     -   —NHC(═O)CH₂NHC(═NH)NH₂;     -   —C(═NH)NH₂;     -   —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH;     -   (C₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j);     -   —(CH₂)₀₋₂C(═O)CH(NH₂)(CH₂)₀₋₂OH;     -   —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂;     -   —(CH₂)₀₋₁—NHCH₂CH₂NR^(h)R^(j);     -   —(CH₂)₀₋₃NHC(═NH)NH₂;     -   —(CH₂)₀₋₁NH(CH₂)₀₋₁ C(═O)(CH₂)₀₋₁NR^(h)R^(j);     -   —(CH₂)₀₋₁NHSO₂(CH₂)₀₋₂NR^(h)R^(j);     -   —(CH₂)₀₋₂NHSO₂CH₃;     -   —ONH₂;     -   —ONHC(═O)CH₂NHCH₃;     -   —C(═O)NH-pyridinyl;     -   —C(═O)-piperazinyl;     -   —C(═O)-pyrolidinyl optionally substituted with —NH₂;     -   —NHCH₂-pyridinyl optionally substituted with one or more groups         selected from     -   —CH3, —OH, and oxo;     -   —NH-pyrimidinyl;     -   —(CH₂)₀₋₁-phenyl;     -   —(CH₂)₀₋₂-piperazinyl;     -   —(CH₂)₀₋₂azetidinyl optionally substituted with —NH₂, —CH₂NH₂,         or —OH;     -   —(CH₂)₀₋₂pyrrolidinyl optionally substituted with —NH₂;     -   —(CH₂)₀₋₂triazolyl optionally substituted with —CH₂NH₂; and     -   —(CH₂)₀₋₂tetrazolyl;

R^(f) is H; —C(═O)N(C₁₋₆alkyl)₂; —SO₂C₁₋₆alkyl; —SO₂N(R^(x))₂; —C(═O)-cyclopentyl-N(R^(x))₂, —C(═O)-pyridinyl optionally substituted with one or more groups selected from oxo, —C₁₋₃alkyl and —OH; —C(═O)-pyrrolidinyl substituted with —NR^(a)R^(b) or halogen; —C(═O)-thiazolidinyl; —SO₂-piperazine; or —SO₂-pyrrolidinyl-N(R^(x))₂;

R^(g) is hydrogen or C₁₋₃alkyl; or

R^(f) and R^(g) are taken together, with the N to which they are attached, to form morpholinyl; piperazinyl; pyrrolidinyl optionally substituted with —CH₃; piperidinyl or thiomorpholinyl optionally substituted with —C₁₋₆alkyl or —N(R^(x))₂; or triazolyl substituted with —CH₂NH₂;

R^(b) and R^(j) is independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl;

R^(i) is —C₁₋₅ amino alkyl; —OC₁₋₆alkyl; —C₁₋₃cyanoalkyl; or —C₁₋₆haloalkyl optionally substituted with —NR^(x)R^(y);

R^(k) is C₁₋₆alkyl; or thiazole substituted with —NH₂;

each R^(x) and R^(y) is independently hydrogen or C₁₋₃alkyl;

wherein when HetA, AryA, AryC, HetC or the rings formed by combining R and R⁰ are substituted, the substituents are 1 to 4 members selected from

-   -   halogen;     -   —OH;     -   oxo;     -   —COOH;     -   —COOC₁₋₆alkyl;     -   C₁₋₆alkyl;     -   C₁₋₆alkoxy;     -   —(CH₂)₀₋₃ O—C₁₋₃ alkyl;     -   C₁₋₆haloalkyl;     -   C₁₋₆hydroxyalkyl;     -   C₃-C₈cycloalkyl;     -   —C(═O)C₁₋₆alkyl;     -   —C(═O)C₁₋₆aminoalkyl;     -   —C(═O)NR^(c)R^(d);     -   —(CH₂)₀₋₃NR^(f)R^(g);     -   —NHCH₂CN;     -   NHC(═O)R^(i);     -   —(CH₂)₀₋₁NHSO₂NR^(x)R^(y);     -   —SO₂NR^(e)R^(d); —CH═NH;     -   —(CH₂)₀₋₂-thienyl;     -   —(CH₂)₀₋₂-tetrazolyl;     -   —(CH₂)₀₋₂-thiazolyl;     -   —(CH₂)₀₋₂-pyridinyl optionally substituted with —CH₃ or         quaternized with —CH₃;     -   —(CH₂)₀₋₂-triazolyl; and     -   4,5-dihydrothiazol-2-yl.

The present invention also relates to a compound of formula (Ia), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof; wherein

wherein:

-   -   A is NR⁰R or -triazolyl substituted with —CH₂OH;

R is:

-   -   —C(═O)—C₁₋₆alkyl-NR^(a)R^(b);     -   —C(═O)CHF₂;     -   —C(═O)CH₂SCHF₂,     -   S—C(═O)CH₂NH(CH₂)₂OMe,     -   —C(═O)CH₂pyrrolidine,     -   —C(═O)CH₂azetidine,     -   —C(═O)CH₂piperazine,     -   —C(═O)CH₂ pyrrolidine optionally substituted with 1 or 2         substituents selected from fluorine and —CH₂NHMe,     -   —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃, —CF₃,     -   —CHF₂, —CH₃, —NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂, or         —COOCH₂CH₃; or —SO₂CH₃;

R⁰ is H;

-   -   R¹ is pyrrolidinyl substituted with 1 or 2 of —CONR^(e)R^(d);         —CH₂NHSO₂NH₂ or —CH₂-pyrrolidinyl optionally substituted with         —NH₂;     -   R^(a) and R^(b) are independently H, —C₁₋₆alkyl,         —C₃₋₈cycloalkyl, —SO₂CH₃, —CH(═NH), —C(═NH)NH or —CH₂C(═O)NH₂;     -   R^(c) and R^(d) are independently H, C₁₋₃alkyl,         —C(═NH)-pyrrolidinyl optionally substituted with —NH₂ or     -   R^(c) and R^(d) are taken together, with the N to which they are         attached, to form a 4- to 12-membered heterocyclic ring or ring         system with 0, 1, 2 or 3 additional heteroatom ring atoms         selected from N and O;     -   wherein any nitrogen ring atom of the heterocyclic ring or ring         system is optionally quadricovalent; the ring system is a         bridged, fused or spiro ring system; and the 4- to 12-membered         heterocyclic ring or ring system is optionally substituted with         1, 2 or 3 substituents selected from         -   (═NH)         -   —C(═O)(CH₂)₁₋₂NH₂,         -   —C(═O)CH₂NHCH₃,         -   —CH₂CH(NH₂)CH₂NH₂,         -   —C(═O) CH(NH₂)CH₂NH₂,         -   —C(═O)CH(F)CH₂NH₂,         -   —C(═O)CH(NH₂)CH₂OH,         -   —CH₂CH(OH)CH₂NH₂,         -   —C(═O)NH CH₂CH(OH)CH₂NH₂,         -   —C(═NH)NH₂,         -   —COOH,         -   —CH₃,         -   —CH₂C(═O)NH₂,         -   —CH₂NH CH₂C(═O)NH₂,         -   —CH₂NR^(h)R^(j),         -   —CH₂CH₂NH₂,         -   —CH₂CH₂NH—C(═NH)—NH₂,         -   —CH₂NHSO₂NH₂,         -   —CH₂OH,         -   —C(CH₃)₂NH₂,         -   —CH₂F,         -   —OH,         -   —OMe,         -   —F,         -   —NR^(h)R^(j),         -   —NHCH═NH,         -   —NH—C(═NH)—NH₂,         -   —NHCOCH₂—NH—C(═NH)—NH₂,         -   —NHCOCH₂NH₂;         -   —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or             halogens;         -   azetidinyl optionally substituted with —OH,         -   piperazinyl, and         -   triazolyl substituted with CH₂NH₂; and     -   R^(h) and R^(j) are independently H, C₁₋₆alkyl, or         C₃₋₈cycloalkyl.

Any of the combinations of A, X, Z, R¹, and R⁴ are encompassed by this disclosure and specifically provided by the invention.

In another aspect, described herein is also a pharmaceutical composition comprising a compound of formula (I), (Ia) or (Ib), or a stereoisomer, pharmaceutically acceptable salt or N-oxide thereof.

In another aspect, the compounds described herein can also be combined with appropriate β-lactamase inhibitors to increase the antibiotic spectrum. In another aspect, the compounds described herein can also be combined with appropriate dehydropeptidase inhibitors.

In another aspect, described herein is a process for preparation of a compound of formula (I), (Ia) or (Ib), or a stereoisomer, pharmaceutically acceptable salt or N-oxide thereof.

In another aspect, described herein is also a method for preventing or treating a bacterial infection comprising administering a therapeutically effective amount of a compound of formula (I), (Ia) or (Ib), or a stereoisomer, pharmaceutically acceptable salt, pharmaceutical composition or N-oxide thereof.

In another aspect, described herein is also a method for preventing or treating a gram negative and/or gram positive bacterial infection comprising administering a therapeutically effective amount of a compound of formula (I), (Ia) or (Ib), or a stereoisomer, pharmaceutically acceptable salt, pharmaceutical composition or N-oxide thereof.

In another aspect, described herein is also a method for preventing or treating a bacterial infection comprising administering a therapeutically effective amount of a compound of formula (I), (Ia) or (Ib), in combination or alternation with one or more other antimicrobial agents.

Embodiments, sub-embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.

DETAILED DESCRIPTION

The present invention is based, in part, on the discovery of carbapenem derivatives that are bacteriocidal against a broad spectrum of bacteria.

In a first embodiment, the present invention relates to compound of formula (I), (Ia) or (Ib), as described above, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof.

In a second embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein A represents —NR⁰R, and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib).

In another embodiment, A represents —NR⁰R. In another embodiment X is —S—. In another embodiment Z is —CH₃

In a third embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein

R⁰ is hydrogen or methyl;

R is

-   -   —(CH₂)_(n) C(═)R²; or     -   —(CH₂)_(n)SO₂R²; or

R and R⁰ together with the N to which they are attached form

-   -   1) [1,2,3-]triazolyl substituted with C₁₋₆alkyl, wherein the         C₁₋₆alkyl is substituted with halo, —NR^(a)R^(b), —OH, or         C₁₋₃alkoxy; or     -   2) tetrazolyl optionally substituted with —NR^(a)R^(b);     -   and the other groups are as provided in the general formula for         formula (I), (Ia) or (Ih), above or in the embodiments.

In another embodiment, R⁰ is hydrogen or methyl;

R is

-   -   —(CH₂)_(n)C(═O)R²; or     -   —(CH₂)_(n)SO₂R²; or

R and R⁰ together with the N to which they are attached form,

-   -   1) [1,2,3-]triazolyl substituted with C₁₋₆alkyl, wherein the         C₁₋₆alkyl is substituted with halo, —NR^(a)R^(b), —OH, or         C₁₋₃alkoxy; or     -   2) tetrazolyl optionally substituted with —NR^(a)R^(b).

In a fourth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein n is 0 or 1, and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above or in the embodiments. In one aspect of this embodiment, n is 0.

In another embodiment, n is 0 or 1. In one aspect of this embodiment, n is 0.

In a fifth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is: —(CH₂)₀₋₂-AryC or —(CH₂)₀₋₁-HetC, and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above or any of the embodiments.

In another embodiment, R¹ is —(CH₂)₀₋₂-AryC or —(CH₂)₀₋₁-HetC.

In another embodiment, R⁴ is —COOH.

In a sixth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein

AryA is 1) a 5- to 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —(CH₂)₀₋₁NR^(x)R^(y), C₃-C₈cycloalkyl, —COOH, —COOC₁₋₆ alkyl, C₁₋₆alkoxy, thienyl, and tetrazolyl, or

-   -   2) a 9- to 10-membered bicyclic aromatic ring with 1 to 6         heteroatom ring atoms independently selected from N, O and S,         optionally substituted with 1 or 2 substituents selected from         halogen, C₁₋₆alkyl, and C₁₋₆haloalkyl;

HetA is a 5- to 10-membered saturated ring with 1 or 2 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halogen, —NR^(x)R^(y), —CH₂NR^(x)R^(y), —OH, and oxo;

AryC is 1) a 5- or 6-membered aromatic ring with 0, 1 or 2 heteroatom ring atoms independently selected from N and S, optionally quaternized with CH₃ and optionally substituted 1 to 3 substituents independently selected from —CH₂NR^(x)R^(y), —CH₂-pyrrolidinyl, —OH, oxo, pyridinyl which is optionally quaternized with methyl or —CH₂CONH₂, or

-   -   2) a 7- to 10-membered bicyclic aromatic ring with 3 heteroatom         ring atoms selected from N; and

HetC is a 4- to 8-membered saturated ring with 1 dr 2 N or O ring atoms, optionally substituted with 1 or 2 substituents independently selected from halogen, —OH, —C₁₋₆alkyl, —(CH₂)₀₋₃NR^(f)R^(g), —CH═NH, —C(═O)C₁₋₆alkyl, —C(═NH) —NH₂; —CH₂—(C═O)-pyrrolidinyl optionally substituted with —NR^(x)R^(y), —NH—C(═NH) —NH₂, —CH₂—NH—C(═NH) —NH₂, —C(═O)C₁₋₆ aminoalkyl, —C(═O)NR^(c)R^(d), —NR^(x)R^(y), —NHSO₂NR^(x)R^(y), —SO₂NR^(c)R^(d), thiazolyl, and 4,5-dihydrothiazol-2-yl; and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above or any of the embodiments.

In another embodiment, AryA is 1) a 5- to 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halo, C₁₋₆alkyl, C₁₋₆haloalkyl, —(CH₂)₀₋₁NR^(x)R^(y), C₁-C₆cycloalkyl, —COOH, —COOC₁₋₆alkyl, C₁₋₆alkoxy, thienyl, and tetrazolyl; or

2) a 9- to 10-membered bicyclic aromatic ring with 1 to 6 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents selected from halo, C₁₋₆alkyl, and C₁₋₆ haloalkyl;

HetA is a 5- or 6-membered saturated ring with 1 or 2 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halo, —NR^(x)R^(y), —OH, and oxo;

AryC is 1) a 5- or 6-membered aromatic ring with 1 or 2 heteroatom ring atoms independently selected from N and S, optionally substituted 1 to 3 substituents independently selected from —CH₂NR^(x)R^(y), —OH, oxo, pyridinyl which is optionally quaternized with methyl; or

-   -   2) a 8-membered bicyclic aromatic ring with 3 heteroatom ring         atoms selected from N; and

HetC is a 4- to 6-membered saturated ring with 1 or 2 N ring atoms, optionally substituted with 1 or 2 substituents independently selected from halo; —C₁₋₆alkyl optionally substituted with —NR^(f)R^(g); —CH═N; —C(═O)C₁₋₆alkyl; —C(═O)C₁₋₆aminoalkyl; —C(═O)NR^(c)R^(d); —NR^(x)R^(y); —NHSO₂NR^(x)R^(y); —SO₂NR^(e)R^(d); thiazolyl and 4,5-dihydrothiazol-2-yl.

In a seventh embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein:

-   -   R^(c) is     -   1) H,     -   2) —CH₂CN,     -   3) —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j),         pyrrolidinyl or —OH,     -   4) —CH₂CH₂C(═O)NR^(x)R^(y),     -   5) —CH₂CH₂C(═O)NHCH₂CH₂OH,     -   6) —CH₂CH₂C(═O)NHOCH₃,     -   7) —CH₂CH₂C(═O)NHOBn,     -   8) —C₁₋₆alkoxy,     -   9) pyridinyl,     -   10) pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y),     -   11) —CC(═NH)-pyrrolidin-1-yl optionally substituted with         NR^(x)R^(y),     -   12) tetrahydro-2H-pyran-4-yl,     -   13) —CH₂CH₂C(═O)-diazepanyl,     -   14) —CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y),     -   15) —CH₂-pyranyl optionally substituted with 1 or 2 substituents         selected from oxo and methoxy,     -   16) —CH₂-pyridinyl optionally substituted with —CH₃, —OH, and         oxo,     -   17) -phenyl-C(═O)-piperazinyl,     -   18) -phenyl-CH₂—NR^(x)R^(y), or     -   19) -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y);

R^(d) is hydrogen, or C₁₋₃alkyl; or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form

-   -   a) a 4- to 8-membered heterocyclic ring with 0, 1, or 2         additional heteroatom ring atoms independently selected from N,         O, and S, or     -   b) a 6- to 12-membered heterocyclic bi- or tricyclic ring with         0, 1, or 2 additional heteroatom ring atoms independently         selected from N, O, and S, wherein the bicyclic ring is         optionally bridged, fused, spirocyclic or any combination of two         thereof,     -   and wherein any nitrogen ring atom of the heterocyclic ring or         heterocyclic bicyclic ring is optionally quadricovalent; and         wherein the heterocyclic ring or heterocyclic bicyclic ring is         optionally substituted with 1, 2 or 3 substituents independently         selected from     -   1) halogen,     -   2) —C₁₋₆alkyl optionally substituted with 1 or 2 substituents         selected from halogen, —CN and —OH,     -   3) —C(═NH)NH₂,     -   4) —(CH₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j) optionally substituted with         —NH₂ or —OH,     -   5) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or         halogens,     -   6) —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH,     -   7) —C(═O)OH,     -   8) —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂,     -   9) —(CH₂)₀₋₂NHCH₂CH₂NR^(h)R^(j),     -   10) —(CH₂)₀₋₃NHC(═NH)NH₂,     -   11) —(CH₂)₀₋₁NH(CH₂)₀₋₁—C(═O)(CH₂)₀₋₁NR^(h)R^(j),     -   12) —(CH₂)₀₋₁NHSO₂NH₂,     -   13) —(CH₂)₀₋₁NHSO₂(CH)₀₋₂NH₂,     -   14) —(CH₂)₀₋₂NHSO₂CH₃,     -   15) —NR^(h)R^(j),     -   16) —NHCH₂CN,     -   17) —NHCH═NH,     -   18) —NHC(═O)R^(i);     -   19) —NHSO₂N(CH₃);     -   20) —NHC(═O)(CH₂)₀₋₂NH(═NH)NH₂,     -   21) —OH,     -   22) —OC₁₋₆alkyl;     -   23) —ONH₂,     -   24) —ONHC(═O)CH₂NHCH₃,     -   25) oxo,     -   26) ═NH,     -   27) —(CH₂)₀₋₁-phenyl,     -   28) —(CH₂)₀₋₂-piperazinyl,     -   29) —C(═O)NH-pyridinyl,     -   30) —C(═O)-piperazinyl,     -   31) —C(═O)-pyrrolidinyl optionally substituted with —NH₂,     -   32) azetidinyl optionally substituted With —CH₂NH₂, —NH₂, or         —OH,     -   33) pyrrolidiny optionally-substituted with —NH₂,     -   34) —NHCH₂-pyridinyl substituted with oxo, —CH₃, and —OH,     -   35) —NH-pyrimidinyl,     -   36) triazolyl optionally substituted with —CH₂NH₂, and     -   37) tetrazolyl;         and the other groups are as provided in the general formula for         formula (I), (Ia) or (Ib), above or any of the embodiments.

In another embodiment, R is H; —CH₂CN; —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j) or —OH; —CH₂CH₂C(═O)NR^(x)R^(y); —CH₂CH₂C(═O)NHCH₂CH₂OH;

—CH₂CH₂C(═O)NHOCH₃; —CH₂CH₂C(═O)NHOBn; —C₁₋₆alkoxy; pyridinyl; pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y); tetrahydro-2H-pyran-4-yl; —CH₂CH₂C(═O)-diazepanyl; —CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y); —CH₂-pyranyl optionally substituted with 1 or 2 substituents selected from oxo and methoxy; —CH₂-pyridinyl optionally substituted with —CH₃, —OH, and oxo; or -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y).

R^(d) is hydrogen or C₁₋₃alkyl; or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form

-   -   a) a 4- to 8-membered heterocyclic ring with 0, 1, or 2         additional heteroatom ring atoms independently selected from N,         O, and S; or     -   b) a 6- to 12-membered heterocyclic bicyclic ring with 0, 1, or         2 additional heteroatom ring atoms independently selected from         N, O, and S, wherein the bicyclic ring is optionally bridged,         fused, spirocyclic or any combination of two thereof;     -   and wherein any nitrogen ring atom of the heterocyclic ring or         heterocyclic bicyclic ring is optionally quadricovalent; and         wherein the heterocyclic ring or heterocyclic bicyclic ring is         optionally substituted with 1 or 2 substituents independently         selected from halo;     -   —C₁₋₆alkyl optionally substituted with 1 or 2 substituents         selected from halo, —CN, —NR^(h)R^(j), and —OH;     -   —C(═NH)NH₂;     -   —(CH₂)₀₋₂C(═O)(CH)₂NR^(h)R^(j);     -   —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or         halogens;     -   —C(═O)C₁ aminoalkyl optionally substituted with —OH;     -   —C(═O)OH;     -   —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂;     -   —(CH₂)₀₋₁NHCH₂CH₂NR;     -   —(CH₂)₀₋₃N NC(═NH)NH₂;     -   —(CH₂)₀₋₁—NH(CH₂)₀₋₁ C(═O)(CH₂)₀₋₁NR^(h)R^(j);     -   —(CH₂)₀₋₁NHSO₂NH₂;     -   —(CH₂)₀₋₁NHSO₂(CH₂)₀₋₂NH₂;     -   —(CH₂)₀₋₂NHSO₂CH₃;     -   —NR^(h)R^(j);     -   —NHCH₂CN;     -   —NHCH═NH;     -   —NHC(═O)R^(i);     -   —NHSO₂N(CH₃)₂;     -   —OH;     -   —ONH₂;     -   —ONHC(═O) CH₂NHCH₃;     -   oxo;     -   —(CH₂)₀₋₁-phenyl;     -   —(CH₂)₀₋₂-piperazinyl;     -   —C(═O)NH-pyridinyl;     -   —C(═O)-piperazinyl;     -   —C(═O)-pyrrolidinyl optionally substituted with —NH₂;     -   azetidinyl optionally substituted with —CH₂NH₂, —NH₂, or —OH;     -   pyrrolidinyl optionally substituted with —NH₂;     -   —NHCH₂-pyridinyl substituted with oxo, —CH₃ and —OH;     -   —NH-pyrimidinyl;     -   triazolyl optionally substituted with —CH₂NH₂; and     -   tetrazolyl.

In an eighth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein:

R⁰ is hydrogen and R is:

-   -   1) —C(═O)CHF₂,     -   2) —C(═O)CF₃,     -   3) —C(═O)CH₂CF₃,     -   4) —C(═O)CF₂CF₃,     -   5) —C(═O)CF₂C₁₋₆alkyl,     -   6) —C(═O)CHFCH₃,     -   7) —C(═O)CF₂CH₂NH₂,     -   8) —C(═O)CF₂CH₂OH,     -   9) —C(═O)CH₂OH,     -   10) —C(═O)CH₂OCOCH₃,     -   11) —C(═O)CH₂CN;     -   12) —C(═O)CH₂SO₂C₁₋₆alkyl,     -   13) —C(═O)CH₂SCHF₂,     -   14) —C(═O)CH₂S(═O)CHF₂,     -   15) —C(═O)CH₂P(═O)(OCH₃)₂,     -   16) —C(═O)CH₂S-tetrazole optionally substituted with —CH₃,     -   17) —C(═O)CH₂-thienyl,     -   18) —C(═O)CH(NH₂)CH₂-tetrazole,     -   19) —C(═O)CH(NH₂)CH₂-pyrazole,     -   20) —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃,         —CF₃, —CHF₂, —CH₃, NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂,         or —COOEt,     -   21) —C(═O)CH₂-triazole optionally substituted with         —CH₂NR^(a)R^(b), or —CH₃ and —CF₃, or —CF₃ and —NH₂,     -   22) —C(═O)CH₂-oxadiazole-CH₂NR^(a)R^(b),     -   23) —C(═O)C(CH₃)₂-tetrazole,     -   24) —C(═O)CH₂-azetidine,     -   25) —C(═O)CH(CH₃)-azetidine optionally substituted with oxo,         hydroxyethyl, or both,     -   26) —C(═O)CH₂-pyrrolidinyl optionally substituted with one or         more —F or —CH₂NHCH₃,     -   27) —C(═O)CF₂-thienyl,     -   28) —C(═O)—C₁₋₆alkyl-NR^(a)R^(b),     -   29) —C(═O)-pyrrolidinyl optionally substituted with F or NH₂,     -   30) —C(═O)-tetrahydrofuran,     -   31) —C(═O)—(CH₂)₀₋₁piperazine,     -   32) —C(O)-pyrazine,     -   33) —C(═O)-thiazolidine optionally substituted with one or more         oxo,     -   34) —C(═O)-pyrazole optionally substituted with CH₃ and CF₃,     -   35) —C(═O)CH(NH₂)C₁₋₆alkyl optionally substituted with —OH or         phenyl,     -   36) —C(═O)CHFC₁₋₆alkyl,     -   37) —C(═O)CH(OH)C₁₋₆alkyl,     -   38) —C(═O)CR^(k)—NOC(CH₃)₂COOH,     -   39) —C(═O)CR^(k)═NOCH₃;     -   40) —C(═S)OC₁₋₆alkyl,     -   41) —C(═O)C(═O)OH,     -   42) —C(═O)C(═O)NR^(a)R^(b),     -   43) —C(═O)(CH₂)₁₋₆C(═O)NR^(a)R^(b),     -   44) —C(═O)C(═O)ONR^(a)R^(b),     -   45) —C(═O)C(═O)OC₁₋₆alkyl,     -   46) —(CH₂)₀₋₆C(═O)OH,     -   47) —(CH₂)₀₋₆C(═O)OC₁₋₆alky,     -   48) —(CH₂)₀₋₆C(═O)(CH₂)₁₋₆ OH,     -   49) —(CH₂)₀₋₆—C(═O)(CH₂)₁₋₆OC₁₋₆alkyl,     -   50) —C(═O)OCH₂CHF₂;     -   51) —C(═O)OCH₂CF₃,     -   52) —C(═O)—OC₃₋₆cycloalkyl substituted with CF₃ or NH₂,     -   53) —C₁₋₆alkyl-NR^(a)R^(b),     -   54) —C₁₋₆alkyl-C₃₋₆cycloalkyl,     -   55) (CH₂)₀₋₆SO₂(CH₂)₀₋₄R^(e),     -   56) —CH(═NH), or     -   57) —C₆alkyl, or         R and R⁰ together with the N to which they are attached form a         [1,2,3-]triazole optionally substituted with —CH₂OH, —CH₂OCH₃,         —CH₂F, —CH₂NH₂, —CH₂NHCH₃, —C(═O)OCH₃, or a tetrazole optionally         substituted with —NH₂; and the other groups are as provided in         the general formula for formula (I), (Ia) or (Ib).

In another embodiment, R⁰ is hydrogen and R is:

—C(═O) CHF₂;

—C(═O)CF₃;

—C(═O)CH₂CF₃;

—C(═O)CF₂CF₃;

—C(═O)CF₂—C₁₋₆alkyl;

—C(═O)CHFCH₃;

—C(═O) CF₂CH₂NH₂;

—C(═O)CF₂CH₂OH;

—C(═O)CH₂OH;

—C(═O)CH₂OCOCH₃;

—C(═O) CH₂CN;

—C(═O)CH₂SO₂C₁₋₆alkyl;

—C(═O)CH₂S(═O)CHF₂.

—C(═O)CH₂P(═O)(OCH₃)₂;

—C(═O) CH₂S-tetrazole optionally substituted with —CH₃;

—C(═O)CH₂-thienyl;

—C(═O)CH(NH₂)CH₂-tetrazole;

—C(═O)CH(NH₂)CH₂-pyrazole;

—C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃; —CF₃, —CHF₂,

-   -   —CH₃; NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂, or —COOEt;

—C(═O)CH₂-triazole optionally substituted with —CH₂NR^(a)R^(b), or —CH₃ and

-   -   —CF₃, or —CF₃ and —NH₂;

—C(═O)CH₂-oxadiazole-CH₂NR^(a)R^(b);

—C(═O)C(CH₃)₂-tetrazole;

—C(═O)CH(CH₃)-azetidine optionally substituted with oxo, hydroxyethyl, or both;

—C(═O)CF₂-thienyl;

—C(═O)—C₁₋₆alkyl-NR^(a)R^(b);

—C(═O)-pyrrolidinyl optionally substituted with F or NH₂;

—C(═O)-tetrahydrofuran;

—C(═O)-piperazine;

—C(═O)-pyrazine;

S—C(═O)-thiazolidine optionally substituted with one or more oxo;

—C(═O)-pyrazole optionally substituted with CH₃ and CF₃;

—C(═O)CH(NH₂)C₁₋₆alkyl optionally substituted with —OH or phenyl;

—C(═O)CHFC₁₋₆alkyl;

—C(═O)CH(OH)C₁₋₆alkyl;

—C(═O)CR^(k)═NOC(CH₃)₂COOH;

—C(═O)CR^(k)═NOCH₃;

—C(═S)OC₁₋₆alkyl;

—C(═O)C(═O)OH;

—C(═O)C(═O)NR^(a)R^(b);

—C(═O)(CH₂)₁₋₆C(═O)NR^(a)R^(b);

—C(═O)C(═O)ONR^(a)R^(b);

—C(═O)C(═O)OC₁₋₆alkyl;

—(CH₂)₀₋₆C(═O)OH;

—(CH₂)₀₋₆C(═O)OC-alkyl;

—(CH₂)₀₋₆C(═O)(CH₂)₁₋₆OH;

—(CH₂)₀₋₆C(═O)(CH₂)₁₋₆OC₁₋₆alkyl;

—C(═O)OCH₂CHF₂;

—C(═O)OCH₂CF₃;

—C(═O)—C₃₋₆cycloalkyl substituted with CF₃ or NH₂;

—C₁₋₆alkyl-NR^(a)R^(b);

—C₁₋₆alkyl-C₃₋₆cycloalkyl;

—(CH₂)₀₋₆SO₂(CH₂)₀₋₄R^(e);

—CH(═NH); or

—C₁₋₆alkyl; or

R and R⁰ together with the N to which they are attached form a [1,2,3-]triazole optionally substituted with —CH₂OH, —CH₂OCH₃, —CH₂F, —CH₂NH₂, —CH₂NHCH₃, or —C(═O)OCH₃; or a tetrazole optionally substituted with —NH₂.

In another embodiment, R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆ alkoxy;

R is:

-   -   1) —(CH₂)_(n)C(═O)R², or     -   2) —(CH₂)_(n)SO₂R², or

R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S.

In another embodiment, R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy;

R is:

-   -   1) —(CH₂)_(n)C(═S)R²,     -   2) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or.     -   3) —CH(═NH), or

R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S.

In a ninth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ih), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R⁰ is hydrogen and R is:

-   -   1) —C(═O)CHF₂,     -   2) —C(═O)CH₂NH₂,     -   3) —C(═O)CH₂NHCH₃,     -   4) —C(═O)CH₂NHC(═NH)NH₂,     -   5) —C(═O)CH₂-tetrazolyl, or     -   6) —SO₂CH₃, or

R and R⁰ combine together to form -triazolyl optionally substituted with —CH₂—OH; and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above.

In another embodiment, R⁰ is hydrogen and R is:

—C(═O)CHF₂;

—C(═O)CH₂NH₂;

—C(═O)CH₂NHCH₃;

—C(═O)CH₂NHC(═NH)NH₂;

—C(═O)CH₂-tetrazolyl; or

—SO₂CH₃; or

R and R⁰ combine together to form -triazolyl optionally substituted with —CH₂—OH. In other embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is:

1) pyrrolidinyl substituted with 1 or 2 of

-   -   a) —CONR^(c)R^(d),     -   b) —CON(CH₃)CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NH₂ or         diazepanyl,     -   c) —CH₂NR^(f)R^(g),     -   d) —CH═NH,     -   e) F,     -   f) —(CH₂)₀₋₁NHC(═NH)NH₂,     -   g) —CH₂NHSO₂-pyrrolidinyl-NH₂,     -   h) —CH₂NH(C═O)-pyrrolidinyl substituted NH₂ or F,     -   i) —CH₂NH(—C═O)pyridinyl substituted with oxo, CH₃ and OH,     -   j) —CH₂NH(C═O)-cyclopentyl-NH₂,     -   k) —CH₂NHSO₂-piperazine,     -   l) —CH₃, or     -   m) OH,

3) —CH₂-pyridinyl,

4) thiazole substituted with pyridinyl wherein the pyridinyl is optionally substituted with —CH₃ or —CH₂C(═O)NH₂,

5) azetidinyl substituted with —C(═NH)NH₂, —SO₂NH, thiazolyl or 4,5-dihydrothiazol-2-yl,

6) —CH₂CH₂-pyridinyl substituted with oxo, CH₂NH₂ and OH,

7) —CH₂-pyrrolidinyl substituted with acetyl and —NH₂, or —NHSO₂NH₂,

8) —CH₂-piperazine,

9) —CH₂CH₂—NH(═NH)NH₂,

11) pyrazole optionally quaternized with —CH₃ and optionally substituted with —CH₂ pyrrolidine, or CH₂ piperidine optionally quaternized with —CH₃ and optionally substituted with —CH₂CH₂NH₂,

12) —CH₂-phenyl substituted with pyrazole optionally quaternized with —CH₃ and substituted with —(CH₂)₃NH₂, or

13) —CH₂CH₂NHCO₂-tert-butyl;

and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above or the seventh or eighth embodiments.

In another embodiment, R¹ is:

1) pyrrolidinyl substituted with 1 or 2 of

-   -   —CONR^(c)R^(d);     -   —CON(CH₃)CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NH₂ or         diazepanyl;     -   —CH₂NR^(f)R^(g);     -   —CH═NH;     -   F;     -   CH₂NHSO₂-pyrrolidinyl-NH₂;     -   —CH₂NH(C═O)-pyrolidinyl substituted NH₂ or F;     -   —CH₂NH(C═O)-pyridinyl substituted with oxo, CH₃ and OH;     -   —CH₂NH(C═O)-cyclopentyl-NH₂;     -   —CH₂NHSO₂-piperazine; or     -   —CH₃;

3) —CH₂-pyridinyl;

4) thiazole substituted with pyridinyl wherein the pyridinyl is optionally substituted with CH₃;

5) azetidinyl substituted with thiazolyl or 4,5-dihydrothiazol-2-yl;

6) —CH₂CH₂-pyridinyl substituted with oxo, CH₂NH₂ and OH;

7) —CH₂-pyrrolidinyl substituted with acetyl and —NH₂ or —NHSO₂NH₂; or

8) —CH₂-piperazine.

In a tenth embodiment, the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is pyrrolidinyl substituted with

-   -   1) —C(═O)NR^(c)R^(d);     -   2) —CH₂NHSO₂NH₂, or     -   3) —CH₂-pyrrolidinyl-NH₂, or     -   4) —CH₂—CO-pyrrolidinyl-NH₂;         wherein

R^(c) is —CH₃,

R^(d) is —CH₃;

R^(c) and R^(d) are taken together, with the N to which they are attached, to form

-   -   1) azetidinyl optionally substituted with —NHC(═NH)NH₂,     -   2) pyrrolidinyl substituted with         -   a. one or two —NH₂,         -   b. —NHCH₃,         -   c. —C(Me)₂NH₂,         -   d. one or two —OH,         -   e. —CH₂NH₂,         -   f. —NHC(═O)CH₂NH₂,         -   g. —NHC(═O)CH₂CH₂NH₂,         -   h. —NHC(═O)CH₂NH(═NH)NH₂,         -   i. —NHCH═NH,         -   j. —F and —NH₂,         -   k. —NH₂ and —OH,         -   l. —NH₂ and —CH₃,         -   m. —NH₂ and —CH₂OH,         -   n. —NH₂ and —CH₂NH₂,         -   o. —NH₂ and —OMe,         -   p. —OH and —CH₂NH₂,         -   q. —CH₂OH and —CH₂NH₂,         -   r. —NH₂ and —COOH,         -   s. —NHC(═NH)NH₂,         -   t. —NHC(═NH)NH₂ and —OH,         -   u. —NHC(═NH)NH₂ and —CH₂OH,         -   v. —NHC(═NH)NH₂ and —NH₂,         -   w. —NH₂ and —CH₂NHSO₂NH₂,         -   x. —CH₂F and NH₂,         -   y. —OH, —NH₂ and —CH₂NH₂,         -   z. —OH, —NH₂ and —CH₂OH, or         -   aa. triazolyl substituted with —CH₂NH₂     -   3) piperidinyl substituted with —(CH₂)₂NH₂, —CH₂NHCH₂C(═O)NH₂,         —CH₂CH₂NH₂, —CH₃ and —NH₂, —CH₂OH and —CH₂—NH₂, —F and —NH₂, —OH         and —NH₂, —CONHCH₂CH(OH)CH₂NH₂, or azetidinyl substituted with         —OH or piperazinyl,     -   4) piperazinyl optionally substituted with one or two —CH₃,         —CH₂NH₂, —CH₂CH₂NH₂, —C(═NH)NH₂, —CH₂CH₂NHC(═NH)NH₂,         C(═O)(CH₂)₁₋₂NH₂, —C(═O)CH(NH₂)NH₂, —CH₂CH(NH₂)CH₂NH₂,         —CH₂CH(F)CH₂NH₂, —C(═O)CH₂NHCH₃, —C(═O)CH(NH₂)CH₂OH, or —CH₃ and         —CH₂C(═O)NH₂;     -   5) morpholinyl optionally substituted with —CH₂NH₂;     -   6) 1,4-diazepane optionally substituted with —C(═NH)NH₂;     -   7) octahydro-1H-pyrrolo[3,2-c]pyridine optionally substituted         with —CH₂CH₂NH₂, —CH₂CH(OH)NH₂, or —C(═NH)NH₂,     -   8) octahydrocyclopenta[c]pyrrole optionally substituted with         -   a. one or -two —NH₂,         -   b. —NH₂ and —CH₂OH,         -   c. —NH₂ and —CH₂NH₂,         -   d. —NH₂,         -   e. —NHC(═NH)NH₂,         -   f. —NHC(═NH)NH₂ and —CH₂OH, or         -   g. s-OH, —NH₂ and —CH₂OH,     -   9) octahydro-1H-pyrrolo[2,3-c]pyridine,     -   10) octahydro-1H-pyrrolo[3,2-c]pyridine optionally substituted         with —CH₂CH(OH)CH₂NH₂,     -   11) octahydro-1H-pyrrolo[3,4-b]pyridine optionally substituted         with —CH₂OH,     -   12) octahydropyrrolo[3,4-b]pyrrole optionally substituted with         —CH₂OH, —CH₂CH₂NH₂, or —C(═NH)NH₂;     -   13) octahydro-1H-pyrrolo[3,4-c]pyridine optionally substituted         with —CH₂OH, or —COOH     -   14) 5,5-dimethyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-5-ium,     -   15) octahydropyrrolo[3,4-c]pyrrole optionally substituted with         —CH₂OH,     -   16) octahydropyrrolo[3,4-d]imidazole optionally substituted with         ═NH,     -   17) octahydro-1H-pyrrolo[3,2-b]pyridine,     -   18) octahydropyrrolo[3,4-b][1,4]oxazine,     -   19) 3,6-diazahicyclo[3.2.0]heptane,     -   20) 1,9-diazaspiro[5.5]undecane,     -   21) decahydro-1,6-naphthyridine,     -   22) 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine optionally         substituted with —NH₂,     -   23) 2,7-diazaspiro[4.4]nonane,     -   24) 2,8-diazaspiro[4.5]decane,     -   25) 2,6-diazaspiro[3.4]octane,     -   26) 1,7-diazaspiro[3.5]nonane,     -   27) 2,7-diazaspiro[3.5]nonane,     -   28) 1,8-diazaspiro[4.5]decane,     -   29) 1,7-diazaspiro[4.5]decane,     -   30) 5-nxa-2-azaspiro[3.4]octane optionally substituted with         —NH₂,     -   31) 3,8-diaza-tricyclo[5.2.1.01,5]decane, or     -   32) 8-azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine;         and the other groups are as provided in the general formula for         formula (I), (Ia) or (Ib), above, or the embodiments.

In another embodiment, R¹ is pyrrolidinyl substituted with

-   -   —C(═O)NR^(c)R^(d);     -   —CH₂NHSO₂NH₂; or     -   —CH₂-pyrrolidinyl-NH₂;         wherein

R^(c) is —CH₃,

R^(d) is —CH₃;

R^(c) and R^(d) are taken together, with the N to which they are attached, to form pyrrolidinyl substituted with

-   -   one or two —NH₂,     -   —NHCH₃,     -   two —OH,     -   —CH₂NH₂,     -   —NHC(═O)CH₂NH₂,     -   —NHCH═NH,     -   —NH₂ and —OH,     -   —NH₂ and —CH₃,     -   —NH₂ and —CH₂OH,     -   —NHC(═NH)NH₂ and —OH, or     -   triazolyl substituted with —CH₂NH₂;     -   piperidinyl substituted with     -   —(CH₂)₀₋₂NH₂,     -   —CH₂NHCH₂C(═O)NH₂,     -   —C₃ and —NH₂,     -   F and —NH₂, or     -   azetidinyl substituted with —OH or piperazinyl;     -   piperazinyl optionally substituted with     -   one or two —CH₃,     -   —CH₂CH₂NH₂,     -   —C(═NH)NH₂,     -   —CH₂CH₂NHC(═NH)NH₂,     -   —C(═O)(CH₂)₁₋₂NH₂,     -   —C(═O)CH₂NHCH₃,     -   —C(═O)CH(NH₂)CH₂OH, or     -   —CH₃ and —CH₂C(═O)NH₂;     -   octahydro-1H-pyrrolo[3,2-c]pyridine;     -   1,7-diazaspiro[3.5]nonane;     -   2,7-diazaspiro[3.5]nonane;     -   1,8-diazaspiro[4.5]decane; or     -   8-azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine].

In an eleventh embodiment, the present invention relates to a compound of formula (Ia), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof,

wherein:

-   -   A is NR⁰R or -triazolyl substituted with —CH₂OH;

R is:

-   -   1) —C(═O)C₁₋₆alkyl-NR^(a)R^(b);     -   2) —C(═O)CHF₂,     -   3) —C(═O)CH₂SCHF₂,     -   4) —C(═O)CH₂NH(CH₂)₂OMe,     -   5) —C(═O)CH₂pyrrolidin,     -   6) —C(═O)CH₂azetidine,     -   7) —C(═O)CH₂piperazine,     -   8) —C(═O)CH₂ pyrrolidine optionally substituted with 1 or 2         substituents selected from fluorine and —CH₂NHMe,     -   9) —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃,         —CF₃, —CHF₂, —CH₃, —NH—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂,         or —COOCH₂CH₃, or     -   10) —SO₂CH₃;

R⁰ is H;

R¹ is

-   -   1) pyrrolidinyl substituted with 1 or 2 of —CONR^(e)R^(d),     -   2) —CH₂NHSO₂NH₂, or     -   3) —CH₂-pyrrolidinyl optionally substituted with —NH₂;

R^(a) and R^(b) are independently H, —C₁₋₆alkyl, —C₃₋₈cycloalkyl, —SO₂CH₃, —CH(═NH), —C(═NH)NH₂, or —CH₂C(═O)NH₂;

R^(c) and R^(d) are independently H, C₁₋₃alkyl, —C(═NH)-pyrrolidinyl optionally substituted with —NH₂, or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form a 4- to 12-membered heterocyclic ring or ring system with 0, 1, 2 or 3 additional heteroatom ring atoms selected from N and O;

wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; the ring system is a bridged, fused or spiro ring system; and the 4- to 12-membered heterocyclic ring or ring system is optionally substituted with 1, 2 or 3 substituents selected from

-   -   1) ═NH,     -   2) —C(═O)(CH₂)₁₋₂NH₂,     -   3) —C(═O)CH₂NHCH₃,     -   4) —CH₂CH(NH₂)CH₂NH₂,     -   5) —C(═O)CH(NH₂)CH₂NH₂,     -   6) —C(═O)CH(F)CH₂NH₂,     -   7) —C(═O)CH(NH₂)CH₂OH,     -   8) —CH₂CH₂CH(OH)CH₂NH₂,     -   9) —C(═O)NH CH₂CH(OH)CH₂NH₂,     -   10) —C(═NH)NH₂,     -   11) —COOH,     -   12) —CH₃,     -   13) —CH₂C(═O)NH₂,     -   14) —CH₂NH CH₂C(═O)NH₂,     -   15) —CH₂NR^(h)R^(j),     -   16) —CH₂CH₂NH₂,     -   17) —CH₂CH₂NH—C(═NH) NH₂,     -   18) —CH₂NHSO₂NH₂,     -   19) —CH₂OH,     -   20) —C(CH₃)₂NH₂,     -   21) —CH₂F,     -   22) —OH,     -   23) —OMe,     -   24) —F,     -   25) —NR^(h)R^(j),     -   26) —NHCH═NH,     -   27) —NH—C(═NH)—NH₂,     -   28) —NHCOCH₂—NH—C(═NH)—NH₂,     -   29) —NHCOCH₂NH₂;     -   30) (CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or         halogens,     -   31) azetidinyl optionally substituted with —OH,     -   32) piperazinyl, and     -   33) triazolyl substituted with CH₂NH₂; and

R^(h) and R^(j) are independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl; and the other groups are as provided in the general formula for formula (I), (Ia) or (Ib), above, or the embodiments.

In another embodiment, the compound has a structure according to formula Ia:

wherein:

-   -   A is NR⁰R or -triazolyl substituted with —CH₂OH;

R is:

-   -   —C(═O)C₁₋₆alkyl-NR^(a)R^(b);     -   —C(═O)CHF₂;     -   —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃, —CF₃,     -   —CHF₂, —CH₃, —NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂, or     -   —COOCH₂CH₃; or     -   —SO₂CH₃;

R⁰ is H;

R¹ is pyrrolidinyl substituted with 1 or 2 of —CONR^(c)R^(d); —CH₂NHSO₂NH₂ or —CH₂— pyrrolidinyl optionally substituted with —NH₂;

R^(a) and R^(b) are independently H, —C₁₋₆alkyl, —C₃₋₈cycloalkyl, —SO₂CH₃, —CH(═NH), —C(═NH)NH₂ or —CH₂C(═O)NH₂;

R^(c) and R^(d) are independently C₁₋₃alkyl, or

R^(c) and R^(d) are taken together, with the N to which they are attached, to form a 4- to 10-membered heterocyclic ring or ring system with 0, 1, or 2 additional heteroatom ring atoms selected from N and O;

wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; the ring system is a bridged, fused or spiro ring system; and the 4- to 12-membered heterocyclic ring or ring system is optionally substituted with 1 or 2 substituents selected from

-   -   —C(═O)(CH₂)₁₋₂NH₂,     -   —C(═O)CH₂NHCH₃,     -   —C(═O)CH(NH₂)CH₂OH,     -   —C(═NH)NH₂,     -   —CH₃,     -   —CH₂C(═)NH₂,     -   —CH₂NH CH₂C(═O)NH₂,     -   —CH₂NR^(h)R^(j),     -   —CH₂CH₂NH₂,     -   —CH₂CH₂NH—C(═NH)—NH₂,     -   —CH₂OH,     -   —OH,     -   —F,     -   —NR^(h)R^(j),     -   —NHCH═NH,     -   —NH—C(═NH)—NH₂,     -   —NHCOCH₂NH₂;     -   —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or         halogens;     -   azetidinyl optionally substituted with —OH,     -   piperazinyl, and     -   triazolyl substituted with CH₂NH₂; and

R^(h) and R^(j) are independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein

R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy;

R is:

-   -   1) —(CH₂)_(n)C(═O)R²,     -   2) —(CH₂)_(n)C(═S)R²,     -   3) —(CH₂)_(n)SO₂R²,     -   4) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or     -   5) —CH(═NH), or

R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S, provided that when R and R⁰ together with the N to which they are attached form triazole, then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable-salt thereof, wherein

R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy;

R is:

-   -   1) —(CH₂)_(n) C(═O)R²,     -   2) —(CH₂)_(n)C(═S)R²,     -   3) —(CH₂)_(n)SO₂R²,     -   4) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or     -   5) —CH(═NH), or     -   R and R⁰ together with the N to which they are attached form a         substituted or unsubstituted 5-6 membered cyclic ring with 0, 1,         2, 3 or 4 additional heteroatom ring atoms independently         selected from N, O and S, provided that when R and R⁰ together         with the N to which they are attached form triazole or         tetrazole, then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein

R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n) C(═O)R², n is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH or NH₂; and

when R and R⁰ combine together to form triazole then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein

R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R², n is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH or NH₂; and

when R and R combine together to form triazole or tetrazole then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein

R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

provided that when R is —(CH₂)_(n)C(═O)R², n is 0 and R⁰ is H, then R^(z) is not-unsubstituted C₁₋₆alkyl; and/or when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂; and/or

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH or NH₂; and/or

when R and R⁰ combine together to form triazole or tetrazole then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (b), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R², h is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH; and

when R and R⁰ combine together to form triazole or tetrazole, then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R², n is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is 0, R⁰ is not H;

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH; and

when R and R⁰ combine together to form triazole then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof, wherein R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R², a is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is 0, R⁰ is not H.

when R is —(CH₂)_(n)SO₂R² and n is hot 0, R² is not OH; and

when R and R^(o) combine together to form triazole or tetrazole then Z is not H.

In another embodiment the present invention relates to a compound of formula (I), (Ia) or (Ib), or a stereoisomer, internal salt N-oxide, or pharmaceutically acceptable salt thereof wherein

R is —(CH₂)_(n)C(═)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R², n is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and n is 0, R⁰ is not H; and

when R is —(CH₂)_(n)SO₂R² and n is not 0, R is not OH.

In another embodiment of the present invention,

R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², —(CH₂)_(n)SO₂R², or —CH(═NH); or

R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S;

with the provisos that

when R is —(CH₂)_(n)C(═O)R² and n is 0, R⁰ is not H;

when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂;

when R is —(CH₂)_(n)SO₂R² and a is 0, R⁰ is not H; and

when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH.

In another embodiment of the present invention, R¹ is C₂₋₆aminoalkyl optionally substituted with —CR^(x)═NR^(x).

In another embodiment, A represents —NR⁰R. In another embodiment, A represents —OR².

In another embodiment, Z represents —H. In another embodiment, Z represents —CH₃.

In another embodiment, X represents —S—. In another embodiment, X represents —CH₂—.

In another embodiment, R⁰ is hydrogen.

In another embodiment, R is —(CH₂)_(n)C(═O)R².

In another embodiment, R¹ is —(CH₂)₀₋₆-HetC or —(CH₂)₁₋₆NH(C═NH)NH₂. In another embodiment, R¹ is HetC or —(CH₂)₂NH(C═NH)NH₂.

In another embodiment, R¹ is —(CH₂)₀₋₆-HetC. In another embodiment, R¹ is —HetC.

In another embodiment, R¹ is —(CH₂)₁₋₆NH(C═NH)NH₂. In another embodiment, R¹ is —(CH₂)₂NH(C═NH)NH₂.

In another embodiment, R² is AryA. In another embodiment, R² is tetrazole.

In another embodiment, R⁴ is —CO₂H.

In one embodiment, HetC is a substituted or unsubstituted pyrrolidine.

In one embodiment, R^(c) is —C(═NH)-pyrrolidin-1-yl substituted with NH₂.

In another embodiment, R^(d) is hydrogen.

In another embodiment, R^(c) and R^(d) are taken together, with the N to which they are attached, to form a a-heterocyclic ring or ring system selected from: azetidine, pyrrolidine, piperazine, octahydropyrrolo[3,4-b]pyrrole, octahydro-1H-pyrrolo[3,2-c]pyridine, 2,7-diazaspiro[4,4]-nonane, octahydropyrrolo[3,4-d]imidazole, and 3,8-diaza-tricyclo[5.2.1.01,5]decane, wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from: ═NH, —(CH₂)₀₋₃OH, —CH₂CH(OH)CH₂NH₂, —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂, —NHC(═O)CH₂NHC(═NH)NH₂, —C(═NH)NH₂, and —(CH₂)₀₋₃NHC(═NH)NH₂.

In another embodiment, R^(c) and R^(d) are taken together, with the N to which they are attached, to form a heterocyclic ring or ring system selected from azetidine, pyrrolidine, piperazine, octahydropyrrolo[3,4-b]pyrrole, octahydro-1H-pyrrolo[3,2-c]pyridine, 2,7-diazaspiro[4,4]-nonane, octahydropyrrolo[3,4-d]imidazole, and 3,8-diaza-tricyclo[5.2.1.01,5]decane, wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from: ═NH, —CH₂OH, OH, —CH₂CH(OH)CH₂NH₂, —(CH₂)₃NH₂ optionally substituted with —NH₂, —CH₂CH(NH₂)CH₂NH₂, —NHC(═O)CH₂NHC(═NH)NH)NH₂, —C(═NH)NH₂, and —NHC(═NH)NH₂.

In another embodiment each R^(x) and R^(y) is independently hydrogen.

In another embodiment, HetC is substituted with one substituent selected from —C(═O)NR^(c)R^(d).

In another embodiment of the present invention, the pharmaceutically acceptable salt is selected from sodium, potassium; calcium, magnesium and ammonium salts.

In a twelfth embodiment of the invention, the compound of the invention is selected from the exemplary species depicted in EXAMPLES 1 to 601 shown below, and pharmaceutically acceptable salts thereof.

In a thirteenth embodiment of the invention, the compound of the invention is selected from the exemplary species depicted in EXAMPLES 32, 44, 95, 103, 106, 112, 120, 121, 124, 129, 132, 135, 146, 149, 157, 158, 159, 161, 168, 169, 176, 178, 184, 186, 218, 219, 221, 242, 264, 278, 283, 298, 314, 324, 352, 360, 361, 362, 363, 364, 365, 366, 367, 368, 391, 395, 396, 397, 398, 400, 404, 411, 412, 413, 414, 419, 420, 425, 426, 427, 429, 431, 432, 433, 435, 437, 438, 439, 457, 481, 493, 505, 521, 523, 544, 545, 560, 566, 567, 571, 575, 576, 580, 584, 585, 593 shown below, and pharmaceutically acceptable salts thereof

Reference to different embodiments with respect to Formula I or (I) compounds, specifically includes different embodiments of Formula I, such as Formulas Ia and Ib, sub-embodiments of Formulas Ia and Ib, other embodiments provided herein, and individual compounds described herein.

Other embodiments of the present invention include the following:

-   -   (a) A pharmaceutical composition comprising a compound of         Formula I or Ia or Ib as defined herein, or a pharmaceutically         acceptable salt thereof, and a pharmaceutically acceptable         carrier.     -   (b) The pharmaceutical composition of (a), further comprising a         beta-lactamase inhibitor.     -   (c) The pharmaceutical composition of (b), wherein the beta         lactamase inhibitor is clinically approved Clavulanic acid and         its salts, Sulbactam and its salts, Tazobactam and its salts,         Avibactam and its salts, and Cilastatin and its salts. Other         beta lactamase inhibitors include Relebactam, RPX 7009 and BAL         30072.     -   (d) A pharmaceutical composition which comprises (i) a compound         of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable         salt thereof, and (ii) a beta lactamase inhibitor, wherein the         compound of formula I or Ia or Ib, and the beta lactamase         inhibitor are each employed in an amount that renders the         combination effective for overcoming drug resistance in a         bacterial infection.     -   (e) The combination of (d), wherein the beta lactamase         inhibitors clinically approved Clavulanic acid and its salts;         Sulbactam and its salts, Tazohactam and its salts, Avibactam and         its salts, and Cilastatin and its salts. Other beta lactamase         inhibitors include Relehactam, RPX 7009 and BAL 30072     -   (f) A method for inhibiting bacterial peptidoglycan synthesis         which comprises administering to a subject in need of treatment         an effective amount of a compound of Formula I or Ia or Ib, or a         pharmaceutically acceptable salt thereof.     -   (g) A method for preventing and/or treating a bacterial         infection which comprises administering to a subject in need of         such treatment an effective amount of a compound of Formula I or         Ia or Ih, or a pharmaceutically acceptable salt thereof.     -   (h) A method for treating a bacterial infection which comprises         administering to a subject in need of such treatment a         therapeutically effective amount of the composition of (a), (b),         (c), (d), or (e).     -   (i) The method of treating a bacterial infection as set forth in         (f), (g), or (h), wherein the bacterial infection is due to         Escherichia spp., or Pseudomonas spp., Staphylococcus spp., or         Streptococcus spp.

The present invention also includes a compound of Formula I or Ia or Ib, or a pharmaceutically acceptable salt thereof,

(1) for use in, (2) for use as a medicament for, or (3) for use in the preparation (or manufacture) of a medicament for, medicine or inhibiting bacterial peptidoglycan synthesis or treating bacterial infection. In these uses, the compounds of the present invention can optionally be employed in combination with one or more beta-lactamase inhibitors.

Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(i) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, sub-embodiments, classes or sub-classes described above. The compound may optionally be used in the form of a pharmaceutically acceptable salt in these embodiments.

In the embodiments of the compounds and salts provided above, it is to be understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound or salt and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (i) above are understood to include all embodiments of the compounds and/or salts, including such embodiments as result from combinations of embodiments.

Additional embodiments of the present invention include each of the pharmaceutical compositions, combinations, methods and uses set forth in the preceding paragraphs, wherein the compound of the present invention or its salt employed therein is substantially pure. With respect to a pharmaceutical composition comprising a compound of Formula I or its salt and a pharmaceutically acceptable carrier and optionally one or more excipients, it is understood that the term “substantially pure” is in reference to a compound of Formula I or its salt per se; i.e., the purity of the active ingredient in the composition.

Definitions

“Alkyl” means saturated carbon chains which may be linear or branched or combinations thereof unless the carbon chain is defined otherwise. Other groups having the prefix “alk”; such as alkoxy and alkanoyl, also may be linear or branched, or combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, and the like.

“Alkenyl” means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched, or combinations thereof unless otherwise defined. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

“Antibiotic” refers to a compound or composition which decreases the viability of a microorganism, or which inhibits the growth or proliferation of a microorganism. The phrase “inhibits the growth or proliferation” means increasing the generation time (i.e., the time required for the bacterial cell to divide or for the population to double) by at least about 2-fold. Preferred antibiotics are those which can increase the generation time by at least about 10-fold or more (e.g., at least about 100-fold or even indefinitely, as in total cell death). As used in this disclosure, an antibiotic is further intended to include an antimicrobial, bacteriostatic, or bactericidal agent.

“About”, when modifying the quantity (e.g., kg, L, or equivalents) of a substance or composition, or the value of a physical property, or the value of a parameter characterizing a process step (e.g., the temperature at which a process step is conducted), or the like refers to variation in the numerical quantity that can occur, for example, through typical measuring, handling and sampling procedures involved in the preparation, characterization and/or use of the substance or composition; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make or use the compositions or carry out the procedures; and the like in certain embodiments, “about” can mean a variation of 0.1, 0.2, 0.3, 0.4; 0.5, 1.0, 2.0, 3.0, 4.0, or 5.0 of the appropriate unit. In certain embodiments, “about” can mean a variation of 1%, 2%, 3%, 4%, 5%, 10%, or 20%.

“Aromatic ring system”, as exemplified herein, by AryA, AryB and AryC, means monocyclic, bicyclic or tricyclic aromatic ring or ring system containing 5-14 ring atoms, wherein at least one of the rings is aromatic. Aromatic ring systems, as used herein, encompass aryls and heteroaryls. The term may be used to describe a carbocyclic ring fused to an aryl group. For example, a 5-7-membered cycloalkyl can be fused through two adjacent ring atoms to a 5-6-membered heteroaryl containing 1, 2, or 3 heteroatom ring atoms selected from N, O, and S. In another example, a heteromonocyclic ring is fused through two ring atoms to a phenyl or 5-6-membered heteroaryl containing 1, 2, or 3 heteroatoms selected from N, O, and S.

“Aryl” means' a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing 6-14 carbon atoms, wherein at least one of the rings is aromatic. Examples of aryl include phenyl and naphthyl.

“Cycloalkyl” means a saturated monocyclic, bicyclic or bridged carbocyclic ring, having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

“Drug resistant” means, a bacterium which is no longer susceptible to at least one previously effective drug; which has developed the ability to withstand antibiotic attack by at least one previously effective drug. A drug resistant strain may relay that ability to withstand to its progeny. Said resistance may be due to random genetic mutations in the bacterial cell that alters its sensitivity to a single drug or to different drugs.

“Halogen” includes fluorine, chlorine, and bromine.

“Heteroaryl” means monocyclic, bicyclic or tricyclic ring or ring system containing 5-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, a N as a quaternary salt, S (including SO and SO₂) and O, wherein at least one of the heteroatom containing rings is aromatic. Examples of heteroaryl include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzopyrazolyl, benzofuranyl, benzothienyl (including S-oxide and dioxide), benzotriazolyl, furo(2,3-b)pyridyl; quinolyl, indolyl, isoquinolyl, quinazolinyl, dibenzofuranyl, and the like.

“Heterocycle” means monocyclic, bicyclic or tricyclic saturated or monounsaturated ring or ring system containing 3-14 carbon atoms and containing at least one ring heteroatom selected from N, NH, a N as a quaternary salt, S (including SO and SO₂) and O. When a heterocycle contains two rings, the rings may be fused, bridged or spiro-linked. Examples of monocyclic heterocycle rings include piperazine, piperidine, and morpholine. When a heterocycle contains two or more rings, the rings may be fused, bridged and/or spiro-linked. Examples of monocyclic heterocycle rings include piperazine, piperidine, and morpholine. Examples of tricyclic ring systems include 8-azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine

“Oxo” means an oxygen atom connected to another atom by a double bond and is can be represented “═O”.

Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, as originally defined or as defined in any of the foregoing embodiments, sub-embodiments, aspects, classes or sub-classes, wherein the compound or its salt is in a substantially pure form. As used herein “substantially pure” means suitably at least about 60 wt. %, typically at least about 70 wt %, preferably at least about 80 wt. %, more preferably at least about 90 wt. % (e.g., from about 90 wt. % to about 99 wt. %), even more preferably at least about 95 wt. % (e.g., from about 95 wt. % to about 99 wt. %, or from about 98 wt. % to 100 wt. %), and most preferably at least about 99 wt. % (e.g., 100 wt. %) of a product containing a compound of Formula I or its salt (e.g., the product isolated from a reaction mixture affording the compound or salt) consists of the compound or salt. The level of purity of the compounds and salts can be determined using a standard method of analysis such as thin layer chromatography, gel electrophoresis, high performance liquid chromatography, and/or mass spectrometry. If more than one method of analysis is employed and the methods provide experimentally significant differences in the level of purity determined, then the method providing the highest level of purity governs. A compound or salt of 100% purity is one which is free of detectable impurities as determined by a standard method, of analysis.

Recitation or depiction of a specific compound in the claims (i.e., a species) without a specific stereoconfiguration designation, or with such a designation for less than all chiral centers, is intended to encompass the racemate, racemic mixtures, each individual enantiomer, a diastereoisomeric mixture and each individual diastereomer of the compound where such forms are possible due to the presence of one or more asymmetric centers:

With respect to a compound of the invention which has one or more asymmetric centers and can occur as mixtures of stereoisomers, a substantially pure compound can be either a substantially pure mixture of the stereoisomers or a substantially pure individual diastereomer or enantiomer. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention.

When any variable (e.g., R¹, R^(a), etc.) occurs more than one time in any constituent or in formula I, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A squiggly line across a bond ii a substituent variable represents the point of attachment.

Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described last, preceded by the adjacent functionality toward the point of attachment.

In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. R¹, R², etc., are to be chosen in conformity with well-known principles of chemical structure connectivity and stability.

The term “substituted” shall be deemed to include multiple degrees of substitution by a named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.

When a group, e.g., C₁₋₈alkyl, is indicated as being substituted, such substitutions can also be occur where such group is part of a larger substituent, e.g., —C₁₋₈alkyl-C₃₋₇cycloalkyl and —C₁₋₈alkyl-aryl.

In the compounds of formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope-having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of formula I. For example, different isotopic forms of hydrogen (H) include protium (¹H) and deuterium (²H or D). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the EXAMPLES herein using appropriate isotopically-enriched reagents and/or intermediates.

Unless expressly stated to the contrary in a particular context, any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.

Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaromatic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also to be understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from “1 to 4 heteroatoms” is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms. Similarly, C₁₋₆ when used with a chain, for example an alkyl chain, means that the chain can contain 1, 2, 3, 4, 5 or 6 carbon atoms. It also includes all ranges contained therein including C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆, C₃₋₆, C₄₋₆, C₅₋₆, and all other possible combinations.

A “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject). The compounds of the present invention are limited to stable compounds embraced by Formula I.

The term “compound” refers to the free compound and, to the extent they are stable, any hydrate or solvate thereof. A hydrate is the compound complexed with water, and a solvate is the compound complexed with an organic solvent.

As indicated above, the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt” refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). A pharmaceutically acceptable salt can be formed, for example, by treating the compound of the invention (e.g., a compound of Formula I) with one molar equivalent of a mild base (e.g., sodium carbonate, sodium bicarbonate, potassium bicarbonate, or sodium acetate). In this case, M is a cation, such as Na⁺ in the event of treatment with a sodium base.

Described herein are also prodrugs of a compound of the invention, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of a compound of the invention that are readily convertible in vivo into compound of formula (I).

As set forth above, the present invention includes pharmaceutical compositions comprising a compound of Formula I of the present invention, optionally one or more other active components, and a pharmaceutically acceptable carrier. The characteristics of the carrier will depend on the route of administration. By “pharmaceutically acceptable” is meant that the ingredients of the pharmaceutical composition must be compatible with each other; do not interfere with the effectiveness of the active ingredient(s), and are not deleterious (e.g., toxic) to the recipient thereof. Thus, compositions according to the invention may, in addition to the inhibitor, contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.

Also as set forth above, the present invention includes a method for treating a bacterial infection which comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. The term “subject” (or, alternatively, “patient”) as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. The term “administration” and variants thereof (e.g., “administering” a compound) in reference to a compound of Formula I mean providing the compound, or a pharmaceutically acceptable salt thereof, to the individual in need of treatment. When a compound or a salt thereof is provided in combination with one or more other active agents, “administration” and its variants are each understood to include provision of the compound or its salt and the other agents at the same time or at different times. When the agents of a combination are administered at the same time, they can be administered together in a single composition or they can be administered separately. It is understood that a “combination” of active agents can be a single composition containing all of the active agents or multiple compositions each containing one or more of the active agents. In the case of two active agents a combination can be either a single composition comprising both agents or two separate compositions each comprising one of the agents; in the case of three active agents a combination can be either a single composition comprising all three agents, three separate compositions each comprising one of the agents, or two compositions one of which comprises two of the agents and the other comprises the third agent; and so forth.

The compositions and combinations of the present invention are suitably administered in effective amounts. The term “effective amount” as used herein with respect to a nargenicin compound means the amount of active compound sufficient to inhibit DnaE and/or cause a bacteriocidal or bacteriostatic effect. In one embodiment, the effective amount is a “therapeutically effective amount” meaning the amount of active compound that can overcome bacterial drug resistance and which is sufficient to inhibit bacterial replication and/or result in bacterial killing. When the active compound (i.e., active ingredient) is administered as the salt, references to the amount of active ingredient are to the free acid or free base form of the compound.

The administration of a composition of the present invention is suitably parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, intraocular, or intrarectal, wherein the composition is suitably formulated for administration by the selected route using formulation methods well known in the art, including, for example, the methods for preparing and administering formulations described in chapters 39, 41, 42, 44 and 45 in Remington—The Science and Practice of Pharmacy, 21^(st) edition, 2006. In one embodiment, compounds of the invention are administered intravenously in a hospital setting. In another embodiment, administration is oral in the form of a tablet or capsule or the like. The dosage of the compounds of the invention and of their pharmaceutically acceptable salts may vary within wide limits and should naturally be adjusted, in each particular case, to the individual conditions and to the pathogenic agent to be controlled. In general, for a use in the treatment of bacterial infections, the daily dose may be between 0.005 mg/kg to 100 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.05 mg/kg to 5 mg/kg, 0.05 mg/kg to 1 mg/kg. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 mg of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

In some embodiments, the compound in the invention is provided in a pharmaceutical formulation for oral; intravenous, intramuscular, nasal, or topical administration. Thus, in some embodiments, the formulation can be prepared in a dosages form, such as but not limited to, a tablet, capsule, liquid (solution or suspension), suppository, ointment, cream, or aerosol. In some embodiments, the presently disclosed subject matter provides such compounds and/or formulations that have been lyophilized and that can be reconstituted to form pharmaceutically acceptable formulations for administration, for example, as by intravenous or intramuscular injection.

Intravenous administration of a compound of the invention can be conducted by reconstituting a powdered form of the compound with an acceptable solvent. Suitable solvents include, for example, saline solutions (e.g., 0.9% Sodium. Chloride Injection) and sterile water (e.g., Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, or Bacteriostatic Water for Injection with 0.9% benzyl alcohol). The powdered form of the compound can be obtained by gamma-irradiation of the compound or by lyophilization of a solution of the compound, after which the powder can be stored (e.g., in a sealed vial) at or below room temperature until it is reconstituted. The concentration of the compound in the reconstituted IV solution can be, for example, in a range of from about 0.1 mg/mL to about 20 mg/mL.

The methods of the presently disclosed subject matter are useful for treating these conditions in that they inhibit the onset, growth, or spread of the condition, cause regression of the condition, cure the condition, or otherwise improve the general well-being of a subject afflicted with, or at risk of, contracting the condition. Thus, in accordance with the presently disclosed subject matter, the terms “treat”, “treating”, and grammatical variations thereof, as well as the phrase “method of treating”, are meant to encompass any desired therapeutic intervention, including but not limited to a method for treating an existing infection in a subject, and a method for the prophylaxis (i.e., preventing) of infection, such as in a subject that has been exposed to a microbe as disclosed herein or that has an expectation of being exposed to a microbe as disclosed herein.

Infections that may be treatable by the compounds of the invention can be caused by a variety of microbes, including fungi, algae, protozoa, bacteria, and viruses. In some embodiments, the infection is a bacterial infection. Exemplary microbial infections that may be treated by the methods of the invention include, but are not limited to, infections caused by one or more of Staphylococcus aureaus, Enterococcus faecalis, Bacillus anthracis, a Streptococcus species (e.g., Streptococcus pyogenes aid Streptococcus pneumoniae), Escherichia coli, Pseudomonas aeruginosa, Burkholderia cepacia, a Proteus species (e.g., Proteus mirabilis and Proteus vulgaris), Klebsiella pneumoniae, Acinetobacter baumannii, and Strenotrophomonas maltophillia.

In certain embodiments, the infection is an infection of a bacterium selected from Pseudomonas spp.; Klebsiella spp., Enterobacter spp., Escherichia spp., Morganella spp., Citrobacter spp., Serratia spp. pr Acintetobacter spp.

In some embodiments, the compound of Formula (I), (Ia) or (Ib), is administered prophylactically to prevent or reduce the incidence of one of: (a) a bacterial infection in a subject at risk of infection; (b) a recurrence of a bacterial infection; and (c) combinations thereof. In some embodiments, the compound of Formula (I), (Ia) or (Ib), is administered to treat an existing bacterial infection. In some embodiments, the compound of Formula ((I), (Ia) or (Ib), is administered to treat an infection of a multi-drug resistant strain of bacterial (i.e., a strain that is resistant to two or more previously known anti-bacterial drugs, such as i) Carbapenemase producing Enterobacteriaceae that are resistant to Cephalosporins and certain carbapenems; ii) Extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae that are resistant to cephalosporins and penicillins; iii) Aminoglycoside and Fluoroquinolone resistant Enterobacteriaceae; iv) Extended spectrum β-lactamase (ESBL) producing P. aeruginosa and v) Aminoglycoside and Fluoroquinolone resistant P. aeruginosa. In some embodiments, the compound of Formula (I), (Ia) or (Ib), has a minimum inhibitory concentration (MIC) against one or bacterial species of 25 μg/mL or less. In some embodiments, the compound of Formula (I), (Ia) or (Ib), is administered to treat an infection of a multi-drug resistant strain.

In some embodiments, the compound of Formula I, Ia, has a minimum inhibitory concentration (MIC) against one or more bacterial species of 25 μg/mL or less. MICs can be determined via methods known in the art, for example, as described in Hurdle et al., 2008, J. Antimicrob. Chemother. 62:1037-1045.

In some embodiments, the methods of the invention further comprise administering to the subject an additional therapeutic compound. In some embodiments, the compound of the invention is administered to the subject before, after, or at the same time as one or more additional therapeutic compounds. In some embodiments, the additional therapeutic compound is an antibiotic.

The invention thus provides in a further aspect, a combination comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with one or more additional therapeutic agents. Examples of such one or more additional therapeutic agents include, but not limited to, β-lactams, aminoglycosides, tetracyclines, macrocycles, oxazolidinones, glycopeptides, lipopeptides, quinolones, etc.,

Thus, the other antibiotic which may be combined with the compounds of formula I or Ia or Ib are, for example, Vancomycin, Linezolid, Tedizolid, Ceftaroline, Ceftobiprole, Ceftalozane, Daptomycin, Dalbavancin, Telavancin, Oritavancin, Aztreonam, Delafloxacin, GSK2140944, Plazomicin, Tigecycline, Solithromycin etc.,

Abbreviations employed herein include the following: ACN=acetonitrile; aq.=aqueous; Bn=benzyl; Boc=tert-butoxy carbonyl; CDCl₃=deuterated chloroform; CDI=carbodiimidazole; DCE=1,2-dichloroethane; DCM=dichloromethane; DIAD=diisopropyl azodicarboxylate; DIPEA=diisopropylethylamine; DMAP=4-dimethylaminopyridine or N,N-dimethylaminopyridine; DMF=. N,N-dimethylformamide; DMSO=dimethyl sulfoxide; Et=ethyl; EtOAc=ethyl acetate; H₂=hydrogen gas, HPLC=high-performance liquid chromatography; LC-MS=liquid chromatography/mass spectrometry; Me=methyl; MeCN=acetonitrile; MeOH=methanol; MIC=minimum inhibitory concentration; MW=molecular weight; MS=mass spectrometry; Pd/C=palladium on carbon; PNB—p-nitrobenzyl; PNZ−]p nitrobenzyl carbamate; PPh₃=triphenylphosphine; RB=round bottom flask; RT=room temperature; TBDMS=tert-butyl dimethylsilyl; TBTU=N,N,N′,N′-tetramethyl-O-(benzotriazol-1-yl) uroniumtetrafluoroborate; TEA=triethylamine; TFA=trifluoroacetic acid; THF=tetrahydrofuran; TLC=thin layer chromatography.

The compounds disclosed herein can be prepared according to the following reaction schemes and EXAMPLES, or modifications thereof; using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variations which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds disclosed herein will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and EXAMPLES.

Described below are processes for the preparation of a compound of formula ((I), (Ia) or (Ib) as shown in the general schemes 1, 2, 2a and 3, wherein all the groups are as defined earlier.

Step 1: The compound of formula (1) was prepared according to known methods available in the literature. The reaction was carried out in the presence of base, alkaline carbonates such as sodium carbonate, potassium carbonate and the like in a suitable solvent such as tetrahydrofuran (THF), dimethoxyethane, ether, dichloromethane(DCM), dimethylformamide (DMF), acetone and the like. Step 2: The silyl group in compound of formula (1) was deprotected by mineral acids such as HCl, H₂SO₄ and the like in presence of solvent such as tetrahydrofuran, dioxane, acetonitrile (ACN), dimethylformamide and the like to yield the compound of formula (2). Step 3: The compound of formula (3) was obtained by reacting a compound of formula (2) with triphenylphosphine (PPh₃), formic acid and Diisopropyl azodicarboxylate (DIAD) in the presence of THF. Step 4: The compound of formula (3) was hydrolyzed according to the procedure given in Bull Chem Soc Japan, 1976, 49, 510 to yield the compound of formula (4). Step 5: The compound of formula (4) was reacted With triphenylphosphine, hydrazoic acid and DIAD according to the procedure given in Tetrahedron Letters, 1983, 49, 554, to yield the compound of formula (5). Step 6: Reducing the Compound of formula (5) using reducing reagents such as triphenylphosphine, trimethylphosphine, triethylphosphine, tributylphosphine, methyl diphenylphosphinite or ethyldiphenylphosphinite and the Like in presence of aqueous organic solvents such as tetrahydrofuran (THF), dioxane, acetonitrile (ACN), acetone, or dimethylformamide (DMF) containing about 1% to 50% water, preferably about 5% to 10% water and the like according to known Staudinger reaction gave the compound of formula (6). Step 7: The compound of formula (7) was synthesized by reacting a compound of formula (6) with amino-protecting group in presence of organic base such as sodium bicarbonate and the like and water soluble solvents such as THF, dioxane and acetone followed by hydrolyzing using base such as LiOH and the like. Suitable amino-protecting groups include, for example, acyl groups such as formyl, acetyl and substituted acetyl (e.g., halogenated acetyl), benzoyl and substituted benzoyl, alkoxycarbonyl, halogenated alkoxycarbonyl, alkenyloxycarbonyl, aralkoxycarbonyl, halogenated aralkoxycarbonyl, benzyl and benzyl derivatives, trityl and trityl derivatives, sulfenyl derivatives, sulfonyl derivatives, diacyl derivatives such as phthalimido or succinimido or derivatives thereof and Schiff bases formed with aldehydes or ketones. Carbamate protection was done by using di-tert-butoxycarbonylanhydride (BOC anhydride) and inorganic base such as sodium bicarbonate in water soluble solvent such as tetrahydrofuran, dioxan and acetone. Step 8: The Compound of formula (7) was reacted with carbodiimidazole and magnesium mono p-nitrobenzyl malonate ester by a known method given in D. G. Melillo et al., Tetrahedron Letters, 1980, 21, 2783 to yield the compound of formula (8) The reaction of a magnesium malonate with the activated carboxy moiety was carried out in organic solvent such as tetrahydrofuran, dioxane, dichloromethane, acetonitrile, benzene, toluene and the like. Step 9: The compound of formula (8) was subjected to a diazo-transfer reaction to yield compound of formula (9) The compound of formula (8) was treated with an azide such as dodecabenzenesulfonylazide, 4-carboxybenzenesulfonylazide, p-toluenesulfonylazide, methanesulfonylazide and the like in presence of a base such as triethylamine (TEA), diethylamine, pyridine or lutidine and the like and solvent such as acetonitrile, dichloromethane, toluene, benzene and the like to yield the Compound of formula (9). Step 10: The compound of formula (10) was synthesized by treating the compound of formula (9) with acids such as trifluoroacetic acid (TFA) or HCl and the like in presence of solvents such as dioxane or ether and the like.

Step 11a: Reacting compound of formula (10) with R^(A)COOH in the presence of coupling agents such as carbodiimides, phosphonium, uronium, guanidinium salts and the like and solvents such as ethyl acetate (EtOAc) and the like gave the compound of formula (11). Step 11b: Reacting compound of formula (10) with R^(A)X (X is Cl, Br, F, I) in the presence of acid binding agents such as alkali acetate, alkali hydroxide, calcium oxide, calcium carbonate, magnesium carbonate or organic bases such as pyridine, N-methyl morpholine, diisopropylethylamine (DIPEA), TEA and the like and solvents such as DCM, dioxane, toluene and the like gave the compound of formula (11). Step 11c: The compound of formula (10) was reacted with carbonylating agent such as phosgene, diphosgene, triphosgene, N,N′-carbonyldiimidazole (CDI), thiophosgene, thiocarbonyldiimidazole and the like in presence of bases such as pyridine, N-methyl morpholine, DIPEA, TEA and the like in solvents such as DCM, 1,2-dichloromethane, toluene, ACN and the like and successively treated with R^(A)OH/R^(A)NH₂ to yield the compound of formula (11) .

Step 11d: The compound of formula (a) was reacted with R³OH in presence of triphenylphosphine and DIAD in solvents such as THF and the like to obtain a compound of formula (11). Step 11e: The compound of formula (b) was reacted with compound (c) in presence of copper iodide and DIPEA in solvents such as toluene and the like to obtain a compound of formula (11).

Step 12: The compound of formula (12) was prepared by reacting a compound of formula (11) with the compound of general formula H—SR¹, wherein the R¹ is as defined earlier in presence of activating agent such as diphenyl chlorophosphate, dimethylaminopyridine (DMAP) and the like and catalyst such as bis(acetylacetonate)Cu(II), copper sulfate, copper powder, rhodium acetate [Rh₂(OAc)₄], rhodium(II)octanoate, Pd(OAc)₂, Pb(OAc)₄ and the like and solvents such as tetrahydrofuran, ethyl acetate, benzene, toluene, hexane, cyclohexane and the like. Step 12a: Reacting the compound of formula (12) with 2-iodoacetamide or iodomethane and the like in presence of solvents such as THF-acetone and the like gave the compound of formula (I), (Ia) or (b). Step 13: The compound of formula (I), (Ia) or (Ib), was prepared by reducing the compound of formula (12) or the compound of formula (12a) with Pd/C in presence of solvents such as THF-water and the like under pressure. Step 14: Hydroxymethylation by a cross coupling reaction between carbapenem-2-triflate and Bu₃SnCH₂OH. Step 15: Allylic carbonate (14) was prepared by isobutylchloroformate in presence of DIPEA, DMAP and in solvents like dichloromethane and tetrahydrofuran. Step 16: Allylic amine (15) was prepared by reaction of allylic carbonate (14) and amine in presence of Palladium catalyst. Step 17: Formula (Ia) was prepared by reducing the compound of formula (15) with Pt/C in presence of solvents such as THF-water and the like under pressure.

The examples below are provided by way of illustration only and should not be considered to limit the scope of the invention.

EXAMPLES Preparation 1: (R)-Benzyl 2-((2S,3S)-3-((R)-1-(t-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)propanoate

To a mixture of (R)-2-((2S,3S)-3-((R)-1-(t-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)propanoic acid (1 g, 3.32 mmoles), potassium carbonate (0.68 g, 4.95 mmoles) and acetone (10 mL), benzyl bromide (0.63 g, 3.67 mmoles) was added and heated to reflux for 5 hours. The reaction mixture was filtered and the residue was washed with ethyl acetate (25 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to afford the title compound as oil. (1.2 g, 92.3%). ¹H NMR (DMSO-d₆) δ ppm: 0.01 (d, 6H), 0.79 (s, 9H), 1.04 (d, 6H), 2.37-2.46 (m, 1H), 2.84 (t, 1H), 3.63-3.65 (d, 1H), 4.02-4.07 (m, 1H), 4.83-4.84 (m, 2H), 7.30-7.38 (m, 5H), 8.06 (s, 1H).

Preparation 2: (R)-Benzyl-2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl) propanoate

Aqueous hydrochloric acid (2 N, 10 mL) was added to 10 g of (R)-benzyl-2-((2S,3S)-3-((R)-1-(t-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)propanoate (10 g) dissolved in acetonitrile (100 mL) and stirred at room temperature for 3 hours. Reaction mixture was concentrated to obtain crude oil, which was dissolved in ethyl acetate (250 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated under vacuum. The residue thus obtained was triturated with hexane (100 mL), filtered and dried to give the product as a white solid (6.2 g, 87.5%). ¹H NMR (DMSO-d₆) δ ppm: 1.08-1.09 (d, 3H), 1.17-1:18 (d, 3H), 2.66-2.73 (m, 1H), 2.86-2.87 (d, 1H), 3.63-3.65 (d, 1H), 3.86-3.91 (m, 1H), 4.85-4.86 (d, 1H), 5.08-5.31 (m, 2H), 7.35-7.42 (m, 5H), 8.17 (s, 1H).

Preparation 3: (R)-Benzyl 2-((2S,3S)-3-((S)-1-(formyloxy)ethyl)-4-oxoazetidin-2-yl) propanoate

To a solution of (R)-benzyl 2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl) propanoate (10 g, 36.05 mmoles) in tetrahydrofuran (100 mL), was added triphenylphosphine (15.2 g, 57.95 mmoles) and 98% formic acid (3.33 g, 72.34 mmoles) at ice-cold condition. Diisopropylazodicarboxylate (11.7 g, 57.86 mmoles) was then added to the reaction mixture, slowly over a period of 15 minutes. The reaction mixture was further stirred at ice-cold condition for a period of 30 minutes. Subsequently, water (50 mL) was added and the reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated under vacuum. The residue thus obtained was stirred with toluene (100 mL) and filtered. The filtrate was concentrated to yield oily crude. The crude thus obtained was purified by column chromatography to yield the product as an oily substance (3.32 g, 30.2%). ¹H NMR (DMSO-d₆) δ ppm: 1.036 (d, 3H), 1.13 (d, 3H), 2.49-2.5 (q, 1H), 2.65 (t, 1H), 2.81-2.83 (q, 1H), 3.58-3.6 (q, 1H), 3.81-3.85 (q, 1H), 4.80 (br, 1H), 5.03-5.12 (dd, 2H), 7.30-7.38 (m, 5H), 8.12 (s, 1H).

Preparation 4: (R)-Benzyl 2-((2S,3S)-3-((S)-1-hydroxyethyl)-4-oxoazetidin-2-yl) propanoate

To a solution of (R)-benzyl 2-((2S,3S)-3-((S)-1-(formyloxy)ethyl)-4-oxoazetidin-2-yl)propanoate (10 g, 32.75 mmoles) in-tetrahydrofuran (100 mL), lithium hydroxide (0.768 g, 32.07 mmoles) dissolved in 30 mL water was added at ice cold condition. After completion of the reaction, the reaction mixture was concentrated and diluted with ethyl acetate (150 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated. The crude product this obtained was purified by column chromatography to yield the product as white color solid. (8 g, 88.1%). H NMR (DMSO-d₆) δ ppm: 1.12 (d, 31H, 1.17 (d, 3H), 2.65-2.70 (q, 1H), 2.84 (q, 1H), 3.48-3.51 (m, 1H), 3.81-3.85 (m, 1H), 5.09 (dd, 2H), 7.35-7.39 (m, 5H), 8.05 (s, 1H).

Preparation 5: (R)-Benzyl 2-((2S,3S)-3-((R)-1-azidoethyl)-4-oxoazetidin-2-yl) propanoate

To a solution of (R)-benzyl 2-((2S,3S)-3-((S)-1-hydroxyethyl)-4-oxoazetidin-2-yl) propanoate (10 g, 36.05 mmoles) in 200 mL of tetrahydrofuran:toluene (1:1) was added triphenylphosphine (15:14 g, 57.72 mmoles) and 85 mL of 0.85 M hydrazoic acid (3.1 g, 72.09 mmoles) at −10° C. under nitrogen atmosphere. To the above, diisopropylazodicarboxylate (11.7 g, 57.86 mmoles) was added slowly over a period of 15 minutes. The mixture was further stirred at ice-cold condition for a period of 30 minutes. To the reaction mixture, water (50 mL) was added and concentrated to half of the volume. Then the reaction mixture was extracted with ethyl acetate (300 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated. The residue thus obtained was stirred with toluene (100 mL) and filtered. The filtrate was concentrated to obtain the oily crude. The crude thus obtained was purified by column chromatography to yield the product as an oily substance. (7.95 g, 72.9%). ¹H NMR (DMSO-d₆) δ ppm: 1.12-1.19 (m, 6H), 2.65-2.71 (q, 1H), 3.01-3.03 (q, 1H), 3.5-3.53 (m, 1H), 3.89-3.92 (m, 1H), 5.06-5.14 (dd, 2H), 7.33-7.39 (m, 5H), 8.37 (s, 1H).

Preparation 6: (R)-Benzyl 2-((2S,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl) propanoate

Triphenylphosphine (6.51 g, 24.8 mmoles) was added to a solution of (R)-benzyl 2-((2S,3S)-3-((R)-1-azidoethyl)-4-oxoazetidin-2-yl)propanoate (5 g, 16.6 mmoles) in tetrahydrofuran (25 mL) and the mixture was stirred at room temperature for 5 hours under nitrogen atmosphere. To the reaction mixture, water (5 mL) was added and it was stirred at room temperature for a period of 16 hours. Brine solution (50 mL) was added to the reaction mixture and extracted with ethyl acetate (100 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated. The residue thus obtained was stirred with toluene (100 mL) and filtered. The filtrate was concentrated to obtain oily crude. The crude thus obtained was purified by column chromatography to yield the product as an oily substance. (4 g, 87.5%). ¹H NMR (DMSO-d₆) δ ppm: 0.963-0.98 (d, 3H), 1.00-1.12 (d, 3H), 2.62-2.66 (m, 1H), 2.69-2.72 (m, 1H), 2.96-2.98 (m, 1H), 3.52-3.54 (m, 1H), 5.08-5.09 (dd, 2H), 7.30-7.39 (m, 5H), 8.15 (s, 1H).

Preparation 7: (R)-Benzyl 2-((2S,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)propanoate

To a mixture of sodium bicarbonate (6.1 g, 72.04 mmoles) and (R)-benzyl 2-((2S,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)propanoate (10 g, 36.18 mmoles) in 150 mL of tetrahydrofuran: water (2:1), di-t-butyldicarbonate (9.5 g, 43.47 mmoles) was added and stirred at room temperature for 6 hours. The reaction mixture was filtered and extracted With ethyl acetate (250 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to obtain the product as a white solid, (10 g, 73.4%). ¹H NMR (DMSO-d₆) δ ppm: 1.09-1.112 (m, 6H), 1.36 (s, 9H), 2.65-2.70 (m, 1H), 2.92 (m, 1H), 3.51-3.53 (m, 1H), 3.60-3.74 (m, 1H), 5.10-5.16 (dd, 2H), 6.73-6.75 (d, 1H), 7.32-7.37 (m, 5H), 8.2 (2, 1H).

Preparation 8: (R)-2-((2S,3R)-3-((R)-1-(t-Butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)propanoic acid

Lithium hydroxide (0.768 g, 32.07 mmoles) was added to the solution of (R)-benzyl 2-((2S,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)propanoate (10 g, 26.56 mmoles) in 50 mL of tetrahydrofuran:methanol:water (1:1:0.5) at ice-cold condition. The reaction mixture was continued to be stirred at room temperature for 1 hour. The reaction mixture was concentrated and diluted with water (150 mL). The aqueous layer was washed with EtOAc (150 mL). The separated aqueous layer was now acidified with citric acid to pH 2 and extracted with ethyl acetate (250 mL). The organic layer was washed with water and brine. After drying over sodium sulphate the organic layer was concentrated to give the product as a white solid. (7.05 g, 92.7%). ¹H NMR (DMSO-d₆) δ ppm: 1.09-1.112 (m, 6H), 1.39 (s, 9H), 2.50-2.51 (m, 1H), 2.88-2:91 (m, 1H), 3.4-3.58 (m, 1H), 3.69-3.75 (m, 1H), 6.7 (d, 1H), 8.15 (s, 1H), 12.35 (s, 1H).

Preparation 9: (R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

To a solution of (R)-2-((2S,3R)-3-((R)-1-(tert-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)propanoic acid (10 g; 34.93 mmoles) in acetonitrile (100 mL), 1,1′-carbonyldiimidazole (6.52 g, 40.21 mmoles) was added and continued to stir for a period of 1 hour at ice-cold condition under nitrogen atmosphere. The above obtained solution was added slowly to a suspension of magnesium salt of mono-p-nitrobenzylmalonate (20132 g, 77.26 mmoles) in acetonitrile (100 mL) and stirred for 5 hours at room temperature and heated to 50° C. for a further period of 6 hours under nitrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated and the obtained crude was diluted with ethyl acetate. The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to give oily crude. The crude thus obtained was-purified by column chromatography to yield the product as a white solid (10 g, 61.78%). ¹H NMR (DMSO-d₆) δ ppm: 1.09-1.112 (m, 6H), 1.39 (s, 9H), 2.87-2.91 (m, 1H), 2.99-3.00 (m, 1H), 3.5-3.52 (m, 1H), 3.73-3.77 (m, 1H), 3.8-3.93 (dd, 2H), 5.29 (s, 2H), 6.7 (d, 1H), 7.60-7.66 (d, 2H), 8.09 (s, 1H), 8.23-8.26 (d, 2H).

Preparation 10: (R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate

To a solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate (10 g, 21.57 mmoles) in acetonitrile (50 mL) was added successively dodecabenzenesulfonylazide (70% in toluene, 13 mL, 25.9 mmoles) and triethylamine (12.7 mL, 91.1 mmoles) at ice-cold condition. The reaction mixture was stirred for 1 hour and then it was concentrated and diluted with ethyl acetate (150 mL). The organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to give oily crude. The crude thus obtained was purified by column chromatography to yield the product as a white solid (10 g, 94.69%). ¹H NMR (DMSO-d₆) δ ppm: 1.00-1.02 (d, 3H), 1.06-1.08 (d, 31H), 1.39 (s, 91H), 3.01-3.03 (m, 1H), 3.47-3.49 (m, 1H), 3.63-3.66 (m, 1H), 3.71-3.73 (m, 1H), 5.43 (s, 2H), 6.55 (d, 1H), 7.69-7.72 (d, 2H), 8.15 (s, 1H), 8.25-8.27 (d, 2H).

Preparation 11: (R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate

Trifluoroacetic acid (1.40 g, 12.3 mmoles) was added to a solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-(t-butoxycarbonylamino)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (2 g, 4.08 mmoles) in dichloromethane (10 mL) at ice-cold condition and stirred for 2 hours at nitrogen atmosphere. The reaction mixture was concentrated and the residue obtained was triturated with diethyl ether to yield the product as a white solid.

Preparation 12: 2-((Z)-1-((R)-1-((2R,3R)-2-((R)-4-diazo-5-(4-nitrobenzyloxy)-3,5-dioxopentan-2-yl)-4-oxoazetidin-3-yl)ethylamino)-1-oxopropan-2-ylideneaminooxy)-2-methylpropanoic acid

A mixture of (Z)-2-(2-methyl-1-(4-nitrobenzyloxy)-1-oxopropan-2-yloxyimino) propanoic acid (1 g, 3.08 mmoles), N,N′,N′-tetramethyl-O-(benzotriazol-1-yl) uroniumtetrafluoroborate (TBTU) (1.19 g, 3.7 mmoles), diisopropylethylamine (1.1 mL, 6.32 mmoles) and ethyl acetate (50 mL) was stirred at room temperature for 30 minutes under nitrogen atmosphere. To the reaction mixture (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1.2 g, 3.08 mmoles) was added and it was stirred for a further period of 30 minutes. The reaction mixture was treated with water (20 mL) and extracted with EtOAc (50 mL). The separated organic layer was washed with water and brine. After drying over sodium sulphate the organic layer was concentrated to give the product as an off-white solid. ¹H NMR (DMSO-d₆) δ ppm: 1.47-1.49 (m, 9H), 1.55 (s, 3H), 2.06-2.08 (d, 1H), 3.06 (t, 111), 3.64-3.72 (d, 1H), 4.31-4.34 (q, 1H), 5.43 (s, 4H), 7.29-7.34 (s, 2H), 7.70-7.77 (dd, 4-), 8.25-8.32 (dd, 4H).

Preparation 13: (R)-4-Nitrobenzyl 2-diazo-4-((2R,3S)-3-((R)-1-(methylsulfonamido)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

Methane sulfonyl chloride (0.19 mL, 25.7 mmoles) was added to a mixture of (R)-4-nitrobenzyl4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1 g, 2.57 mmoles) and diisopropylethylamine (0.92 mL, 51.4 mmoles) in dichloromethane (20 mL) at ice-cold condition under nitrogen atmosphere. The reaction mixture was treated with water (20 mL) and extracted with dichloromethane (50 mL). The separated organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to obtain crude, which on purification by column chromatography yielded the product as an off-white solid. H NMR (DMSO-d₆) δ ppm: 1.14-1.18 (d, 3H), 1.19-1.22 (d, 31H), 2.85-2.89 (d, 1H), 2.91 (s, 3H), 3.52-3.57 (m, 2H), 3.69-3.72 (m, 1H), 5.39-5.47 (dd, 2H), 7.08-7.10 (d, 1H), 7.70-7.72 (d, 2H), 8.25-8.27 (dd, 3H).

Preparation 14: (R)-4-Nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(methoxycarbonyl amino)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

Methyl chloroformate (0.2 mL, 2.58 mmoles) was added to a mixture of (R)-4-nitrobenzyl-4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxo pentanoate (1 g, 2.57 mmoles) and diisopropylethylamine (0.92 mL, 51.4 mmoles) in dichloromethane (20 mL) at ice-cold condition under nitrogen atmosphere. The reaction mixture was treated with water (20 mL) and extracted with dichloromethane (50 mL). The separated organic layer was washed with water and brine. After drying over sodium sulphate the organic layer was concentrated to obtain crude which on column purification yield an off-white solid. ¹H NMR (DMSO-d₆) δ ppm: 1.01-1.02 (d, 31H), 1.06-1.09 (d, 3H), 2.82-2.85 (d, 1H), 3.44-3.48 (m, 1H), 3.49 (s, 3H), 3.65-3.69 (m, 2H), 5.41-5.44 (m, 2H), 7.10-7.12 (d, 1H), 7.69-7.73 (d, 2H), 8.25-8.27 (m, 3H).

Preparation 15: (R)-4-Nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(methoxycarbono thioylamino)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

To an ice-cold solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1 g, 2.57 mmoles) in dichloromethane (10 mL) was added aqueous solution of NaHCO₃ (0.6 g in 10 mL, 7.14 mmoles). Thiophosgene (0.25 mL, 3.34 mmoles) was added to the above and stirred for 1 hour. After completion of the reaction, the reaction mixture was filtered. The organic layer was washed with water and evaporated td obtain a crude product. The crude thus obtained was purified by column chromatography. The compound obtained was dissolved in methanol (10 mL) and heated to reflux for 5 hours. The reaction mixture was evaporated and purified by column chromatography to obtain the title compound. ¹H NMR (DMSO-d₆) δ ppm: 1.10-1.15 (d, 3H), 1.21-1.22 (d, 3H), 2.00 (d, 1H), 2.88-2.89 (d, 1H), 3.50-3.51 (m, 1H), 3.61-3.62 (s, 3H), 3.68-3.70 (m, 1H), 5.42 (m, 2H), 6.89-6.90 (d, 11H), 7.70-7.75 (d, 2H), 8.24-8.26 (d, 2H), 8.34 (s, 1H).

Preparation 16: (R)-4-Nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(2-methoxy-2-oxo acetamido)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

A mixture of 2-methoxy-2-oxoacetic acid (0.14 g, 1.35 mmoles), N,N,N,N′-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU, 0.43 g, 1.35 mmoles) and diisopropyl ethylamine (0.25 mL; 1.46 mmoles) in ethyl acetate (10 mL) was stirred for 30 minutes. To the above reaction mixture a solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (0.6 g, 1.22 mmoles) in ethyl acetate (5 mL) was added and stirred for 2 hours. After completion of the reaction, the reaction mixture was diluted with water. The organic layer was separated and washed with water and brine successively. After drying over sodium sulphate, the organic layer was concentrated to obtain crude which on purification by column chromatography yielded the product as oily substance. (0.25 g-42.8%). ¹H NMR (DMSO-d₄) δ ppm: 1.11-1.18 (d, 3H), 1.20-1.21 (d, 3H), 2.08 (d, 1H), 2.86-2.88 (d, 1H), 3.50-3.51 (m, 1H), 3.61-3.62 (s, 3H), 3.65-3.70 (m, 1H), 5.42 (m, 2H), 6.91-6:96 (d, 1H), 7.70-7.71 (d, 2H), 8.22-8.25 (d, 2H), 8.13 (s, 1H).

Preparation 17: (R)-4-Nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(2,2-difluoroacetamido)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

By following the procedure provided in preparation 16, (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (5 g, 12.84 mmoles) was derivatised with difluoroacetic acid to yield the title product (3.7 g. 78.7%). ¹H NMR (DMSO-d₆) δ ppm: 1.10-1.12 (d, 3H), 1.21-1.23 (d, 3H), 2.06 (d, 1H), 2.87-2.91 (d, 1H), 3.51-3.55 (m, 1H), 3.67-3.69 (m, 1H), 5.43 (m, 2H), 6.94-6.96 (t, 1H), 7.70-7.72 (d, 2H), 8.14-8.16 (d, 2H), 8.20 (s, 1H).

Preparation 18: (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-cyanamidoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate

Cyanogen bromide (0.14 g, 1.28 mmol) was added to a solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (0.5 g, 1.28 mmol) in dichloromethane (10 mL) at ice cold condition. Triethylamine (0.3 mL, 2.15 mmol) was added to above and stirred at ice-cold condition for. 1 hour. After completion of the reaction, the reaction mixture was treated with water. The organic layer was separated and washed with water and brine solution. After drying over sodium sulphate, the organic layer was concentrated to obtain crude which on purification by column chromatography yields the product as a white solid. (0.33 g, 62%). ¹H NMR (DMSO-d₆) δ ppm: 1.11-1.18 (d, 3H), 1.21-1.23 (d, 3H), 2.08 (d, 1H), 2.87-2.89 (d, 11H), 3.51-3.54 (q, 1H), 3.68-3.71 (q, 1H), 5.43 (s, 2H), 6.95-6.96 (d, 1H), 7.69-7.71 (d, 2H), 8.24-8.26 (d, 2H), 8.34 (s, 1H).

Preparation 19: (R)-2-diazo-4-((2R,3S)-3-((R)-1-(isoxazol-3-yloxy)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoic 4-nitrobenzoic anhydride

To a solution of (R)-4-nitrobenzyl 2-diazo-4-((2R,3 S)-3-((S)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate (2.15 g, 5.34 mmoles) in tetrahydrofuran (10 mL) was added triphenylphosphine (2.24 g, 8.54 mmoles) and isoxazol-3-ol (0.9 g, 10.62 mmoles) at 0° C. Diisopropyl azodicarboxylate (1.73 g, 8.56 mmoles) was added slowly at 0° C. for 10 minutes. The reaction mixture was stirred for 5 hours at room temperature. On completion of reaction (as measured by TLC), the reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (25 mL) and brine (25 mL). The organic layer was dried over sodium sulfate and the solvent was evaporated to obtain the crude as an oily substance. The crude product was treated with toluene (10 mL) and stirred at 0° C. for 30 minutes, filtered and washed with 10 mL of toluene (cold). The filtrate and the washings were mixed together and concentrated to obtain crude product. The crude product on purification by column chromatography (15% EtOAc in hexane) yields the title product (0.9 g, 34.6%).

Preparation 20: (R)-4-nitrobenzyl 2-diazo-4-((2R,3S)-3-((R)-1-(4-(((4-nitrobenzyloxy) carbonylamino)methyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-oxoazetidin-2-yl)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

A mixture of (4R)-4-nitrobenzyl 4-(3-((R)-1-azidoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1 g, 2.41 mmoles), 4-nitrobenzyl prop-2-ynylcarbamate (0.56 g, 2.41 mmoles) and copper iodide (0.09 g, 0.48 mmoles) in toluene (10 mL) was stirred for −18 hours. The solvent was evaporated and the obtained crude product was purified by flash chromatography to afford the title compound. (Eluted in 6% acetone-DCM).

Preparation 21: (R)-4-nitrobenzyl2-diazo-4-((2R,3R)-3-((R)-1-(2-(methyl((4-nitrobenzyloxy)carbonyl)amino)acetamido)ethyl-4-oxoazetidin-2-yl)-3-oxopentanoate

To a mixture of p-nitrobenzyloxycarbonyl-Sarcosine (10 g, 37.28 mmoles) and diisopropylethylamine (9.3 mL, 56.26 mmoles) in ethyl acetate (60 mL) was added TBTU (14.36 g, 44.72 mmoles) and stirred for 0.5 hour at room temperature. A solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (14.5 g, 37.24 mmoles) in EtOAc (25 mL) was added to the above at 0° C. and the reaction mixture was stirred for 3 hours at room temperature. After completion of the reaction, the reaction mixture was diluted with EtOAC (150 mL) and washed with water and brine. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure to obtain crude product as an oily substance. The crude product on purification by column chromatography (20% acetone in dichloromethane) yields the title compound as a pale yellow solid. (10.7 g, 65%).

Preparation 22: 1-(2-amino-2-oxoethyl)-1-methyl-4-((2S,4S)-4-((4R,5S,6S)-4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-2-((4-nitrobenzyloxy)carbonyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-ylthio)-1-((4-nitrobenzyloxy)carbonyl) pyrrolidine-2-carbonyl)piperazin-1-ium iodide

(4R,5S,6 S)-4-nitrobenzyl 4-methyl-3-((3S,5S)-5-(4-methylpiperazine-1-carbonyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (0.5 g, 0.6 mmoles) was dissolved in tetrahydrofuran (2 mL) and acetone (5 mL). 2-Iodoacetamide (0.55 g, 2.97 mmoles) was added to the reaction mixture and heated to reflux for 4 hours. The reaction mixture was concentrated under vacuum and triturated with ethyl acetate (10 mL) to obtain solid. The solid obtained was filtered and dried to obtain the product as an off-white solid. (0.36 g, 60%). ¹H NMR (DMSO-d₆) δ ppm: 1.15-1.19 (d, 3H), 1.24-1.28 (d, 3H), 2.92 (s, 3H), 3.16-3.29 (m, 2H), 3.54-3.57 (s, 2H), 3.61-3.66 (m, 4H), 3.73-3.82 (m, 4H), 3.86-3.91 (m, 3H), 4.0-4.03 (m, 3H), 4.15-4.23 (m, 4H), 5.21-5.47 (m, 4H), 7.33-7.35 (d, 1H), 7.52-7.54 (d, 1H), 7.64-7.66 (d, 1H), 7.69-7.71 (d, 1H), 7.76-7.79 (d, 1H), 8.22-8.24 (4H).

Preparation 23: (R)-4-nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(2-ethoxy-2-oxoethylamino)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate

Ethyl bromoacetate (0.342 g 2.05 mmole) was added to a mixture of solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1 g, 2.05 mmoles), diisopropylethylamine (0.45 mL, 2.58 mmoles) and catalytic amounts of dimethylaminopyridine in dichloromethane (15 mL) at 0° C. and stirred for 16 hours at room temperature. After regular work up, the crude obtained was purified by chromatography to obtain the title compound (0.37 g, 30%). ¹H NMR (DMSO-d_(b)) δ ppm: 1.08 (d, 3H), 1.12 (d, 3H), 1.29 (t, 3H), 2.85 (d, 1H), 3.40-3.42 (m, 1H), 3.63-3.66 (m, 1H), 3.77 (s, 2H), 3.99 (m, 1H), 4.13 (q, 2H), 5.44 (s, 2H), 8.25 (m, 2H), 8.32 (s, 2H).

Preparation 24: (R)-4-nitrobenzyl 4-((2R,3S)-3-((R)-1-(butyl((4-nitrobenzyloxy)carbonyl)amino)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate

Step (i): A solution of mixture of 1-bromobutane (0.56 g 4.09 mmole) and (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (1 g, 2.05 mmoles) in dimethylformamide (20 mL) was heated at 50-55° C. for 16 hr. After regular work up, the crude obtained was purified by chromatography to obtain (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-(butylamino)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (0.5 g, 43.7.%). ¹H NMR (CDCl₃) δ ppm: 0.93 (t, 3H), 1.27 (m, 6H), 1.42 (m, 3H), 1.60 (m, 3H), 2.88 (d, 1H), 3.42 (m, 1H), 3.74 (m, 1), 3.80 (m, 1H), 5.35 (s, 2H), 6.01 (s, 1H), 7.53 (m, 2H), 8.25 (m, 2H). Step (ii): 4-nitrobenzylchloroformate (0.42 g, 1.96 mmoles) was added to a mixture of solution of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-(butylamino)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (0.5 g, 1.12 mmoles), triethylamine (0.34 g, 2.45 mmoles) and catalytic amount of dimethylaminopyridine at 0° C. and stirred at room temperature for 16 hr. After regular work up, the crude obtained was purified by column chromatography to obtain the title compound (0.31 g-44.2%). H NMR (DMSO-d₆) δ ppm: 0.84 (t, 3H), 1.1 (d, 3H), 1.26 (m, 611) 1.50 (m, 3H), 3.08 (m, 1H), 3.47 (m, 1H), 3.56 (m, 1), 4.01 (m, 1H), 5.19 (dd, 2H), 5.34 (s, 2H), 7.60 (m, 2H), 7.67 (m, 2H), 8.24 (m, 4H).

Preparation 25: Ethyl 2-pivalamidoacetate

O-(1H-Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU, 70.8 g, 0.22 mol) was added to a mixture of pivalic acid (15 g, 0.147 mol) and triethylamine (35 mL, 0.25 mol) in ethyl acetate (150 mL) and stirred for 0.5 hour at room temperature. Glycine ethyl ester HCl (20.52 g, 0.147 mol) was added to the above at 0° C. and the reaction mixture was stirred for 16 hours at room temperature. After the completion of the reaction, the reaction mixture was diluted with EtOAC (150 mL) and washed with water and brine. After drying over sodium sulphate, the organic layer was evaporated under reduced pressure to obtain crude product as oil. The crude on purification by column chromatography (10% MeOH in dichloromethane) yielded the title compound as an off-white solid. (18.4 g, 67%). ¹H NMR (CDCl₃) S=1.26 (s, 9H), 1.41 (t, 3H), 4.01 (m, 2H), 4.23 (q, 2H), 6.17 (brs, 1H).

Preparation 26: Ethyl 2-(5-tert-buty-1H-tetrazol-yl)acetate

A solution of ethyl 2-pivalamidoacetate (10 g, 0.053 mol) in acetonitrile (200 mL) was treated with sodium azide (14 g, 0.22 mol) and tetrachlorosilane (10 mL, 0.087 mol). The solution was heated to 90° C. under nitrogen for 16 hours. A further amount of sodium azide (7 g, 0.1 mol) and tetrachlorosilane (6 mL, 0.052 mol) were added and continued the reflux for additional 16 hours. The reaction mixture was poured into cold 5% aqueous sodium bicarbonate solution and extracted with ethyl acetate (150 mL×3) The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford a crude solid (1.68 g). The solid was purified by column chromatography to obtain the product as an oil (9.5 g, 83.8%) ¹H NMR (CDCl₃) 5-1.29 (t, 31-), 1.47 (s, 9H), 4.27 (q, 2H), 5.24 (s, 2H).

Preparation 27: 2-(5-Tert-butyl-1H-tetrazol-1-yl)acetic acid

At 0° C., a solution of ethyl 2-(5-tert-butyl-1H-tetrazol-1-yl)acetate (9 g, 0.042 mol) in tetrahydrofuran-MeOH (90 mL:45 mL) was treated with a solution of lithium hydroxide monohydrate (2.68 g 0.064 mol) in 45 mL of water. The reaction mixture was warmed to room temperature and stirred for 3 hours. The reaction mixture was neutralized with 1N HCl to pH=6-7 and concentrated. The crude was treated with aqueous lithium hydroxide (2.6 g in 100 mL) and a washed with ethyl acetate (150 mL). The aqueous layer was acidified with 1N HCl to pH 2 and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine solution (150 mL). The organic layer was evaporated after drying over sodium sulphate to obtain the title product as a white solid (6.8 g, 87%). ¹H NMR (DMSO-d₆) δ=1.39 (s, 9), 5.46 (s, 2H), 13.78 (brs, 1H).

Example 1: (4R,5S,6S)-3-((3S,5S)-5-(Dimethylcarbamoyl)pyrrolidin-3-ylthio)=4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Step 1: (4R,5S,6S)-4-Nitrobenzyl 3-((3S,5S)-5-(dimethylcarbamoyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

To a solution of (R)-4-nitrobenzyl-2-diazo-4-((2R,3S)-3-((R)-1-(methyl sulfonamido)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate (preparation 13) in acetone (10 mL), Rhodium octanoate (0.008 g, 0.01 mmoles) was added and heated to reflux for 1 hour. The reaction mixture was cooled to room temperature and then to −50 to −40° C. using dry ice-acetone bath Diisopropylethylamine (0.25 mL, 1.43 mmoles), catalytical amount of dimethylaminopyridine and diphenylchlorophosphate (0.26 mL, 1.28, mmoles) were added successively to the reaction mixture and stirred for 30 minutes at −50 to −40° C. (2S,4S)-4-nitrobenzyl-2-(dimethylcarbamoyl)-4-mercaptopyrrolidine-1-carboxylate (0.374 g; 1.06 mmoles) and diisopropylethylamine (0.25 mL, 1.43 mmoles) were added to the reaction mixture and continued stirring at −20° C. for 1 hour. The reaction mixture was then warmed to 0° C. and the stirring was continued for a further period of 3 hours. The reaction mixture was treated with water (20 mL) and extracted with ethyl acetate (50 mL). The separated organic layer was washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated to obtain the crude, which on purification by column chromatography, yielded a white-solid 0.4 g-48% (compound eluted with 20-30% acetone in dichloromethane). ¹H NMR (DMSO-d₆) δ ppm: 1.14-1.18 (d, 6H), 1.6-1.8 (m, 1H), 2.83-2.86 (m, 3H), 2.94 (m, 1H), 2.99-3.01 (d, 3H), 3.20 (m, 1H), 3.40-3.43 (m, 1H), 3.59-3.61 (m, 2H), 3.88-4.22 (m, 3H), 4.23-4.27 (m, 2H) 4.78-4.88 (m, 1H), 5.09-5.32 (d, 2H), 5.43-5.47 (d, 1H), 5.47-5.5 (d, 1H), 7.20-7.21 (d, 1H) 7.55-7.57 (d, 1H), 7.66-7.68 (d, 1H), 7.73-7.75 (m, 2H), 8:13-8.15 (d, 1H), 8.25-8.27 (m, 4H).

Step 2: (4R,5S,6S)-3-((3S,5S)-5-(Dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

To a solution of (4R,5S,6S)-4-nitrobenzyl 3-((3S,5S)-5-(dimethylcarbamoyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate obtained from step 1 (0.2 g, 0.258 mmoles) in THF:water (15 mL, 1:1) was subjected to hydrogenation in the presence of Pd/C. The reaction mixture was filtered over celite. The filtrate was washed with EtOAc (30 mL×6) The aqueous layer was then lyophilised to yield the title compound as a white solid (90 mg, 75%). ¹H NMR (D₂O) δ ppm: 1.21-1.23 (d, 3H), 1.33-1.39 (d, 3H), 1.92-1.96 (m, 1H), 2.99-3.00 (s, 3H), 3.01-3.03 (m, 1H), 3.11 (m, 1H), 3.47 (s, 6H), 3.46-3.48 (m, 2H), 3.97-3.99 (m, 2H), 4.03-4.21 (d, 1H), 4.73-4.75 (d, 1H), 4.8-4.86 (d, 1H). MS m/z: 460.7.

Examples 2-6, 17, 21, 26, 28, 31, 32, 35, 37-38, 40, 42-46, 49-50, 53-56, 58-68, 70-85 and 87-94 were prepared by treating the compound of formula (10) with appropriate R^(A)COOH according to the procedure given in the preparations 12, 16 and 17, followed by the procedure given in Example 1.

Examples 7-16, 18-19, 23-25, 27, 29-30, 33-34, 39, 48, 51, 57 and 86 were prepared by treating the compound of formula (10) with appropriate R^(A)X according to the procedure given in preparation 13 and 14, followed by the procedure given in Example 1.

Examples 20, 22, 36, 41, 47; 52 and 69 were prepared by treating the compound of formula (10) with appropriate carbonylating agents according to the procedure given in the preparation 15 followed by the procedure given in example 1. The quaternization of the heterocyclic rings in Examples 39, 45, 46, 80 and 94 were carried out according to the procedure given in preparation 19.

Example Structure Analytical Data 2

¹H NMR (D₂O) δ ppm: 1.12 (d, 1H), 1.29 (d, 3H), 1.33 (d, 3H), 1.36 (d, 2H), 1.98 (m, 1H), 2.99 (s, 3H), 3.06 (s, 3H), 3.19 (m, 1H), 3.41 (t, 1H), 3.85 (m, 1H), 3.98 (m, 1H), 4.24 (m, 1H), 4.51 (d, 1H), 4.78 (d, 1H), 4.79-4.83 (m, 1H), 7.02-7.03 (q, 1H), 7.16 (d, 1H) 7.42 (d, 1H). MS m/z: 505.1 (M − 1). 3

¹H NMR (D₂O) δ ppm: 1.39 (d, 3H), 1.48 (d, 3H), 1.58 (d, 6H), 2.04 (s, 3H), 2.99 (d, 3H), 3.08 (d, 6H), 3.41-3.45 (m, 2H), 3.61 (d, 1H), 3.73-3.78 (m, 1H), 4.0 (t, 2H), 4.54- 4.58 (m, 1H). MS m/z: 552 (M − 1). 4

¹H NMR (D₂O) δ ppm: 1.25 (d, 3H), 1.34 (d, 3H), 1.36 (s, 3H), 1.50 (s, 3H), 1.92 (m, 1H), 2.23 (m, 1H), 2.97 (s, 3H), 2.99 (d, 1H), 3.02 (s, 3H), 3.36-3.42 (q, 2H), 3.50-3.76 (m, 2H), 4.03-4.23 (m, 2H), 4.82-4.88 (d, 1H), 6.98 (s, 1H). MS m/z: 637.8 5

¹H NMR (D₂O) δ ppm: 1.27 (d, 3H), 1.32 (d, 3H), 1.96-2.04 (m, 1H), 2.96 (d, 1H), 3.00 (s, 4H), 3.07 (s, 4H), 3.41-3.45 (m, 2H), 3.71- 3.77 (m, 1H), 3.80-3.85 (m, 1H), 3.99-4.03 (m, 1H), 4.36 (s, 2H), 4.54-4.57 (m, 1H), 7.09 (t, 1H), 7.15 (d, 1H), 7.48 (d, 1H). MS m/z: 506.6 6

¹H NMR (D₂O) δ ppm: 1.40 (d, 3H), 1.45 (d, 3H), 1.58 (d, 6H), 2.05 (s, 3H), 2.99 (d, 3H), 3.08 (s, 3H), 3.10 (s, 3H), 3.42-3.49 (m, 1H), 3.61 (d, 1H), 3.74-3.78 (m, 2H), 3.96-4.07 (dd, 2H), 4.51-4.73 (m, 1H). MS m/z: 553.7 7

¹H NMR (D₂O) δ ppm: 1.22-1.25 (d, 3H), 1.37-1.39 (d, 3H), 1.73-1.76 (m, 1H), 2.71- 2.75 (m, 1H), 3.11 (s, 3H), 3.14 (s, 3H), 3.35-3.55 (m, 2H), 3.90-3.91 (d, 1H), 3.99- 4.02 (m, 2H), 4.20-4.23 (d, 1H), 4.79-4.85 (d, 1H). MS m/z: 497.6 8

¹H NMR (D₂O) δ ppm: 1.24 (d, 3H), 1.36 (d, 3H), 1.94 (m, 1H), 2.96 (s, 3H), 2.97 (m, 1H) 3.07 (m, 1H), 3.14 (m, 1H), 3.36-3.43 (m, 6H), 3.61 (m, 2H), 3.68 (m, 1H), 3.93 (t, 1H), 4.01 (m, 1H), 4.23 (d, 1H). MS m/z: 460.7 9

¹H NMR (D₂O) δ ppm: 1.13 (m, 6H), 1.92 (m, 1H), 3.01 (s, 3H), 3.02 (m, 1H), 3.08 (s, 3H), 3.08 (m, 1H) 3.34-3.41 (m, 1H), 3.81 (m, 1H), 3.92 (d, 1H), 3.94 (d, 2H), 3.96 (d, 6H), 4.75 (d, 2H), 7.23 (d, 1H), 7.47 (s, 1H) 7.61 (d, 1H). MS m/z: 582.6 10

¹H NMR (D₂O) δ ppm: 1.20-1.21 (t, 3H), 1.37-1.38 (d, 6H), 1.92-1.97 (m, 2H), 2.99- 3.00 (s, 3H), 3.23 (s, 3H), 3.21-3.26 (m, 2H), 3.42-3.44 (m, 2H), 3.67-3.74 (d, 1H), 3.76 (d, 1H), 3.92-3.95 (m, 2H), 4.02-4.03 (d, 1H), 4.23-4.25 (d, 1H). MS m/z: 474.6 11

¹H NMR (D₂O) δ ppm: 1.09-1.14 (m, 6H), 1.93 (d, 1H), 3.00 (s, 3H), 3.13 (s, 3H), 3.15 (d, 1H) 3.41 (d, 2H), 3.68 (t, 1H), 3.87 (t, 1H), 3.99 (d, 2H), 4.71 (d, 1H), 4.94 (d, 1H), 7.65-7.69 (t, 2H) 7.75 (d, 1H), 7.96 (d, 2H). MS m/z: 522.7 12

¹H NMR (D₂O) δ ppm: 1.09-1.10 (d, 3H), 1.14-1.16 (d, 3H), 1.92-1.94 (s, 1H), 3.00- 3.02 (d, 3H), 3.03 (m, 1H), 3.04-3.07 (s, 3H) 3.08 (m, 1H) 3.20-3.21 (t, 1H), 3.40-3.42 (d, 2H), 3.66-3.69 (m 1H), 3.70-3.85 (m, 1H), 4.10-4.04 (m, 2H), 7.37-7.41 (m, 2H), 7.97- 8.00 (m, 2H). MS m/z: 540.7 13

¹H NMR (D₂O) δ ppm: 1.22-1.23 (d, 3H), 1.37-1.39 (d, 3H), 1.99-2.01 (m, 2H), 3.00- 3.01 (s, 3H), 3.12 (s, 3H), 3.47-3.48 (m, 1H), 3.61-3.63 (d, 1H), 3.72-3.77 (d, 1H), 4.06- 4.17 (m, 1H), 4.19-4.20 (m, 1H), 4.47-4.50 (m, 3H). MS m/z: 513.1 (M − 1). 14

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.27-1.29 (d, 3H), 1.96-1.97 (m, 1H), 3.00 (s, 3H), 3.07 (s, 3H), 3.31 (m, 2H), 3.43-3.46 (m, 2H), 3.66 (s, 3H), 4.03 (m, 2H), 4.15- 4.17 (m, 2H), 4.53 (m, 1H). MS m/z: 439 (M − 1) 15

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.27-1.29 (d, 3H), 1.96-1.97 (m, 2H), 3.00 (s, 3H), 3.07 (s, 3H), 3.31 (m, 2H), 3.43-3.46 (m, 2H), 3.66 (s, 3H), 4.03 (m, 3H), 4.15- 4.17 (m, 2H), 4.53 (m, 1H). MS m/z: 455.7 (M + 1) 16

¹H NMR (D₂O) δ ppm: 1.19 (s, 3H), 1.31- 1.32 (d, 3H), 1.90-1.93 (m, 1H), 3.00-3.03 (s, 3H), 3.07-3.08 (s, 3H) 3.09 (m, 1H) 3.29- 3.33 (m, 2H), 3.33 (m, 1H), 3.64 (m, 1H), 3.66-3.69 (m, 1H), 3.86-3.89 (m, 1H), 3.99- 4.00 (m, 1H), 4.13-4.16 (m, 1H), 4.54 (s, 2H), 7.49 (m, 5H). MS m/z: 537.2 (M + 1) 17

¹H NMR (D₂O) δ ppm: 1.19 (d, 3H) 1.27 (d, 3H), 1.35 (m, 4H), 2.86 (m, 1H) 2.98 (s, 3H), 3.07 (s, 3H), 3.23 (m 1H), 3.34 (d, 2H), 3.54 (d, 1H), 3.89 (d, 1H), 4.12 (d, 2H), 4.40 (d, 2H). MS m/z: 519.1 (M + 1) 18

¹H NMR (D₂O) δ ppm: 0.8-0.9 (m, 3H), 1.28 (d, 3H) 1.34-1.39 (m, 3H), 1.42 (m, 2H), 1.68 (m, 2H) 1.8 (s, 3H), 2.70 (m, 1H), 2.88 (s, 3H), 2.97 (s, 3H), 3.12-3.18 (m, 4H), 3.37-3.39 (m, 2H), 4.10-4.15 (m, 2H). MS m/z: 503.2 (M + 1) 19

¹H NMR (D₂O) δ ppm: 1.25 (s, 3H), 1.39 (s, 3H), 1.62 (m, 1H), 1.92 (m, 1H), 2.62 (m, 1H), 3.2 (d, 1H), 3.40 (m, 2H) 3.50 (m, 1H), 3.60 (m, 1H), 3.7 (m, 1H), 3.90 (m, 1H) 4.10 (d, 1H), 4.20 (m, 1H). MS m/z: 552 (M + 1) 20

¹H NMR (D₂O) δ ppm: 1.25-1.42 (m, 9H), 1.96-2.01 (m, 3H), 2.97-3.02 (s, 6H), 3.12- 3.17 (m, 1H), 3.34-3.38 (m, 1H), 3.48-3.56 (m, 2H), 3.77 (m, 1H) 4.11 (m, 4H). MS m/z: 471.7 (M + 1). 21

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.27-1.29 (d, 3H), 1.96-1.97 (m, 1H), 2.35- 2.6 (m, 2H), 3.00 (s, 3H), 3.07 (s, 3H), 3.30 (s, 3H), 3.4 (m, 1H), 3.43-3.46 (d, 2H), 3.53 (m, 2H), 3.63 (m, 1H) 4.03 (d, 1H), 4.15- 4.17 (d, 1H), 4.53 (d, 1H). MS m/z: 455 (M + 1) 22

¹H NMR (D₂O) δ ppm: 1.12-1.18 (m, 12H) 2.90 (d, 5H), 2.9 (s, 3H), 3.27 (d, 2H), 3.41 (d, 1H) 3.49 (m, 1H), 3.88 (d, 1H), 4.05 (m, 2H), 4.63 (d, 1H), 4.70 (m, 1H). MS m/z: 469.1 (M + 1) 23

¹H NMR (D₂O) δ ppm: 1.10-1.12 (d, 3H), 1.21-1.23 (s, 3H), 1.75-1.81 (m, 1H), 2.39- 2.50 (s, 3H), 2.84 (m, 4H), 2.88-3.03 (m, 4H), 3.22-3.30 (m, 3H) 3.39-3.45 (m, 3H), 3.45-3.48 (m, 2H), 3.85-3.88 (t, 2H), 4.10- 4.45 (d, 1H), 4.50 (m, 1H). MS m/z: 516.1 (M + 1) 24

¹H NMR (D₂O) δ ppm: 1.21-1.23 (d, 3H), 1.33-1.34 (d, 3H), 1.41-1.43 (m, 2H), 1.94- 1.98 (m, 4H), 2.92-2.94 (dd, 2H), 3.01 (s, 3H), 3.24 (s, 3H) 3.34-3.36 (d, 2H), 3.41- 3.42 (dd, 2H), 3.62-3.65 (dd, 4H), 4.12-4.14 (d, 1H). MS m/z: 517.2 (M + 1) 25

¹H NMR (D₂O) δ ppm: 1.11-1.12 (d, 3H), 1.28-1.30 (d, 3H), 1.82 (m, 1H), 2.53 (s, 3H), 2.85 (s, 3H), 3.25 (d, 1H), 3.50-3.32 (s, 3H) 3.8 (m, 3H), 3.92 (d, 2H), 4.06-4.08 (d, 4H), 4.38 (d, 1H). MS m/z: 568 (M − 1). 26

¹H NMR (D₂O) δ ppm: 1.09-1.11 (d, 3H), 1.22-1.24 (d, 3H), 1.84-1.88 (m, 1H), 2.10 (s, 3H), 2.91 (s, 3H), 2.97 (s, 3H), 2.98 (m, 1H) 3.24 (m, 2H), 3.34-3.36 (m, 1H) 3.44-3.45 (d, 1H), 3.61-3.66 (m, 1H), 3.93-3.98 (m, 1H), 4.02-4.04 (m, 1H), 4.29-4.33 (m, 1H), 4.52 (s, 2H). MS m/z: 483.1 (M + 1). 27

¹H NMR (D₂O) δ ppm: 1.11-1.12 (d, 3H), 1.21-1.23 (d, 3H), 1.81-1.84 (m, 1H), 2.88 (m, 1H), 3.00-3.03 (d, 3H), 3.28 (d, 2H), 3.39-3.41 (d, 2H) 3.54 (m, 2H), 3.67 (m, 3H), 3.85-3.90 (m, 4H), 4.11-4.12 (d, 1H) 4.59 (m, 2H). MS m/z: 503.1 (M + 1). 28

¹H NMR (D₂O) δ ppm: 1.11-1.15 (d, 3H), 1.23-1.26 (d, 3H), 1.81 (m, 1H), 2.89 (s, 3H), 2.96 (s, 3H), 3.25-3.29 (m 3H), 3.49-3.51 (d, 2H) 3.60-3.62 (d, 1H), 3.68-3.71 (m, 1H), 3.89-3.90 (m, 1H), 4.04-4.06 (m, 1H), 4.25- 4.27 (m, 2H), 4.31-4.35 (d, 3H). MS m/z: 483.2 (M + 1). 29

¹H NMR (D₂O) δ ppm: 1.09-1.11 (d, 3H), 1.20 (s, 3H), 1.81 (s, 1H), 2.87 (s, 1H), 3.32 (m, 2H), 3.5 (m, 3H), 3.60 (s, 3H) 3.70-3.80 (s, 6H), 3.90 (m, 1H), 4.10 (d, 1H), 4.30 (t, 1H) 4.04-4.50 (m, 1H). MS m/z: 555.1 (M − 1). 30

¹H NMR (D₂O) δ ppm: 1.30-1.32 (d, 3H), 1.42-1.45 (d, 3H), 1.79 (m, 2H), 1.81-1.91 (m, 3H), 2.88-2.92 (t, 1H), 3.09-3.13 (t, 1H), 3.27-3.30 (d, 3H), 3.50-3.54 (t, 2H), 3.64- 3.67 (d, 2H) 3.91 (s, 1H), 4.01 (m, 3H), 4.10 (d, 1H), 4.40 (t, 1H) 4.42 (s, 1H). MS m/z: 571 (M + 1). 31

¹H NMR (D₂O) δ ppm: 1.01 (d, 9H), 1.1 (m, 1H), 1.30-1.31 (d, 3H), 1.32-1.35 (m, 3H), 2.88 (s, 3H), 3.00 (s, 3H), 3.08-3.12 (d, 1H), 3.35-3.37 (m, 3H) 3.59-3.60 (d, 1H), 3.74- 3.80 (d, 2H), 3.86-3.89 (m, 1H), 4.14-4.17 (d, 1H) 4.30-4.32 (d, 1H) 4.40-4.44 (m, 1H). MS m/z: 496.2 (M + 1). 32

¹H NMR (D₂O) δ ppm: 1.09-1.1 (d, 3H), 1.25-1.27 (d, 3H), 1.98 (m, 1H), 2.89 (s, 3H), 2.95 (s, 3H), 3.22-3.26 (d, 2H), 3.36-3.37 (d, 2H), 3.48-3.50 (dd, 1H), 3.61 (m, 1H) 3.91- 3.93 (d, 1H), 4.07-4.08 (m, 1H), 4.35-4.37 (d, 1H) 6.07-6.25 (m, 1H). MS m/z: 461.1 (M + 1). 33

¹H NMR (D₂O) δ ppm: 1.13 (d, 3H), 1.18 (d, 3H) 1.94 (m, 1H), 3.05 (m, 3H) 3.07 (s, 3H), 3.25 (m, 2H), 3.44 (m, 2H), 3.72 (m, 1H), 3.90 (m, 1H), 4.03 (m, 2H), 4.8 (m, 1H), 7.24 (t, 1H), 7.78 (d, 1H), 7.88 (d, 1H). MS m/z: 529 (M + 1). 34

¹H NMR (D₂O) δ ppm: 1.2 (d, 3H), 1.4 (s, 3H), 2.1 (m, 4H) 2.98 (m, 1H), 3.35 (q, 2H), 3.60 (m, 5H), 3.77 (m, 1H), 4.17 (d, 1H), 4.46 (m, 1H), 4.54 (m, 2H). MS m/z: 555 (M − 1). 35

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.37 (d, 3H), 1.83-1.85 (m, 1H), 1.91 (d, 1H), 2.69-2.76 (m, 4H), 2.9-2.94 (m, 1H), 3.31-3.36 (q, 2H), 3.52 (d, 1H), 3.36 (d, 1H), 3.78-3.80 (m, 2H) 3.90-3.91 (d, 2H), 4.13- 4.14 (d, 1H), 4.43 (t, 1H) 4.47 (t, 1H) 6.02- 6.28 (t, 1H). MS m/z: 519.1 (M + 1). 36

¹H NMR (D₂O) δ ppm: 1.21-1.29 (d, 6H), 1.99-2.06 (m, 1H), 3.01 (s, 6H), 3.08 (s, 3H), 3.7 (s, 3H), 3.36 (d, 1H), 3.47-3.54 (m, 2H), 3.77 (d, 1H) 4.12 (d, 2H). MS m/z: 457 (M + 1). 37

¹H NMR (D₂O) δ ppm: 1.07 (d, 3H), 1.35 (d, 3H), 1.74 (m, 3H), 2.07 (m, 4H), 2.55 (m, 1H), 2.91 (m, 1H), 3.24 (m, 1H), 3.35 (d, 1H), 3.44 (m, 1H), 3.58 (m, 1H) 3.66 (m, 1H), 3.81 (m, 2H), 4.02 (m, 1H), 4.17 (m, 1H) 4.32 (m, 1H), 4.47 (m, 1H), 6.02-6.28 (t, 1H). MS m/z: 545.2 (M + 1). 38

¹H NMR (D₂O) δ ppm- 1.20-1.21 (d, 3H), 1.35-1.35 (d, 3H), 1.70-1.76 (m, 1H), 1.91 (s, 1H), 2.71-2.73 (m, 1H), 3.34-3.35 (t, 2H), 3.38-3.40 (d, 1H), 3.39-3.40 (d, 1H), 3.41- 3.43 (m, 1H), 3.64-3.67 (d, 1H) 3.86-3.88 (m, 1H), 3.90 (d, 1H), 4.14-4.16 (d, 1H), 4.43-4.46 (d, 1H) 4.45-4.46 (m, 1H). MS m/z: 498.1 (M + 1). 39

¹H NMR (D₂O) δ ppm: 1.35 (d, 3H), 1.38-1.40 (d, 3H), 1.88-1.93 (m, 1H), 2.93- 2.99 (m, 1H), 3.15 (s, 3H), 3.46 (d, 2H), 3.52 (s, 3H), 3.57-3.59 (d, 1H), 3.78-3.93 (m, 4H), 3.99 (d, 1H) 4.00-4.16 (m, 4H), 4.18 (s, 2H), 4.32-4.34 (d, 1H), 4.64-4.69 (d, 2H), 4.81 (m, 1H). MS m/z: 573.2. 40

¹H NMR (D₂O) δ ppm: 1.08-1.1 (d, 3H), 1.28 (d, 3H) 1.82 (m, 1H), 2.88-2.89 (s, 2H), 2.97- 3.01 (s, 3H), 3.1-3.34 (m, 3H), 3.30-3.33 (d, 2H), 3.43-3.45 (d, 1H), 3.56-3.59 (m, 1H), 3.90-3.92 (d, 1H), 4.03-4.04 (d, 1H), 4.29- 4.31 (m, 1H), 4.62-4.66 (m, 2H). MS m/z: 493.1 (M + 1). 41

¹H NMR (D₂O) δ ppm: 1.08-1.1 (d, 3H), 1.28 (d, 3H) 1.82 (m, 1H), 2.88-2.89 (s, 2H), 2.97-3.01 (s, 3H), 3.1-3.34 (m, 3H), 3.30- 3.33 (d, 2H), 3.43-3.45 (d, 1H), 3.56-3.59 (m, 1H), 3.90-3.92 (d, 1H), 4.03-4.04 (d, 1H), 4.29-4.31 (m, 1H), 4.62-4.66 (m. 2H). MS m/z: 491.1 (M + 1). 42

¹H NMR (D₂O) δ ppm: 1.12 (s, 3H) 1.26 (s, 3H), 2.97 (m, 6H), 3.25 (t, 1H), 3.35 (d, 1H) 3.50 (d, 1H), 3.64 (m, 1H), 3.70 (d, 1H), 3.95 (m, 2H), 4.07 (m, 2H), 4.36 (m, 2H), 4.8 (m, 1H), 6.06 (t, 1H). MS m/z: 535 (M + 1). 43

¹H NMR (D₂O) δ ppm: 1.16 (d, 3H), 1.27 (d, 3H) 2.55 (s, 3H), 2.90-2.99 (s, 3H), 3.01 (m, 2H) 3.31 (m, 2H), 3.54 (m, 3H), 3.64 (m, 4H), 3.90 (m, 2H), 4.07 (m, 1H), 4.37 (m, 1H), 4.70 (m, 1H), 5.92-6.19 (t, 1H). MS m/z: 516.1 (M + 1). 44

¹H NMR (D₂O) δ ppm: 1.11-1.15 (d, 3H), 1.17-1.19 (d, 3H) 1.82-1.84 (m, 1H), 2.89- 2.92 (s, 3H), 2.98-3.01 (s, 3H), 3.23-3.25 (m, 2H), 3.48-3.50 (d, 1H), 3.56-3.58 (d, 1H), 3.61-3.68 (m, 3H), 3.91-3.94 (m, 1H), 4.04-4.06 (d, 1H), 4.60-4.62 (m, 1H), 4.7- 4.76 (m, 2H). MS m/z: 440.1 (M + 1). 45

¹H NMR (D₂O) δ ppm: 1.10 (d, 3H), 1.26 (d, 3H) 1.81 (d, 1H), 2.88 (m, 1H), 3.17 (s, 6H), 3.27 (m, 2H), 3.47 (m, 6H), 3.83-3.88 (m, 5H), 4.06 (d, 1H), 4.32-4.36 (m, 1H), 4.58-4.70 (m, 1H), 5.91-6.18 (t, 1H). MS m/z: 530.2. 46

¹H NMR (D₂O) δ ppm: 1.20 (d, 3H), 1.40 (d, 3H) 1.83 (m, 1H), 1.86 (m, 1H), 2.87-2.93 (m, 1H), 3.25 (m, 1H), 3.27 (m, 1H), 3.45 (s, 3H), 3.58-3.60 (m, 1H), 3.82-3.97 (m, 6H), 4.14-4.17 m, 2H), 4.30-4.33 (m, 1H), 4.47- 4.51 (m, 2H), 4.64-4.69 (d, 2H), 4.81 (m, 1H) 6.03-6.29 (t, 1H). MS m/z: 573.2. 47

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.31 (d, 3H) 1.97 (m, 1H), 2.98 (s, 3H), 3.04 (s, 3H), 3.34 (m, 1H), 3.43 (m, 1H), 3.53-3.54 (dd, 2H), 3.67-3.71 (m, 2H), 4.03 (t, 1H), 4.12-4.18 (m, 2H), 4.56-4.62 (m, 2H). MS m/z: 509 (M + 1) 48

¹H NMR (D₂O) δ ppm: 1.39 (d, 3H), 1.42- 1.43 (d, 3H) 1.92-1.96 (m, 1H), 2.99 (s, 3H), 3.05 (s, 3H), 3.24-3.25 (d, 1H), 3.40-3.43 (d, 1H), 3.57-3.67 (m, 3H), 3.97-4.05 (m, 2H), 4.58-4.59 (d, 1H), 4.61-4.68 (m, 1H), 8.81 (s, 1H). MS m/z: 410.1 (M + 1). 49

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.32-1.37 (d, 3H) 1.96-1.98 (m, 1H), 3.00 (m 1H), 3.37 (dd, 6H), 3.53-3.60 (d, 2H), 4.03 (d, 4H), 4.15-4.17 (d, 2H), 4.43-4.47 (m, 2H), 6.02-6.29 (m, 1H). MS m/z: 550.1. 50

¹H NMR (D₂O) δ ppm: 1.05-1.07 (s, 3H), 1.36-1.38 (d, 3H), 3.38 (t, 1H), 3.66 (d, 1H), 4.24 (m, 2H), 4.47 (m, 2H), 4.91-4.94 (d, 1H), 5.07 (d, 2H), 6.02-6.29 (m, 1H), 9.03 (d, 2H). MS m/z: 428.1 (M⁺). 51

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.40 (d, 3H), 1.92 (s, 2H), 3.00 (s, 3H), 3.07 (m, 3H), 3.10 (m, 3H), 3.30-3.40 (m, 3H), 3.53- 3.55 (d, 1H), 3.6 (m, 1H), 4.00-4.02 (m, 3H), 4.13-4.16 (d, 2H) 4.34-4.38 (m, 1H), 4.68 (m, 1H). MS m/z: 532.1 (M + 1). 52

¹H NMR (D₂O) δ ppm: 1.25 (d, 3H), 1.31 (d, 3H), 1.58-1.66 (m, 1H), 2.60-2.68 (m, 1H), 3.22-3.26 (m, 1H), 3.41-3.46 (m, 3H), 3.50- 3.52 (m, 2H), 3.71-3.79 (m, 1H), 3.94 (t, 1H), 4.13-4.15 (m, 2H), 4.44-4.64 (m, 2H). MS m/z: 546.1 (M + 1). 53

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.36 (d, 3H), 2.97 (s, 3H), 3.02 (s, 3H), 3.07-3.12 (s, 3H), 3.30-3.34 (m, 2H 3.36 (m, 1H), 3.57 (m, 1H), 3.48-3.51 (m, 1H) 3.80 (m, 1H), 4.00 (s, 3H), 4.15 (m, 2H) 4.53 (m, 1H) 4.68 (m, 1H). MS m/z: 482.1 (M + 1). 54

¹H NMR (D₂O) δ ppm: 1.30-1.32 (d, 3H), 1.42-1.44 (d, 3H), 2.64 (s, 3H), 2.84 (m, 2H), 2.98 (s, 3H), 3.02 (s, 3H), 3.07 (s, 3H), 3.24 (m, 1H), 3.48-3.51 (m, 1H), 3.86 (m, 1H), 3.98 (m, 3H), 4.26 (m, 1H), 4.53 (m, 1H). MS m/z: 482.1 (M + 1). 55

¹H NMR (D₂O) δ ppm: 1.16 (d, 3H), 1.29 (d, 3H), 1.41 (m, 1H) 2.00 (s, 2H), 2.99 (s, 3H), 3.06 (s, 3H), 3.42 (m, 2H), 3.75 (m, 2H), 3.90 (m, 1H), 4.06 (m, 1H), 4.46 (m, 1H). MS m/z: 410 (M − CO₂). 56

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.32 (d, 3H), 1.41 (m, 1H) 2.69 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.34 (m, 2H), 3.55 (m, 1H), 3.72-4.14 (m, 5H), 4.15 (m, 1H), 4.47 (m, 1H) 4.68 (m, 1H). MS m/z: 468.1 (M − 1). 57

¹H NMR (D₂O) δ ppm: 1.19 (d, 3H), 1.30- 1.32 (d, 3H) 2.70 (s, 6H) 2.87 (s, 3H), 2.95 (s, 3H), 3.23 (m, 2H), 3.37 (m, 1H), 3.45 (m, 1H), 3.77 (m, 1H), 3.80 (m, 2H), 4.13 (m, 1H), 4.40 (m, 1H), 4.63 (m, 1H). MS m/z: 490.1 (M + 1). 58

¹H NMR (D₂O) δ ppm: 1.19 (d, 3H), 1.35 (d, 3H), 1.97 (m, 4H) 2.16 (m, 1H), 2.25 (m, 1H), 3.00 (s, 3H), 3.06 (s, 3H), 3.21 (d, 2H), 3.39 (m, 3H), 3.45 (m, 2H), 3.70 (m, 2H), 3.90 (m, 2H). MS m/z: 481.1 (M + 1). 59

¹H NMR (D₂O) δ ppm: 1.09-1.11 (d, 3H) 1.19-1.20 (d, 3H), 1.38-1.42 (d, 3H), 1.70 (m, 1H) 2.81 (d, 1H), 2.96 (s, 6H), 3.17-3.20 (d 1H), 3.25-3.27 (m, 1H), 3.35-3.36 (m, 1H), 3.45-3.46 (d, 1H), 3.83-3.87 (d, 1H), 4.03-4.06 (d, 1H), 4.33-4.35 (m, 1H). MS m/z: 454.2 (M + 1). 60

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H) 1.39-1.41 (d, 3H), 1.95-1.99 (m, 1H) 2.97 (s, 3H), 3.06 (s, 3H), 3.39-3.47 (m, 2H), 3.68- 3.73 (d, 1H), 3.94-3.96 (d, 2H), 4.32-4.34 (d, 1H), 4.46-4.51 (m, 1H), 4.69 (d, 1H). MS m/z: 441.1 (M + 1). 61

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.27 (d, 3H), 1.87 (s, 3H) 1.97 (m, 1H), 3.00 (s, 3H), 3.02 (m, 1H), 3.07 (s, 3H), 3.09 (m, 1H) 3.35 (m, 1H), 3.45 (m, 1H), 3.60 (t, 1H), 4.02 (m, 1H), 4.16 (d, 1H), 4.42 (d, 1H), 4.47 (d, 1H). MS m/z: 475.1 (M + 1). 62

¹H NMR (D₂O) δ ppm: 1.29 (d, 3H) 1.49 (d, 3H), 1.97-2.06 (m, 2H) 2.97 (s, 3H), 3.04 (s, 3H), 3.45-3.49 (dd, 1H), 3.56 (m, 1H), 3.73-3.78 (m, 1H), 3.89 (m, 1H), 3.91 (m, 1H), 4.04-4.08 (m, 1H), 4.50 (m, 1H), 4.83 (m, 1H), 8.75 (s, 1H). MS m/z: 411.1 (M + 1). 63

¹H NMR (D₂O) δ ppm: 1.19 (d, 3H) 1.39 (d, 3H), 1.92-1.98 (m, 1H) 2.92 (s, 3H), 3.00 (s, 3H), 3.37 (m, 1H), 3.39-3.43 (dd, 2H), 3.46 (t, 1H), 3.67 (m, 1H), 3.69-3.72 (m, 1H), 4.04 (m, 1H), 4.46-4.49 (m, 1H), 4.81 (m, 1H). MS m/z: 517.1 (M + 1). 64

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H) 1.41 (d, 3H), 2.98 (s, 3H), 3.05 (s, 3H), 3.12-3.18 (m, 1H), 3.31 (d, 1H), 3.37-3.41 (m, 2H), 3.78 (m, 3H), 4.03 (d, 1H), 4.10 (t, 1H), 4.53 (t, 1H), 7.33 (s, 1H), 8.11 (d, 1H) 8.25 (d, 1H). MS m/z: 479.1 (M + 1). 65

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H) 1.41 (d, 3H), 2.98 (s, 3H), 3.05 (s, 3H), 3.12-3.18 (m, 1H), 3.31 (d, 1H), 3.37-3.41 (m, 2H), 3.78 (m, 3H), 4.03 (d, 1H), 4.10 (t, 1H), 4.53 (t, 1H), 7.33 (s, 1H), 8.11 (d, 1H) 8.25 (d, 1H). MS m/z: 543 (M + 1). 66

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H) 1.34-1.36 (d, 3H), 1.94-1.99 (m, 1H) 2.98- 3.00 (s, 6H), 3.10 (s, 6H), 3.35-3.40 (m, 1H), 3.40-3.47 (dd, 1H), 3.610-3.63 (d, 1H), 3.72-3.77 (dd, 1H), 4.01-4.06 (m, 1H), 4.18- 4.21 (m, 1H), 4.47-4.50 (m, 1H). MS m/z: 482.1 (M + 1). 67

¹H NMR (D₂O) δ ppm: 1.26 (d, 6H) 1.33 (d, 3H), 1.39 (d, 3H), 1.56 (m, 1H), 1.68 (m, 2H), 2.94 (m, 1H), 2.98 (s, 3H), 3.05 (s, 3H), 3.19 (m, 1H), 3.48 (d, 1H), 3.57 (dd, 1H), 3.67 (m, 1H), 3.94-3.98 (m, 1H), 4.02 (m, 1H), 4.12-4.17 (m, 1H), 4.38 (t, 1H), 4.49-4.52 (dd, 1H), 5.10 (dd, 1H). MS m/z: 497 (M + 1). 68

¹H NMR (DMSO-d₆) δ ppm: 1.12 (d, 3H) 1.19 (d, 3H), 1.39 (d, 3H), 1.70 (m, 1H) 2.8 (s, 3H), 2.95 (s, 3H), 3.18-3.24 (dd 3H), 3.38-3.43 (d, 3H), 3.6 (dd, 1H), 3.82-3.87 (m, 4H), 4.02-4.03 (d, 1H), 4.28-4.32 (m, 1H), 4.43 (m, 1H) 4.6 (d, 1H). MS m/z: 454.1 (M + 1). 69

¹H NMR (DMSO-d₆) δ ppm: 1.24 (d, 3H) 1.28-1.29 (d, 3H), 1.98 (m, 1H), 2.99 (s, 3H) 3.03 (s, 3H), 3.07-3.12 (dd, 2H), 3.35-3.40 (dd 4H), 3.44-3.46 (d, 1H), 3.70 (dd, 4H), 3.80-3.82 (d, 2H), 3.93-3.95 (d, 1H), 4.15- 4.19 (m, 1H), 4.22-4.26 (m, 2H). MS m/z: 496 (M + 1). 70

¹H NMR (D₂O) δ ppm: 1.15 (d, 3H), 1.29 (d, 3H), 2.95 (s, 3H), 3.00 (s, 3H) 3.04 (s, 3H), 3.27 (m, 1H), 3.36 (m, 1H), 3.73 (m, 2H), 3.86 (s, 2H), 4.01 (m, 1H), 4.07-4.11 (m, 1H), 4.47 (m, 2H), 4.61 (m, 2H). MS m/z: 518.1 (M + 1). 71

¹H NMR (D₂O) δ ppm: 0.97 (d, 3H), 1.18 (d, 3H), 2.97 (s, 3H), 3.08 (s, 3H) 3.08-3.13 (dd, 2H), 3.20-3.25 (dd, 2H), 3.25 (m, 2H), 3.39-3.44 (dd, 1H), 3.53 (m, 2H), 3.66-3.70 (m, 2H), 4.06-4.13 (m, 1H), 4.29 (m, 1H), 7.23-7.42 (m, 5H). MS m/z: 530.2 (M + 1). 72

¹H NMR (D₂O) δ ppm: 1.06-1.08 (d, 3H) 1.26 (d, 3H), 2.95 (s, 3H), 3.03 (s, 3H), 3.08 (m, 2H), 3.11-3.13 (d, 2H), 3.16-3.20 (m, 2H), 3.21 (d, 1H), 3.40 (m, 2H), 3.51 (d, 2H), 4.21-4.22 (m, 1H), 4.54 (m, 1H), 7.23- 7.42 (m, 5H). MS m/z: 530.2 (M + 1). 73

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H) 1.34- 1.35 (m, 9H), 1.94-1.98 (m, 1H), 3.00 (s, 3H), 3.06 (d, 3H), 3.32-3.34 m, 2H), 3.36 (d, 2H), 3.60-3.62 (d, 1H), 3.70-3.72 (m, 1H), 4.03 (m, 1H), 4.14-4.17 (d, 1H), 4.42-4.22 (m, 1H), 5.13-5.16 (t, 1H). MS m/z: 495.1 (M + 1). 74

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H) 1.36-1.38 (d, 3H), 1.93-2.0 (d, 1H), 3.00 (s, 1H), 3.08 (s, 3H), 3.32-3.35 (q, 1H), 3.44- 3.47 (q, 1H), 3.60-3.62 (d, 1H), 3.72-3.76 (q, 1H), 3.90 (s, 3H), 4.01 (t, 1H), 4.15-4.17 (d, 1H), 4.42-4.46 (t, 1H). MS m/z: 469.1 (M + 1). 75

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.36-1.37 (d, 3H) 1.92-1.95 (m, 1H), 2.84 (s, 3H), 3.03 (s, 3H), 3.32 (s, 3H), 3.33 (m, 2H), 3.41 (dd, 1H), 3.60-3.62 (d, 1H), 3.68- 3.71 (t, 1H), 4.02 (t, 1H), 4.13 (d, 1H), 4.39- 4.41 (t, 1H), 4.76-4.81 (d, 1H). MS m/z: 468.1 (M + 1). 76

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.37 (d, 3H) 2.09-2.13 (m, 3H), 3.02 (m, 1H), 3.35-3.37 (dd, 2H), 3.57-3.60 (d, 2H), 3.64-3.65 (d, 2H), 3.75 (d, 2H), 4.09 (m, 1H), 4.15-4.16 (d, 2H), 4.43-4.47 (m, 2H), 4.74 (m, 1H), 6.02-6.29 (m, 1H). MS m/z: 537.1 (M + 1). 77

¹H NMR (D₂O) δ ppm: 1.14-1.21 (d, 3H), 1.35-1.37 (d, 3H) 2.01-2.09 (m, 2H), 3.01 (m, 1H), 3.35 (m, 3H), 3.42-3.46 (t, 3H), 3.47-3.70 (dd, 3H), 4.01 (t, 1H), 4.1-4.19 (d, 1H), 4.45-4.47 (t, 1H), 4.70-4.81 (q, 2H), 6.02-6.29 (t, 1H). MS m/z: 503.1 (M + 1). 78

¹H NMR (D₂O) δ ppm: 1.1-1.19 (d, 3H) 1.41-1.43 (d, 3H), 3.00 (s, 3H), 3.08 (s, 3H), 3.25 (s, 2H), 3.33-3.35 (m, 2H), 3.41-3.46 (dd, 2H), 3.54-3.56 (d, 2H), 4.01-4.04 (t, 2H), 4.15-4.19 (d, 2H), 3.22-4.26 (m, 2H), 4.40- 4.44 (m, 1H). MS m/z: 503.1 (M + 1). 79

¹H NMR (D₂O) δ ppm: 1.27 (d, 3H) 1.33 (m, 3H), 1.65-1.74 (m, 6H), 2.99 (s, 3H), 3.09 (d, 3H), 3.31-3.42 (m, 2H), 3.55-3.56 (m, 2H), 3.62-3.63 (dd, 2H), 4.01 (m, 2H), 4.06- 4.13 (d, 2H), 4.41-4.44 (m, 2H), 4.68-4.70 (m, 2H). MS m/z: 499.2 (M + 1). 80

¹H NMR (D₂O) δ ppm: 1.11 (d, 3H), 1.20- 1.22 (d, 3H), 1.49 (m, 1H), 2.24 (m, 4H), 2.72 (m, 1H), 3.04-3.17 (m, 2H), 3.30 (s, 3H), 3.38 (m, 2H), 3.56-3.61 (m, 5), 3.79 (m, 2H), 4.13-4.15 (m, 1H), 4.43-4.46 (m, 1H), 4.73 (m, 1H), 6.02-6.29 (m, 1H). MS m/z: 487.2. 81

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.37 (d, 3H), 1.51 (d, 1H), 2.08 (d, 4H), 2.67 (t, 1H), 3.06-3.13 (d, 1H), 3.40 (m, 8H), 3.73 (d, 1H), 3.83 (d, 2H), 4.15 (t, 1H), 4.17-4.54 (t, 1H), 6.02-6.29 (t, 1H). MS m/z: 473.2 (M + 1). 82

¹H NMR (D₂O) δ ppm: 1.05-1.12 (d, 3H), 1.15 (d, 3H), 1.19 (d, 3H), 1.31 (d, 3H), 1.96-1.99 (m, 2H), 2.94-3.07 (s, 1H), 3.27- 3.29 (m, 1H), 3.31 (m, 1H), 3.59-3.63 (d, 2H), 3.84-3.85 (d, 2H), 3.93-4.02 (d, 2H), 4.35 (m, 1H), 4.79 (m, 1H). MS m/z: 523.1 (M + 1). 83

¹H NMR (D₂O) δ ppm: 0.96-0.98 (d, 6H), 1.19 (d, 3H), 1.38 (d, 3H), 1.90-1.92 (d, 2H), 1.99 (m, 1H), 3.02-3.03 (s, 6H), 3.26-3.29 (m, 1H), 3.31 (d, 1H), 3.57-3.59 (m, 2H), 4.00-4.06 (d, 2H), 4.14 (m, 2H), 4.65-4.67 (m, 1H), 4.80-4.86 (d, 1H). MS m/z: 517.2 (M + 1). 84

¹H NMR (D₂O) δ ppm: 1.21-1.28 (d, 3H) 1.33-1.35 (d, 3H), 1.50-1.52 (d, 3H), 3.00 (s, 3H), 3.07 (s, 3H), 3.39-3.42 (m, 2H), 3.56-3.58 (d, 2H), 3.65-3.66 (m, 2H), 4.00 (d, 2H), 4.14 (t, 2H), 4.42 (d, 1H). MS m/z: 457.2 (M + 1). 85

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H) 1.37 (d, 3H), 2.73 (m, 2H) 3.13 (s, 3H), 3.36 (m, 3H), 3.60 (m, 3H), 3.85 (d, 2H), 4.05 (d, 1H), 4.17 (t, 1H), 4.45 (d, 1H), 6.02-6.29 (t, 1H). MS m/z: 497.1 (M + 1). 86

¹H NMR (D₂O) δ ppm: 1.21-1.25 (d, 3H) 1.30-1.32 (d, 3H), 2.73 (s, 3H), 3.13 (s, 3H), 3.34 (m, 4H), 3.60-3.61 (m, 2H), 3.97 (m, 2H), 4.16-4.17 (d, 2H), 4.44-4.47 (t, 1H), 4.61-4.80 (d, 1H). 87

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H) 1.38-1.40 (d, 3H), 3.00-3.07 (s, 3H), 3.35 (s, 3H), 3.35-3.42 (m, 2H), 3.60-3.62 (m, 2H), 4.06 (m, 2H), 4.16-4.18 (m, 2H), 4.48 (m, 1H), 4.71-4.80 (m, 1H). 88

¹H NMR (D₂O) δ ppm: 1.05-1.11 (d, 3H), 1.21 (d, 3H), 3.32-3.34 (d, 1H) 3.61-3.63 (d, 2H), 4.21-4.23 (m, 1H), 4.43-4.45 (m, 1H), 5.98-6.25 (t, 1H), 7.86 (d, 1H), 8.22 (s, 1H), 8.6 (d, 1H). MS m/z: 481.2 (M + 1). 89

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.30-1.37 (d, 3H) 2.64 (m, 1H), 2.92 (s, 6H), 3.32 (dd, 2H), 3.46 (m, 1H), 3.58-3.59 (dd, 2H), 3.73-3.74 (d, 2H), 3.97 (m, 2H), 4.13- 4.16 (d, 2H), 4.43-4.47 (t, 1H), 6.02-6.29 (t, 1H). MS m/z: 490.2 (M + 1). 90

¹H NMR (D₂O) δ ppm: 1.27 (d, 3H), 1.35- 1.37 (d, 3H) 2.57-2.69 (dd, 1H) 2.70-2.77 (dd, 2H), 2.82-2.88 (m, 3H) 3.34-3.38 (dd, 3H), 3.58-3.60 (d, 2H), 3.63-3.64 (m 2H), 3.77 (m, 4H), 4.14 (d, 2H), 4.42 (t, 1H), 6.02-6.29 (t, 1H). MS m/z: 489.2 (M + 1). 91

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.32- 1.41 (d, 3H), 2.66 (s, 2H) 3.00 (s, 3H), 3.07 (s, 3H), 3.47 (d, 1H), 3.53 (m, 2H), 3.55-3.60 (d, 2H), 3.72 (s, 6H), 3.81-3.84 (d, 2H), 4.16 (m, 2H), 4.36-4.38 (m, 1H). MS m/z: 533.1 (M + 1). 92

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.27-1.29 (d, 3H), 2.93-2.94 (m, 1H), 3.11- 3.14 (dd, 2H) 3.17-3.19 (dd, 1H), 3.59-3.60 (d, 1H) 4.13-4.16 (m, 1H), 4.43-4.47 (t, 1H) 6.02-6.29 (t, 1H). MS m/z: 364.1 (M + 1). 93

¹H NMR (D₂O) δ ppm: 1.00-1.02 (d, 3H), 1.19-1.22 (d, 3H), 1.36 (d, 9H), 2.67 (d, 1H), 3.03-3.06 (m, 2H) 3.24 (m, 1H), 3.77- 3.80 (d, 1H) 4.16-4.18 (t, 1H), 6.08-6.35 (t, 1H) 7.12-7.13 (d, 1H), 8.90-8.92 (d, 1H). MS m/z: 462 (M − 1). 94

¹H NMR (D₂O) δ ppm: 1.09-1.19 (d, 3H), 1.33-1.35 (d, 3H), 3.63-3.64 (m, 1H) 3.64- 3.65 (d, 1H), 4.22-4.23 (m, 1H), 4.25 (s, 3H), 4.36 (d, 1H), 5.98-6.11 (t, 1H), 8.37-8.39 (dd, 2H), 8.6 (d, 1H), 8.75-8.77 (dd, 2H). MS m/z: 495.1.

Example 95: (4R,5S,6R)-3-((3R,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-6-((S)-1-(2-(methylamino) acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Step-1: (4R,5R,6R)-4-nitrobenzyl 3-(diphenoxyphosphoryloxy)-4-methyl-6-((R)-1-(2-(methyl((4-nitrobenzyloxy)carbonyl)amino)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

Rhodium octanoate (0.1 g, 0.128 mmoles) was added to a solution of (R)-4-nitrobenzyl 2-diazo-4-((2R,3R)-3-((R)-1-(2-(methyl((4-nitrobenzyloxy)carbonyl)amino) acetamido)ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate (3 g, 4.69 mmoles) in acetone (60 mL) and heated to reflux for 1.5 hours. The reaction mixture was cooled to −50 to −40° C. and diphenyl chlorophosphate (1.64 g, 6.1 mmoles), diisopropylethylamine (1.1 mL, 6.71 mmoles) and dimethylaminopyridine (0.05 g, 0.41 mmoles) were added successively and continued stirring for a period of 1 hour at −10° C. The reaction mixture was treated with 0.5 M phosphate buffer (pH 7.4) and extracted with ethyl acetate (150 mL). The organic layer was separated and washed with water and brine. After drying over sodium sulphate the organic layer was evaporated to obtain the oily product. The crude product on purification by column chromatography yields the title compound as a pale yellow solid. (2 g, 49.6%).

Step-2: (4R,5S,6R)-4-nitrobenzyl4-methyl-6-((R)-1-(2-(methyl((4-nitrobenzyloxy) carbonyl)amino)acetamido)ethyl)-3-((3S,5S)-1-((4-nitrobenzyloxy)carbonyl)-5-((R)-3-((4-nitrobenzyloxy)carbonylamino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

A cooled solution (0° C.) of (4R,5R,6R)-4-nitrobenzyl3-(diphenoxyphosphoryloxy)-4-methyl-6-((R)-1-(2-(methyl((4-nitrobenzyloxy)carbonyl)amino)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (5 g, 8.72 mmoles) and (2S,4R)-4-nitrobenzyl4-mercapto-2-((R)-3-((4-nitrobenzyloxy) carbonylamino)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate (7.5 g, 8.72 mmoles) in acetonitrile was degassed using nitrogen for 10 minutes and N,N-diisopropylethylamine (2.2 mL; 13.3 mM) was added and degassed using nitrogen for a further period of 10 minutes. The reaction mixture was stirred for 3 hours at 0° C. under nitrogen. The reaction mixture was treated with 0.5 M phosphate buffer (pH 7.4) and extracted with EtOAc (150 mL). The organic layer was separated and washed with water and brine. After drying over sodium sulphate the organic layer was evaporated to obtain the oily product. The crude product on purification by column chromatography (15-17% methanol in dichloromethane) yields the title compound as an off-white solid. (6.2 g, 60%)

Step-3: (4R,5 S,6R)-3-((3R,5 S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-6-((R)-1-(2-(methylamino)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5S,6R)-4-nitrobenzyl4-methyl-6-((R)-1-(2-(methyl((4-nitrobenzyloxy) carbonyl)amino)acetamido)ethyl)-3-((3 S, 5S)-1-(4-nitrobenzyloxy)carbonyl)-5-((R)3-((4-nitrobenzyloxy)carbonylamino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (0.5 g) in 20 mL of tetrahydrofuran:water (2:1) mixture and suspension of Pd/C (2 g) was hydrogenated for a period of 1.5 hours. The reaction mixture was filtered over celite and washed with 30 mL of tetrahydrofuran:water (2:1) mixture. The filtrate was washed with EtOAc (30 mL×6) The aqueous layer was treated with charcoal (1 g) and filtered. The filtrate was lyophilized to yield the title compound (0.1 g, 50%). ¹H NMR (D₂O) −1.67-1.08 (d, 3H), 1.20-1.29 (d, 3H), 1.92 (m, 1H), 2.12 (m, 21H), 2.46 (m, 21H), 2.76 (s, 3H), 2.92 (m, 1H), 3.34-3.38 (m, 2H), 3.40 (d, 3H), 3.60-3.64 (d, 2H), 3.76-3.78 (d, 3H), 3.93-3.96 (m, 1H), 4.02 (m, 1H), 4.48 (m, 1H). MS m/z: 493.6 (M-1).

Examples 96, 97, 100-135, 137-145, 147-166, 168-176, 178-186, 188-200, 202, 205-206, 209-231, 235-238, 241-273, 275-292, 294-297, 299-312, 314-318, 320-325, 329-361 and 363-368 were prepared by treating the compound of formula (10) with appropriate R^(A)COOH according to the procedure given in the preparations 12, 16 and 17, followed by the procedure given in Example 1.

Examples 136, 201, 203, 204, 239, 240 and 362 were prepared by following the procedure provided in preparation 13.

Example 187 was prepared by following the procedure provided in preparation 19.

Example 98 and 99 were prepared by following the procedure given in preparation 23.

Examples 146, 167, 177, 207, 208, 232-234 were prepared by following the procedure described in the preparation 20 using appropriate alkynes (cf. Scheme 2a).

Example 274 and 293 were prepared by following the procedure provided in preparation 24.

Ex- am- ples Structure Analytical Data  96

¹H NMR (D₂O) δ ppm: 1.15 (d, 3H), 1.34 (d, 3H), 3.30 (t, 1H), 3.54 (d, 1H), 4.02 (m, 2H), 4.19 (m, 2H), 6.14 (t, 1H), 7.46 (t, 1H), 7.92 (d, 1H), 8.52 (d, 2H). MS m/z: 412.4 (M + 1)  97

¹H NMR (D₂O) δ ppm: 1.15 (d, 3H), 1.34 (d, 3H), 3.26 (t, 1H), 3.54 (d, 1H), 3.95 (d, 1H), 4.02 (d, 1H), 4.18 (d, 1H), 4.40 (t, 1H), 6.14 (t, 1H), 7.47 (d, 2H), 8.47 (d, 2H). MS m/z: 412.4 (M + 1)  98

¹H NMR (D₂O) δ ppm: 1.24 (d, 3H), 1.29 (d, 3H), 1.96 (m, 2H), 2.99 (d, 3H), 3.07 (s, 3H), 3.37 (m, 3H), 3.48 (d, 2H), 3.54 (d, 1H), 4.06 (m, 2H), 4.24 (m, 2H), 4.26 (m, 3H). MS m/z: 469.5 (M + 1)  99

¹H NMR (D₂O) δ ppm: 1.52 (t, 3H), 1.53 (t, 3H), 1.98 (m, 2H), 3.07 (d, 3H), 3.08 (d, 3H), 3.4-3.5 (m, 2 H), 3.5 (m, 1H), 3.55 (d, 2H), 3.72 (d, 1H), 3.79 (m, 1H), 4.65 (m, 1H), 4.29 (d, 2H). MS m/z: 439 (M − 1) 100

¹H NMR (D₂O) δ ppm: 1.71 (t, 3H), 1.75 (t, 3H), 1.92 (t, 1H), 2.29 (s, 1H), 2.80-2.89 (m, 6H), 2.98 (d, 2H), 3.07 (s, 3H), 3.09 (d, 3H), 3.20 (d, 1H), 3.58 (d, 1H), 3.72 (d, 1H), 4.16 (d, 2H), 4.36-4.39 (d, 1H), 4.45 (t, 1H), 4.82 (t, 1H). MS m/z: 466.6 (M − 1) 101

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.37 (d, 3H), 2.08 (d, 1H), 2.81 (s, 3H), 2.90 (t, 1H), 3.36 (m, 2H), 3.60 (d, 1H), 3.71 (m, 1H), 3.99 (s, 1H), 4.17 (d, 1H), 4.39-4.47 (dd, 2H), 6.16 (t, 1H): MS m/z: 447.5 (M + 1) 102

¹H NMR (D₂O) δ ppm: 1.28 (d, 3H), 1.37 (d, 3H), 1.47 (s, 1H), 2.03 (t, 1H), 2.97 (d, 6H), 2.96 (t, 1H), 2.97 (t, 3H), 3.22 (d, 2H), 3.67 (d, 2H), 3.91 (m, 1H), 4.16 (d, 2H), 4.45 (s, 1H), 6.16 (t, 1H). MS m/z: 504.6 (M + 1) 103

¹H NMR (D₂O) δ ppm: 1.20 (d, 3H), 1.38 (d, 3H), 1.35 (d, 1H), 2.09-2.21 (dd, 1H), 2.19-2.49 (dd, 1H), 2.81-2.87 (m, 1H), 3.18 (m, 1H), 3.36 (dd, 2H), 3.59 (d, 2H), 3.77 (m, 2H), 3.78-3.88 (m, 2H), 3.98 (m, 1H), 4.14-4.23 (m, 2H), 4.45 (t, 1H), 6.16 (t, 1H). MS m/z: 502.5 (M + 1) 104

¹H NMR (D₂O) δ ppm: 1.2 (d, 3H), 1.37 (d, 3H), 2.08 (d, 1H), 2.91 (m, 1H), 3.36 (d, 2H), 3.41 (s, 3H), 3.6 (d, 1H), 3.69 (s, 3H), 3.98 (s, 1H), 4.17 (d, 1H), 4.44-4.47 (dd, 1H), 4.81 (t, 1H), 6.16 (t, 1H). MS m/z: 477.5 (M + 1) 105

¹H NMR (D₂O) δ ppm: 1.24 (d, 3H), 1.35 (m, 1H), 1.49 (d, 3H), 2.37 (m, 1H), 2.85 (m, 1H), 3.36 (m, 1H), 3.58 (d, 1H), 3.60 (q, 1H), 3.76 (s, 3H), 3.96 (t, 1H), 3.98 (d, 1H), 4.28 (t, 1H), 4.45 (t, 1H), 6.16 (t, 1H). MS m/z: 516.6 (M + 1) 106

¹H NMR (D₂O) δ ppm: 1.36 (d, 3H), 1.82 (d, 3H), 1.92 (s, 1H), 2.11 (s, 1H), 2.18 (d, 1H), 2.45-2.55 (m, 2H), 2.77 (s, 2H), 2.89 (d, 1H), 3.39 (m, 1H), 3.65 (d, 3H), 3.74- 3.79 (m, 4H), 4.45 (d, 2H), 4.75 (d, 1H), 4.81 (d, 1H), 6.16 (t, 1H). MS m/z: 515.58 (M + 1) 107

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.38 (3, 3H), 1.92 (m, 1H), 2.09 (m, 1H), 2.54 (m, 1H), 2.78 (s, 2H), 2.83 (s, 3H), 3.26 (dd, 1H), 3.59 (d, 2H), 3.75-3.82 (m, 4H), 3.94- 4.14 (m, 4H), 4.41 (d, 2H), 4.45-4.74 (m, 2H) 6.16 (t, 1H). MS m/z: 530.6 (M + 1) 108

¹H NMR (D₂O) δ ppm: 1.23 (d, 3H), 1.47 (d, 3H), 2.99 (s, 3H), 3.02 (m, 1H), 3.10 (s, 3H), 3.36 (m, 1H), 3.37-3.53 (m, 2H), 3.59 (m, 1H), 4.00 (m, 1H), 4.09-4.18 (m, 2H), 4.46 (m, 2H), 5.20 (m, 1H), 6.02 (t, 1H). MS m/z: 488.5 (M + 1) 109

¹H NMR (D₂O) δ ppm: 1.07 (d, 3H), 1.24- 1.34 (m, 6H), 1.85-1.92 (m, 2H), 2.15-2.30 (m, 2H), 2.92 (m, 2H), 3.25 (m, 1H), 3.35 (m, 1H), 3.57 (m, 1H), 3.65 (m, 2H), 3.83 (d, 1H), 3.92 (d, 1H), 4.16 (m, 2H), 4.39 (m, 2H), 4.42-4.92 (m, 2H). MS m/z: 524.60 (M + 1) 110

¹H NMR (D₂O) δ ppm: 1.32 (d, 3H), 1.38 (d, 3H), 1.92 (d, 1H), 2.00 (dd, 1H), 2.34 (m, 1H), 2.97 (m, 1H), 3.15 (s, 3H), 3.36 (s, 2H), 3.54 (m, 1H), 3.59 (d, 3H), 3.86 (d, 1H), 3.97 (t, 1H), 4.17 (d, 1H), 4.43-4.80 (m, 2H), 4.80 (t, 2H), 6.16 (t, 1H). MS m/z: 580.64 (M + 1) 111

¹H NMR (D₂O) δ ppm: 1.27 (d, 3H), 1.33 (d, 3H), 2.36-2.43 (m, 2H), 2.82 (m, 1H), 3.33 (m, 1H), 3.39 (m, 2H), 3.56-3.58 (m, 2H), 3.71 (m, 1H), 3.99 (m, 1H), 4.13-4.16 (m, 2H), 4.39-4.46 (m, 2H), 4.91 (s, 2H), 6.02 (t, 1H) 7.47 (d, 2H), 7.38-7.45 (m, 3H). MS m/z: 610.64 (M + 1) 112

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.26 (d, 3H), 1.87 (m, 1H), 2.76 (s, 3H), 2.99 (s, 3H), 3.09 (s, 3H), 3.59 (s, 2H), 3.78 (d, 3H), 3.85 (m, 2H), 3.99 (t, 1H), 4.16 (d, 1H), 4.47 (t, 1H), 4.61 (t, 1H). MS m/z: 452.5 (M − 1) 113

¹H NMR (D₂O) δ ppm: 0.92-0.99 (m, 6H), 1.17 (d, 3H), 1.22 (d, 1H), 1.28 (d, 2H), 1.69-1.80 (m, 3H), 2.99 (s, 3H), 3.07 (s, 3H), 3.33 (dd, 1H), 3.43 (d, 2H), 3.52 (m, 2H), 3.54 (m, 2H), 4.14 (m, 2H), 4.57 (m, 2H). MS m/z: 496.64 (M + 1) 114

¹H NMR (D₂O) δ ppm: 1.69 (d, 3H), 1.27 (d, 3H), 1.90-1.98 (m, 1H), 2.59 (d, 2H), 2.82 (s, 4H), 2.96 (s, 3H), 3.36-3.48 (m, 3H), 3.62 (m, 1H), 3.65 (m, 1H), 4.04 (m, 1H), 4.33 (m, 2H), 4.70 (m, 2H), 6.16 (t, 1H). MS m/z: 515.6 (M + 1) 115

¹H NMR (D₂O) δ ppm: 1.12 (d, 3H), 1.92 (d, 3H), 2.22 (m, 1H), 2.23-2.69 (m, 2H), 2.73 (m, 1H), 3.13-3.20 (s, 3H), 3.13-3.19 (m, 2H), 3.39-3.52 (s, 3H), 3.79 (m, 1H), 3.82-3.96 (m, 2H), 4.21-4.61 (m, 2H), 6.14 (t, 1H). MS m/z: 534.6 (M + 1) 116

¹H NMR (D₂O) δ ppm: 1.08 (3, 3H), 1.12 (d, 3H), 2.51-2.54 (m, 2H), 2.82 (m, 2H), 3.18 (d, 2H), 3.18-3.37 (m, 3H), 3.48-3.66 (m, 4H), 3.67 (m, 2H), 4.15 (d, 2H), 4.47 (m, 1H), 6.16 (t, 1H). MS m/z: 548.5 (M + 1) 117

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.27 (d, 3H), 1.92-1.98 (m, 2H), 2.09 (m, 1H), 2.82 (s, 6H) 3.05 (d, 1H), 3.36 (m, 1H), 3.37-3.47 (m, 3H), 3.61 (d, 2H), 3.83 (m, 2H), 4.18 (d, 2H), 4.46 (m, 2H), 4.82 (d, 1H), 6.16 (t, 1H). MS m/z: 609.6 (M + 1) 118

¹H NMR (D₂O) δ ppm: 1.38 (d, 3H), 1.47 (d, 3H), 1.89-1.99 (m, 2H), 1.99-2.29 (m, 1H), 2.89 (d, 6H), 3.34-3.40 (m, 3H), 3.59- 3.67 (dd, 4H), 3.75 (m, 2H), 3.85 (d, 1H), 4.18 (d, 1H), 4.47 (m, 1H), 4.48 (m, 1H), 4.88 (m, 1H), 6.16 (t, 1H). MS m/z: 573.6 (M + 1) 119

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.42 (d, 3H), 1.98 (m, 1H), 2.72-2.34 (dd, 1H), 2.97 (m, 1H), 3.36-3.49 (m, 3H), 3.51 (d, 1H), 3.62-3.74 (m, 2H), 3.80 (m, 2H), 3.85 (m, 1H), 3.90 (m, 1H), 4.17 (d, 2H), 4.81 (m, 4H), 6.16 (t, 1H). MS m/z: 569.6 (M + 1) 120

¹H NMR (D₂O) δ ppm: 1.06 (d, 3H), 1.22 (d, 3H), 1.80 (m, 1H), 2.71 (m, 1H), 2.89 (m, 1H), 3.25-3.36 (m, 5H), 3.44 (m, 1H), 3.58 (d, 1H), 3.64 (m, 1H), 3.84-3.91 (m, 5H), 4.15 (d, 1H), 4.45 (d, 1H), 6.02 (t, 1H). MS m/z: 502.6 (M + 1) 121

¹H NMR (D₂O) δ ppm: 0.99 (d, 3H), 1.09 (d, 3H), 1.36 (d, 3H), 1.96 (dd, 1H), 2.21 (dd, 1H), 2.78 (d, 1H), 3.18 (m, 3H), 3.18- 3.31 (m, 3H), 3.52 (t, 3H), 3.66 (t, 1H), 4.21 (d, 1H), 4.52 (m, 2H), 6.05 (t, 1H). MS m/z: 559.60 (M + 1) 122

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.31 (d, 3H), 1.36 (d, 2H), 1.73 (m, 1H), 1.93 (d, 1H), 2.2 (d, 1H), 3.17-3.22 (q, 2H), 3.31- 3.36 (q, 2H), 3.39-3.47 (m, 2H), 3.59 (m, 1H), 3.72-4.15 (m, 2H), 4.16 (m, 1H), 4.18 (m, 1H), 4.44 (m, 1H), 4.47 (m 2H), 6.16 (t, 1H). MS m/z: 516.6 (M + 1) 123

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.38 (3, 3H), 2.54 (m, 1H), 2.78 (s, 3H), 2.83 (s, 3H), 3.26 (dd, 1H), 3.59 (d, 2H), 3.75-3.82 (m, 3H), 3.94-4.14 (m, 4H), 4.41 (d, 1H), 4.41-4.74 (m, 2H), 6.16 (t, 1H). MS m/z: 560.6 (M + 1) 124

¹H NMR (D₂O) δ ppm: 1.32 (d, 3H), 1.38 (d, 3H), 1.99 (d, 2H), 2.09 (d, 1H), 2.19 (m, 1H), 3.05 (m, 1H), 3.36 (m, 1H), 3.44 (m, 1H), 3.48 (d, 1H), 3.66 (m, 1H), 3.89-3.73 (m, 3H), 4.06 (m, 1H), 4.40 (d, 1H), 4.47 (m, 1H), 4.68 (m, 1h), 4.82 (m, 1H), 6.16 (t, 1H). MS m/z: 502.6 (M + 1) 125

¹H NMR (D₂O) δ ppm: 0.92-0.99 (m, 6H) 1.15 (d, 3H), 1.17 (d, 3H), 1.75 (m, 1H), 1.77 (d, 2H), 1.91 (d, 3H), 2.04 (m, 1H), 2.23 (m, 2H), 2.85 (d, 2H), 3.19 (m, 2H), 3.36 (m, 2H), 3.57 (m, 1H), 3.75 (m, 1H), 4.14 (d, 2H), 4.44 (m, 2H), 6.29 (t, 1H). MS m/z: 615.70 (M + 1) 126

¹H NMR (D₂O) δ ppm: 1.19-1.21 (m, 3H), 1.35-1.37 (m, 3H), 1.82-1.84 (m, 1H), 2.85- 2.88 (m, 2H), 3.07-3.13 (m, 2H), 3.24-3.27 (m, 1H), 3.32-3.33 (m, 3H), 3.45 (m, 3H), 3.57-3.68 (m, 2H), 3.81-3.93 (m, 2H), 4.14- 4.16 (m, 1H), 4.32-4.35 (m, 1H), 4.43-4.47 (m, 1H) 6.29 (t, 1H). MS m/z: 532.6 (M + 1) 127

¹H NMR (D₂O) δ ppm: 1.17-1.19 (m, 3H), 1.28-1.32 (m, 3H), 1.92 (m, 1H), 2.82 (m, 2H), 3.07-3.12 (m, 2H), 3.21-3.27 (m, 2H), 3.34-3.44 (m, 3H), 3.57-3.86 (m, 3H), 3.91 (m, 2H), 4.06-4.09 (m, 1H), 4.14-4.16 (m, 1H), 4.32-4.47 (m, 2H) 6.29 (t, 1H). MS m/z: 532.6 (M + 1) 128

¹H NMR (D₂O) δ ppm: 1.20-1.21 (m, 3H), 1.30-1.31 (m, 3H), 1.95-2.01 (m, 1H), 3.00- 3.33 (d, 6H), 3.35-3.37 (m, 2H), 3.45-3.48 (m, 1H), 3.56-3.58 (m, 2H), 3.70-3.77 (m, 3H), 4.04 (m, 1H), 4.15-4.17 (m, 1H), 4.36- 4.39 (m, 1H). MS m/z: 450.5 (M + 1) 129

¹H NMR (D₂O) δ ppm: 1.20-1.22 (m, 3H), 1.25-1.29 (m, 3H), 1.91 (m, 1H), 2.09 (m, 1H), 2.23 (m, 1H), 2.47 (m, 2H), 2.75 (s, 3H), 3.19 (m, 1H), 3.39 (m, 2H), 3.58 (m, 3H), 3.6-3.87 (m, 4H), 4.03 (m, 1H), 4.13 (m, 1H), 4.25 (m, 1H), 4.46 (m, 1H). MS m/z: 493.6 (M − 1) 130

¹H NMR (D₂O) δ ppm: 1.20-1.24 (m, 3H), 1.29-1.37 (m, 3H), 1.93 (m, 1H), 2.12-2.19 (m, 2H), 2.39-2.40 (m, 1H), 2.87-2.89 (m, 1H), 3.33-3.49 (m, 3H), 3.62-3.68 (m, 2H), 3.70-3.73 (m, 2H), 3.80 (m, 2H), 4.17-4.29 (m, 1H), 4.43-4.51 (m, 2H) 6.02 (t, 1H). MS m/z: 502.6 (M + 1) 131

¹H NMR (D₂O) δ ppm: 1.19-1.21 (m, 3H), 1.25-1.29 (m, 3H), 1.92 (m, 1H), 2.83 (m, 2H), 3.27-3.34 (m, 2H), 3.53-3.59 (m, 2H) 3.93 (m, 2H), 4.07-4.47 (m, 5H), 4.60-4.64 (m, 1H) 6.09 (t, 1H). MS m/z: 488.52 (M + 1) 132

¹H NMR (D₂O) δ ppm: 1.21-1.22 (m, 3H), 1.30-1.37 (m, 3H), 1.57-1.63 (m, 3H), 1.92 (m, 1H), 2.13-2.16 (m, 2H), 2.81-2.92 (m, 2H), 3.26-3.36 (m, 3H), 3.51-3.59 (m, 3H), 3.94 (m, 2H), 4.14-4.16 (m, 1H), 4.43- 4.48 (m, 2H), 6.02-6.29 (m, 1H). MS m/z: 516.6 (M + 1) 133

¹H NMR (D₂O) δ ppm: 1.05-1.21 (m, 3H), 1.30-1.37 (m, 3H), 2.01 (m, 2H), 2.30-2.34 (m, 2H), 2.98 (m, 2H), 3.35 (m, 2H), 3.47- 3.49 (m, 2H), 3.60-3.62 (m, 2H), 3.74-3.76 (m, 2H), 3.78 (m, 2H), 3.94 (m, 2H), 4.14- 4.17 (m, 2H), 4.43-4.46 (m, 1H), 6.01 (t, 1H). MS m/z: 609.7 (M + 1) 134

¹H NMR (D₂O) δ ppm: 1.19-1.21 (m, 3H), 1.32-1.37 (m, 3H), 1.92 (m, 1H), 2.19-2.23 (m, 1H), 2.43-2.46 (m, 1H), 2.92 (m, 1H), 3.08-3.10 (s, 3H), 3.28-3.37 (m, 3H), 3.50 3.68 (m, 6H), 3.96 (m, 1H), 4.14-4.17 (m, 1H), 4.43-4.47 (m, 1H), 4.59-4.63 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 516.6 (M + 1) 135

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.35-1.37 (d, 6H), 1.82-1.84 (m, 1H), 2.96 (m, 1H), 3.15-3.57 (m, 6H), 3.59 (m, 1H), 3.84-3.91 (m, 5H) 4.14-4.17 (m, 1H), 4.20 (m, 1H), 4.42-4.47 (m, 1H), 6.02 (t, 1H). MS m/z: 516.6 (M + 1) 136

¹H NMR (D₂O) δ ppm: 1.32-1.37 (m, 3H), 1.37 (m, 3H), 2.56-2.62 (m, 1H), 2.99-3.08 (m, 4H), 3.32 (m, 3H), 3.39-3.48 (m, 3H), 3.52-3.59 (m, 4H), 3.82-3.98 (m, 1H), 4.05- 4.25 (m, 3H), 4.55 (m, 1H). MS m/z: 490.61 (M + 1) 137

¹H NMR (D₂O) δ ppm: 1.23-1.32 (m, 6H), 2.96-2.99 (m, 1H), 3.29-3.45 (m, 2H), 3.57- 3.59 (m, 1H), 3.69-3.74 (m, 1H), 3.78 (s, 3H), 4.00-4.03 (m, 2H), 4.13-4.16 (m, 1H), 4.38-4.49 (m, 4H), 6.20-6.29 (m, 1H), 6.51 (s, 1H), 8.08 (s, 1H). MS m/z: 571.6 (M + 1) 138

¹H NMR (D₂O) δ ppm: 1.20-1.22 (m, 3H), 1.29-1.32 (m, 3H), 2.96-3.00 (m, 4H), 3.07-3.11 (m, 3H), 3.31-3.39 (m, 4H), 3.60 3.66 (m, 2H), 3.81 (m, 1H), 4.01 (m, 1H), 4.16-4.18 (m, 1H), 4.46-4.49 (m, 1H), 4.71- 4.81 (m, 1H). MS m/z: 490.5 (M + 1) 139

¹H NMR (D₂O) δ ppm: 0.98-1.08 (m, 6H), 1.20-1.29 (m, 5H), 1.70-1.82 (m, 3H), 2.96- 3.07 (m, 7H), 3.27-3.59 (m, 4H), 3.83-3.86 (m, 2H), 3.91-3.94 (m, 2H), 4.13-4.15 (m, 1H), 4.46-4.47 (m, 1H). MS m/z: 480.6 (M − 1) 140

¹H NMR (D₂O) δ ppm: 1.27-1.30 (m, 3H), 1.35-1.37 (m, 3H), 3.08 (m, 2H), 3.35-3.37 (m, 2H), 3.44-3.48 (m, 4H), 3.54 (m, 3H), 3.73-3.76 (m, 4H), 4.03 (m, 1H), 4.15-4.18 (m, 1H), 4.44-4.47 (m, 1H) 6.02 (t, 1H). MS m/z: 521.6 (M + 1) 141

¹H NMR (D₂O) δ ppm: 1.32-1.37 (m, 6H), 2.77-2.89 (m, 2H), 3.00 (s, 3H), 3.19-3.23 (m, 4H), 3.33-3.37 (m, 2H), 3.57-3.59 (m, 2H), 3.77-3.90 (m, 2H), 4.10-4.16 (m, 2H), 4.43-4.47 (m, 2H), 6.20-6.29 (t, 1H). MS m/z: 559.60 (M + 1) 142

¹H NMR (D₂O) δ ppm: 1.20-1.37 (m, 6H), 2.69-2.82 (m, 6H), 3.20-3.21 (m, 1H), 3.33- 3.39 (m, 3H), 3.57-3.59 (m, 2H), 3.77-3.80 (m, 2H), 3.91-4.00 (m, 2H), 4.07-4.16 (m, 3H), 4.30 (m, 1H), 4.43-4.47 (m, 1H), 4.74- 4.89 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 573.6 (M + 1) 143

¹H NMR (D₂O) δ ppm: 1.13-1.33 (m, 6H), 3.00-3.07 (d, 6H), 3.31-3.35 (m, 2H), 3.39- 3.42 (m, 1H), 3.56-3.59 (m, 1H), 3.95-4.01 (m, 3H), 4.13-4.15 (m, 3H), 4.46-4.50 (m, 1H), 4.71 (m, 1H). MS m/z: 491.5 (M + 1) 144

¹H NMR (D₂O) δ ppm: 1.19-1.46 (m, 6H), 2.08 (m, 1H), 2.84-2.87 (m, 3H), 2.95-2.97 (m, 6H), 3.25-3.35 (m, 3H), 3.58-3.59 (m, 3H), 3.98 (m, 1H), 4.43-4.47 (m, 2H), 6.02- 6.29 (m, 1H). MS m/z: 475.6 (M + 1) 145

¹H NMR (D₂O) δ ppm: 1.32-1.37 (m, 6H), 1.58-1.61 (m, 1H), 2.65-2.89 (m, 6H), 3.27 (m, 4H), 3.30-3.37 (m, 2H), 3.49-3.60 (m, 2H), 3.77-3.96 (m, 2H), 4.13-4.16 (m, 2H), 4.43-4.7 (m, 1H), 6.02-6.29 (m 1H). MS m/z: 488.6 (M + 1) 146

¹H NMR (D₂O) δ ppm: 1.12-1.14 (d, 3H), 1.67-1.87 (d, 3H), 2.90-3.05 (m, 3H), 3.11 (d, 3H), 3.22-3.26 (d, 1H), 338-3.39 (d, 1H), 3.96-3.98 (dd, 2H), 4.12-4.14 (m, 2H), 4.15 (d, 1H), 4.74 (m, 4H), 5.25-5.29 (m, 1H), 7.21-7.23 (d, 1H). MS m/z: 465.5 (M + 1) 147

¹H NMR (D₂O) δ ppm: 1.21 (d, 3H), 1.33 (d, 3H), 2.09-2.11 (m, 2H), 2.33-2.37 (m, 2H), 2.98 (m, 2H), 3.32-3.39 (d, 3H), 3.51- 3.53 (d, 2H), 3.60-3.63 (d, 2H), 3.9-3.98 (m, 2H), 4.15-4.17 (d, 2H), 4.42-4.45 (d, 1H), 4.52-4.55 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 609.6 (M + 1) 148

¹H NMR (D₂O) δ ppm: 1.05-1.07 (d, 3H), 1.25-1.37 (d, 3H), 1.92 (m, 2H), 3.1 (m, 2H), 3.12-3.33 (m, 3H), 3.55-3.59 (m, 3H), 3.71-75 (d, 3H), 4.15-4.17 (m, 2H), 4.81 (s, 2H), 6.02-6.29 (t, 1H). MS m/z: 518.6 (M + 1) 149

¹H NMR (D₂O) δ ppm: 1.03-1.07 (d, 3H), 1.20-1.21 (d, 3H), 1.92 (m, 1H), 2.01 (d, 1H), 2.21 (m, 1H), 2.41-2.48 (m, 2H), 2.70- 2.75 (m, 3H), 3.18-3.21 (d, 3H), 3.5-3.8 (m, 6H), 4.02-4.15 (d, 2H), 4.41 (d, 1H), 6.02- 6.29 (t, 1H). MS m/z: 516.6 (M + 1) 150

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.22-1.28 (d, 3H), 2.32 (m, 1H), 2.46-2.48 (d, 1H), 2.72-2.78 (m, 2H), 2.80-2.82 (d, 2H), 2.88-2.89 (d, 2H), 3.32-3.33 (d, 2H), 3.35-3.37 (d, 2H), 3.58-3.60 (m, 2H), 3.87- 3.88 (m, 2H), 4.14-4.17 (m, 1H), 4.45 (d, 2H), 6.02-6.29 (t, 1H). MS m/z: 488.5 (M + 1) 151

¹H NMR (D₂O) δ ppm: 1.05-1.07 (d, 3H), 1.20-1.22 (d, 3H), 2.23-2.25 (m, 2H), 2.47- 2.50 (m, 2H), 2.73-2.77 (d, 2H), 2.98 (m, 2H), 3.35-3.53 (2, 3H), 3.4-3.7 (m, 4H), 3.82 (m, 3H), 4.15-4.17 (m, 2H), 4.25 (d, 1H), 4.53 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 589.6 (M + 1) 152

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.22-1.28 (d, 3H), 2.32 (m, 1H), 2.46- 2.48 (m, 2H), 2.72-2.78 (m, 2H), 2.81-2.83 (d, 2H), 2.88-2.89 (m, 2H), 3.31-3.32 (d, 2H), 3.33 (s, 3H), 3.35-3.37 (d, 2H), 3.57- 3.59 (m, 1H), 3.87-3.88 (m, 2H), 4.15-4.16 (m, 1H), 4.46 (d, 2H), 6.20-6.29 (t, 1H). MS m/z: 502.5 (M + 1) 153

¹H NMR (D₂O) δ ppm: 1.21-1.23 (d, 3H), 1.31-1.33 (d, 3H), 2.98 (m, 2H), 3.12 (d, 2H), 3.33-3.34 (m, 4H), 3.51-3.53 (m, 4H), 3.82-3.84 (m, 3H), 4.35-4.45 (d, 2H), 4.47 (m, 2H), 6.02-6.29 (t, 1H). MS m/z: 559.60 (M + 1) 154

¹H NMR (D₂O) δ ppm: 1.27-1.29 (d, 3H), 1.32-1.37 (d, 3H), 3.02 (d, 2H), 3.35-3.43 (m, 6H), 3.51-3.52 (m, 3H), 3.81-3.82 (m, 4H), 4.01-4.15 (m, 2H), 4.43-4.45 (m, 2H), 4.57 (d, 1H), 6.02-6.29 (t, 1H). MS m/z: 559.6 (M + 1) 155

¹H NMR (D₂O) δ ppm: 1.02-1.07 (d, 3H), 1.20-1.28 (d, 3H), 2.23-2.27 (m, 2H), 2.82- 3.14 (m, 4H), 3.15-3.17 (m, 5H), 3.61-3.62 (s, 3H), 3.81-3.83 (d, 4H), 4.02 (d, 2H), 4.41 (d, 2H), 6.02-6.29 (t, 1H). MS m/z: 573.6 (M + 1) 156

¹H NMR (D₂O) δ ppm: 1.17-1.19 (d, 3H), 1.21-1.29 (d, 3H), 2.99-3.00 (m, 3H), 3.07- 3.09 (d, 3H), 3.37-3.46 (m, 3H), 3.51-3.52 (m, 3H), 3.81-3.82 (m, 2H), 4.01-4.15 (m, 2H), 4.43-4.45 (m, 2H), 4.57 (d, 1H), 6.02- 6.29 (t, 1H). MS m/z: 495.6 (M − 1) 157

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.32-1.37 (d, 3H), 2.86 (m, 1H), 3.19-3.22 (m, 2H), 3.32-3.37 (d, 3H), 3.46-3.57 (m, 5H), 3.61-3.62 (m, 4H), 3.90 (m, 1H), 4.14- 4.16 (m, 1H), 4.36-4.38 (m, 1H) 6.02 (t, 1H). MS m/z: 544.6 (M + 1) 158

¹H NMR (D₂O) δ ppm: 1.19-1.27 (d, 3H), 1.30-1.37 (d, 3H), 2.91 (s, 3H), 3.31-3.33 (m, 2H), 3.54-3.56 (m, 3H), 3.5-3.57 (m, 4H), 3.63-3.68 (d, 4H), 3.94 (d, 4H), 4.14- 4.19 (m, 2H), 4.55 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 573.6 (M + 1) 159

¹H NMR (D₂O) δ ppm: 1.21-1.27 (d, 3H), 1.29-1.35 (d, 3H), 2.89-2.91 (m, 3H), 3.27- 3.33 (d, 2H), 3.35-3.37 (d, 3H), 3.57-3.59 (d, 3H), 3.62-3.64 (d, 2H), 3.70-3.71 (d, 2H), 3.92-3.98 (d, 2H), 4.05-4.06 (d, 1H), 4.14-4.16 (d, 1H), 4.75-4.81 (d, 2H), 6.02- 6.29 (t, 1H). MS m/z: 559.60 (M + 1) 160

¹H NMR (D₂O) δ ppm: 1.27-1.29 (d, 3H), 1.32-1.36 (d, 3H), 3.02 (m, 3H), 3.35- 3.43 (m, 5H), 3.48-3.56 (d, 3H), 3.82 (m, 3H), 4.01-4.15 (m, 2H), 4.18 (m, 1H), 4.43- 4.53 (m, 1H), 4.57-4.79 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 559.6 (M + 1) 161

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.21-1.25 (d, 3H), 3.13 (m, 2H), 3.33 (m, 4H), 3.46 (m, 3H), 3.58-3.59 (m, 3H), 3.82 (m, 3H), 3.98 (m, 2H), 4.15-4.17 (m, 1H), 4.43-4.47 (t, 2H), 6.02-6.29 (t, 1H). MS m/z: 516.6 (M − 1) 162

¹H NMR (D₂O) δ ppm: 1.06-1.10 (d, 3H), 1.30-1.37 (d, 3H), 2.75 (d, 4H), 2.95 (m, 1H), 3.01-3.11 (d 3H), 3.30 (m, 4H), 3.60- 3.62 (d, 3H), 3.72 (d, 1H), 3.80-4.01 (m, 2H), 4.15-4.17 (d, 1H), 4.58 (m, 1H), 6.02- 6.29 (t, 1H). MS m/z: 516.6 (M + 1) 163

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.30-1.37 (d, 3H), 2.20-2.21 (m, 2H), 3.01 (m, 1H), 3.33-3.39 (m, 6H), 3.55-3.58 (d, 2H), 3.60 (d, 1H), 3.78 (d, 2H), 3.78-3.82 (d, 2H), 4.15-4.17 (d, 2H), 4.15-4.17 (d, 1H), 4.43-4.47 (t, 1H), 6.02-6.29 (t, 1H). MS m/z: 504.6 (M + 1) 164

¹H NMR (D₂O) δ ppm: 1.05-1.07 (d, 3H), 1.30-1.37 (d, 3H), 2.02-2.14 (m, 2H), 3.04 (m, 1H), 3.33-3.35 (d, 1H), 3.37 (dd, 1H), 3.41-3.42 (d, 1H), 3.52-3.58 (d, 4H), 3.72- 3.74 (d, 2H), 4.02-4.04 (d, 1H), 4.15-4.18 (d, 1H), 4.43-4.47 (m, 1H), 4.56-4.60 (m, 1H), 4.63-4.65 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 518.6 (M + 1) 165

¹H NMR (D₂O) δ ppm: 1.02-1.05 (d, 3H), 1.08-1.11 (d, 3H), 2.81 (m, 3H), 3.01-3.21 (s, 3H), 3.22-3.25 (d, 3H), 3.26-3.29 (d, 3H), 3.51-3.52 (m, 3H) 3.80 (d, 2H), 4.02-4.06 (m, 1H), 4.09-4.13 (m, 1H), 4.61 (d, 1H). MS m/z: 452.6 (M − 1) 166

¹H NMR (D₂O) δ ppm: 0.86-0.88 (m, 3H), 1.21-1.34 (d, 3H), 2.50-2.85 (s, 3H), 2.86- 3.01 (s, 3H), 3.26-3.29 (m, 6H), 3.51-3.52 (m, 3H) 3.80 (m, 3H), 4.02-4.07 (d, 2H), 4.09-4.13 (m, 1H), 4.49 (d, 1H) 4.61 (d, 1H). MS m/z: 466.6 (M − 1) 167

¹H NMR (D₂O) δ ppm: 0.9-0.95 (d, 3H), 1.01-1.19 (d, 6H), 1.92-2.60 (m, 5H), 3.24 (m, 1H), 3.34-3.36 (d, 2H), 3.63-3.68 (d, 3H), 3.70 (d, 1H), 3.96 (d, 2H), 4.96 (m, 2H), 7.21-7.23 (s, 1H). MS m/z: 506.6 (M + 1) 168

¹H NMR (D₂O) δ ppm: 1.07-1.08 (d, 3H), 1.20-1.22 (d, 3H), 2.60-2.62 (m, 2H), 2.75- 2.76 (d, 3H), 2.96 (m, 2H), 3.28-3.33 (m, 4H), 3.58-3.59 (d, 3H), 3.81-3.88 (dd, 1H), 3.92 (m, 4H), 4.13 (m, 2H), 4.13-4.15 (d, 1H) 4.46 (d, 1H). MS m/z: 493.6 (M − 1) 169

¹H NMR (D₂O) δ ppm: 1.21-1.22 (d, 3H), 1.25-1.29 (d, 3H), 2.75 (s, 3H), 3.36-3.38 (d, 3H), 3.38 (m, 2H), 3.50 (m, 2H), 3.61 (m, 2H), 3.87 (m, 2H), 4.52 (m, 2H) 4.63 (m, 1H). MS m/z: 489.6 (M + 1) 170

¹H NMR (D₂O) δ ppm: 0.88 (m, 4H), 1.02 (m, 1H), 1.21-1.27 (d, 3H), 1.46 (d, 3H), 2.44-2.66 (3H, m), 3.00-3.03 (m, 1H), 3.35- 3.4 (d, 2H), 3.60-3.64 (d, 2H), 3.72-3.77 (d, 2H), 3.79 (d, 2H), 4.01-4.08 (d, 2H), 4.11- 4.15 (d, 2H), 4.43-4.47 (d, 1H), 6.02-6.29 (t, 1H). MS m/z: 542.6 (M + 1) 171

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.21 (d, 3H), 2.76 (m, 4H), 3.03-3.09 (t, 3H), 3.33-3.35 (d, 3H), 3.73 (m, 3H), 4.16-4.18 (d, 2H), 4.26 (d, 1H), 4.30 (d, 2H), 6.02-6.29 (t, 1H). MS m/z: 529.6 (M + 1) 172

¹H NMR (D₂O) δ ppm: 1.07-1.20 (d, 3H), 1.26-1.28 (d, 3H), 1.80-1.82 (m, 1H), 2.82 (s, 3H), 2.89 (s, 3H), 3.07 (s, 3H), 3.17 (d, 2H), 3.26 (d, 3H), 3.34-3.35 (d, 3H), 3.57- 3.59 (m, 3H), 4.14-4.16 (m, 2 H), 4.45-4.63 (d, 2H), 6.02-6.29 (t, 1H). MS m/z: 587.7 (M + 1) 173

¹H NMR (D₂O) δ ppm: 1.21-1.23 (d, 3H), 1.28-1.35 (d, 3H), 2.30 (m, 2H), 2.48 (d, 2H), 2.64-2.66 (m, 2H), 2.77 (d, 2H), 2.96 (d, 2H), 3.09-3.27 (s, 3H), 3.27 (m, 2H), 3.61 (m, 2H), 3.71 (m, 3H), 4.01 (d, 2H), 4.21 (d, 1H), 4.44 (d, 1H), 6.02-6.29 (t, 1H). MS m/z: 587.7 (M + 1) 174

¹H NMR (D₂O) δ ppm: 1.05-1.07 (d, 3H), 1.20-1.37 (d, 6H), 2.75 (m, 3H), 2.95 (m, 3H), 3.08 (m, 3H), 3.32-3.46 (m, 6H), 3.58- 3.59 (d, 2H), 3.74-3.81 (d, 2H), 4.14 (d, 2H), 4.45 (m, 3H), 6.02-6.29 (t, 1H). MS m/z: 601.6 (M + 1) 175

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.36 (d, 3H), 1.97-1.99 (m, 1H), 2.22- 2.35 (m, 2H), 3.02-3.15 (m, 1H), 3.32-3.36 (m, 1H), 3.44-3.48 (m, 2H), 3.58-3.70 (m, 3H), 3.73-3.78 (m, 2H), 3.81-3.88 (m, 2H), 4.04-4.06 (m, 1H), 4.14-4.15 (m, 2H), 4.43- 4.44 (m, 1H), 4.67-4.81 (m, 1H), 6.01-6.28 (t, 1H). MS m/z: 541.6 (M + 1) 176

¹H NMR (D₂O) δ ppm: 1.17-1.20 (d, 3H), 1.36-1.37 (d, 3H), 1.92 (m, 1H), 2.57-2.74 (m, 3H), 3.11 (m, 2H), 3.31-3.46 (m, 2H), 3.58-3.59 (m, 1H), 3.72-3.77 (m, 3H), 3.87 (m, 1H), 4.04-4.07 (m, 2H), 4.16 (m, 1H), 4.34 (m, 2H), 4.41-4.45 (m, 1H), 5.44 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 583.6 (M + 1) 177

¹H NMR (D₂O) δ ppm: 1.01-1.03 (d, 3H), 1.67-1.69 (d, 3H), 1.75-1.77 (d, 1H), 1.92 (m, 2H), 2.99 (s, 3H), 3.09 (s, 3H), 3.35 (m, 3H), 3.75-3.78 (m, 2H), 3.84-3.97 (m, 2H), 4.35 (s, 2H), 8.24 (s, 1H). MS m/z: 464.6 (M + 1) 178

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.14-1.16 (d, 3H), 1.92 (m, 1H), 2.76 (s, 3H), 2.96 (m, 2H), 3.11 (m, 2H), 3.38-3.40 (d, 3H), 3.40-3.41 (m, 2H), 3.58-3.60 (m, 2H), 3.76-3.78 (d, 3H), 3.93-3.96 (m, 2H), 4.01-4.03 (m, 3H), 4.25 (s, 2H). MS m/z: 574.6 (M − 1) 179

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.15-1.17 (d, 3H), 1.91 (m, 1H), 2.12 (m, 1H), 2.43-2.47 (m, 2H), 2.48 (m, 2H), 2.99 (m, 1H), 3.02 (m, 1H), 3.13 (m, 3H), 3.45- 3.47 (m, 4H), 3.58-3.60 (m, 2H), 3.76-3.78 (d, 3H), 3.93-3.96 (m, 2H), 4.02 (m, 2H), 4.34 (m, 1H). MS m/z: 507.6 (M − 1) 180

¹H NMR (D₂O) δ ppm: 1.08-1.10 (d, 3H), 1.20-1.22 (d, 3H), 1.91 (m, 1H), 2.46 (m, 2H), 2.81 (s, 6H), 2.92 (m, 1H), 3.59 (d, 2H), 3.34-3.38 (m, 2H), 3.40 (d, 3H), 3.60- 3.64 (m, 2H), 3.71 (d, 1H), 3.82 (m, 3H), 4.01 (m, 1H), 4.46 (m, 1H). MS m/z: 507.6 (M − 1) 181

¹H NMR (D₂O) δ ppm: 1.18-1.19 (d, 3H), 1.20-1.21 (d, 3H), 1.27-1.29 (d, 2H), 1.91 (m, 1H), 2.23 (d, 1H), 2.73 (s, 3H), 3.05 (m, 2H), 3.22-3.26 (d, 2H), 3.35 (d, 1H), 3.48- 3.50 (dd, 1H), 3.76-3.78 (dd, 2H), 4.01 (m, 1H), 4.12 (s, 2H), 4.35-4.37 (d, 1H) 4.63 (m, 1H). MS m/z: 491.6 (M − 1) 182

¹H NMR (D₂O) δ ppm: 1.07-1.08 (d, 3H), 1.22-1.29 (d, 3H), 1.82-1.85 (m, 1H), 2.60- 2.62 (m, 2H) 2.55 (m, 1H), 2.76 (s, 3H), 2.91-2.93 (m, 1H), 3.30 (s, 6H), 3.47 (m, 1H), 3.76-3.78 (m, 8H), 4.21 (m, 1H), 4.44- 4.52 (m, 2H). MS m/z: 507.6 (M − 1) 183

¹H NMR (D₂O) δ ppm: 1.07 (d, 3H), 1.32- 1.35 (d, 3H), 1.91-1.95 (m, 2H), 2.46 (m, 1H), 2.56 (m, 4H), 2.48 (m, 1H), 3.31 (m, 2H), 3.55 (d, 1H), 3.74-3.76 (m, 1H), 3.92 (m, 1H), 4.00-4.02 (m, 1H), 4.14-4.17 (d, 1H), 4.34-4.47 (m, 3H), 6.02-6.29 (t, 1H). MS m/z: 531.6 (M + 1) 184

¹H NMR (D₂O) δ ppm: 1.06-1.07 (d, 3H), 1.32-1.35 (d, 3H), 2.16-2.27 (m, 1H), 2.95 (m, 1H), 2.81-2.87 (m, 2H), 3.18 (m, 2H), 3.35 (m, 2H), 3.58-3.60 (d, 3H), 3.71- 3.72 (m, 3H), 4.15-4.17 (m, 2H), 4.42 (d, 2H), 6.02-6.29 (t, 1H). MS m/z: 529.6 (M + 1) 185

¹H NMR (D₂O) δ ppm: 1.11-1.16 (d, 3H), 1.32-1.35 (d, 3H), 1.79-1.80 (m, 2H), 2.46 (m, 2H), 2.75-2.76 (s, 3H), 2.86 (m, 2H), 3.23-3.26 (d, 3H), 3.34 (m, 1H), 3.56 (d, 1H), 3.73 (m, 1H), 3.92 (m, 1H), 4.06-4.07 (d, 1H), 4.15-4.17 (d, 1H), 4.39-4.45 (m, 3H), 6.19 (t, 1H). MS m/z: 545.6 (M + 1) 186

¹H NMR (D₂O) δ ppm: 1.21-1.26 (d, 3H), 1.30-1.32 (d, 3H), 1.79-1.80 (m, 2H), 2.65- 2.69 (m, 1H), 2.81-2.82 (m, 1H), 3.22-3.32 (d, 2H), 3.34 (m, 1H), 3.57-3.59 (m, 3H), 3.90-3.92 (m, 1H), 4.06-4.08 (m, 3H), 4.15- 4.17 (d, 1H) 4.39-4.47 (dd, 3H), 6.19 (t, 1H). MS m/z: 532.6 (M + 1) 187

¹H NMR (D₂O) δ ppm: 0.93-0.96 (d, 3H), 1.25-1.36 (d, 3H), 1.87-1.91 (m, 1H), 3.00 (s, 3H), 3.07 (s, 3H), 3.22-3.26 (d, 2H), 3.39-3.40 (m, 2H) 3.54-3.60 (d, 1H), 3.81 (d, 1H), 4.07-4.08 (m, 1H), 4.35 (d, 1H), 5.12 (m, 1H), 6.22 (s, 1H), 8.39-8.45 (s, 1H). MS m/z: 451.5 (M + 1) 188

¹H NMR (D₂O) δ ppm: 1.04-1.06 (d, 3H), 1.13-1.21 (d, 3H), 1.79-1.80 (m, 2H), 2.46- 2.51 (d, 1H), 2.65-2.69 (m, 1H), 2.73 (s, 3H), 2.81-2.82 (m, 1H), 3.06 (m, 1H), 3.22- 3.32 (d, 2H), 3.35 (d, 1H), 3.58-3.61 (m, 2H), 3.80-3.83 (d, 2H), 4.04-4.08 (d, 3H), 4.15-4.17 (d, 1H) 4.34-4.35 (m, 3H). MS m/z: 523.6 (M + 1) 189

¹H NMR (D₂O) δ ppm: 1.13-1.15 (d, 3H), 1.19-1.20 (d, 3H), 2.12-2.13 (m 3H), 2.55- 2.56 (m, 1H), 2.75-2.76 (s, 3H), 2.92-2.95 (m, 2H), 3.29-3.38 (d, 3H), 3.54-3.58 (d, 2H), 3.83-3.85 (d, 2H), 3.87-3.89 (m, 1H), 4.01-4.05 (d, 1H), 4.41-4.45 (m, 1H), 4.51- 4.52 (m, 1H). MS m/z: 479.6 (M − 1) 190

¹H NMR (D₂O) δ ppm: 1.13-1.15 (d, 3H), 1.19-1.21 (d, 3H), 1.60-1.63 (m, 2H), 2.13- 2.17 (m, 3H), 2.55-2.57 (m, 2H), 2.76-2.77 (s, 3H), 2.93-2.95 (m, 3H), 3.29-3.38 (m, 3H), 3.54-3.59 (d, 2H), 3.83-3.85 (d, 2H), 3.86-3.87 (m, 1H), 4.14-4.16 (d, 1H), 4.45- 4.46 (m, 1H), 4.52-4.53 (d, 1H). MS m/z: 507.6 (M − 1) 191

¹H NMR (D₂O) δ ppm: 1.03-1.06 (m, 3H), 1.17-1.25 (m, 3H), 1.89 (m, 1H), 2.46 (m, 2H), 2.67-2.71 (m, 2H), 2.86 (d, 3H), 3.21- 3.28 (m, 3H), 3.40-3.42 (m, 2H), 3.56 (d, 1H), 3.72-3.91 (m, 4H), 3.92 (m, 1H) 4.06- 4.07 (d, 1H), 4.13-4.28 (m, 2H), 4.41 (m, 1H). MS m/z: 522.6 (M − 1) 192

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.28-1.29 (d, 3H), 1.81 (m, 1H), 2.09-2.10 (m, 2H), 2.76 (s, 3H), 2.94 (m, 1H), 3.30 (m, 1H), 3.43-3.46 (m, 2H), 3.50-3.55 (m, 3H), 3.65-3.69 (m, 3H), 3.72-3.76 (m, 2H), 3.94 (m, 1H), 4.13-4.15 (m, 1H), 4.45-4.48 (m, 1H), 4.55-4.59 (m, 1H). MS m/z: 494.6 (M − 1) 193

¹H NMR (D₂O) δ ppm: 1.15-1.21 (m, 3H), 1.23-1.29 (m, 3H), 1.42-1.53 (m, 3H), 1.92 (m, 1H), 2.05-2.08 (m, 3H), 2.7 (s, 3H), 3.00-3.02 (m, 3H), 3.33-3.37 (m, 3H), 3.61- 3.65 (m, 2H), 3.77 (s, 2H), 3.81-3.82 (m, 2H), 4.01-4.14 (m, 2H), 4.16-4.29 (m, 1H), 4.46-4.48 (m, 1H). MS m/z: 564.6 (M − 1) 194

¹H NMR (D₂O) δ ppm: 1.13-1.22 (m, 3H), 1.26-1.28 (m, 3H), 1.92 (m, 1H), 3.00-3.02 (m, 1H), 3.21-3.22 (m, 1H), 3.32-3.37 (m, 4H), 3.40-3.48 (m, 2H), 3.88-3.90 (m, 3H), 4.03-4.16 (m, 2H), 4.29-4.45 (m, 2H) 6.19 (t, 1H). MS m/z: 517.6 (M + 1) 195

¹H NMR (D₂O) δ ppm: 1.29-1.31 (d, 3H), 1.35-1.37 (m, 3H), 1.92-1.95 (m, 1H), 3.02 (m, 1H), 3.35-3.43 (m, 3H), 3.58-3.60 (m, 3H), 3.68-3.70 (m, 2H), 3.78-3.82 (m, 1H), 4.01 (m, 1H), 4.15-4.18 (m, 1H), 4.25-4.27 (m, 2H), 4.44-4.59 (m, 2H) 6.19 (t, 1H). MS m/z: 544.6 (M + 1) 196

¹H NMR (D₂O) δ ppm: 1.27-1.29 (d, 3H), 1.35-1.37 (m, 3H), 1.81 (m, 1H), 2.24-2.25 (m, 2H), 3.01-3.03 (m, 2H), 3.35 (m, 2H), 3.46 (m, 2H), 3.69 (m, 2H), 3.77 (m, 2H), 3.84 (m, 2H), 4.08-4.17 (m, 1H), 4.44-4.47 (m, 2H), 4.60-4.63 (m, 1H) 6.19 (t, 1H). MS m/z: 601.6 (M + 1) 197

¹H NMR (D₂O) δ ppm: 0.75 (d, 3H), 1.02- 1.04 (m, 2H), 1.24-1.35 (d, 6H), 1.92 (m, 2H), 2.00-2.11 (m, 2H), 2.24 (m, 2H), 2.46 (m, 2H), 2.54 (m, 1H), 3.38-3.58 (d, 2H), 3.66 (d, 3H), 3.87-3.88 (m, 2H), 4.11-4.13 (m, 2H), 4.42 (d, 1H). MS m/z: 519.6 (M − 1) 198

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.37 (d, 3H), 3.02-3.06 (m, 1H), 3.02- 3.06 (m, 1H), 3.33-3.35 (m, 2H), 3.44-3.45 (dd, 2H), 3.60-3.62 (d, 2H), 3.71-3.78 (m, 3H), 4.03-4.05 (m, 1H), 4.16-4.18 (d, 1H), 4.30-4.34 (m, 1H), 4.47 (m, 1H), 4.65 (m, 1H), 6.29 (t, 1H). MS m/z: 519.5 (M + 1) 199

¹H NMR (D₂O) δ ppm: 1.07-1.09 (d, 3H), 1.17-1.27 (d, 3H), 1.83 (m, 1H), 2.31 (m, 1H), 2.57 (m, 2H), 2.76 (m, 3H), 2.96-2.98 (m, 2H), 3.32-3.25 (m, 2H), 3.40-3.51 (m, 4H), 3.88-3.92 (m, 4H), 4.04 (m, 1H), 4.13- 4.15 (m, 1H), 4.39-4.48 (m, 2H). MS m/z: 520.6 (M − 1) 200

¹H NMR (D₂O) δ ppm: 1.07-1.08 (d, 3H), 1.20-1.22 (d, 3H), 1.81-1.82 (m, 1H), 2.76 (m, 1H), 2.81 (m, 2H), 2.95 (m, 2H), 3.12- 3.13 (d, 1H), 3.35-3.53 (m, 3H), 3.61 (d, 1H), 3.62-3.71 (m, 3H), 3.81-3.99 (m, 3H), 4.05 (d, 1H), 4.11 (d, 1H), 4.3-4.41 (m, 1H), 4.51 (m, 1H). MS m/z: 508.6 (M − 1) 201

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.37 (d, 3H), 1.98 (m, 1H), 2.55-2.57 (m, 1H), 2.88-2.89 (d, 1H), 3.14 (s, 3H), 3.20-3.26 (m, 2H), 3.31 (d, 3H), 3.49-3.50 (d, 4H), 3.59-3.78 (d, 3H), 3.88-3.90 (m, 1H), 3.96-3.99 (m, 1H), 4.20-4.22 (m, 1H). MS m/z: 520.6 (M + 1) 202

¹H NMR (D₂O) δ ppm: 1.07-1.09 (d, 3H), 1.13-1.28 (d, 3H), 1.98 (m, 1H), 2.43-2.44 (m, 2H), 2.81 (s, 3H), 2.95 (d, 2H), 3.08-3.1 (d, 3H), 3.21-3.26 (m, 2H), 3.76-3.79 (m, 3H), 3.82-3.87 (m, 3H), 3.97 (d, 3H), 4.13- 4.15 (m, 1H), 4.45 (m, 1H). MS m/z: 511.6 (M − 1) 203

¹H NMR (D₂O) δ ppm: 1.23-1.25 (d, 3H), 1.34-1.39 (d, 3H), 2.08-2.12 (m, 2H), 2.31 (m, 2H), 2.55-2.57 (m, 1H), 2.98 (m, 1H), 3.11 (s, 3H), 3.14-3.18 (d, 2H), 3.20-3.26 (m, 2H), 3.38-3.34 (d, 2H), 3.78-3.80 (m, 2H), 4.15 (m, 1H), 4.22 (m, 1H), 4.70-4.77 (m, 1H). MS m/z: 581.7 (M + 1) 204

¹H NMR (D₂O) δ ppm: 1.03-1.05 (d, 3H), 1.20-1.21 (d, 3H), 1.98 (m, 1H), 2.02-2.03 (m, 1H), 2.43-2.45 (d, 1H), 2.92 (m, 1H), 3.17-3.18 (m, 1H), 3.35-3.36 (m, 2H), 3.43- 3.45 (m, 2H), 3.59-3.60 (m, 3H), 3.78-3.80 (m, 2H), 4.04-4.15 (m, 1H), 4.17 (d, 1H), 4.49 (t, 1H). MS m/z: 556.6 (M + 1) 205

¹H NMR (D₂O) δ ppm: 1.15-1.20 (d, 3H), 1.29-1.30 (d, 3H), 1.75-1.78 (m, 1H), 2.21- 2.22 (m, 3H), 2.46-2.48 (m, 2H), 2.85 (m, 1H), 3.20-3.22 (d, 1H), 3.37-3.38 (m, 2H), 3.60 (m, 3H), 3.72-3.78 (m, 3H), 3.87-3.90 (m, 3H), 4.04-4.08 (m, 2H), 4.13-4.16 (d, 1H), 4.35 (m, 1H), 4.44-4.46 (m, 1H). MS m/z: 519.6 (M − 1) 206

¹H NMR (D₂O) δ ppm: 1.15-1.20 (d, 3H), 1.29-1.30 (d, 3H), 1.75-1.78 (m, 1H), 2.21- 2.22 (m, 3H), 2.46-2.48 (m, 2H), 2.85 (m, 1H), 3.20-3.22 (d, 1H), 3.37-3.38 (m, 2H), 3.60 (m, 3H), 3.72-3.78 (m, 3H), 3.87-3.90 (m, 3H), 4.04-4.08 (m, 2H), 4.13-4.16 (d, 1H), 4.35 (m, 1H), 4.44-4.46 (m, 1H). MS m/z: 519.6 (M − 1) 207

¹H NMR (D₂O) δ ppm: 0.95-0.97 (d, 3H), 1.63-1.92 (m, 3H), 2.72 (m, 1H), 3.22-3.24 (m, 6H), 3.60-3.64 (m, 2H), 3.82-3.85 (m, 8H), 4.02 (m, 1H), 8.31 (s, 1H), 5.31 (s, 1H), 5.6 (s, 1H). MS m/z: 508.6 (M + 1) 208

¹H NMR (D₂O) δ ppm: 0.95 (d, 3H), 1.72- 1.76 (d, 3H), 1.98 (m, 1H), 2.72-2.76 (d, 2H), 2.87 (s, 3H), 3.06-3.09 (s, 3H), 3.10 (s, 3H), 3.22-3.26 (d, 2H), 3.36-3.37 (d, 2H), 3.48-3.50 (dd, 1H), 3.61 (m, 1H) 3.81 (m, 2H), 4.07-4.08 (m, 1H) 4.39 (m, 1H). MS m/z: 478.6 (M + 1) 209

¹H NMR (D₂O) δ ppm: 1.19-1.21 (d, 3H), 1.35-1.37 (d, 3H), 1.47 (s, 1H), 1.92-2.10 (m, 3H), 2.34-2.4 (m, 1H), 3.00-3.07 (d, 2H), 3.33-3.41 (m, 2H), 3.58-3.60 (m, 3H), 3.72-3.77 (m, 2H), 3.82-3.98 (m, 1H), 4.15- 4.17 (m, 1H), 4.44-4.47 (m, 1H), 4.63 (m, 1H) 5.36-5.52 (m, 1H), 6.02-6.2 (t, 1H). MS m/z: 505 (M + 1) 210

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.36-1.37 (d, 3H), 1.48 (s, 1H), 1.92-2.3 (m, 4H), 3.00-3.07 (d, 2H), 3.33-3.4 (m, 2H), 3.58-3.60 (m, 3H), 3.72-3.77 (m, 2H), 3.82- 3.98 (m, 1H), 4.15-4.17 (m, 1H), 4.44-4.47 (m, 1H), 4.63 (m, 1H), 5.36-5.52 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 505 (M + 1) 211

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.29-1.30 (d, 3H), 1.98-2.00 (m, 2H), 2.56- 2.89 (m, 4H), 3.31-3.59 (m, 6H), 3.94 (m, 2H), 4.16-4.31 (m, 2H), 4.45-4.47 (m 2H), 6.02-6.29 (t, 1H). MS m/z: 518 (M − 1) 212

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.29-1.30 (d, 3H), 1.34-1.37 (m, 2H), 1.92 (m, 1H), 1.98-2.00 (m, 2H), 2.47-2.51 (m, 1H), 2.87-2.94 (m, 1H), 3.27-3.35 (m, 3H), 3.49-3.59 (m, 3H), 3.87-3.94 (m, 1H), 4.14- 4.16 (m, 1H), 4.31-4.45 (m, 1H), 4.45-4.47 (m, 2H), 6.02-6.29 (t, 1H). MS m/z: 610 (M + 1) 213

¹H NMR (D₂O) δ ppm: 1.20 (d, 3H), 1.36- 1.37 (d, 3H), 1.79 (m, 1H), 2.90 (m, 1H), 3.30-3.35 (m, 2H), 3.53-3.63 (m, 3H), 3.71 (m, 2H), 3.78-3.80 (m, 3H), 3.92 (m, 1H), 4.02-4.12 (m, 1H), 4.15-4.17 (m, 1H), 4.45 (m, 1H), 4.61 (m, 1H). MS m/z: 516 (M − 1) 214

¹H NMR (D₂O) δ ppm: 1.09-1.12 (m, 3H), 1.28-1.34 (d, 3H), 2.47-2.49 (m, 2H), 2.76 (s, 3H), 2.99-3.09 (m, 1H), 3.30 (m, 1H), 3.35-3.39 (m, 1H), 3.34-3.46 (m, 2H), 3.50- 3.55 (m, 3H), 3.65-3.69 (m, 3H), 3.72-3.76 (m, 2H), 3.94 (m, 1H), 4.12-4.14 (m, 1H), 4.16-4.18 (d, 1H) 4.45-4.48 (m, 1H), 4.55- 4.59 (m, 1H). MS m/z: 498 (M + 1) 215

¹H NMR (D₂O) δ ppm: 1.05-1.07 (d, 3H), 1.30-1.31 (d, 3H), 2.43-2.45 (d, 2H), 2.76 (s, 3H), 2.99-3.09 (dd, 1H), 2.76 (s, 3H), 3.30 (m, 1H), 3.43-3.46 (m, 2H), 3.50-3.55 (m, 3H), 3.58-3.63 (m, 2H), 3.72-3.76 (m, 2H), 4.14-4.16 (m, 1H), 4.18-4.19 (m, 1H), 4.46-4.48 (m, 1H) 4.55-4.59 (m, 1H). MS m/z: 498 (M + 1) 216

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.32-1.34 (d, 3H), 1.98-2.00 (m, 2H), 2.07- 2.09 (m, 1H), 2.47-2.51 (m, 1H), 2.63-2.74 (m, 1H), 3.05-3.12 (m, 1H), 3.32-3.35 (m, 3H), 3.39-3.49 (m, 2H), 3.53-3.55 (m, 1H), 3.57-3.59 (m, 1H), 3.74-3.78 (d, 1H), 3.81- 3.90 (m, 4H), 4.07-4.15 (m, 1H), 4.23-4.29 (m, 1H), 4.29-4.31 (m, 2H), 4.45-4.46 (d, 1H). MS m/z: 603 (M + 1) 217

¹H NMR (D₂O) δ ppm: 1.07-1.08 (d, 3H), 1.22-1.29 (d, 3H), 2.02-2.05 (m, 1H), 2.03- 2.04 (m, 1H), 2.75-.276 (d, 3H), 2.98-2.99 (m, 1H), 3.24-3.25 (m, 1H), 3.32-3.41 (m, 3H), 3.52-3.56 (m, 1H), 3.73-3.82 (m, 2H), 3.87-3.93 (m, 4H), 4.13-4.15 (m, 1H), 4.41- 4.45 (m, 1H), 4.46-4.48 (m, 1H), 4.49-4.58 (m, 1H). MS m/z: 512 (M+) 218

¹H NMR (D₂O) δ ppm: 1.07-1.8 (d, 3H), 1.25-1.27 (d, 3H), 1.79 (m, 1H), 2.7 (s, 3H), 2.84 (m, 1H), 3.23 (d, 1H), 3.40-3.42 (m, 2H), 3.43-3.44 (m, 1H), 3.52-3.58 (m, 1H), 3.7 (m, 2H), 3.79-3.81 (m, 5H), 4.02-4.12 (m, 1H), 4.13-4.15 (m, 1H), 4.4 (m, 1H), 4.58 (m, 1H). MS m/z: 510 (M+) 219

¹H NMR (D₂O) δ ppm: 1.20 (d, 3H), 1.26 (d, 3H), 1.35 (m, 2H), 1.86 (m, 1H), 1.92 (m, 1H), 2.27 (m, 1H), 2.93 (m, 1H), 3.11 (m, 2H), 3.22 (m, 1H), 3.35 (m, 2H), 3.45 (m, 1H), 3.58 (m, 2H), 3.67 (m, 1H), 3.78 (m, 2H), 3.9 (m, 1H), 4.15 (m, 1H), 4.45 (m, 2H), 6.15 (t, 1H). MS m/z: 515 (M+) 220

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.28 (d, 3H), 1.29 (m, 1H), 1.35 (m, 2H), 1.86 (m, 1H), 1.92 (m, 1H), 2.0 (m, 1H), 2.27 (m, 1H), 1.69 (m, 2H), 2.93 (m, 1H), 3.11 (m, 2H), 3.22 (m, 1H), 3.35 (m, 2H), 3.45 (m, 1H), 3.58 (m, 2H), 3.67 (m, 1H), 3.78 (m, 2H), 3.9 (m, 1H), 4.15 (m, 1H), 4.45 (t, 2H), 6.15 (t, 1H). MS m/z: 508 (M+) 221

¹H NMR (D₂O) δ ppm: 1.0 (d, 3H), 1.29 (d, 3H), 2.43-2.48 (m, 2H), 2.58-2.62 (m, 4H), 2.68-2.72 (m, 4H), 2.81-2.83 (m, 2H), 2.9 (m, 2H), 3.02 (m, 2H), 3.17 (m, 2H), 3.39 (m, 2H), 3.64-3.69 (m, 2H), 3.8 (m, 2H) 3.93 (m, 3H). MS m/z: 538 (M + 1) 222

¹H NMR (D₂O) δ ppm: 1.04-1.08 (d, 3H), 1.18-1.20 (m, 3H), 2.47-2.53 (m, 2H), 2.73 (m, 2H), 2.81-2.83 (m, 1H), 3.02 (m, 1H), 3.19-3.22 (m, 6H), 3.64-3.69 (m, 6H), 3.81 (m, 2H), 3.98 (m, 6H), 4.02-4.24 (m, 4H). MS m/z: 680 (M + 1) 223

¹H NMR (D₂O) δ ppm: 1.03-1.09 (d, 3H), 1.18-1.30 (d, 3H), 1.90 (m, 2H), 2.06-2.08 (m, 1H), 2.46-2.51 (m, 2H), 2.99-3.00 (m, 4H), 3.07-3.11 (m, 3H), 3.36-3.44 (m, 4H), 3.61-3.67 (m, 1H), 3.76 (m, 1H), 4.15 (m, 2H), 4.54 (m, 2H). MS m/z: 497 (M+) 224

¹H NMR (D₂O) δ ppm: 1.07-1.09 (d, 3H), 1.19-1.26 (d, 3H), 1.34 (m, 1H), 1.92 (m, 4H), 2.15 (m, 2H), 2.47 (m, 2H), 2.99 (m, 4H), 3.07-3.09 (m, 3H), 3.35-3.39 (m, 4H), 3.60 (m, 2H), 3.73-3.77 (m, 2H), 4.69 (m, 2H). MS m/z: 496 (M + 1) 225

¹H NMR (D₂O) δ ppm: 1.22 (d, 3H), 1.29- 1.30 (d, 3H), 1.72-1.75 (m, 2H), 1.92 (m, 2H), 2.44-2.47 (m, 2H), 2.69-2.77 (m, 1H), 3.32-3.48 (m, 7H), 3.62-3.67 (m, 2H), 3.4- 3.76 (d, 1H), 3.85-3.86 (d, 1H), 4.02 (m, 1H), 4.14-4.16 (m, 1H), 4.42-4.43 (m, 1H), 4.45 (m, 1H). MS m/z: 516 (M + 1) 226

¹H NMR (D₂O) δ ppm: 1.29-1.31 (d, 3H), 1.34 (d, 3H), 1.72-1.74 (m, 1H), 1.92 (m, 2H), 2.07-2.08 (m, 2H), 2.46-2.47 (m, 1H), 2.73-2.76 (m, 1H), 3.32-3.38 (m, 4H), 3.67- 3.74 (m, 2H), 3.77 (m, 1H), 3.89-4.01 (m, 1H), 4.14 (m, 1H), 4.15-4.17 (m, 1H), 4.33- 4.35 (m, 1H), 4.44 (m, 1H), 4.46-4.47 (m, 1H), 4.69-4.74 (m, 1H). MS m/z: 516 (M+) 227

¹H NMR (D₂O) δ ppm: 1.06-1.08 (d, 3H), 1.22-1.26 (d, 3H), 1.86 (m, 1H), 1.91 (m, 1H), 2.46 (m, 2H), 2.99 (m, 3H), 3.36 (m, 3H), 3.45 (m, 3H), 3.59 (m, 3H), 3.74-3.77 (m, 1H), 3.97 (m, 1H), 4.15-4.17 (m, 1H), 4.36 (m, 2H), 4.46 (m, 1H), 4.61 (m, 1H). MS m/z: 480 (M + 1) 228

¹H NMR (D₂O) δ ppm: 1.22-1.25 (d, 3H), 1.31-1.34 (d, 3H), 1.89-1.92 (m, 1H), 2.06- 2.08 (m, 2H), 2.45-2.46 (m, 2H), 2.99 (s, 3H), 3.07 (s, 3h), 3.36-3.40 (m, 3H), 3.44- 3.46 (m, 2H), 3.55-3.58 (m, 1H), 3.78-3.82 (m, 1H), 3.92-3.98 (m, 1H), 4.14-4.16 (m, 1H), 4.33-4.35 (m, 1H), 4.42-4.44 (m, 1H), 4.45-4.48 (m, 1H). Mass 478 (M − 1). MS m/z: 478 (M − 1) 229

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.31-1.34 (d, 3H), 1.89-1.92 (m, 1H), 2.04- 2.08 (m, 1H), 2.10-2.12 (m, 1H), 2.46-2.48 (m, 2H), 2.88-2.92 (m, 1H), 3.07 (s, 3H), 3.22-3.28 (m, 2H), 3.32-3.40- (m, 2H), 3.60- 3.63 (m, 2H), 3.66-3.67 (m, 2H), 3.89-3.91 (m, 2H), 4.07-4.12 (m, 2H), 4.22-4.24 (m, 1H), 4.45-4.48 (m, 1H). MS m/z: 522 (M + 1) 230

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.27-1.29 (d, 3H), 1.89-1.92 (m, 1H), 2.01- 2.03 (m, 1H), 2.08-2.12 (m, 1H), 2.48-2.52 (m, 2H), 2.82-2.89 (m, 1H), 3.04 (s, 3H), 3.45-3.45 (m, 1H), 3.48-3.49 (m, 1H), 3.57- 3.60 (m, 1H), 3.75-3.79 (m, 3H), 3.87-3.91 (m, 2H), 3.94-3.96 (m, 1H), 4.12-4.17 (m, 2H), 4.38-4.44 (m, 1H), 3.43-3.46 (m, 1H). 231

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.27-1.29 (d, 3H), 1.80-1.83 (m, 1H), 2.02- 2.03 (m, 1H), 2.44-2.46 (m, 1H), 2.95-2.96 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.08- 3.11 (m, 2H), 3.33-3.35 (m, 2H), 3.49-3.52 (m, 1H), 3.93-3.97 (m, 1H), 4.14-4.18 (m, 3H), 4.45-4.47 (m, 2H). MS m/z: 496 (M + 1) 232

¹H NMR (D₂O) δ ppm: 1.24-1.26 (d, 3H), 1.66-1.68 (m, 1H) 1.76-1.78 (m, 3H), 2.06- 2.08 (m, 1H), 2.18-2.22 (m, 1H) 2.32-2.34 (m, 1H), 2.40-2.43 (m, 1H), 2.46-2.5 (m, 1H), 2.88-2.92 (m, 1H), 3.40 (s, 3H), 3.66- 3.71 (m, 2H), 3.73-3.77 (m, 1H), 3.87-3.91 (m, 4H), 3.92-3.94 (m, 2H) 3.96-3.98 (m, 1H), 4.06-4.12 (m, 1H), 4.13-4.15 (m, 1H) 8.19 (s, 1H). MS m/z: 520 (M + 1) 233

¹H NMR (D₂O) δ ppm: 1.12-1.14 (d, 3H), 1.67-1.68 (m, 1H), 1.76-1.78 (d, 3H), 1.95- 1.98 (m, 1H), 2.99 (s, 3H), 3.06 (s, 3H), 3.09-3.12 (m, 2H), 3.24-3.26 (m, 1H), 3.40 (s, 3H), 3.41 (m, 1H), 3.67-3.72 (m, 3H), 3.97-3.99 (m, 2H), 4.13-4.15 (m, 1H), 8.19 (s, 1H). MS m/z: 477 (M − 1) 234

¹H NMR (D₂O) δ ppm: 1.13-1.14 (d, 3H), 1.69-1.72 (m, 1H), 1.76-1.78 (d, 3H), 2.69- 2.73 (m, 2H), 3.22-3.24 (m, 1H), 3.36 (s, 3H), 3.39-3.44 (m, 2H) 3.54-3.55 (m, 2H), 3.62-3.67 (m, 2H), 3.92-3.99 (m, 3H), 4.13- 4.15 (m, 1H), 8.19 (s, 1H). MS m/z: 514 (M − 1) 235

¹H NMR (D₂O) δ ppm: 1.14-1.18 (d, 3H), 1.35-1.36 (d, 3H), 1.95 (m, 1H), 2.66 (d, 1H), 2.99-3.01 (m, 1H), 3.23-3.33 (d, 1H), 3.44-3.47 (m, 2H), 3.54-3.59 (d, 2H), 3.81- 3.89 (m, 3H), 4.03-4.08 (m, 2H), 4.40 (M, 2H), 4.64 (m, 1H), 6.15-6.29 (t, 1H). MS m/z: 571 (M + 1). 236

¹H NMR (D₂O) δ ppm: 1.02-1.2 (d, 3H), 1.21-1.27 (d, 3H), 1.7-1.72 (m, 1H), 2.13 (m, 1H), 2.46 (m, 1H), 2.68 (m, 1H), 3.34- 3.45 (m, 6H), 3.60-3.65 (m, 5H), 3.83 (m, 1H), 4.05 (m, 1H), 4.43 (m, 1H), 4.80 (m, 1H), 6.02-6.09 (t, 1H). MS m/z: 566 (M+) 237

¹H NMR (D₂O) δ ppm: 1.07-1.20 (d, 3H), 1.28-1.30 (m, 3H), 1.9 (m, 1H), 2.16 (m, 1H), 2.47-2.48 (m, 1H), 2.71-2.73 (m, 1H), 3.32-3.46 (m, 6H), 3.65 (m, 5H), 3.85 (m, 1H), 4.12 (m, 1H), 4.43 (m, 1H), 4.47 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 566 (M+) 238

¹H NMR (D₂O) δ ppm: 1.02-1.2 (d, 3H), 1.26-1.28 (d, 3H), 1.42 (m, 1H), 2.13-2.49 (m, 3H), 3.59 (m, 2H), 3.63-3.66 (m, 2H), 3.34-3.89 (m, 2H), 3.94-3.97 (m, 3H), 4.09- 4.14 (m, 2H), 4.44 (m, 1H), 6.02-6.29 (m, 1H) 7.65-7.92 (m, 3H), 8.2 (s, 1H). MS m/z: 620 (M+) 239

¹H NMR (D₂O) δ ppm: 1.01-1.2 (d, 3H), 1.21-1.28 (d, 3H), 1.95 (m, 1H), 2.51-2.53 (m, 1H), 2.91 (s, 3H), 3.01 (s, 3H), 3.35- 3.43 (m, 2H), 3.65-3.67 (m, 2H), 3.80-3.84 (m, 2H), 4.08-4.09 (m, 2H). MS m/z: 462 (M + 1) 240

¹H NMR (D₂O) δ ppm: 0.97-1.09 (d, 3H), 1.23-1.29 (d, 3H), 2.13-2.25 (m, 4H), 2.63 (m, 2H), 2.79-2.82 (m, 2H), 3.35-3.50 (m, 2H), 3.61-3.64 (m, 1H), 3.90 (m, 3H), 4.01 (m, 1H), 4.24 (m, 1H), 4.64 (m, 1H). MS m/z: 502 (M+) 241

¹H NMR (D₂O) δ ppm: 1.06-1.30 (d, 6H), 1.92 (m, 1H), 2.95 (s, 3H), 3.14 (s, 3H), 3.32 (m, 2H), 3.4 (m, 2H), 3.73-3.76 (m, 2H), 3.88-3.99 (m, 2H), 4.02 (m, 1H), 4.30- 4.32 (m, 1H), 4.45 (m, 1H). MS m/z: 481 (M+) 242

¹H NMR (D₂O) δ ppm: 1.19-1.22 (d, 3H), 1.26-1.30 (d, 3H), 1.72-1.83 (m, 1H), 2.15- 2.18 (m, 1H), 2.33-2.35 (m, 1H), 2.43-2.46 (m, 1H), 2.74-2.78 (m, 1H), 3.09-3.12 (m, 1H), 3.23-3.26 (m, 1H), 3.36-3.39 (m, 2H), 3.54-3.57 (m, 1H), 3.68-3.73 (m, 2H), 3.74- 3.78 (m, 2H), 3.98-4.02 (m, 2H), 4.13-4.15 (m, 1H), 4.34-4.43 (m, 1H), 4.45-4.47 (m, 1H). 243

¹H NMR (D₂O) δ ppm: 1.07-1.17 (d, 3H), 1.37-1.38 (d, 3H), 3.04 (m, 2H), 1.86-1.92 (1H), 3.15 (s, 3H), 3.31-3.37 (m, 3H), 3.47 (m, 1H), 3.74 (s, 3H), 3.75 (m, 1H), 3.97 (m, 1H), 4.17 (m, 1H), 4.46 (m, 1h), 4.6-4.68 (m, 1H), 6.08-6.29 (t, 1H), 6.38 (s, 1H), 7.65 (s, 1H). 244

¹H NMR (D₂O) δ ppm: 1.20-1.21 (d, 3H), 1.35-1.37 (d, 3H), 1.89-1.93 (m, 1H), 2.06- 2.08 (m, 1H), 2.44-2.68 (m, 1H), 3.08-3.12 (m, 1H), 3.34-3.35 (m, 1H), 3.43-3.46 (m, m2H), 3.57-3.59 (m, 1H), 3.67-3.71 (m, 1H), 3.84-3.86 (m, 1H), 4.13-4.16 (m, 1H), 4.25-4.26 (m, 1H), 6.02-6.29 (t, 1H). MS m/z: 419 (M + 1) 245

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.31-1.33 (d, 3H), 1.88-1.92 (m, 1H), 2.10- 2.13 (m, 1H), 2.22-2.24 (m, 1H), 2.47-2.49 (m, 1H), 2.89-2.93 (m, 1H), 3.23-3.27 (m, 1H), 3.38-3.40 (m, 1H), 3.48-3.49 (m, 1H), 3.57-3.58 (m, 2H), 3.63-3.67 (m, 1H), 3.70- 3.72 (m, 1H), 3.78-3.80 (m, 2H), 3.84-3.86 (m, 2H), 3.91-4.05 (m, 1H), 4.13-4.16 (m, 1H), 4.34-4.36 (m, 1H), 4.44-4.45 (m, 1H). 246

¹H NMR (D₂O) δ ppm: 1.20-1.22 (d, 3H), 1.35-1.37 (d, 3H), 1.84-1.88 (m, 1H), 1.98- 2.00 (m, 1H), 2.22-2.27 (m, 1H), 2.88-2.92 (m, 1H), 3.36-3.43 (m, 2H), 3.46-3.48 (m, 2H), 3.57-3.59 (m, 3H), 3.65-3.71 (m, 3H), 3.74-3.80 (m, 2H), 3.82-3.85 (m, 2H), 4.01- 4.03 (m, 1H), 4.14-4.16 (m, 1H), 4.32-4.34 (m, 1H), 4.44-4.45 (m, 1H), 6.02-6.29 (t, 1H), 6.61 (s, 1H), 7.43 (s, 1H). MS m/z: 639 (M + 1) 247

¹H NMR (D₂O) δ ppm: 1.25-1.27 (d, 3H), 1.35-1.37 (d, 3H), 1.96-1.98 (m, 1H), 2.06- 2.10 (m, 1H), 3.02-3.04 (m, 1H), 3.20-3.22 (m, 1H), 3.34-3.38 (m, 1H), 3.41-3.48 (m, 1H), 3.60-3.64 (m, 1H), 3.69-3.78 (m, 2H), 3.90-3.93 (m, 1H), 4.00-4.02 (m, 1H), 4.25- 4.26 (m, 1H), 4.27-4.27 (m, 1H), 4.28-4.30 (m, 1H), 4.43-4.51 (m, 2H) 6.02-6.29 (t, 1H). MS m/z: 559 (M+) 248

¹HNMR (D₂O)- 1.28 (d, 3H), 1.36 (d, 3H), 2.38-2.50 (m, 1H), 2.96 (s, 3H), 2.99 (m, 2H), 3.01 (m, 1H), 3.29 (m, 1H), 3.36 (s, 3H), 3.42-3.5 (m, 1H), 3.61-3.68 (m, 1H), 4.01 (d, 1H), 4.18 (d, 1H), 4.44-4.47 (m, 1H), 6.03-6.29 (t, 1H). Mass-(460.50) 461.1 249

¹HNMR (D₂O)- 1.22 (d, 3H), 1.28 (d, 3H), 1.34 (m, 1H), 1.57 (m, 1H), 1.82 (m, 1H), 2.08 (d, 1H), 2.30 (m, 1H), 2.30 (m, 1H), 2.99 (s, 3H), 3.12 (d, 3H), 3.32-3.46 (m, 3H), 3.60-3.81 (m, 2H), 4.00 (d, 2H), 4.42 (m, 1H), 4.59 (m, 1H), 4.72 (m, 1H), 5.25 (m, 1H). Mass (494.61) 495.1. 250

¹HNMR (D₂O)- 1.10 (d, 3H), 1.21 (d, 3H), 1.98 (m, 1H), 2.15 (m, 1H), 2.55 (m, 2H), 2.89 (m, 1H), 3.27-3.45 (m, 2H), 3.41 (d, 1H), 3.59 (m, 5H), 3.84 (d, 2H), 3.96 (m, 1H), 4.56 (m, 1H), 4.74 (m, 1H), 5.28 (m, 1H). Mass (535.66) 536.2. 251

¹HNMR (D₂O)- 1.22 (d, 3H), 1.37 (d, 3H), 1.47 (m, 1H), 1.92-2.03 (m, 2H), 2.40 (m, 1H), 3.07 (d, 2H), 3.37-3.44 (m, 2H), 3.54- 3.75 (m, 6H), 4.18 (d, 1H), 4.47 (d, 1H), 4.67-4.86 (m, 1H), 5.42-5.62 (dd, 1H), 6.08- 6.29 (t, 1H). Mass (533.56) 533.1. 252

¹HNMR (D₂O)- 1.22 (d, 3H), 1.32 (d, 3H), 1.62-1.68 (m, 1H), 1.76-1.83 (m, 1H), 2.45- 2.51 (m, 2H), 2.60-2.66 (m, 2H), 2.73 (s, 3H), 2.78 (m, 1H), 3.32-3.37 (m, 3H), 3.44- 3.48 (m, 3H), 3.55-3.61 (m, 2H), 3.72-3.78 (m, 2H), 3.81-3.90 (m, 3H), 4.12-4.16 (dd, 1H), 4.44-4.48 (m, 1H). Mass (559.70) 560.1. 253

¹HNMR (D₂O)- 1.22 (d, 3H), 1.29 (d, 3H), 1.79-1.83 (m, 1H), 2.08-2.12 (m, 1H), 2.44- 2.50 (m, 2H), 2.73 (m, 2H), 2.75 (d, 2H), 3.30-3.33 (m, 2H), 3.46 (m, 2H), 3.48 (m, 2H), 3.52 (m, 1H), 3.59 (m, 1H), 3.59-3.62 (m, 1H), 3.72-3.79 (m, 1H), 3.84 (m, 1H), 3.86 (m, 1H), 4.04-4.05 (m, 1H), 4.14-4.16 (m, 1H), 4.36-4.39 (m, 1H), 4.44-4.48 (m, 1H). Mass (559.70) 560.2. 254

¹HNMR (D₂O)- 1.21 (d, 3H), 1.29 (d, 3H), 1.69 (m, 1H), 2.74 (m, 1H), 2.75 (d, 6H), 3.28-3.38 (m, 2H), 3.55 (m, 2H), 3.73 (m, 1H), 3.76-3.84 (m, 1H), 3.90 (s, 3H), 4.47 (s, 3H), 6.74 (s, 1H), 7.06 (s, 1H). Mass (562.64) 561.1 255

¹HNMR (D₂O)- 1.21 (d, 3H), 1.29 (d, 3H), 1.84-1.89 (m, 2H), 1.91 (m, 3H), 1.96-1.98 (m, 1H), 2.32-2.39 (m, 1H), 2.63-2.70 (m, 1H), 3.75 (s, 3H), 2.97-3.01 (m, 1H), 3.28- 3.38 (m, 2H), 3.54 (d, 1H), 3.58-3.59 (dd, 3H), 3.78-3.85 (m, 2H), 3.86 (d, 2H), 3.97 (br, 1H), 4.14 (d, 1H), 4.44-4.47 (m, 1H). Mass (522.66) 522. 256

¹HNMR (D₂O)- 1.16-1.18 (d, 3H), 1.25- 1.27 (d, 3H), 1.92 (s, 1H), 2.77 (s, 3H), 3.17-3.21 (m, 3.56-3.58 (m, 1H), 3.60-3.64 (m, 2H), 3.87 (d, 2H), 3.97-4.01 (m, 2H), 4.10-4.13 (dd, 1H), 4.15 (br, s, 1H), 4.18- 4.25 (m, 2H), 4.34-4.35 (m, 1H), 4.44-4.47 (m, 1H), 4.69-4.71 (m, 2H). Mass (453.58) 454.1 257

¹HNMR (D₂O)- 1.05 (d, 3H), 1.24 (d, 3H), 1.39-1.42 (m, 1H), 1.92 (s, 1H), 2.77 (d, 2H), 2.80 (m, 2H), 2.98 (m, 1H), 3.05-3.21 (m, 1H), 3.44-3.49 (m, 2H), 3.51-3.55 (m, 1H), 3.72-3.74 (m, 1H), 3.92-4.03 (m, 3H), 4.1-4.25 (m, 2H), 4.40 (d, 3H), 6.62 (d, 1H), 7.70 (s, 1H). Mass (479.55) 480.1 258

¹HNMR (D₂O)- 1.21 (d, 3H), 1.31 (d, 3H), 1.84-1.86 (m, 1H), 2.07-2.08 (m, 2H), 2.32- 2.33 (m, 2H), 2.46-4.48 (m, 3H), 2.97-2.98 (m, 2H), 3.32-3.33 (m, 2H), 3.50-3.52 (m, 2H), 3.72-3.74 (m, 2H), 3.98-4.01 (m, 1H), 3.4.014-4.17 (m, 1H), 4.27-4.29 (m, 1H) 4.45-54.48 (m, 1H) 6.16 (t, 1H). Mass- (529.60) 530. 259

¹HNMR (D2O)- 1.21 (d, 3H), 1.35 (d, 3H), 2.46-2.48 (m, 1H), 2.61-2.68 (m, 2H), 3.05 (d, 1H), 3.34 (m, 2H), 3.58-3.65 (m, 4H), 3.89-4.16 (m, 3H), 4.10 (d, 1H), 4.44 (d, 1H), 6.15 (t, 1H). Mass (530.59) 531.2. 260

¹HNMR (D₂O)- 1.21 (d, 3H), 1.33 (d, 3H), 1.84-1.87 (m, 1H), 2.08-2.11 (m, 2H), 2.31- 2.33 (m, 2H), 2.64-2.68 (m, 2H), 2.86-2.99 (m, 2H), 3.33-3.35 (m, 2H), 3.49 (m, 1H), 3.52-3.56 (m, 2 H), 3.60-3.64 (m, 1H), 3.68-3.69 (m, 1H), 3.71 (m, 1H), 3.77-3.79 (m, 1H), 4.14-4.16 (m, 1H), 4.30-4.47 (m, 1H), 6.16 (t, 1H). Mass (529.60) 530.2. 261

¹HNMR (D₂O)- 1.21 (d, 3H), 1.36 (d, 3H), 2.32-2.33 (m, 1H), 2.45-2.48 (m 2H), 3.07- 3.10 (m, 1 H), 3.30-3.33 (m, 4H), 3.52-3.57 (m, 4H), 3.74-3.79 (m, 3H), 3.91-3.94 (m, 3H), 4.07-4.11 (m, 2H), 6.15 (t, 1H). Mass (530.59) 531.2. 262

¹HNMR (D₂O)- 1.21 (d, 3H), 1.28 (d, 3H), 1.84-1.89 (m, 2H), 1.96-1.98 (m, 1H), 2.32- 2.39 (m, 2H), 2.63-2.70 (m, 2H), 3.75 (s, 3H), 2.97-3.01 (m, 2H), 3.28-3.38 (m, 2H), 3.54 (d, 1H), 3.58-3.59 (dd, 3H), 3.78-3.85 (m, 2H), 3.86 (d, 2H), 3.97 (br, 1H), 4.14 (d, 1H), 4.44-4.47 (m, 1H). Mass (522.66) 523. 263

¹HNMR (D₂O)- 1.17 (d, 3H), 1.36 (d, 3H), 3.18-3.19 (m, 1H), 3.56-3.62 (m, 2H), 3.63- 3.65 (m, 2H), 3.98-4.01 (m, 2H), 4.12-4.14 (m, 1H), 4.23-4.26 (m, 1H), 4.42-4.46 (m, 2H), 4.56 (m, 2H), 6.16 (t, 1H). Mass (460.52) 461.0. 264

¹HNMR (D₂O)- 1.22 (d, 3H), 1.32 (d, 3H), 1.78-1.81 (m, 1H), 2.2 (m, 1H), 2.76 (s, 3H), 2.86 (m, 2H), 3.20-3.22 (m, 2H), 3.32- 3.36 (m, 3H), 3.57-3.58 (m, 2H), 3.76-3.78 (m, 3H), 3.84-3.85 (m, 3H), 3.89 (m, 2H), 4.12-4.15 (m, 1H), 4.29-4.37 (m, 2H), 4.4- 4.48 (m, 1H). Mass (522.66) 523.2. 265

¹HNMR (D₂O)- 1.18 (d, 3H), 1.36 (d, 3H), 1.99-2.01 (m, 1H), 2.16 (s, 3H), 2.7-2.75 (m, 1H), 2.87-2.92 (m, 1H), 3.41-3.44 (m, 1H), 3.48 (m, 1H), 3.57-3.59 (m, 2H), 3.86- 3.90 (m, 1H), 4.10-4.13 (m, 2H), 4.22-4.24 (m, 1H), 4.42-4.47 (m, 1H), 6.16 (t, 1H). Mass (460.50) 461.1. 266

¹HNMR (D₂O)- 1.27 (d, 3H), 1.37 (d, 3H), 1.8-1.86 (m, 2H), 1.91-1.96 (m, 2H), 2.14- 2.20 (m, 2H), 2.31-2.33 (m, 1H), 2.59-2.60 (m, 1H), 2.95-296 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.21-3.22 (m, 1H), 3.40-3.45 (m, 2H), 3.73-3.77 (m, 2H), 3.91 (m, 1H), 4.13-4.15 (m, 1H), 4.43-4.47 (m, 2H). MS (493.62) 494. 267

¹HNMR (D₂O)- 1.19 (d, 3H), 1.36 (d, 3H), 1.71-1.73 (m, 1H), 2.60-2.68 (m, 1H), 3.05- 3.07 (m, 1H), 3.16-3.18 (m, 2H), 3.33-3.35 (m, 2H), 3.57-3.58 (m, 2H), 3.603.63 (m, 1H), 4.06-4.08 (m, 2H), 4.43-4.47 (m, 1H), 6.16 (t, 1H). Mass (497.54) 498.0. 268

¹HNMR (D₂O)- 1.17 (d, 3H), 1.42 (d, 3H), 1.92 (s, 3H), 3.04 (s, 5H), 3.28-3.31 (m, 2H), 3.34-3.38 (m, 2H), 3.41-3.48 (t, 1H), 3.53-3.65 (m, 2H), 3.91-3.99 (m, 3H), 4.16 (d, 1H), 4.35-4.39 (q, 1H), 4.55-4.58 (dd, 1H), 4.61-4.65 (m, 2H). Mass (467.65)- 468.1. 269

¹HNMR (D₂O)- 1.24 (d, 3H), 1.30 (d, 3H), 1.47-1.48 (m, 4H), 2.43-2.50 (m, 1H), 2.63- 2.72 (m, 4H), 2.75 (s, 3H), 3.18-3.23 (q, 2H), 3.32-3.35 (m, 1H), 3.59-3.65 (m, 1H), 3.72-3.79 (m, 1H), 3.84 (m, 2H), 4.13-4.23 (m, 1H), 4.36-4.47 (m, 1H). Mass (490.60) 491.2. 270

¹HNMR (D₂O)- 1.20 (d, 3H), 1.31 (d, 3H), 1.52 (s, 1H), 1.91 (m, 2H), 2.68 (s, 1H), 2.99 (s, 4H), 3.07 (s, 3H), 3.14-3.35 (m, 1H), 3.35 (m, 3H), 3.59 (m, 2H), 4.00 (m, 2H), 4.12-4.17 (m, 2H), 4.27-4.39 (m, 2H), 4.57-4.73 (m, 2H). Mass (497.63) 498.1. 271

¹HNMR (D₂O)- 1.21 (d, 3H), 1.32 (d, 3H), 1.52 (m, 1H), 1.84 (m, 1H), 1.91 (m, 1H), 2.12 (m, 1H), 2.24 (m, 1H), 2.48 (m, 2H), 2.68 (m, 2H), 2.84 (m, 2H), 3.12-3.15 (m, 4H), 3.37 (m, 2H), 3.58-3.61 (m, 2H), 3.70- 3.76 (m, 2H), 3.87 (s, 2H), 3.99-4.25 (m, 4H), 4.39-4.71 (m, 1H). Mass (538.68) 537. 272

¹HNMR (D₂O)- 1.33 (d, 3H), 1.46 (d, 3H), 1.92-1.97 (m, 2H), 2.56 (m, 1H), 2.73 (s, 3H), 2.76 (s, 3H), 2.95-2.99 (m, 2H), 3.07 (m, 2H), 3.09 (m, 2H), 3.11 (m, 1H), 3.25- 3.29 (m, 2H), 3.36-3.4 (m, 2H), 3.71-3.77 (m, 1H), 3.92-3.98 (m, 2H), 4.12-4.75 (m, 2H). Mass (481.57) 482.2 273

¹HNMR (D₂O)- 1.24 (d, 3H), 1.33 (d, 3H), 1.82-1.83 (m, 2H), 2.53-2.56 (m, 2H), 2.76 (s, 3H), 3.05 (m, 2H), 3.17-3.20 (m, 2H), 3.32-3.37 (m, 2H), 3.72-3.73 (m, 2H), 3.78 (d, 2H), 4.02-4.07 (m, 2H). Mass (468.57) 469.5 274

¹HNMR (D₂O)- 0.96 (s, 3H), 1.22 (d, 3H), 1.25 (d, 3H), 1.31 (d, 3H), 1.49-1.56 (m, 2H), 2.99 (m, 1H), 3.04 (s, 3H), 3.07 (s, 3H), 3.09 (m, 1H), 3.35-3.45 (m, 2H), 3.58- 3.59 (m, 1H), 3.72-3.73 (m, 1H), 3.82 (m, 1H), 3.86 (m, 1H), 4.00 (m, 1H), 4.26 (d, 1H), 4.62 (m, 1H). Mass (438.58) 439.2 275

¹HNMR (D₂O)- 1.24 (d, 3H), 1.33 (d, 3H), 1.82-1.83 (m, 2H), 2.53-2.56 (m, 2H), 2.76 (s, 3H), 3.05 (m 3H), 3.17-3.20 (m, 4H), 3.32-3.37 (m, 4H), 3.72-3.73 (m, 2H), 3.72- 3.73 (m, 2H), 3.78 (d, 2H), 4.02-4.07 (m, 2H), 7.31 (d, 2H), 7.45 (d, 2H). Mass (598.76) 599.5 276

¹HNMR (D₂O)- 1.21 (d, 3H), 1.29 (d, 3H), 1.55-1.64 (m, 3H), 1.78 (m, 1H), 2.43-2.47 (m, 3H), 2.76 (s, 3H), 2.97 (m, 1H), 3.12 (m, 1H), 3.33 (m, 1H), 3.44-3.47 (m, 2H), 3.58-3.78 (m, 3H), 3.86 (d, 2H), 3.99 (m, 1H), 4.08-4.13 (m, 2H), 4.40 (m, 1H), 4.49 (m, 1H), 4.55-4.59 (m, 1H). Mass (522.66) 523.2 277

¹HNMR (D₂O)- 1.21 (d, 3H), 1.35 (d, 3H), 1.74-1.81 (m, 2H), 2.00-2.12 (m 4H), 2.47- 2.58 (m, 1H), 2.76 (s, 3H), 3.00-3.05 (m, 1H), 3.34-3.46 (m, 2H), 3.59-3.68 (m, 2H), 3.72-3.78 (m, 2H), 3.81 (m, 1H), 3.85 (m, 1H), 3.89 (d, 2H), 4.05 (d, 1H), 4.37 (m, 1H), 4.45-4.48 (m, 1H), 4.71-4.76 (m, 1H). Mass (551.66) 552.2 278

¹HNMR (D₂O)- 1.21 (d, 3H), 1.33 (d, 3H), 1.50 (s, 3H), 1.81-1.84 (m, 3H), 2.43-2.50 (m, 2H), 2.76 (s, 3H) 2.90-.299 (m, 1H), 3.20-3.33 (m, 2H), 3.38-3.50 (m, 2H), 3.59- 3.60 (m, 1H), 3.72-3.78 (m, 2H), 3.88 (d, 2H), 3.96 (m, 1H), 4.05-4.08 (m, 2H), 4.46- 4.49 (m, 1H), 4.54-4.56 (m, 1H). Mass (522.66) 523.4 279

¹HNMR (D₂O)- 1.22 (d, 3H), 1.36 (d, 3H), 1.57-1.60 (m, 2H), 1.87 (m, 2H), 2.06 (m, 2H), 2.56-2.60 (m, 2H), 2.76 (s, 3H), 3.07 (m, 1H), 3.20-3.22 (m, 1H), 3.35-3.42 (m, 2H), 3.54-3.59 (m, 2H), 3.72 (m, 2H), 3.97 (m, 1H), 4.00-4.09 (m, 2H), 4.12-4.14 (m, 1H), 4.46 (m, 1H). Mass (509.62) 509.61. 280

¹HNMR (D₂O)- 1.21 (d, 3H), 1.33 (d, 3H), 1.92-1.95 (m, 1H), 2.26 (m, 2H), 2.47-2.52 (m, 2H), 2.75-2.78 (m, 2H), 2.95-3.00 (m, 2H), 3.30-3.39 (m, 2H), 3.61-3.67 (m, 3H), 3.70-3.79 (m, 2H), 3.91 (m, 2H), 4.07-4.26 (m, 1H), 4.26-4.28 (m, 2H), 4.14-4.47 (m, 1H). Mass (570.68) 570.1 281

¹HNMR (D₂O)- 1.24 (d, 3H), 1.33 (d, 3H), 1.74-1.78 (m, 2H), 2.79-2.81 (m, 2H), 3.32- 3.49 (m, 4H), 3.52-3.55 (m, 2H), 3.63-3.68 (m, 1H), 3.93-3.96 (m, 1H), 4.03-4.06 (m, 1H), 4.10-4.13 (m, 2H), 4.40-4.49 (m, 2H). Mass (566.67) 566.5 282

¹HNMR (D₂O)- 1.21 (d, 3H), 1.28 (d, 3H), 1.86 (m, 2H), 2.08 (m, 2H), 2.23 (m, 1H), 2.47-2.48 (m, 1H), 2.60-2.68 (m, 1H), 2.70 (m, 1H), 2.75 (s, 3H), 3.33-3.42 (m, 3H), 3.56-3.63 (m, 2H), 3.72-3.76 (m, 2H), 3.86 (d, 2H), 4.05 (m, 1H), 4.13-4.16 (m, 1H), 4.40-4.43 (m, 1H), 5.30-5.49 (d, 1H). Mass (526.62) 527.1. 283

¹HNMR (D₂O)- 1.28 (d, 3H), 1.34 (d, 3H), 1.97-1.99 (m, 1H), 2.99 (s, 3H), 3.00 (s, 3H), 3.04 (m, 1H), 3.31-3.36 (m, 1H), 3.44- 3.48 (m, 1H), 3.57-3.60 (m, 1H), 3.73-3.77 (m, 1H), 4.05 (m, 1H), 4.13-4.16 (m, 1H), 4.40-4.43 (m, 1H), 5.42 (d, 2H), 9.27 (s, 1H). Mass (492.55) 493.8 284

¹HNMR (D₂O)- 1.29 (d, 3H), 1.36 (d, 3H), 1.84 (m, 1H), 2.60-2.79 (m, 2H), 3.00 (s, 3H), 3.05 (m, 1H), 3.07 (s, 3H), 3.38 (m, 2H), 3.48 (d, 2H), 3.63 (m, 2H), 3.76 (m, 1H), 4.06-4.17 (m, 2H), 4.42 (m, 2H). Mass (529.63) 529.1. 285

¹HNMR (D₂O)- 1.21 (d, 3H), 1.31 (d, 3H), 1.92 (m, 1H), 2.94 (d, 3H), 3.00 (d, 3H), 3.04 (m, 2H), 3.07 (m, 2H), 3.20-3.25 (m, 2H), 3.48 (m, 2H), 3.59-3.60 (m, 4H), 3.96 (m, 2H), 3.99-4.00 (m, 1H), 4.52-4.55 (m, 1H). Mass (494.61) 495.1 286

¹HNMR (D₂O)- 1.27 (m, 6H), 1.33 (d, 3H), 1.39 (d, 3H), 2.98 (d, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.08 (m, 1H), 3.18-3.20 (m, 1H), 3.40-3.44 (m, 2H), 3.55-3.58 (m, 1H), 3.71- 3.76 (m, 1H), 3.86-3.88 (m, 1H), 3.95-3.96 (m, 2H), 3.99-4.02 (m, 2H), 4.10 (m, 1H), 4.52-4.55 (m, 1H). Mass (551.66) 522. 287

¹HNMR (D₂O)- 1.24 (d, 3H), 1.31 (d, 3H), 1.35 (d, 3H), 1.72-1.75 (m, 1H), 2.08 (m, 1H), 2.45 (m, 2H), 2.70 (m, 2H), 2.76 (s, 3H), 2.89 (m, 1H), 3.29-3.40 (m, 2H), 3.58 (m, 2H), 3.74-3.76 (m, 1H), 3.96 (d, 2H), 4.15 (d, 2H), 4.21-4.23 (m, 1H), 4.45-4.46 (m, 1H). Mass (508.63) 509. 288

¹HNMR (D₂O)- 1.23 (d, 3H), 1.32 (d, 3H), 1.92 (m, 1H), 2.46 (m, 1H), 2.76 (s, 3H), 2.98 (m, 1H), 3.34 (m, 1H), 3.52-3.89 (m, 4H), 3.94-3.95 (m, 2H), 4.02-4.08 (m, 2H), 4.11-4.14 (m, 2H), 4.47 (m, 1H), 7.37-7.50 (m, 5H). Mass (570.70) 571.3. 289

¹HNMR (D₂O)- 1.26 (d, 3H), 1.36 (d, 3H), 2.75-2.81 (m, 2H), 2.94-3.00 (m, 1H), 3.21- 3.28 (m, 3H), 3.34-3.42 (m, 2H), 3.55-3.58 (m, 2H), 4.15 (d, 2H), 4.46 (m, 1H), 6.16 (t, 1H). Mass (418.46) 419.2. 290

¹HNMR (D₂O)- 1.26 (d, 3H), 1.36 (d, 3H), 1.39-1.46 (m, 1H), 1.89 (m, 1H), 2.28 (m, 1H), 2.76 (m, 3H), 2.98 (m, 1H), 3.36-3.42 (m, 1H), 3.49 (m, 3H), 3.58 (m, 1H), 3.65 (m, 1H), 3.74-3.76 (m, 2H), 3.87 (d, 2H), 3.98 (m, 1H), 4.13 (d, 1H), 4.26 (m, 1H), 4.47 (m, 1H), 4.60 (m, 2H). Mass (506.62) 507.3 291

¹HNMR (D₂O)- 1.11 (d, 3H), 1.26 (d, 3H), 1.55 (m, 1H), 1.69 (m, 1H), 1.92 (s, 2H), 2.67 (m, 1H), 2.70-2.76 (m, 3H), 3.18-3.22 (m, 1H), 3.56-3.60 (m, 2H), 3.91-3.92 (m, 1H), 3.98 (d, 3H), 4.12-4.15 (m, 3H), 4.44 (m, 1H), 4.46-4.47 (m, 1H), 4.69 (m, 1H), 4.82 (m, 1H). Mass (526.67) 527.1. 292

¹HNMR (D₂O)- 1.22 (d, 6H), 1.67 (d, 3H), 1.92 (d, 3H), 2.46-2.47 (m, 1H), 2.60-2.61 (m, 2H), 2.76-2.78 (m, 2H), 3.32 (m, 1H), 3.85 (m, 2H), 3.88-3.89 (m, 2H), 4.17 (m, 2H), 4.42-4.46 (m, 2H), 4.81-4.84 (m, 2H). Mass (494.61) 495.2 293

¹HNMR (D₂O)- 0.71 (d, 3H), 1.23 (d, 3H), 1.28-1.29 (m, 2H), 1.46-1.49 (m, 2H), 1.57- 1.58 (m, 1H), 2.32 (m, 1H), 2.94-2.99 (m, 1H), 3.02-3.06 (m, 1H), 3.10-3.11 (m, 2H), 3.12-3.13 (m, 2H), 3.16-3.19 (m, 1H), 3.42- 3.46 (m, 2H), 3.73 (m, 2H), 3.75-3.88 (m, 2H), 3.89-3.91 (m, 1H), 4.25-4.27 (m, 1H), 4.73-4.74 (m, 1H), 4.80 (m, 1H). Mass (436.57) 437.4. 294

¹HNMR (D₂O)- 1.16 (d, 3H), 1.33 (d, 3H), 3.55-3.62 (m, 2H), 3.98-4.01 (m, 2H), 4.11 (d, 2H), 4.19-4.24 (m, 2H), 4.35-4.42 (m, 1H), 4.73 (d, 2H), 4.85 (d, 2H), 5.41 (d, 2H), 9.27 (s, 1H). Mass (492.58) 493.4 295

¹HNMR (D₂O)- 1.22 (d, 3H), 1.31 (d, 3H), 1.92-1.96 (m, 3H), 2.72-2.76 (s, 3H), 2.99- 3.00 (s, 3H), 3.15 (m, 3H), 3.38-3.39 (m, 3H), 4.07 (d, 4H), 4.39-4.45 (m, 4H). Mass (535.62) 536 296

¹HNMR (D₂O)- 1.24 (d, 3H), 1.34 (d, 3H), 3.00-3.11 (s, 3H), 3.31-3.35 (s, 3H), 3.40 (d, 2H), 3.43 (d, 2H), 3.56 (d, 2H), 3.67-3.71 (m, 2H), 4.13 (d, 1H), 4.37-4.43 (m, 1H), 4.71-4.74 (m, 1H), 5.28-5.30 (m, 2H), 7.85 (s, 1H). Mass (491.56) 492.6 297

¹HNMR (D₂O)- 1.22 (d, 3H), 1.29 (d, 3H), 1.92 (m, 1H), 2.75-2.78 (m, 2H), 2.90-2.91 (d, 1H), 3.25-3.27 (m, 1H), 3.55-3.58 (m, 1H), 3.69 (m, 1H), 3.72 (m, 1H), 3.74 (d, 1H), 3.80 (m, 1H), 3.83 (s, 3H), 3.85 (m, 1H), 3.88 (d, 1H), 3.92 (m, 1H), 4.14 (d, 1H), 4.36 (d, 1H), 4.47 (d, 1H), 4.51 (d, 1H), 4.61 (d, 1H). Mass (510.61) 511.2

Preparation of example 298: (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl) acetamido)ethyl)-3-((3S,5 S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Step 1: (R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate

1H-Tetrazole-1-acetic acid (6.33 g, 49 mmol) was taken in a RB. To this ethylacetate (1.5 L), TBTU (18.7 g, 58 mmol), diisopropylethylamine (14 mL, 80.38 mmol) was added under N₂ atmosphere and reaction mixture was stirred for 1 hour. Trifluoroacetate salt of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (17.5 g, 44 mmol) was diluted with ethyl acetate (75 mL) and was neutralized using diisopropylethylamine (5 mL) at 0° C. This solution was then added to the aforementioned reaction mixture at 0° C. tinder N₂ atmosphere. After the addition was complete the reaction mixture was brought to room temperature and stirred for 14 hours under N₂ atmosphere. After the completion of the reaction, the reaction mixture was diluted with water and extracted by ethyl acetate. The organic layer was dried using sodium sulphate and evaporated under vacuum. The crude was then purified by column chromatography to give the product (14 g, 63%). ¹H NMR (DMSO-d₆, 400 MHz): 9.35 (1H, s), 8.44-8.42 (1H, d), 8.31 (1H, s), 8.27-8.25 (2H, d), 7.72-7.70 (2H, d), 5.45-5.44 (2H, d), 5.23-5.09 (2H, m), 4.08-4.02 (1H, m), 3.64-3.63 (1H, t), 3.45-3.43 (1H, q), 2.94-2.78 (1H, q), 1.2-1.19 (3H, d), 1.17-1.16 (3H, d).

Step 2: (4R,5R,6R)-4-Nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(diphenoxyphosphoryloxy)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (4 g, 8 mmol) was dissolved in 100 mL of acetone under N₂ atmosphere. To this solution was added rhodium octanoate (100 mg, 0.128 mmoles) and heated to 60° C. for 2.5 hours. After the completion of the reaction, the reaction mixture was then cooled to −30° C. and diphenylchlorophosphate (2.72 mL, 0.128 mmoles), diisopropylethylamine (2.6 mL, 13.6 mmol) and catalytic amount of dimethylaminopyridine (292 mg, 2.4 mmol) was added successively. The reaction mixture was then stirred for 1 hour at −10° C. Diisopropylethylamine (1.7 mL) and buffer solution pH=7 was added and the reaction mixture was quenched with water. The aqueous layer was extracted with dichloromethane and the organic layer evaporated under vacuum at room temperature. The crude thus obtained was purified by column chromatography to give the product as a solid (2.7 g, 47%). ¹H NMR: 9.35 (1H, s), 8.62-8.60 (1H, d), 8.14-8.12 (2H, m), 7.62-7.60 (2H, d), 7.46-7.37 (4H, m), 7.32-7.20 (6H, m), 5.33-5.31 (2H, d), 5.28-5.24 (2H, q), 4.23-4.21 (1H, d), 4.17-4.14 (1H, m), 3.59-3.56 (1H, q), 3.5-3.4 (1H, d), 1.23-1.21 (3H, d), 1.18-1.17 (3H, d).

Step 3: (4R,5S,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-1-((4-nitrobenzyloxy)carbonyl)-5-((R)-3-((4-nitrobenzyloxy)carbonylamino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(4R,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(diphenoxyphosphoryloxy)-4-methyl-7-oxo-I-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (1.5 g; 21 mmoles) was taken in acetonitrile (150 mL) at 0° C. The solution was then degassed for 10 minutes using N₂ atmosphere. To this solution was added the thiol (1.22 g, 21 mmoles) at 0° C. under N₂ followed by addition of diisopropylethylamine (0.58 mL, 1.5 eq.). The resultant solution was degassed again for 15 minutes. The reaction mixture was stirred under N₂ at 0° C. for 2 hours. After the completion of reaction, the reaction mixture was quenched using water and extracted by ethyl acetate. The organic layer was then washed with water, brine, dried over sodium sulphate and evaporated under vacuum to give the crude. The crude reaction mixture was purified by column chromatography to give the product (1.45 g, 66%) as a solid. M/S: 1027 (M+1); HPLC: 85.35%; ¹H NMR (DMSO-d₆, 400 MHz): 9.345 (1H, d), 8.64-8.61 (1H, t), 8.24-8.22 (511, m), 7.77-7.70 (2H, t), 7.65-7.60 (2H, t), 7.54-7.52 (1H, d), 7.49-7.47 (1H, d), 5.76-5.45 (2H, d), 5.33-5.29 (2H, d), 5.24-5.20 (1H, d), 5.17-5.12 (2H, d), 5.07-5.04 (2H, d), 4.64-4.62 (1H, d), 4.21-4.12 (4H, m), 3.91-3.83 (2H, d), 3.59-3.53 (2H, d), 3.46-3.45 (2H, d), 3.23-3.14 (2H, m), 2.85-2.80 (2H, d), 1.70-1.68 (3H, t), 1.24-1.23 (3H, d), 1.19-1.17 (3H, d)

Step 4: (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5 S, 6R)-4-nitrobenzyl 6-((R)-1-(2-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3 S,5S)-1-((4-nitrobenzyloxy)carbonyl)-5-((R)-3-((4-nitrobenzyloxy)carbonyl amino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (1.45 g, 1 mmol) was taken in a Parr shaker vessel and to this was added 80 mL of THF, 40 mL of water and 4.35 g of Pd/C. The reaction was kept for 1.5 hours at 5 Kg hydrogen pressure. The reaction mixture was then filtered through filter paper and was washed with ethyl acetate (5×50 mL). The reaction mixture was treated with charcoal and filtered. The aqueous layer was again given ethyl acetate washing and was kept under lyophilization for 2 days to give the final product as a white solid (400 mg, 51.34%).

The compounds of Examples 299-312 were prepared according to the procedure for Example 298.

Ex- am- ple Structure Analytical Data 298

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 3.33- 3.40 (m, 1H), 3.67-3.71 (m, 1H), 3.73 (m, 1H), 3.78 (d, 2H), 3.90 (m, 1H), 4.12-4.14 (m, 4H), 4.14-4.15 (m, 2H), 4.16 (d, 1H), 4.41 (d, 1H), 4.60 (d, 1H), 4.84 (d, 1H), 5.42 (d, 2H), 9.27 (s, 1H). Mass (533.60) 534.5 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1- ylacetamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 299

¹HNMR (D₂O)-1.29 (d, 3H), 1.40 (d, 3H), 1.92- 1.98 (m, 1H)), 2.04-2.08 (m, 1H), 2.26 (s, 1H), 2.46-2.60 (m, 2H), 2.82 (d, 2H), 3.01 (d, 1H), 3.31- 3.37 (m, 2H), 3.71-3.79 (m, 2H), 4.02-4.07 (m, 2H), 4.35-4.41 (m, 1H), 4.54-4.58 (m, 1H), 4.60- 4.62 (m, 2H), 4.75-4.82 (m, 1H). Mass (508.59) 509.2 (4R,5S,6R)-6-((R)-1-(3-amino-3- oxopropanamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 300

¹HNMR (D₂O)-1.23 (d, 3H), 133 (d, 3H), 1.92- 1.97 (m, 2H), 3.00 (s, 3H), 3.41-3.42 (s, 3H), 3.50- 3.56 (m, 1H), 3.71-3.77 (m, 2H), 4.31-4.39 (m, 2H), 4.72-4.75 (m, 2H), 4.74-4.82 (s, 1H), 5.10- 5.15 (m, 2H), 8.11 (s, 1H), 8.51 (s, 1H). Mass (491.56) 492.6. (4R,5S,6R)-6-((R)-1-(2-(1H-1,2,4-triazol-1- yl)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 301

¹HNMR (D₂O)-1.33 (d, 3H), 1.42 (d, 3H), 1.96- 1.99 (m, 1H), 2.99 (s, 3H), 3.06-3.11 (s, 4H) 3.38- 46 (m, 3H), 3.67-3.72 (m, 2H), 3.90-3.99 (m, 2H), 4.38-4.44 (m, 5H), 4.58 4.61 (m, 1H). Mass (506.58) 507.2 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2-(2-methyl-2H-tetrazol-5- yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 302

¹HNMR (D₂O)-1.33 (d, 3H), 1.42 (d, 3H), 1.92 (m, 1H), 2.11-2.25 (m, 1H), 2.48-2.49 (m, 2H), 3.28-3.49 (m, 2H), 3.51-3.63 (m, 3H), 3.71-3.77 (m, 2H), 3.87-3.90 (m, 3H), 3.92-3.97 (m, 4H), 4.06-4.15 (m, 2H), 4.73 (m, 2H). Mass (547.63) 548.4 (4R,5S,6R)-3-((3S,5S)-5-((R)-5- aminopyrrolidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-6-((R)-1-(2-(2-methyl-2H- tetrazol-5-yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 303

¹HNMR (D₂O)-1.21 (d, 3 H), 1.45 (d, 3H), 2.99- 3.02 (s, 3H), 3.04-3.09 (m, 2H), 3.33-3.36 (s, 3H), 3.40-3.42 (m, 2H) 3.65-3.71 (m, 2H), 4.25 (d, 2H), 4.65-4.72 (m, 2H), 8.74-8 85 (m, 2H), 9.17 (s, 1H). Mass (488.56) 489.6 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-6-((R)-1-(pyrazine-2- carboxamido)ethyl)-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 304

¹HNMR (D₂O)-1.22 (d, 3H), 1.33 (d, 3H), 2.99- 3.02 (s, 3H), 3.09-3.11 (m, 4H), 3.34-3.38 (s, 3H), 3.46-3.56 (m, 3H), 3.58-3.65 (m, 2H), 3.74-3.78 (m, 3H), 4.02 (d, 2H), 4.31-4.38 (m, 1H). Mass (506.58) 507.2 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2-(1-methyl-1H-tetrazol-5- yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 305

¹HNMR (D₂O)-1.16 (d, 3H), 1.35 (d, 3H), 3.32- 3.45 (m, 2H), 3.56-3.58 (m, 3H), 3.68-3.73 (m, 3H), 3.95-4.04 (m, 2H), 4.14 (d, 1H), 4.38-4.72 (m, 1H), 5.41 (d, 2H), 9.26 (s, 1H). Mass (529.59) 530.6 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1- yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)- 5-((sulfamoylamino)methyl)pyrrolidin-3-ylthio)- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 306

¹HNMR (D₂O)-1.24 (d, 3H), 1.35 (d, 3H), 3.35- 3.39 (m, 1H), 3.64-3.65 (m, 2H), 4.22 (d, 2H), 4.43- 4.45 (m, 2H), 5.05-5.14 (m, 2H), 5.43 (d, 2H), 9.03 (d, 1H), 9.26 (d, 1H). Mass (459.48) 460 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1- yl)acetamido)ethyl)-3-(6,7-dihydro-5H- pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylate 307

¹HNMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 2.97- 2.99 (s, 3H), 3.08 (d, 3H), 3.32-3.38 (m, 2H), 3.55- 3.59 (m, 2H), 3.98 (m, 2H), 4.13 (d, 1H), 4.15-4.17 (m, 1H), 4.42 (d, 2H), 5.61-5.63 (m, 2H), 8.85 (s, 1H). Mass (492.55) 493.1 (4R,5S,6R)-6-((R)-1-(2-(2H-tetrazol-2- yl)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 308

¹HNMR (D₂O)-1.33 (d, 3H), 1.46 (d, 3H), 2.97 (s, 3H), 3.02 (s, 3H), 3.03-3.04 (m, 2H), 3.09-3.11 (m, 1H), 3.23 (m, 2H), 3.48-3.51 (m, 2H), 3.98-4.01 (m, 5H), 4.53 (m, 1H), 7.95 (s, 1H). Mass (558.57) 559.2 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(1-methyl-3-(trifluoromethyl)- 1H-pyrazole-4-carboxamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 309

¹HNMR (D₂O)-1.21 (d, 3H), 1.32 (d, 3H), 1.78 (m, 1H), 2.92-2.94 (m, 2H), 2.99 (s, 3H), 3.11 (s, 3H), 3.40-3.44 (m, 3H), 3.45-3.48 (m, 2H), 3.57 (m, 2H), 3 94 (m, 1H), 4.15-4.18 (m, 1H), 4.40 (s, 2H), 4.44-4.46 (m, 1H), 5.32 (m, 2H), 8.19-8.22 (s, 1H). Mass (534.63) 535.6 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2-(4-((methylamino)methyl)- 1H-1,2,3-triazol-1-yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 310

¹HNMR (D₂O)-1.21 (d, 3H), 1,28 (d, 3H), 2.47 (m, 1H), 2.66 (m, 3H), 2.94-3.11 (m, 2H), 3.22- 3.23 (m, 1H), 3.44-3.49 (m, 3H), 3.72 (m, 1H), 3.87 (m, 3H), 4.03-4.26 (m, 5H), 4.44 (d, 2H), 5.77 (m, 1H), 8.81 (s, 1H). Mass (547.63) 548.1 (4R,5S,6R)-3-((3S,5S)-5-((S)-3-(2H-tetrazol-2- yl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2- (methylamino)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 311

¹HNMR (D₂O)-1.11 (d, 3H), 1.13 (d, 3H), 2.99 (s, 3H), 3.08 (s, 3H), 3.50-3.51 (m, 3H), 3.64-3.75 (m, 3H), 3.97-4.08 (m, 4H), 4.25-4.28 (m, 1H), 4.43- 4.48 (m, 2H), 6.39 (m, 1H), 7.62-7.63 (d, 2H). Mass (519.62) 520.4 (4R,5S,6R)-6-((R)-1-((S)-2-amino-3-(1H- pyrazol-1-yl)propanamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 312

¹HNMR (D₂O)-1.21 (d, 3H), 1.33 (d, 3H), 2.62 (s, 3H). 3.00 (s, 3H), 3.09 (s, 3H), 3.35-3.40 (m, 3H), 3.59-3.64 (m, 3H), 3.98-4.01 (m, 1H), 4.15-4.17 (d, 1H), 4.35 (m, 2H), 4.42-4.45 (m, 1H), 4.71-4.73 (m, 1H), 5.44 (s, 2H). Mass (535.62) 536.2 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2-(5-((methylamino)methyl)- 1H-tetrazol-1-yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Preparation of example 313: (4R,5S,6S)-6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Steps 2B & 3B

Similar to the procedure described in Step 2A and Step 3A, (R)-4-nitrobenzyl 4-((2R,3S)-3-((R)-1-(2H-tetrazol-2-yl)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (600 mg) to (4R,5 S,6S)-4-nitrobenzyl 6-((R)-1-(2H-tetrazol-2-yl)ethyl)-3-((3 S,5 S)-5-(dimethylcarbamoyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate was converted to its enol phosphate (0.28 g, 39.9%) and then finally to the titled product (270 mg, 27%). ¹H NMR: 9.53 (1H, s), 8.21-8.26 (4H, m), 7.71 (2H, m), 7.64-7.62 (1H, m), 7.53-7.51 (1H, d), 5.47-5.43 (1H, m), 5.29-5.20 (2H, m), 5.06-5.02 (2H, m), 4.83-4.72 (1H, m), 4.26-4.21 (1H, m), 4.12-4.08 (1H, m), 4.01-4.00 (1H, m), 3.85-3.81 (1H, m), 3.59-3:53 (1H, m), 3.18-3.12 (1H, m), 3.01-2.95 (3H, d), 2.86 (3H, d), 2.80 (1H, m), 1.70 (3H, d), 1.62-1.60 (1H, m), 1.14 (3H, d).

Step 4B: (4R,5S,6S)-6-((R)-1-(2H-tetrazol-2-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5S,6S)-4-nitrobenzyl 6-((R)-1-(2H-tetrazol-2-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin 3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (270 mg) was converted to the above title product by following the similar procedure described in Step 4A (100 mg, 67%).

Example Structure Analytical Data 313

¹H NMR (D₂O)-1.19 (d, 3H), 1.84 (d, 3H), 2.99 (s, 3H), 3.06 (s, 3H), 3.27-3.31 (m, 2H), 3.37-3.40 (m, 1H), 3.63-3.67 (m, 1H), 3.8 (m, 1H), 4.10 (d, 1H), 4.20 (d, 1H), 4.68 (m, 2H), 5.59-5.63 (m, 1H), 8.82 (s, 1H). Mass (435.50) 436.1 (4R,5S,6S)-6-((R)-1-(2H-tetrazol-2-yl)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 314

¹H NMR (D₂O)-1.26 (d, 3H), 1.34 (d, 3H), 1.8S-1.92 (m, 1H), 2.94-3.26 (m, 2H), 3.46- 3.49 (m, 4H), 3.57-3.58 (m, 2H), 3.62-3.72 (m, 1H), 3.73-3.76 (m, 1H), 3.80-3.84 (m, 2H), 3.87-3.92 (m, 1H), 3.94-4.13 (m, 1H), 4.30 (d, 1H), 4.43-4.49 (m, 1H), 4.51-4.53 (m, 1H), 5.47 (m, 2H), 9.27 (s, 1H). Mass (533.60) 534.6 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1- yl)acetamido)ethyl)-4-methyl-7-oxo-3- ((3S,5S)-5-(piperazine-1-carbonyl)pyrrolidin-3- ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2- 315

¹H NMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.89-1.92 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.32-3.36 (m, 2H), 3.56 (d, 1H), 3.66 (m, 1H), 3.98 (m, 1H), 4.14 (d, 1H), 4.40- 4.42 (m, 1H), 4.60-4.62 (m, 2H), 5.34 (d, 2H). Mass (507.57) 508.2 (4R,5S,6R)-6-((R)-1-(2-(5-amino-2H-tetrazol- 2-yl)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 316

¹H NMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.80-1.85 (m, 1H), 2.08-2.30 (m, 2H), 2.44-2.48 (m, 2H), 2.70-3.00 (m, 3H), 3.19 (d, 3H), 3.29-3.57 (m, 3H), 3.54-3.78 (m, 2H), 4.14 (d, 1H), 4.38-4.42 (m, 1H), 5.29- 5.32 (m, 1H). Mass (548.62) 549.1 (4R,5S,6R)-6-((R)-1-(2-(5-amino-2H-tetrazol- 2-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 317

¹H NMR (D₂O)-1.12 (d, 3H), 1.33 (d, 3H), 2.25-2.26 (m, 2H), 2.48-2.50 (m, 1H), 2.60-2.67 (m, 1H), 2.8-3.00 (m, 1H), 3.34 (d, 2H), 3.55 (d, 2H), 3.65 (d, 2H), 3.76 (d, 2H), 3.88 (d, 2H), 3.94 (d, 1H), 4.13-4.15 (m, 1H), 4.41-4.57 (m, 2H). Mass (615.63) 616.1 (4R,5S,6R)-6-((R)-1-(2-(5-amino-3- (trifluoromethyl)-1H-1,2,4-triazol-1- yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrolidin-3- ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 318

¹H NMR (D₂O)-1.15 (d, 3H), 1.35 (d, 3H), 1.88-1.93 (s, 6H), 3.01 (s, 3H), 3.07 (s, 3H), 3.34-3.40 (m, 2H), 3.49 (d, 2H), 3.63- 3.64 (m, 2H), 4.00-4.17 (m, 2H), 4.37-4.41 (m, 1H), 4.674.71 (m, 1H), 9.36 (s, 1H). Mass-(520.61) 521 (4R,5S,6R)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-6-((R)-1-(2-methyl-2-(1H-tetrazol-1- yl)propanaraido)ethyl)-7-oxo-1- azabicyclop[3.2.0]hept-2-ene-2-carboxylic acid

Preparation of example 319: (4R,5S,6S)-6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Step 1: (R)-4-nitrobenzyl 4-((2R,3S)-3-((R)-1-(1H-tetrazol-1-yl)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (A) and (R)-4-nitrobenzyl 4-((2R,3S)-3-((R)-1-(2H-tetrazol-2-yl)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (B)

To a solution of (R)-4-nitrobenzyl 2-diazo-4-((2R,3S)-3-((S)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate (900 mg, 2.307 mmol), triphenylphosphine (967 mg, 3.691 mmol) and tetrazole (193 mg, 2.768 mmol) in tetrahydrofuran (9 mL) was added. Then diisopropylazodicarboxylate (746 mg, 3.691 mmol) at 0° C. was added to the reaction mixture and was brought to room temperature and stirred for 10 hours. After the completion of the reaction, the reaction mixture was quenched with water and the crude product extracted with ethyl acetate. The organic layer was evaporated to get the crude product which was purified by column chromatography to obtain products A (300 mg, 29.3%) and B (480 mg, 47%). ¹H NMR: Product A: (DMSO-d₆, 400 MHz): 9.36 (s, 1H), 8.50 (s, 1H), 8.27-8.25 (d, 2H), 8.28-7.70 (d, 2H), 5.43 (s, 2H), 5.16-5.12 (t, 1H) 3.54 (s, 2H), 3.45-3.42 (d, 1H), 1.59-1.57 (d, 3H), 0.98-0.96 (d, 3H). Product B: (DMSO-d₆, 400 MHz): 8.95 (s, 1H), 8.48 (s, 1H), 8.27-8.25 (d, 2H), 5.43 (s, 2H), 3.56-3.47 (m, 2H), 1.61-1.59 (d, 3H), 0.96-0.95 (d, 3H).

Step 2A: (4R,5R,6S)-4-nitrobenzyl 6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-(diphenoxyphosphoryloxy)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(R)-4-nitrobenzyl 4-((2R,3S)-3-((R)-1-(2H-tetrazol-2-yl)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (530 mg, 1.19 mmol) was taken in 30 mL of acetone under N₂ atmosphere. To this solution was added rhodium octanoate (0.025 g, 0.0324 mmol) and the resultant reaction mixture was heated to 65-70° C. for 1.5 hours. After the completion of reaction, the reaction mixture was cooled to −40° C. followed by addition of diphenylchlorophosphate (0.4 mL, 1.93 mmol), diisopropylethylamine (0.35 mL, 2 mmol) and catalytic amount of dimethylaminopyridine. The reaction mixture was brought to −20° C. and stirred for 1 hour. At −20° C. Disopropylethylamine (0.35 mL) was added to the reaction mixture and was quenched with water and extracted with dichloromethane. The organic layer was then dried over sodium sulphate and concentrated under vacuum at room temperature to give the crude product. This crude product was purified by column chromatography to give the product as a solid (250 mg, 32.2%).

Step 3A: (4R,5S,6S)-4-nitrobenzyl 6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)-1=((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

The product obtained (0.25 g, 0.39 mmol) from step 2A was taken in 10 mL of acetonitrile and cooled to 0° C. and degassed for 10 minutes. To this reaction mixture was added the thiol (0.22 g, 0.39 mmol) followed by diisopropylethylamine (0.1 mL, 0.57 mmol) under N₂ atmosphere. The reaction mixture was again degassed for 10-15 minutes. Further the reaction mixture was stirred at 0° C. for 2 hours. After the completion of reaction, the reaction mixture was added with water and extracted using ethyl acetate. The organic layer was concentrated and the resultant crude mixture was purified by column chromatography to give the product (260 mg, 33.6%). 1H NMR: (DMSO-d₆, 400 MHz): 9.05 (1H, s), 8.26-8.21 (4H, m), 7.72-7.51 (4H, m), 5.65-5.61 (1H, q), 5.47-5.06 (4H, m), 4.81-4.72 (1H, m), 4.06-4.05 (1H, m), 3.83-3.81 (2H, m), 3.58-3.56 (2H, m), 3.10 (1H, m), 3.02-2.95 (3H, d), 2.81 (3H, d), 2.80 (1H, m), 1.73-1.71 (3H, d), 1.60 (II, m), 1.18-1.16 (3H, d).

Step 4A: (4R,5S,6S)-6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5 S,6S)-4-nitrobenzyl 6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3 S,5 S)-5-(dimethylcarbamoyl)-1-((4-nitrobenzyloxy)carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (250 mg, 0.33 mmol) Was hydrogenated using Pd/C (500 mg) in a mixture of THF-H₂O (20 mL: 10 mL) for 1.5 hours at 5 Kg hydrogen pressure. After the regular work up, the titled compound was obtained (70 mg, 49%).

Examples 326-328 were prepared by following the procedure described in preparations 313 & 319 using appropriately substituted tetrazoles.

Example 328 was prepared by reacting compound obtained by Step 2A with appropriate R₁—SH group followed by the procedure of steps 3A and 4A or Example 319.

Examples 334 and 335 were prepared by reacting compound obtained by Step 2 with appropriate R1-SH group followed by the procedure in step 3 of Example 347.

Ex- am- ple Structure Analytical Data 319

¹HNMR (D₂O)-1.17 (d, 3H), 1.81 (d, 3H), 2.99 (s, 3H), 3.06 (d, 3H), 3.31 (d, 1H), 3.35-3.40 (m, 1H), 3.61-3.66 (m, 2H), 3.99 (d, 1H), 4.03-4.06 (m, 1H), 4.20-.4.23 (m, 1H), 4.67-4.71 (m, 2H), 5.39-5.42 (m, 1H), 9.34 (s, 1H). Mass (435.50) 436 (4R,5S,6S)-6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 320

¹HNMR (D₂O)-1.33 (d, 3H), 1.19 (d, 3H), 2.99-3.00 (s, 3H), 3.04 (d, 1H), 3.09 (d, 3H), 3.30-3.34 (m, 1H), 3.42-3.47 (m, 1H), 3.55-3.58 (m, 1H), 3.69-3.74 (m, 1H), 4.01-4.04 (m, 1H), 4.13-4.16 (m, 1H), 4.39- 4.43 (m, 1H), 4.75-.477 (m, 3H), 4.8- 4.87 (m, 1H). Mass (574.58) 575.1 (4R,5S,6R)-6-((R)-1-(2-(5-amino-3-(trifluoromethyl)-1H- 1,2,4-triazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabiayclo[3.2.0]hept-2-ene-2-carboxylic acid 321

¹HNMR (D₂O)-1.12 (d, 3H), 1.29 (d, 3H), 3.00 (s, 3H), 3.08 (s, 3H), 3.10-3.14 (m, 1H), 3.20-3.24 (m, 1H), 3.43-3.48 (m, 1H), 3.49-3.51 (m, 2H), 3.80-3.85 (m, 2H), 3.92- 3.94 (m, 2H), 4.03-4.12 (m, 4H), 4.32-4.36 (m, 1H), 4.81-4.84 (m, 1H). Mass (538.64) 539.5 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcirbamoyl)pyrrolidin-3- ylthio)-4-methyl-6-((R)-1-(2-(1-methyl-1H-tetrazol-5- ylthio)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 322

¹H NMR (D₂O)-1.65 (d, 3H), 1.20 (d, 3H), 2.4-2.6 (m 1H), 3.00 (s, 3H), 3.07-3.08 (s, 3H), 3.22-3.36 (m, 2H), 3.45 (d, 2H), 3.74-3.77 (m, 1H), 3.99-4.04 (m, 3H), 4.28-4.32 (m, 1H), 4.70-4.82 (m, 3H) 9.24 (s, 1H). Mass (521.59) 522.3 (4R,5S,6R)-6-((R)-1-((S)-2-amino-3-(1H-tetrazol-1- yl)propanamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 323

¹H NMR (D₂O)-1.15 (d, 3H), 1.20 (d, 3H), 2.40-2.46 (m, 1H), 2.99 (s, 3H), 3.07-3.09 (s, 3H) 3.33-3.42 (m, 3H), 3.50 (d, 1H), 3.63-3.67 (m, 2H), 4.04-4.09 (m, 3H), 4.27-4.30 (m, 1H), 4.65-4.74 (m, 1H), 4.94-5.04 (m, 1H), 8.81 (s, 1H). Mass (521.59) 522.5 (4R,5S,6R)-6-((R)-1-((S)-2-amino-3-(2H-tetrazol-2- yl)propanamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 324

¹H NMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H) 3.23-3.26 (m, 1H), 3.31-3.36 (m, 1H), 3.45-3.48 (m, 1H), 3.58 (d, 1H), 3.67-3.79 (m, 2H), 3.83 (d, 2H), 3.93-4.04 (m, 4H), 4.14 (d, 2H), 4.32-4.38 (m, 3H), 5.40-5.47 (m, 2H), 9.25 (s, 1H). Mass (533.60) 534 (4R,5S,6R)-6-((R)-1-(2-((1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-((S)-3-aminopyrrolidine-1-carbonyl)pyrrolidin- 3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 325

¹H NMR (D₂O)-1.22 (d, 3H), 1.37 (d, 3H), 1.82 (d, 1H), 2.98 (d, 3H), 3.08 (d, 3H), 3.29-3.33 (m, 2H), 3.49 (d, 2H), 3.60 (d, 1H), 3.98 (s, 3H), 4.20-4.23 (m, 1H), 4.52-4.54 (m, 2H), 4.55 (d, 1H), 8.9 (s, 1H). Mass (565.67) 566.2 (4R,5S,6R)-6-((R)-1-((Z)-2-(2-aminothiazol-4-yl)-2- (methoxyimino)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 326

¹H NMR (D₂O)-1.19 (d, 3H), 1.75 (d, 3H), 2.99 (s, 3H), 3.06-3.09 (s, 3H), 3.27-331 (m, 2H), 3.36 (d, 1H), 3.61-3.64 (m, 1H), 3.94 (d, 2H), 4.16 (d, 1H), 4.17-4.20 (m, 2H), 5.33 (d, 1H). Mass (450.52) 451 (4R,5S,6S)-6-((R)-1-(5-amino-2H-tetrazol-2-yl)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 327

¹H NMR (D₂O)-1.19 (d, 3H), 1.75 (d, 3H), 2.14 (d, 1H), 2.39-2.51 (m, 2H), 2.89-2.92 (m, 1H), 3.25-3.31 (m, 2H), 3.44-3.48 (m, 1H), 3.50- 3.59 (m, 1H), 3.71-3.77 (m, 4H), 3.86-3.88 (m, 1H), 3 90-3.98 (m, 1H), 4.04 (d, 1H, 4.14 (d, 1H), 5.31- 5.35 (m, 1H). Mass (491.57) 492.5 (4R,5S,6S)-6-((R)-1-(5-amino-2H-tetrazol-2-yl)ethyl)-3- ((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 328

¹H NMR (D₂O)-1.18 (d, 3H), 1.77 (d, 3H), 2.00-2.25 (m, 2H), 2.45-2.49 (m, 2H), 2.88-3.00 (m, 1H), 3.23- 3.33 (m, 1H), 3.44-3.47 (m, 1H), 3.60 (d, 1H), 3 69-3.77 (m, 3H), 3.86-3.91 (m, 2H), 4.03-4.10 (m, 2H), 4.20-4.22 (m, 1H), 4.38 (m, 1H), 5.39-5.42 (m, 1H). Mass (476.55) 477.2 (4R,5S,6S)-6-((R)-1-(1H-tetrazol-1-yl)ethyl)-3-((3S,5S)-5- ((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 329

¹H NMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.88-1.92 (m, 1H), 2.92-2.97 (m, 1H), 3.27-3.37 (m, 2H), 3.51- 3.57 (m, 3H), 3.59-3.70 (m, 3H), 3.78-3.95 (m, 3H), 4.15 (d, 1H), 4.35-4.46 (m, 3H), 5.38-5.47 (m, 2H). Mass (549.60) 550.5 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-((3R,4R)-3-amino-4-hydroxypyrrolidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 330

¹H NMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 1.86-1.93 (m, 1H), 2.60 (s, 3H), 2.99 (s, 3H), 3.09 (s, 3H), 3.3- 3.40 (m, 2H), 3.58-3.65 (m, 2H), 3.98-4.01 (m, 2H), 4.16 (d, 1H), 4.40-4.44 (m, 1H), 4.64-4.68 (m, 1H), 5.31 (s, 2H). Mass (506.58) 507.2 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3- ylthio)-4-methyl-6-((R)-1-(2-(5-methyl-1H-tetrazol-1- yl)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 331

¹H NMR (D₂O)-1.22 (d, 3H), 1.34 (d, 3H), 1.87 (m, 1H), 2.24 (dd, 1H), 2.23 (m, 1H), 2.57 (s, 3H), 2.87 (m, 1H), 3.22 (m, 1H), 3.24 (m, 2H), 3.36 (m, 2H), 3.58 (m, 2H), 3.85 (dd, 2H), 3.91 (dd, 1H), 4.04 (d, 1H), 4.30 (m, 1H), 4.42 (t, 1H), 5.03 (s, 3H). Mass (547.63) 548.1 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-6-((R)-1-(2-(5- methyl-1H-tetrazal-1-yl)acetamido)ethyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 332

¹H NMR (D₂O)-1.03 (d, 3H), 1.27 (d, 3H), 1.50 (s, 3H), 1.85-1.99 (m, 2H), 3.26 (m, 1H), 3.33 (d, 1H), 3.57 (d, 1H), 3.59 (m, 3H), 3.79 (m, 4H), 3.98 (m, 1H), 4.40 (m, 4H), 4.43 (d, 1H), 4.63 (t, 1H), 5.44 (d, 2H), 9.27 (s, 1H). Mass (561.66) 562.5 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(4-amino-4-methylpiperidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 333

¹H NMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 1.80 (m, 1H), 1.92 (m, 2H), 2.12 (dd, 2H), 2.47 (m, 1H), 2.84 (m, 1H), 3.30-3.32 (m, 2H), 3.56 (d, 2H), 3.56-3.63 (d, 2H), 3.62-3.89 (m, 3H), 4.19 (d, 1H), 4.42 (dd, 1H), 5.43 (m, 2H), 9.27 (d, 1H). Mass (545.61) 546.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(6-amino-3-azabicyclo[3.1.0]hexane-3- carbonyl)pyrrolidin-3-ylthin)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 334

¹H NMR (D₂O)-1.22 (d, 3H), 1.37 (d, 3H), 2.23 (m, 1H), 2.49 (m, 2H), 2.90 (m, 1H), 324 (t, 1H), 3.44-3.35 (m, 2H). 3.59 (m, 2H), 3.76-3.68 (m, 2H), 3.86-3.91 (m, 2H), 4.04 (m, 1H), 4.15 (d, 1H), 4.26-4.33 (dd, 1H), 4.44 (m, 1H), 5.76 (t, 2H). Mass (601.60) 602.3 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-6-((R)-1-(2-(5- (trifluoromethyl)-2H-tetrazol-2-yl)acetamido)ethyl)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 335

¹H NMR (D₂O)-1.22 (d, 3H), 1.37 (d, 3H), 1.98 (m, 1H), 1.98-(m, 1H), 2.98-3.00 (m, 1H), 3.04 (s, 3H), 3.08 (s, 3H), 3.34-3.41 (m, 2H), 3.68 (dd, 2H), 4.01 (t, 1H), 4.18 (d, 1H), 4.42 (t, 1H), 4.68 (t, 1H), 5.73 (s, 2H). Mass (560.55) 561.1 (4R,5S,4R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-2H- tetrazol-2-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 336

¹H NMR (D₂O)-1.21 (d, 3H) 1.35 (d, 3H), 1.57 (m, 1H), 1.79 (m, 2H), 1.92 (m, 1H), 2.17 (m, 1H), 3.27 (m, 1H), 3.42 (m, 2H), 3.44 (m, 3H), 3.58 (d, 2H), 3.65 (m, 2H), 3.94 (m, 1H), 4.16 (d, 2H), 4.42 (dd, 2H), 5.43 (d, 2H), 9.28 (s, 1H). Mass (547.63) 548.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-((R)-3-aminopiperidine-1-carbonyl)pyrrolidin- 3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 337

¹H NMR (D₂O)-1.22 (d, 3H), 1.38 (d, 3H), 1.90 (m, 2H), 2.99 (s, 3H), 3.04 (m, 1H), 3.09 (s, 3H), 3.36 (m, 2H), 3.62 (m, 2H), 4.01 (m, 1H), 4.18 (d, 1H), 4.46 (t, 1H), 4.65 (m, 1H), 6.16 (t, 1H). Mass (460.50) 461.1 (4S,5S,6R)-6-((R)-1-(2,2-difluoroacetamido)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 338

¹H NMR (D₂O)-1.22 (d, 3H), 1.37 (d, 3H), 1.40-1.44 (m, 3H), 1.82-1.84 (m, 1H), 1.87 (m, 1H), 2.99 (s, 3H), 3.09 (s, 3H), 3.37 (m, 2H), 3.55 (m, 2H), 3.98 (m, 1H), 4.17 (m, 1H), 4.41 (m, 1H), 4.57 (m, 3H), 5.65 (d, 2H). Mass (564.61) 565.5 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3- ylthio)-6-((R)-1-(2-(5-(ethoxycarbonyl)-1H-tetrazol-1- yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 339

¹H NMR (D₂O)-1.23 (d, 3H), 1.32 (d, 3H), 1.42 (m, 3H), 2.12 (m, 1H), 2.24 (m, 1H), 2.49 (m, 1H), 2.90 (m, 1H), 3.34 (m, 1H), 3.37-3.39 (m, 2H), 3.57-3.60 (m, 2H), 3.70-3.75 (m, 2H), 3.88 (m, 2H), 4.07 (m, 1H), 4.29 (m, 1H), 4.35 (m, 2H), 4.52 (m, 2H), 5.65 (d, 2H). Mass (605.67) 606.1 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1- carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2-(5- (ethoxycarbonyl)-1H-tetrazol-1-yl)acetamido)ethyl)-4- methyl-7-oxo-1-azabicyclo[3.2.0]bept-2-ene-2-carboxylic acid 340

¹H NMR (D₂O)-1.21 (d, 3H), 1.33 (d, 3H), 1.57-1.60 (m, 2H), 1.84 (m, 1H), 2.17 (m, 2H), 2.93 (m, 2H), 3.29-3.37 (m, 3H), 3.50-3.58 (m, 3H), 3.96 (m, 2H), 4.16 (d, 1H), 4.42 (m, 1H), 4.48-4.57 (m, 2H), 5.44 (d, 2H), 9.28 (s, 1H). Mass (547.63) 548.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(4-aminopiperidine-1-carbonyl)pyrrolidin-3- ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 341

¹H NMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.66-1.8 (m, 2H), 1.92 (s, 3H), 2.90-2.93 (m, 1H), 3.13-3.19 (m, 1H), 3.27-3.43 (m, 3H), 3.45- 3.50 (m, 2H), 3.56 (d, 1H), 3.70-3.73 (m, 1H), 3.93 (d, 1H), 4.15 (d, 1H), 4.36-4.47 (m, 2H), 4.50-4.80 (m, 1H), 5.38-5.48 (m, 2H), 9.27 (s, 1H). Mass (547.63) 548.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-((S)-3-aminopiperidin-1-carbonyl)pyrrolidin- 3-ylthio)-4-methyl-7-oxo-1-azabicycio[3.2.0]hept-2-ene-2- carboxylic acid 342

¹H NMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.76-1.81 (m, 1H), 1.91 (m, 1H), 2.83-2.89 (m, 2H), 2.99-3.02 (m, 2H), 3.19-3.35 (m, 3H), 3.45- 3.49 (m, 3H), 3.58 (m, 3H), 3.87- 3.97 (m, 3H), 4.04 (d, 2H), 4.14 (d, 1H), 4.40-4.43 (m, 2H), 4.47-4.54 (m, 1H), 5.43 (d, 2H), 9.27 (s, 1H). Mass (602.71) 603.2. (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(4-(3-aminoazetidin-1-yl)piperidine-1- carbonyl)pyrrolidin-3-ylthino)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 343

¹H NMR (D₂O)-1.26 (d, 3H), 1.32 (d, 3H), 1.81 (m, 1H), 1.91 (m, 1H), 2.00 (m, 3H), 2.81-2.90 (m, 3H), 3.02 (d, 2H), 3.18-3,35 (m, 5H), 3.48-3.57 (m, 4H), 3.87-3.95 (3H), 4.14 (d, 1H), 4.42-4.53 (m, 3H), 5.43 (d, 2H), 9.27 (s, 1H) C₂₇H₄₀N₁₀O₅S; HPLC-96.6%; Mass (616.74) 617.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(4-(3-(aminomethyl)azetidin-1-yl)piperidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicycio[3.2.0]hept-2-ene-2-carboxylic acid 344

¹H NMR (D₂O)-1.20 (d, 3H), 1.32 (d, 3H), 1.80-1.82 (m, 1H), 1.92 (m, 1H), 2.74 (m, 1H), 3.12 (m, 1H), 3.35 (d, 2H), 3.54 (d, 2H), 3.74-3.85 (m, 2H), 4.04-4.15 (m, 1H), 4.32 (d,- 2H), 4.42 (m, 1H), 4.56 (d, 2H), 5.44 (d, 2H), 9.27 (s, 1H). Mass (551.59) 552.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(3-(aminomethyl)-3-fluoroazetidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 345

¹H NMR (D₂O)-1.21 (d, 3H), 1.37 (d, 3H), 1.60-(m, 1H), 1.73-1.79 (m, 1H), 1.91 (m, 2H), 2.23 (m, 2H), 2.52 (d, 3H), 320-3.22 (m, 3H), 3.52-3.64 (m, 6H), 3.75 (m, 1H), 3.77-4.13 (m, 3H), 4.22-4.51 (m, 1H), 5.44 (d, 2H), 9.27 (s, 1H). Mass (573.67) 574.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-((1R,5S,8S)-8-amino-3- azabicyclo[3.2.0]octane-3-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 346

¹H NMR (D₂O)-1.29 (d, 3H), 1.64 (d, 3H), 1.80 (m, 2H), 2 23 (m, 3H), 2.56 (m, 2H), 2.92 (m, 2H), 3.25- 3.30 (m, 2H), 3.59 (m, 3H), 3.75 (m, 2H), 3.96 (m, 1H), 4.42 (m, 2H), 5.43 (m, 3H), 9.28 (s, 1H). Mass (579.65) 580. (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(4-(aminomethyl)-4-fluoropiperidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Preparation of example 347 ((4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid)

Preparation of C

Step (i): Ethyl 2-(2,2,2-trifluoroacetamido)acetate

Ethyl trifluoroacetate (10.7 g, 0.075 moles) was dissolved in methanol (mL) and cooled to 0° C. Glycine ester hydrochloride (10.5 g, 0.075 mol) was added to this solution and the reaction mixture was stirred for 5 minutes. Triethylamine (15.7 mL, 0.112 moles) was added dropwise at 0° C. and stirred for 15 minutes. The reaction mixture was then brought to room temperature and stirred overnight. The solvent of the reaction mixture was evaporated under vacuum and water was added to the crude followed by extraction with ethyl acetate. The organic layer was then washed with water, brine, dried over sodium sulphate and concentrated to give the crude product (15 g). NMR: (CDCl₃, 400 MHz): 6.85 (s, 1H), 4.25-4.30 (m, 2H), 4.12-4.15 (m, 2H), 1.30-1.33 (m, 3H).

Step (ii): Ethyl 2-(2,2,2-trifluoroethanethioamido)acetate

Ethyl 2-(2,2,2-trifluoroacetamido)acetate (15 g, 0.0753 mol) was dissolved in toluene (20 mL) and cooled to 0° C. Solid NaHCO₃ was added to the reaction mixture and stirred for 5 minutes. P₂S₅(10 g, 0.045 mmol, 0.6 eq.) was added portion wise very slowly and stirred for 10 minutes at 0° C. The reaction mixture was then heated to 70° C. for 6 hours. After the completion of reaction, the reaction mixture was brought to room temperature and quenched with water slowly at 0° C. and extracted with ethyl acetate. The organic layer was washed with 5% NaHCO₃ solution, water and brine respectively and dried over sodium sulphate. The crude reaction mixture was then concentrated under vacuum and the product was isolated by column chromatography (11 g, 67.8%). ¹H NMR: (CDCl3, 400 MHz): 8.46 (s, 1H), 4.29-4.38 (m, 2H), 4.12-4.15 (m, 2H), 1.30-1.35 (m, 3H).

Step (iii): Ethyl 2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetate

Ethyl 2-(2,2,2-trifluoroethanethioamido)acetate (11 g, 0.051 mol) was dissolved in dichloromethane (110 mL) at ambient temperature. Azidotrimethylsilane (13.5 ml, 0.102 mol) was added dropwise to this solution and stirred for 10 minutes. A solution of SnCl₄ (13.3 mL, 0.127 mmol) in dichloromethane (mL) was added dropwise and stirred for 15 minutes. The reaction mixture was then stirred overnight at room temperature. The reaction mixture was then quenched with saturated NaHCO₃ solution slowly at 0° C., filtered through celite bed, washed with dichloromethane. The organic layer was then separated, washed with water, brine, dried over sodium sulphate and concentrated under vacuum to give the crude product. The crude product was then purified by column chromatography to give the product (6 g, 52.6%). ¹H NMR (DMSO-d₆, 400 MHz): 5.83 (s, 2H), 4.20-4.26 (m, 2H), 1.18-1.23 (m, 3H).

Step (iv): 2-(5-(Trifluoromethyl)-1H-tetrazol-1-yl)acetic acid

2-(5-(Trifluoromethyl)-1H-tetrazol-1-yl)acetic acid (7.3 g, 0.033 moles) Was dissolved in THF (70 mL). A solution of LiOH.H₂O (1.5 g, 0.036 mol) in water (80 mL) was added dropwise at room temperature and the resultant reaction mixture was stirred for 2 hours. After the completion of reaction, the solvent was evaporated under vacuum and the resultant crude was dissolved in water. The aqueous layer was washed with ethyl acetate and was then acidified with 2N HCl and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over sodium sulfate and concentrated under vacuum to give the desired product (5.6 g, 87.6%). ¹H NMR (DMSO-d₆ 400 MHz): 14.00 (br s, 1H), 5.69 (s, 2H).

Preparation of Example 347 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Step 1: (R)-4-Nitrobenzyl2-diazo-3-oxo-4-((2R,3R)-4-oxo-3-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)azetidin-2-yl)pentanoate

5-Trifluoro-Tetrazole acetic acid (2.1 g, 0.011 mol) was dissolved in ethyl acetate (mL) cooled to 0° C. and to this solution was added TBTU (4.47 g, 0.014 mol) and stirred for 5 minutes at the same temperature. Diisopropylethylamine (3.8 ml, 0.022 mol) was added dropwise and stirred for 10 minutes at 0° C. The reaction mixture was then brought to room temperature and further stirred for 1 hour. The reaction mixture was again cooled to 0° C. and to it was added a solution of the trifluoroacetate salt of (R)-4-nitrobenzyl 4-((2R,3R)-3-((R)-1-aminoethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate, (3.7 g, 0.007 mol) in ethyl acetate (25 mL) followed by diisopropylethylamine (3.8 mL) drop wise and stirred for 10 minutes at 0° C. The reaction mixture was then brought to room temperature and stirred overnight. After the completion of the reaction, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic layer was washed with water, followed by brine, dried over sodium sulphate and concentrated under vacuum to give the crude which was then purified by column chromatography to give the product (1 g, 23.9%). ¹H NMR (CDCl₃, 400 MHz): 1:19-1.21 (3H, d), 1.35-1.37 (3H, d), 2.86-2.88 (1H, m), 3.58-3.69 (2H, m), 4.24-4.33 (1H, m), 5.22-5.29 (2H, m), 5.35 (2H, s), 6.04 (11, s), 6.71-6.73 (1H, d), 7.53-7.55 (2H, d), 8.25-8.28 (2H, d).

Step 2: (4R,5R,6R)-4-nitrobenzyl 3-(diphenoxyphosphoryloxy)-4-methyl-7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(R)-4-nitrobenzyl 2-diazo-3-oxo-4-((2R,3R)-4-oxo-3-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)azetidin-2-yl)pentanoate (1.1 g, 1.94 mmol) was dissolved in 50 mL of acetone under N₂ atmosphere. To this solution was added rhodium octanoate (40 mg, 0.051 mmol) and heated to 70° C. for 1 hour. The reaction mixture was then cooled to −40° C. and diphenylchlorophosphate (0.64 mL, 3.1 mmol), diisopropylethylamine (0.6 mL, 3.44 mmol) and catalytic amount of dimethylaminopyridine was added successively. The reaction mixture was then stirred for 1 hour at −20° C. Diisopropylethylamine (0.6 mL) was again added to the reaction mixture and was quenched with water. The aqueous layer was extracted with dichloromethane and the organic layer evaporated under vacuum at room temperature. The crude thus obtained was purified by column chromatography to give the product as a solid (850 mg).

Step 3: (4R,5S,6R)-4-Nitrobenzyl 4-methyl-3-((3S,5S)-1-((4-nitrobenzyloxy) carbonyl)-5-((R)-3-((4-nitrobenzyloxy)carbonylamino) pyrrolidine-1-carbonyl) pyrrolidin-3-ylthio)-7-oxo-6-((R)-1-2-(5-(trifluoromethyl)-1H-tetrazol-1-yl) acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(4R,5R,6R)-4-Nitrobenzyl 3-(diphenoxyphosphoryloxy)-4-methyl-7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (500 mg, 0.65 mmol) was taken in acetonitrile (10 mL) at 0° C. The solution was then degassed for 10 minutes using N₂ atmosphere. To this solution was added the thiol (0.372 g, 0.65 mmol) at 0° C. under N₂ atmosphere followed by addition of diisopropylethylamine (0.2 mL, 1.15 mmol). The resultant solution was degassed again for 15 minutes. The reaction mixture was stirred under N₂ at 0° C. for 2 hours. After the completion of reaction, the reaction mixture was quenched using water and extracted by ethyl acetate. The organic layer was then washed with water, brine, dried over sodium sulphate and evaporated under vacuum to give the crude. The crude reaction mixture was purified by column chromatography to give the product (450 mg, 64%) as a solid. H NMR (DMSO-d₆, 400 MHz): 1.18-1.19 (3H, d), 1.22-1.24 (3H, d), 1.73 (2H, m), 2.83 (1H, m), 3.14-3.17 (2H, m), 3.47-3.69 (4H, m), 3.88-3.90 (2H, m), 4.12-4.22 (4H, m), 4.54 (1H, m), 5.07-5.09 (1H, m), 5.17-5.2 (3H, m), 5.41-5.44 (1H, d), 5.48-5.52 (3H, m), 7.47-7.49 (2H, m), 7.52-7.54 (2H, m), 7.60-7.62 (3H, m), 7.70-7.72 (1H, m), 8.20-8.24 (6H, m), 8.75-8.77 (1H, d).

Example 348 was prepared by reacting compound obtained by Step 2 with appropriate R¹—SH group followed by the procedure of step 3 of Example 347.

Exam- ple Structure Analytical Data 347

¹HNMR (D₂O)-1.27 (d, 3H), 1.36 (d, 3H), 1.86 (m, 1H), 2.49 (d, 1H), 2.89 (m, 2H), 3.43 (m, 2H), 3.58 (m, 2H), 3.62 (d, 2H), 3.73 (d, 2H), 4.06 (d, 2H), 4.16 (d, 1H), 4.28-4.42 (m, 2H), 5.62 (m, 2H). Mass (601.60) 602.5 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamidn)ethyl)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 348

¹HNMR (D₂O)-1.22-(d, 3H), 1.36 (d, (d, 3H), 1.86 (m, 1H), 3.07 (s, 3H), 3.12 (s, 3H), 3.37 (d, 3H), 3.59 (m, 2H), 3.98 (m, 1H), 4.86 (d, 1H), 4.41 (m, 1H), 4.61 (m, 1H), 5.61 (s, 2H). Mass (560.55) 561.1 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-6-((R)-1-(2-(5-(trifluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 349

¹HNMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 1.92 (m, 1H), 1.92-2.38 (m, 1H) 2.40-2.49 (m, 2H), 2.89-2.96 (m, 2H), 3.23-3.34 (m, 2H), 3.47 (m, 1H), 3.57 (m, 2H), 4.06 (m, 2H), 4.13-4.15 (m, 2H), 4.40-4.80 (m, 2H), 5.55 (s, 2H), 7.46 (t, 1H). Mass(583.61) 584.2 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2- (5-(difluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 350

¹HNMR (D₂O)-1.21 (d, 3H), 1.36 (d, 3H), 1.84-1.89 (m, 1H), 3.03 (s, 3H), 3.07 (s, 3H), 3.33-3.38 (m, 2H), 3.56- 3.62 (m, 2H), 3.99 (m, 2H), 4.16 (d, 1H), 4.42 (m, 1H), 4.63 (m, 1H), 5.35 (s, 2H), 7.46 (t, 1H). Mass (542.56) 543.5 (4R,5S,6R)-6-((R)-1-(2-(5-(difluoromethyl)-1H-tetrazol-1-yl)acetamido)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 351

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 1.82 (m, 4H), 1.92 (m, 2H), 2.39 (m, 2H), 3.04 (d, 1H), 3.44 (m, 3H), 3.59 (m, 3H), 3.66-3.70 (m, 3H), 3.89-4.00 (m, 1H), 4.02 (m, 1H), 4.16 (d, 1H), 4.44 (m, 1H), 5.42 (m, 2H), 9.27 (s, 1H). Mass (623.68) 624.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3,3-difluoro-1,8- diazaspiro[4.5]decane-8-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 352

¹HNMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 1.89 (m, 1H), 1.98 (d, 5H), 2.15 (m, 4H), 2.92 (m, 1H), 3.29 (m, 2H), 3.33-3.47 (m, 4H), 3.58 (d, 1H), 3.79 (d, 1H), 4.16 (d, 1H), 4.42 (m, 2H), 4.52 (m, 1H), 4.53 (m, 1H), 5.43 (s, 2H), 9.28 (s, 1H). Mass (587.69) 588.5 (4R,5S,6R)-3-((3S,5S)-5-(1,8-diazaspiro[4.5]decane-8-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 353

¹HNMR (D₂O)-1.28 (d, 3H), 1.35 (d, 3H), 1.92 (s, 4H), 2.88-3.11 (m, 1H), 3.32-3.35 (m, 1H), 3.39 (m, 2H), 3.57 (d, 1H), 3.59-3.76 (m, 5H), 3.91-4.00 (m, 2H), 4.16 (d, 1H), 4.40 (m, 1H), 4.57 (m, 1H), 4.87 (m, 1H), 5.43 (s, 2H), 9.28 (s, 1H). Mass (575.64) 576.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-((4aS,7aR)- octahydropyrrolo[3,4-b][1,4]oxazine-6-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 354

¹HNMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 2.23 (m, 1H), 3.12 (m, 2H), 3.30 (d, 2H), 3.32-3.33 (m, 2H), 3.35 (m, 2H), 3.59 (m, 2H), 3.89 (m, 1H), 4.09 (m, 1H), 4.13-4.19 (m, 2H), 4.22 (m, 1H), 4.41 (m, 1H), 5.43 (d, 2H), 9.27 (s, 1H). Mass (565.67) 566.0 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-((R)- thiazolidine-4-carboxamido)methyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 355

¹HNMR (D₂O)-1.22 (d, 3H), 1.36 (d, 3H), 1.46 (s, 9H), 1.92 (m, 1H), 2.08- 2.24 (m, 1H), 2.23-2.50 (m, 2H), 2.89-2.95 (m, 1H), 3.30-3.54 (m, 2H), 3.56-3.58 (m, 2H), 3.71-3.81 (m, 2H), 3.87-3.94 (m, 2H), 4.06-4.16 (m, 2H), 4.41-4.43 (m, 2H), 5.47 (d, 2H). Mass (589.71)-590 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2- (5-tert-hutyl-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 356

¹HNMR (D₂O)-1.22 (d, 3H), 1.36 (d, 3H), 1.46 (s, 9H) 1.96 (m, 1H), 3.07 (s, 3H), 3.30 (s, 3H), 3.39 (m, 1H), 3.43 (m, 1H), 3.59 (d, 1H), 3.66-3.69 (m, 1H), 4.02 (m, 1H), 4.42 (m, 1H), 4.69 (m, 1H), 4.71 (d, 2H), 5.48-5.51 (m, 2H). Mass (548.66) 549. (4R,5S,6R)-6-((R)-1-(2-(5-tert-butyl-1H-tetrazol-1-yl)acetamido)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 357

¹HNMR (D₂O)-1.14 (d, 3H), 1.33 (d, 3H), 2.99 (s, 3H), 3.07 (s, 3H), 3.18 (m, 1H), 3.20 (m, 2H), 3.33 (d, 2H), 3.48-3.52 (m, 1H), 3.94 (m, 1H), 4.08 (d, 1H), 4.34-4.38 (m, 1H), 4.58 (m, 1H), 5.58 (s, 2H) 7.35 (s, 1H), 7.74 (s, 1H), 7.91 (d, 1H). Mass (574.68) 574.8 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-6-((R)-1-(2-(5-(thiophen-2-yl)-1H-tetrazol-1-yl)acetamido)ethyl)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 358

¹HNMR (D₂O)-1.21 (d, 3H), 1.36 (d, 3H), 1.73-1.80 (m, 3H), 2.23 (m, 1H), 2.45-2.49 (m, 1H), 2.83-2.91 (m, 1H), 3.19 (d, 2H), 3.31-3.37 (m, 1H), 3.48 (d, 1H), 3.62 (d, 1H), 3.70 (m, 1H), 3.79 (m, 2H), 4.07 (d, 1H), 4.20-4.27 (m, 1H), 4.34-4.38 (m, 1H), 5.57 (s, 2H), 7.36 (m, 1H), 7.74 (m, 1H), 7.91 (d, 1H). Mass 615.73 615.8 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-6-((R)-1-(2-(5-(thiophen-2-yl)-1H-tetrazol-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 359

¹HNMR (D₂O)-1.21 (d, 3H), 1.35 (d, 3H), 2.64 (s, 3H), 2.98 (m, 4H), 3.36 (m, 2H), 3.58 (m, 3H), 3.99 (m, 4H), 4.15 (m, 2H), 4.43 (m, 1H), 4.63 (d, 1H), 4.81 (d, 1H), 5.43 (m, 2H), 9.37 (s, 1H). Mass (547.63) 547.9 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-(4- methylpiperazine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 360

¹HNMR (D₂O)-1.26 (d, 3H), 1.34 (d, 3H), 1.84-1.88 (m, 1H), 2.89-2.96 (m, 1H), 3.20-3.36 (m, 7H), 3.50 (m, 2H), 3.52 (m, 2H), 3.75 (m, 5H), 3.96 (m, 1H), 4.15 (m, 1H), 4.43-4.56 (m, 2H), 4.81 (m, 1H), 4.81 (m, 1H), 5.47-5.48 (m, 2H), 9.28 (s, 1H). Mass (iodide 689.57, free base, 562.66) 561.9 4-((2S,4S)-((4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-2-carboxy-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-ylthio)pyrrolidine-2-carbonyl)-1,1-dimethylpiperazin- 1-ium iodide 361

¹HNMR (D₂O)-1.15-1.17 (d, 3H), 1.28-1.30 (d, 3H), 2.43 (m, 1H) 2.69 (s, 3H), 2.70-2.74 (m, 2H), 3.10-3.12 (m, 2H), 3.15-3.16 (m, 1H), 3.37-3.38 (m, 2H), 3.61-3.74 (m, 4H), 3.78-3.82 (m, 5H), 4.12-4.17 (m, 2H), 4.45-4.47 (m, 1H), Mass 537.2 (M + 1) HPLC 92.1%, C₂₃H₃₆N₈O₅S (4R,5S,6R)-3-((3S,5S)-5-(4-carbamimidoylpiperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 6-((R)-1-(2-(methylamino)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 362

¹HNMR (D₂O)-1.21-1.23 (d, 3H), 1.37-1.39 (d, 3H), 2.26 (m, 1H), 2.48 (m, 1H), 2.94-2.97, (s, 3H), 3.14 (m, 1H), 3.39-3.40 (m, 2H), 3.50-3.51 (m, 2H), 3.55-3.61 (m, 1H), 3.75-3.89 (m, 2H), 3.90-4.07 (m, 3H), 4.07 (m, 1H), 4.22-4.24 (d, 1H), 4.45-4.46 (m, 1H), HPLC 93.1%; C₂₀H₃₁N₅O₆S₂ Mass 502.4 (M + H). (4R,5S,6S)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)- 4-methyl-6-((R)-1-(methylsulfonamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 363

¹HNMR (D₂O) 1.19-1.20 (d, 3H), 1.33-1.34 (d, 3H), 2.83 (m, 1H), 3.18-3.22 (m, 1H), 3.27 (m, 1H), 3.36 (m, 1H), 3.45 (s, 3H), 3.56 (d, 1H), 3.80 (m, 3H), 3.89 (m, 3H), 3.99 (m, 3H), 4.12-4.15 (d, 2H), 4.30 (m, 2H), 4.41 (m, 2H), 5.42 (m, 2H), 9.27 (s, 1H); C₂₅H₃₇IN₁₀O₆S; HPLC 90.1%; Mass 606.2 (M + 1) 4-((2S,4S)-4-((4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-2-carboxy-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-en-3-ylthio)pyrrolidine-2-carbonyl)-1-(2-amino-2-oxoethyl)-1-methylpiperazin- 1-ium iodide 364

¹HNMR (D₂O) 1.24-1.25 (d, 3H), 1.31-1.32 (d, 3H), 2.55-2.69 (m, 4H), 2.71-2.73 (m, 3H), 2.84-2.86 (m, 1H), 3.14-3.17 (m, 2H), 3.20-3.24 (m, 1H), 3.39-3.42 (m, 2H), 3.67-3.68 (m, 1H), 3.70-3.71 (m, 4H), 3.89-3.92 (m, 1H), 4.17-4.20 (m, 1H), 4.40-4.80 (m, 2H), 5.42 (d, 2H), 9.26 (s, 1H); C₂₄H₃₆N₁₀O₅S; HPLC 91.1%; Mass 577.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2-aminoethyl)piperazine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 365

¹HNMR (D₂O)-1.06-1.08 (d, 3H), 1.20-1.22 (d, 3H), 1.62 (m, 1H), 1.99- 2.08 (m, 4H), 2.38-2.43 (m, 2H), 2.78-2.82 (m, 1H), 3.09-3.19 (m, 1H), 3.22-3.30 (m, 3H), 3.43-3.45 (d, 1H), 3.50-3.60 (m, 2H), 3.79 (m, 2H), 3.90-3.94 (m, 2H), 4.00-4.02 (m, 1H), 4.29-4.30 (d, 2H), 5.29-5.30 (d, 2H), 9.14 (s, 1H), Mass 574.2 (M + 1); C₂₅H₃₅N₉O₅S HPLC 90.4% (4R,5S,6R)-3-((3S,5S)-5-(1,7-diazaspiro[3.5]nonane-7-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(1H-tetrazol-1-yl)acetamidn)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 366

¹HNMR (D₂O)-1.13-1.15 (d, 3H), 1.20-1.22 (d, 3H), 1.69 (m, 1H), 1.95 (m, 4H), 2.60-2.43 (m, 2H), 2.72-2.80 (m, 1H), 3.09 (m, 4H), 3.22-3.24 (m, 1H), 3.44-3.45 (d, 1H), 3.72-3.80 (m, 3H), 3.92-4.03 (m, 3H), 4.17-4.19 (m, 1H), 4.28 (m, 1H), 5.30 (d, 2H), 9.14 (s, 1H), Mass 574.2 (M + 1); C₂₅H₃₅N₉O₅S HPLC 90% (4R,5S,6R)-6-((R-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,7- diazaspiro[3.5]nonane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 367

¹HNMR (D₂O)-1.07-1.09 (d, 3H), 1.21-1.23 (d, 3H), 2.76 (m, 1H), 3.21- 3.30 (m, 3H), 3.49-3.50 (m, 5H), 3.63-3.64 (m, 5H), 3.80 (m, 1H), 4.01-4.03 (m, 1H), 4.28-4.31 (m, 2H), 5.31 (m, 2H), 9.14 (s, 1H), Mass 576.4 (M + 1); C₂₃H₃₃N₁₁O₅S; HPLC 91% (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4- carbamimidoylpiperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 368

¹HNMR (D₂O)-1.17-1.19 (d, 3H), 1.32-1.33 (d, 3H), 1.79 (m, 1H), 1.90 (m, 4H), 2.92 (m, 1H), 3.30-3.34 (m, 2H), 3.48-3.52 (m, 3H), 3.55-3.57 (m, 3H), 3.97 (m, 5H), 4.11-4.13 (m, 1H), 4.38-4.42 (m, 1H), 4.53 (m, 1H), 5.40-5.41 (m, 2H) 9.26 (s, 1H), Mass 574.2 (M + 1); C₂₅H₃₅N₉O₅S; HPLC 91.5% (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,7- diazaspiro[3.5]nonane-7-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid

Examples 369-378 and 383-451 were prepared by treating the compound of formula (10) with appropriate R^(A)COOH according to the procedure given in the preparations 12, 16 and 17, followed by the procedure given in Example 1.

The cyclisation to obtain carbapenem and reaction of its enolic phosphate with various R¹—SH is similar to that described for preparation of Example 1 (Step 1 & Step 2) or Example 95 (Step 1 to 3) or Example 298 (Step 2 to 4).

Ex- am- ple Structure Analytical Data 369

¹HNMR (D₂O)-1.11 (d, 3H) 1.23 (d, 3H), 2.04-2.08 (m, 1H), 2.51-2.72 (m, 2H), 2.95 (m, 1H), 3.07-3.19 (m, 2H), 3.34-3.46 (m, 3H); 3.63-3.70 (m, 6H), 3.73 (m, 1H), 3.78 (m, 2H, 3.8-4.28 (m, 3H), 9.24 (s, 1H); C23H33N9O5S; HPLC 98.9%; Mass 548.3 (M + 1) (4R,5S,6R)-6-((R)-1-(3-(1H-tetrazol-1-yl)propanamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methy-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 370

¹HNMR (D₂O)-1.26 (d, 3H), 1.31 (d, 3H), 3.01-3.10 (m, 4H), 3.33-3.35 (m, 3H), 3.78-3.82 (m, 3H), 3.80- 3.82 (m, 5H), 4.0-4.1 (m, 4H), 5.4 (m, 2H), 8.3-8.31 (m, 3H), 9.26 (s, 1H); C27H35N11O5S; HPLC 90.1%; Mass 626.20 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-(4-(pyrimidin-2- ylamino)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 371

¹HNMR (D₂O)-1.20 (d, 3H), 1.29 (d, 3H), 1.76 (m, 2H), 2.80 (m, 2H), 3.01 (m, 1H), 3.34-3.40 (m, 2H), 3.5 (m, 2H), 3.34-3.40 (m, 2H), 3.5 (m, 4H), 3.86-3.89 (m, 2H), 4.0 (m, 1H), 4.14-4.16 (m, 1H), 4.42 (m, 1H), 5.42 (m, 2H), 9.27 (s, 1H); C25H34N10O5S; HPLC 91%; Mass 587.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-amino-4- (cyanomethyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 372

¹HNMR (D₂O)-0.98-1.10 (m, 2H) 1.19-1.21 (d, 3H), 1.25-1.27 (m, 2H) 1.32 (m, 3H), 1.60-2.00 (m, 3H), 2.03-2.04 (m, 2H), 2.09-2.31 (m, 1H), 2.32-2.60 (m, 1H), 2.70-3.06 (m, 1H), 3.18-3.42 (m, 2H), 3.60- 3.63 (m, 1H), 3.70-3.72 (m, 1H), 3.75-3.78 (m, 2H), 3.88-3.93 (m, 2H), 4.03-4.15 (m, 1H), 4.41-4.44 (m, 1H), 5.40 (s, 2H); C25H35N9O5S; HPLC 90.1%; Mass 574.2 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2- (5-cyclopropyl-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 373

¹HNMR (D₂O)-1.18 (d, 3H), 1.34 (d, 3H), 3.00 (s, 3H), 3.02 (m, 1H), 3.06 (s, 3H), 3.07-3.08 (m, 1H), 3.40- 3.45 (m, 3H), 3.63-3.75 (m, 1H), 4.02-4.04 (m, 2H), 4.25-4.47 (m, 1H), 4.52-4.68 (m, 1H), 7.69-7.78 (m, 4H), 9.57 (s, 1H); C25H30N8O5S; HPLC 92.2% Mass 555.1 (M + 1) 374

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.91 (m, 1H), 2.89-2.30 (m, 1H), 3.25 (m, 1H), 3.31 (m, 1H), 3.42-3.44 (m, 2H), 3.44-3.50 (m, 2H), 3.60-3.69 (m, 1H), 3.73-3.79 (m, 2H), 3.85-3.90 (m, 2H), 4.02- 4.04 (m, 2H), 4.36-4.38 (m, 1H), 4.40 (m, 1H), 7.69 (m, 1H), 7.70- 7.81 (m, 3H), 9.57 (s, 1H); C27H33N9O5S; HPLC 96.6%; Mass 596.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)benzamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 375

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.89 (m, 2H), 3.29 (m, 2H), 3.31 (s, 3H), 3.36 (m, 2H), 3.56-3.64 (m, 8H), 3.90-3.98 (m, 5H), 4.09 (m, 1H), 4.40-4.43 (m, 2H), 5.42-5.43 (m, 2H), 9.27 (s, 1H); C25H39IN10O5S; HPLC 91.1%; Mass 592.2 free base (M + 1) 4-((2S,4S)-4-((4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-2-carboxy-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-en-3-ylthio)pyrrolidine-2-carbonyl)-1-(2-aminoethyl)-1-methylpiperazin-1-ium iodide 376

¹HNMR (D₂O)-1.22 (d, 3H), 1.31 (d, 3H), 3.18-3.21 (m, 1H), 3.52-3.54 (m, 1H), 3.76-3.82 (m, 2H), 4.08- 4.15 (m, 2H), 4.24-4.29 (m, 2H), 4.38-4.41(m, 1H), 5.41-5.45 (m, 2H), 9.25 (s, 1H); C16H22N8O6S2; HPLC 90.2%; Mass 487.1 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-(1- sulfamoylazetidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 377

¹HNMR (D₂O)-1.11 (d, 3H), 1.24 (d, 3H), 1.72 (m, 6H), 1.82 (m, 4H), 2.90-2.94 (m, 1H), 2.9 (m, 2H), 3.12- 3.26 (m, 1H), 3.41-3.45 (m, 3H), 3.45-3.46 (m, 4H), 3.47-3.48 (m, 1H), 4.02-4.05 (m, 1H), 4.26-4.32 (m, 2H), 4.71 (m, 1H), 5.30-5.32 (m, 2H), 9.17 (s, 1H); C28H39N9O5S; HPLC 91.2%; Mass 614.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(8- azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine]-8-ylcarbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 378

  (4R,5S,6R)-6-((R)-1-2-(5-cyclopropyl-1H-tetrazol-1-yl)acetamido)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.02-1.05 (m, 2H) 1.20 (d, 3H), 1.25-1.27 (m, 2H), 1.32 (d, 3H), 1.95-2.02 (m, 3H), 2.99-3.01 (s, 3H), 3.30 (s, 4H), 3.32-3.34 (m, 1H), 3.43-3.48 (m, 1H), 3.58-3.60 (m, 1H), 3.73-3.77 (m, 1H), 4.02- 4.05 (m, 1H), 4.14-4.17 (m, 1H), 4.39-4.43 (m, 1H), 5.38 (s, 2H); C23H32N8O5S; HPLC 96.1%; Mass 533.3 (M + 1) 379

¹HNMR (D₂O)-1.16 (d, 3H), 1.27 (d, 3H), 1.77-1.80 (m, 2H)T, 2.86- 2.88 (m, 3H), 2.90-2.97 (m, 2H), 3.26-3.31 (m, 2H), 3.35-3.37 (m, 3H), 3.51-3.56 (m, 1H), 3.88-3.92 (m, 1H), 4.11-4.13 (m, 1H), 4.56- 4.58 (m, 1H), 6.00-6.01 (m, 2H), 9.4 (s, 1H); C19H28N8O6S2; HPLC 96.9%; Mass 529.5 (M + 1) (4R,5S,6S)-6-((R)-1-((1H-tetrazol-1-yl)methylsulfonamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxcylic acid 380

¹HNMR (D₂O)-1.08 (d, 3H), 1.25 (d, 3H), 2.35-2.37 (m, 1H), 2.80-2.90 (m, 1H), 3.16-3.20 (m, 2H), 3.28- 3.43 (m, 3H), 3.48-3.55 (m, 1H), 3.56-3.68(m, 3H), 3.74-3.84 (m, 2H), 3.86-4.10 (m, 2H), 4.10-4.13 (m, 1H), 4.13-4.29 (m, 1H), 6.00 (m, 2H), 9.36 (s, 1H); C21H31N9O6S2; HPLC 92.5%; Mass 570.6 (M + 1) (4R,5S,6S)-6-((R)-1-((1H-tetrazol-1-yl)methylsulfonamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 381

¹HNMR (D₂O)-0.96 (d, 3H), 1.16 (d, 3H), 1.80-1.83 (m, 1H), 2.67 (s, 3H), 2.85 (s, 3H), 3.05-3.09 (m, 1H), 3.12-3.18 (m, 2H), 3.21-3.33 (m, 2H), 3.71-3.73 (m, 2H), 3.99-4.02 (m, 1H), 4.27-4.32 (m, 1H), 4.46- 4.48 (m, 1H), 6.0 (s, 1H), 8.6 (s, 1H) C19H28N8O6S2; Mass 528.61 (M + 1) (4R,5S,6S)-6-((R)-1-(2H-tetrazol-2-yl)methylsulfonamido)ethyl)-3-((3S,5S)- 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 382

¹HNMR (D₂O)-1.12 (d, 3H), 1.28 (d, 3H), 2.38-2.42 (m, 2H), 2.82 (m, 1H), 3.18-322 (m, 1H), 3.21-3.41 (m, 3H), 3.51-3.72 (m, 4H), 3.77- 3.91 (m, 2H), 3.03-3.97 (m, 2H), 4.16-4.18 (m, 1H), 4.31 (m, 1H), 6.19-6.24 (m, 2H), 8.85 (s, 1H) C21H31N9O6S2; HPLC 93% Mass 570.3 (M + 1) (4R,5S,6S)-6-((R)-1-((2H-tetrazol-2-yl)methylsulfonamido)ethyl)-3-((3S,5S)-5-((R)-3- aminopyrroldine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 383

¹HNMR (D₂O)-1.16 (d, 3H), 1.22 (d, 3H), 1.72-1.75 (m, 1H), 2.83 (s, 3H), 2.95 (s, 9H), 3.19-3.26 (m, 3H), 3.46-3.47 (m, 2H), 3.86 (m, 1H), 4.03-4.05 (m, 1H), 4.30-4.33 (m, 1H), 4.50-4.70 (m, 1H), 5.1 (s, 2H) C22H33N9O5S; HPLC 94.4%; Mass 536.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(5-(dimethylamino)-1H-tetrazol-1-yl)acetamido)ethyl)- 3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 384

¹HNMR (D₂O)-1.16 (d, 3H), 1.22 (d, 3H), 1.8 (m, 1H), 2.03-2.23 (m, 1H), 2.34-2.36 (m, 1H), 2.84 (m, 2H), 2.94 (m, 6H), 3.17 (m, 1H), 3.38-3.39 (m, 2H), 3.46-3.47 (m, 2H), 3.58-3.60 (m, 2H), 3.75-3.78 (m, 2H), 3.94-3.99 (m, 2H), 4.31- 4.33 (m, 1H), 5.1 (s, 2H); C24H36N10O5S; HPLC 90%; Mass 575.7 (M − 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(5-(dimethylamino)-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 385

¹HNMR (D₂O)-1.12 (d, 3H), 1.22 (d, 3H), 1.80-1.85 (m, 1H), 2.91 (s, 3H), 2.95 (s, 3H), 3.19 (m, 2H), 3.20- 3.24 (m, 2H), 3.45-3.46 (m, 1H), 3.55-3.59 (m, 1H), 3.90 (m, 1H), 4.02 (m, 1H), 4.12 (s, 3H), 4.27-4.30 (m, 1H), 4.99 (s, 2H); C21H30N8O6S; HPLC 96.1%; Mass 523.4 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-(2- (5-methoxy-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 386

¹HNMR (D₂O)-1.11 (d, 3H), 1.22 (d, 3H), 2.14-2.15 (m, 1H), 2.35-2.39 (m, 1H), 2.85-3.00 (m, 1H), 3.20- 3.26 (m, 2H), 3.45-3.46 (m, 2H), 3.50-3.56 (m, 2H), 3.81-3.86 (m, 2H), 3.96-3.97 (m, 2H), 4.02-4.04 (m, 2H), 4.12 (s, 3H), 4.26-4.28 (m, 1H), 4.36 (m, 1H), 4.94-4.95 (m, 2H); C23H33N9O6S; HPLC 90.9%; Mass 564.4 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbooyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(5-methoxy-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 387

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (m, 3H), 2.49-2.56 (m, 1H), 3.11- 3.18 (m, 1H), 3.33 (m, 1H), 3.55- 3.57 (m, 2H), 3.73-3.78 (m, 1H), 3.96 (m, 2H), 4.02-4.04 (m, 2H), 4.23 (m, 2H), 4.34-4.49 (m, 2H), 4.75-4.82 (m, 1H), 5.38 (s, 2H), 9.26 (s, 1H); C21H29N9O5S; HPLC 91.1%; Mass 520.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl-3-(1-((2S,4S)-4- aminopyrrolidine-2-carbonyl)azetidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 388

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 1.94-1.99 (m, 1H), 3.00 (s, 3H), 3.06 (s, 3H), 3.27 (m, 2H), 3.44-3.48 (m, 2H), 3.71-3.73 (m, 2H), 4.02-4.09 (m, 3H), 4.45 (m, 1H); C20H28F3N5O5S; HPLC 94.9%; Mass 508.3 (M + 1) (4R,5S,6R)-6-((1R-1-(2-amino-3,3,3-trifluoropropanamido)ethyl-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 389

¹HNMR (D₂O)-1.21 (d, 3H), 1.33 (d, 3H), 1.92 (m, 1H), 3.02 (s, 3H), 3.07 (s, 3H), 3.35-3.42 (m, 3H), 3.59-3.61 (m, 3H), 4.02-4.17 (m, 3H), 4.41 (m, 1H); C20H28F3N5O5S; HPLC 91.7%; Mass 508.3 (M + 1) (4R,5S,6R)-6-((1R)-(2-amino-3,3,3-trifluoropropanamido)ethyl)-3- ((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 390

¹HNMR (D₂O)-1.12 (d, 3H), 1.18 (d, 3H), 3.0-3.1 (m, 4H), 3.15-3.20 (m, 5H), 3.30-3.34 (m, 4H), 3.44- 3.55 (m, 3H), 3.58-3.61 (m, 4H), 4.29-4.30 (m, 1H), 4.32-4.41 (m, 3H), 4.42-4.75 (m, 1H); C25H36N10O5S; HPLC 91.5%; Mass 589.2 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2-(5,6- dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 391

¹HNMR (D₂O)-1.20 (d, 3H), 1.27 (d, 3H), 1.92 (m, 3H), 2.66-2.67 (m, 2H), 2.73-2.79 (m, 2H), 2.84-2.95 (m, 4H), 3.31-3.32 (m, 2H), 3.58- 3.59 (m, 2H), 3.89 (s, 2H), 4.12 (s, 1H), 4.39-4.41 (m, 1H), 5.41 (m, 2H), 9.26 (s, 1H); C22H33N9O4S; HPLC 97.8%; Mass 520.4 (M + 1) (4R,5S,6R)-6-((R-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(((R)-3- aminopyrrolidin-1-yl)methyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 392

¹HNMR (D₂O)-1.20 (d, 3H), 1.32 (d, 3H), 2.08 (m, 1H), 2.97-2.98 (m, 1H), 2.99 (s, 3H), 3.07-3.08 (m, 1H), 3.11 (s, 3H), 3.30-3.32 (m, 2H), 3.55 (m, 2H), 3.96 (m, 1H), 4.13-4.15 (m, 1H), 4.40-4.55 (m, 1H), 5.05-5.07 (d, 2H); C20H29N9O5S; HPLC 90.1%; Mass 508.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(5-amino-1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)- 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 393

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.91-3.10 (m, 1H), 3.32- 3.40 (m, 2H), 3.47-3.52 (m, 1H), 3.59-3.63 (d, 5H), 3.70-3.75 (m, 2H), 4.00 (m, 1H), 4.14-4.16 (m, 2H), 4.40- 4.43 (m, 1H), 4.56-4.59 (m, 2H), 5.42-5.43 (d, 2H), 9.27 (s, 1H); C22H30N8O6S; HPLC 95%; Mass 535.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 394

¹HNMR (D₂O)-1.21 (d, 3H), 1.34 (d, 3H), 1.71-1.90 (m, 1H), 2.32-2.56 (m, 1H), 2.75-2.94 (m, 1H), 3.20- 3.23 (d, 2H), 3.36-3.42 (m, 2H), 3.55-3.61 (m, 2H), 3.64-3.76 (m, 3H), 3.85-3.90 (m, 2H), 4.04-4.08 (m, 2H), 4.13-4.15 (m, 1H), 4.17- 4.29 (m, 1H), 4.39-4.42 (m, 1H); C24H30F3N7O6S; HPLC 90.1%; Mass 602.3 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-6- ((R)-1-(2-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 395

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.94-2.98 (m, 1H), 3.35 (m, 3H), 3.56-3.71 (m, 10H), 3.97 (m, 1H), 4.07 (m, 2H), 4.13-4.15 (m, 1H), 4.41-4.43 (m, 1H), 4.61-4.79 (m, 1H), 5.42 (m, 2H), 9.27 (s, 1H); C24H34N10O6S; HPLC 91%; Mass 591.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2-aminoacetyl)piperazine- 1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 396

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.08-2.14 (m, 1H), 2.99-3.03 (m, 1H), 3.32-3.38 (m, 2H), 3.51- 3.69 (m, 4H), 3.75-3.81 (m, 2H), 4.01-4.03 (m, 1H), 4.14-4.16 (m, 1H), 4.29-4.34 (m, 2H), 4.40-4.43 (m, 1H), 4.58-4.62 (m, 1H), 5.42- 5.43 (m, 2H), 9.27 (s, 1H) C22H30N8O7S; KPLC 90.1%; Mass 551.5 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4R)-3,4- dihydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 397

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.04-2.08 (m, 5H), 2.22-2.23 (m, 6H), 2.91-2.92 (m, 1H), 3.28- 3.40 (m, 4H), 3.49-3.58 (m, 2H), 3.63-3.77 (m, 2H), 3.94-3.95 (m, 1H), 4.14 (m, 3H), 4.34-4.41 (m, 2H), 5.42 (m, 2H), 9.27 (s, 1H); C28H39N9O5S; HPLC 94.3%; Mass 614.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(8- azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine]-1′-ylcarbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 398

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.99-2.13 (m, 1H), 2.19-2.30 (m, 1H), 2.79-3.10 (m, 1H), 3.32- 3.34 (d, 2H), 3.46-3.59 (m, 1H), 3.77 (m, 4H), 3.95 (m, 4H), 4.14 (m, 1H), 4.15-4.24 (m, 1H), 4.46-4.51 (m, 3H), 5.42 (m, 2H), 9.27 (s, 1H); C24H34N10O6S; HPLC 90.15; Mass 591.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-(2- aminoacetamido)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 399

¹HNMR (D₂O)-1.07 (d, 3H), 1.28- 1.30 (d, 3H), 1.73-1.80 (m, 2H), 1.92 (m, 2H), 3.02-3.08 (m, 2H), 3.34- 3.36 (m, 2H), 3.58-3.78 (m, 4H), 4.00 (m, 1H), 4.13-4.16 (m, 1H), 4.41 (m, 2H), 4.58 (m, 1H), 5.41 (m, 2H), 9.27 (s, 1H); C23H33N11O5S; HPLC 90.1%; Mass 576.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-guanidinopyrrolidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 400

¹HNMR (D₂O)-1.18 (d, 3H), 1.34 (d, 3H), 2.97 (m, 1H), 3.36-3.37 (m, 2H), 3.63-3.65 (m, 2H), 3.95-3.99 (m, 2H), 4.13-4.16 (m, 4H), 4.52- 4.54 (m, 2H), 4.55-4.63 (m, 3H), 5.46 (m, 2H), 9.27 (s, 1H); C22H31N9O6S; HPLC 94.4% Mass 550.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4S)-3-amino-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 401

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 2.95 (m, 4H), 3.13-3.23 (m, 1H), 3.30-3.34 (m, 2H), 3.35-3.50 (m, 2H), 3.59-3.63 (m, 2H), 3.72- 3.76 (m, 2H), 3.98 (m, 2H), 4.13- 4.16 (m, 4H), 4.40-4.50 (m, 2H), 5.43 (m, 2H), 9.27 (s, 1H); C24H36N10O5S; HPLC 90%; Mass 577.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-(2- aminoethylamino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 402

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 3.27-3.34 (m, 3H), 3.56-3.65 (m, 3H), 4.11-4.14 (m, 2H), 4.39- 4.42 (m, 2H), 5.42 (m, 2H), 7.71- 7.72 (m, 2H), 8.49-8.51 (m, 2H) 9.27 (s, 1H); C23H27N9O5S; HPLC 91.56%; Mass 542.8 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)- 5-(pyridin-4-ylcarbamoyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 403

¹HNMR (D₂O)-1.17 (d, 3H), 1.36 (d, 3H), 2.28 (m, 1H), 2.49 (m, 1H), 3.05 (m, 1H), 3.38-3.58 (m, 2H), 3.49-3.51 (m, 2H), 3.64-3.67 (m, 2H), 3.74-3.80 (m, 3H), 3.90 (m, 2H), 3.93-4.10 (m, 2H), 4.69 (m, 1H), 5.52 (m, 2H); C23H31N9O7S; HPLC 94.3%; Mass 578.3 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(5-carboxy-1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 404

¹HNMR (D₂O)-1.19 (d, 3H), 1.29 (m, 3H), 1.87 (m, 4H), 1.92 (m, 1H), 2.94-2.95 (m, 1H), 3.23 (m, 3H), 3.30-3.33 (m, 1H), 3.56-3.58 (m, 2H), 3.80 (m, 2H), 4.10-4.15 (m, 2H), 4.39-4.40 (m, 1H), 4.82 (m, 2H), 4.89 (m, 1H), 5.40-5.42 (m, 3H), 9.27 (s, 1H); C24H35N9O5S; HPLC 90.1%; Mass 562.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4- (aminomethyl)piperidine-1-carbanoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 405

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.63 (s, 3H), 2.84 (m, 1H), 3.35 (m, 2H), 3.58 (m, 3H), 3.73 (m, 1H), 3.94 (m, 1H), 4.13-4.16 (m, 2H), 4.32-4.38 (m, 4H), 5.41-5.42 (d, 2H), 9.27 (s, 1H); C22H31N9O5S; HPLC 90%; Mass 533.60 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-3- methylazetidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 406

¹HNMR (D₂O)-1.27 (d, 3H), 1.33- 1.35 (d, 3H), 2.0-2.05 (m, 1H), 3.21 (m, 1H), 3.31-3.35 (m, 1H), 3.47 (m, 1H), 3.58-3.61 (m, 9H), 3.70-3.78 (m, 2H), 3.79 (m, 2H), 3.90 (m, 4H), 4.11-4.13 (m, 1H), 4.38-4.42 (m, 1H), 5.41-5.46 (m, 3H), 8.0 (m, 1H), 9.27 (s, 1H); C26H38N10O5S; HPLC 96.4%; Mass 603.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-(4- ((S)-pyrrolidin-3-yl]piperazine-1-carbonyl]pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 407

¹HNMR (D₂O)-1.14 (d, 3H), 1.33 (d, 3H), 3.15 (m, 1H), 3.55-3.57 (m, 1H), 4.0-4.1 (m, 4H), 4.12 (m, 1H), 4.31-4.35 (m, 2H), 4.52-4.59 (m, 2H), 9.27 (s; 1H); C16H21N7O4S; HPLC 99.9%; Mass 408.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(azetidin- 3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 408

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 2.50 (d, 2H), 2.99 (m, 2H), 3.30-3.32 (m, 1H), 3.43-3.58 (m, 1H), 3.63-3.67 (m, 1H), 3.69-3.72 (m, 6H), 3.90 (m, 4H), 4.10-4.13 (m, 1H), 4.15-4.22 (m, 4H), 4.39-4.43 (m, 1H), 5.41-5.42 (m, 2H), 9.27- 9-31 (d, 1H); C25H36N10O5S; HPLC 97.3%; Mass 590.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(azetidin-3- yl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 409

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 2.86-2.89 (m, 1H), 3.18-3.20 (m, 1H), 3.22-3.27 (m, 2H), 3.55- 3.59 (m, 9H), 3.64-3.69 (m, 1H), 3.71-3.85 (m, 4H), 4.13-4.35 (m, 1H), 4.35-4.39 (m, 2H). 4.40-4.43 (m, 1H), 4.82 (m, 1H), 5.4-5.42 (m, 3H), 7.21-7.33 (m, 1H), 7.41-7.43 (m, 1H), 9.27 (s, 1H); C27H40N10O5S; HPLC 90%; Mass 617.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((R)-3- aminopyrrolidin-1-yl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 410

¹HNMR (D₂O)-1.24 (d, 3H), 1.33 (m, 3H), 2.31 (m, 1H), 2.56 (m, 1H), 2.90 (s, 6H), 3.10-3.2 (m, 1H), 3.54- 3.6 (m, 1H), 3.59 (m, 2H), 3.71-3.76 (m, 2H), 3.95 (m, 1H), 4.0 (m, 4H), 4.13-4.16 (m, 2H), 4.40-4.43 (m, 1H), 4.50-4.80 (m, 1H), 5.30-5.42 (m, 2H), 9.25 (s, 1H); C24H35N9O5S; HPLC 94.55%; Mass 562.6 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3- (dimethylamino)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 411

¹HNMR (D₂O)-1.77 (d, 3H), 1.79 (d, 6H), 2.46 (m, 1H), 2.70-2.74 (m, 1H), 3.70-3.73 (m, 2H), 3.77 (m, 2H), 3.88 (m, 1H), 4.03-4.05 (m, 2H), 4.08 (m, 1H), 4.13-4.15 (m, 1H), 4.21-4.23 (m, 1H), 4.33 (m, 1H), 4.39-4.41 (m, 1H), 4.42-4.65 (m, 1H), 4.82-4.90 (m, 2H), 5.41- 5.42 (m, 1H), 9.27 (s, 1H); C23H33N9O5S; HPLC 93.8%; Mass 548.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2R,4S)-4-amino-2- methylpyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 412

¹HNMR (D₂O)-1.07 (d, 3H), 1.29 (d, 3H), 2.94 (m, 2H), 3.32 (m, 2H), 3.57-3.59 (m, 2H), 3.62-3.65 (m, 2H), 3.96 (m, 1H), 4.07-4.10 (m, 3H), 4.13-4.15 (m, 4H), 4.41 (m, 2H), 5.40-5.42 (m, 2H), 9.25-9.27 (s, 1H); C23H33N9O6S HPLC 92.7%; Mass 564.0 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-4-amino-2- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 413

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (3, 3H), 2.96-3.00 (m, 1H), 3.33-3.36 (m, 2H), 3.49 (m, 1H), 3.55-3.58 (m, 1H), 3.61-3.63 (m, 2H), 3.71 (m, 2H), 3.92-3.97 (m, 2H), 4.08 (m, 1H), 4.13-4.16 (m, 1H), 4.39-4.43 (m, 1H), 4.50 (m, 1H), 4.82 (m, 1H), 5.42-5.47 (m, 2H), 9.27 (s, 1H); C22H32N10O5S HPLC 90.6%; Mass 549.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3,4- diaminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 414

¹HNMR (D₂O)-1.29 (d, 3H), 1.34 (d, 3H), 1.92 (m, 2H), 3.21-3.31 (m, 1H), 3.59-3.63 (m, 2H), 3.89-3.92 (m, 4H), 4.00-4.03 (m, 1H), 4.14- 4.16 (m, 3H), 4.40-4.43 (m, 1H), 4.61-4.63 (m, 2H); 5.41-5.46 (m, 2H), 9.27 (s, 1H); C22H31N9O6S; HPLC 95%; Mass 550.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4S)-3- amino-4-hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 415

¹HNMR (D₂O)-1.14 (d, 3H), 1.28 (d, 3H), 3.01-3.05 (m, 1H), 3.23-3.27 (m, 1H), 3.38-3.40 (m, 2H), 3.57- 3.59 (m, 1H), 3.72 (m, 1H), 4.12- 4.15 (m, 1H), 4.40-4.43 (m, 1H), 4.82 (m, 1H), 5.40-5.47 (m, 1H), 9.27 (s, 1H); C15H21N7O4S; HPLC 90.95; Mass 396.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(2- aminoethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 416

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.92 (m, 1H), 2.55-2.69 (m, 3H) 2.84-3.01 (m, 4H), 3.32-3.39 (m, 4H), 3.57-3.61 (m, 2H), 3.80-3.83 (m, 2H), 4.00 (m, 2H), 4.13-4.15 (m, 1H), 4.40-4.43 (m, 1H), 4.69-4.71 (m, 1H), 4.82 (m, 1H), 5.41-5.42 (m, 2H) 9.27 (s, 1H); C24H35N9O6S; HPLC 96.1%; Mass 578.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2- hydroxyethyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 417

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.86-1.92 (m, 1H), 2.60-2.63 (m, 3H), 3.01-3.18 (m, 1H), 3.32- 3.36 (m, 3H), 3.57-3.62 (m, 2H), 3.71-3.99 (m, 4H), 4.14-4.16 (m, 1H), 4.40-4.43 (m, 1H), 4.63-4.67 (m, 1H), 4.82 (m, 1H), 5.37-5.42 (m, 2H), 7.21-7.23 (m, 1H), 7.39-7.43 (m, 1H), 9.27 (s, 1H); C24H34N10O6S; HPLC 96.7%; Mass 591.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2-amino-2- oxoethyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 418

¹HNMR (D₂O)-1.34 (d, 3H), 1.79 (d, 3H), 1.95 (m, 3H), 2.45 (m, 5H), 3.22 (m, 3H), 3.34 (m, 2H), 3.57 (m, 3H), 3.72 (m, 3H), 3.97 (m, 3H), 4.13 (m, 2H), 4.41 (m, 2H), 5.40-5.42 (m, 2H), 9.27 (s, 1H); C27H39N9O5S; HPLC 93.7%; Mass 602.4 (M + 1) (4R,5S,6R)-3-((3S,5S)-5-(1,9-diazaspiro[5.5]undecane-9-carbonyl)pyrrolidin-3-ylthio)-6-((R)- 1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 419

¹HNMR (D₂O)-1.29 (d, 3H), 1.34 (d, 3H), 1.86-1.92 (m, 2H) 2.93 (m, 3H), 3.28-3.31 (m, 4H), 3.55-3.61 (m, 9H), 4.13-4.15 (m, 1H), 4.59- 4.61 (m, 1H), 4.75 (m, 1H), 4.89 (m, 1H), 5.37-5.47 (m, 2H), 9.27 (m, 1H); C25H36N10O6S; HPLC 92.3%; Mass 605.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(3- aminopropanoyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 420

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 3.07-3.21 (m, 1H), 3.36-3.55 (m, 3H), 3.71-3.73 (m, 9H), 3.85- 3.98 (m, 4H), 4.24-4.28 (m, 1H), 4.49-4.51 (m, 2H), 4.79-4.87 (m, 1H), 5.42 (m, 2H), 9.27 (s, 1H); C25H36N10O7S; HPLC 96.3%; Mass 621.2(M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((S)-2-amino-3- hydroxypropanoyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 421

¹HNMR (D₂O)-1.21 (d, 3H), 1.34 (d, 3H), 2.89 (m, 1H), 3.32-3.36 (m, 2H), 3.57-3.62 (m, 2H), 3.96 (m, 1H), 4.13-4.16 (d, 1H), 4.42-4.45 (m, 4H), 4.75-4.82 (m, 3H), 5.3-5.37 (m, 2H), 5.5 (m, 1H), 8.1 (s, 1H), 8.54 (s, 1H), 9.27 (s, 1H); C23H29N11O5S; HPLC 93.5% Mass 572.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-(2H-1,2,3-triazol- 2-yl)azetidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 422

¹HNMR (D₂O) 1.29 (d, 3H), 1.34 (d, 3H), 1.82 (m, 4H), 2.47 (m, 1H), 2.79 (m, 1H), 2.94 (m, 1H), 3.2 (m, 2H), 3.34 (m, 1H), 3.57 (m, 4H), 3.76 (m, 4H), 3.98 (m, 1H), 4.13 (m, 1H), 4.40 (m, 1H), 4.54 (m, 2H), 5.42-5.43 (m, 2H), 9.27 (s, 1H); C26H38N10O6S; HPLC 90%; Mass 619.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((2- aminoacetamido)methyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 423

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 1.83 (m, 6H), 2.84 (m, 1H), 3.0 (m, 1H), 3.32 (m, 1H), 3.48 (m, 1H), 3.57 (m, 2H), 3.70 (m, 1H), 3.78 (m, 3H), 4.0 (m, 1H), 4.13 (m, 1H), 4.40 (m, 2H), 5.42 (m, 3H), 9.27 (s, 1H); C24H34N8O6S; HPLC 90.2%; Mass 563.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4- (hydroxymethyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 424

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (3, 3H), 1.85-1.92 (m, 1H), 2.82 (m, 2H), 3.0 (m, 3H), 3.26 (m, 1H), 3.34 (m, 1H), 3.56 (m, 2H), 3.97 (m, 2H), 4.12-4.15 (m, 2H), 4.40-4.50 (m, 2H), 5.4 (m, 2H), 9.27 (s, 1H); C23H30N10O5S; HPLC 91.9%; Mass 559.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-3- (cyanomethyl)azetidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 425

¹HNMR (D₂O)-1.04 (d, 3H), 1.34 (d, 3H) 1.75 (m, 2H), 2.90 (m, 3H), 3.25-3.34 (m, 5H), 3.56-3.72 (m, 4H), 3.98-3.99 (m, 1H), 4.12-4.14 (m, 1H), 4.40-4.48 (m, 2H), 5.43 (d, 2H), 9.27 (s, 1H); C23H32FN9O5S; HPLC 92.7%; Mass 566.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-amino-3- fluoropiperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 426

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(3- hydroxyazetidin-1-yl]piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.20 (d, 3H), 1.3 (d, 3H), 1.83-1.85 (m, 2H), 2.82-2.97 (m, 3H), 3.21-3.35 (m, 4H), 3.52- 3.58 (m, 4H), 3.89-3.95 (m, 4H), 4.15-4.29 (m, 1H), 4.41-4.43 (m, 2H), 4.48-4.51 (m, 1H), 4.58-4.65 (m, 1H), 4.67-4.68 (m, 1H), 4.76- 4.83 (m, 1H), 5.43(m, 2H), 9.27 (s, 1H); C26H37N9O6S; HPLC 96.6%; Mass 604.2 (M + 1) 427

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.82 (m, 2H), 2.85 (m, 1H), 3.35 (m, 1H), 3.63 (m, 3H), 3.74 (m, 3H), 3.89-4.07 (m, 3H), 4.13 (m, 1H), 4.41-4.45 (m, 2H), 5.42-5.43 (m, 2H), 9.27 (s, 1H); C23H33N11O6S; HPLC 94.1%; Mass 592.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4S)-3-guanidino-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 428

¹HNMR (D₂O)-1.20 (d, 3H), 1.30 (d, 3H), 1.45 (m, 2H), 1.92 (m, 4H), 2.38-2.48 (m, 1H), 2.89-2.93 (m, 3H), 3.28-3.33 (m, 3H), 3.57-3.59 (m, 3H), 3.76-3.78 (m, 4H), 4.0 (m, 3H), 4.13 (m, 1H), 4.40-4.43 (m, 2H), 5.47-5.54 (m, 2H), 9.27 (s, 1H); C28H40N10O6S; HPLC 91%; Mass 645.6 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((R)-3- aminopyrrolidine-1-carbonyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 429

¹HNMR (D₂O)-1.20-(d, 3H), 1.34 (d, 3H), 2.7 (m, 3H), 3.24-3.32 (m, 6H), 3.50-3.58 (m, 4H), 3.95 (m, 1H), 4.13-4.15 (m, 2H), 4.18-4.23 (m, 4H), 4.39-4.43 (m, 2H), 5.42- 5.47 (m, 3H), 9.27 (s, 1H); C25H36N10O5S; HPLC 90% Mass 589.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-(3-(piperazin- 1-yl)azetidine-1-carbonyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-carboxylic acid 430

¹HNMR (D₂O)-1.19 (d, 3H), 1.30 (d, 3H), 1.57-1.67 (m, 2H), 1.87-1.90 (m, 3H), 2.9 (m, 2H), 3.1 (m, 1H), 3.26 (m, 5H), 3.5 (m, 4H), 3.83 (m, 2H), 3.87 (m, 2H), 3.98 (m, 3H), 4.4 (m, 3H), 5.4-5.45 (d, 2H), 9.26 (s, 1H); C28H40N10O6S; Mass 644.75 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-(4- (piperazine-1-carbonyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 431

¹HNMR (D₂O)-1.17 (d,3 H), 1.30 (d, 3H), 2.81 (m, 1H), 3.17 (m, 1H), 3.30-3.34 (m, 2H), 3.53-3.57 (m, 3H), 3.92-3.93 (m, 2H), 4.12-4.21 (m, 2H), 4.36-4.40 (m, 2H), 4.44- 4.55 (m, 1H), 4.88 (m, 2H), 5.44 (m, 2H), 9.24 (s, 1H); C22H31N9O6S; HPLC 90.6%; Mass 550.1 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)- 3-amino-4-hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 432

¹HNMR (D₂O)-1.16 (d. 3H), 1.31 (d, 3H), 1.80-1.82 (m, 1H). 2.55-2.68 (m, 4H), 2.87-2.91 (m, 1H), 3.26- 3.37 (m, 4H), 3.51-3.54 (m, 4H), 3.66 (m, 2H), 3.93 (m, 1H), 4.09- 4.12 (m, 1H), 4.37-4.40 (m, 1H), 4.49-4.53 (m, 1H), 4.89 (m, 2H), 5.40 (s, 2H), 9.24 (s, 1H); C25H38N12O5S; HPLC 96.5%; Mass 619.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2- guanidinoethyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 433

¹HNMR (D₂O)-1.16 (d, 3H), 1.31 (d, 3H), 1.81-1.84 (m, 1H), 2.88-2.90 (m, 2H), 3.27-3.33 (m, 4H). 3.42- 3.44 (m, 1H), 3.48 (m, 1H), 3.53- 3.54 (m, 1H), 3.69 (m, 2H) 3.92 (m, 1H), 4.09-4.11 (m, 1H), 4.27-4.34 (m, 1H), 4.36-4.40 (m, 1H), 4.55- 4.57 (m, 1H), 4.90 (m, 1H), 5.40 (s, 2H), 9.24 (s, 1H); C23H32FN9O5S; HPLC 93.7% Mass 566.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-amino- 3-fluoropiperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 434

¹HNMR (D₂O)-1.16 (d, 3H), 1.30 (d, 3H), 1.90 (m, 2H), 2.66-2.67 (m, 1H), 2.97-2.98 (m, 1H), 3.11-3.12 (m, 1H), 3.27-3.34 (m, 3H), 3.57- 3.58 (m, 2H), 3.65-3.67 (m, 5H), 3.92-3.95 (m, 2H), 4.09-4.11 (m, 1H), 4.36-4.39 (m, 2H), 4.64-4.65 (m, 2H), 4.98 (m, 2H), 5.39 (s, 2H), 9.23 (s, 1H); C27H39N11O6S HPLC 93%; Mass 646.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((2R,4R)-4- aminopyrrolidine-2-carbonyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 435

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.67-1.68 (m, 2H), 1.70-1.71 (m, 2H), 1.82-1.85 (m, 1H), 2.94- 297 (m, 1H), 3.19-3.20 (m, 2H), 3.32-3.35 (2H), 3.37-3.42 (m, 4H), 3.43-3.45 (m, 4H), 3.50-3.53 (m, 1H), 3.54-3.56 (m, 1H), 3.96-3.98 (m, 1H), 4.10-4.11 (m, 1H), 4.37-4.39 (m, 1H), 4.58-4.60 (m, 1H), 5.38- 5.40 (m, 2H), 9.24 (s, 1H); C26H37N9O5S; HPLC 90.1%; Mass 588.49 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,8- diazaspiro[4.5]decane-8-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 436

¹HNMR (D₂O)-1.12 (d, 3H), 1.31 (d, 3H), 2.5 (m, 1H), 3.32-3.35 (m, 1H), 3.42-3.44 (m, 1H), 3.46-3.49 (m, 2H), 3.53-3.56 (m, 2H), 3.57 (m, 2H), 3.59-3.60 (m, 2H), 3.74-3.95 (m, 1H), 4.11-4.13 (m, 1H), 4.37- 4.39 (m, 1H), 4.41-4.63 (m, 1H), 4.80-4.85 (m, 1H), 4.85 (m, 2H), 5.37-5.40 (m, 2H), 9.23 (s, 1H) C22H32N8O7S; HPLC 90.1%; Mass 553.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(bis(2- hydroxyethyl)carbarnoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 437

¹HNMR (D₂O)-1.17 (d, 3H) 1.31 (d, 3H), 1.86-1.89 (m, 2H), 2.04-2.06 (m, 1H), 2.82-2.84 (m, 1H), 2.91- 2.93 (m, 3H), 3.2-3.24 (m, 1H), 3.29- 3.32 (m, 3H), 3.52-3.58 (m, 4H), 3.79-3.80 (m, 3H), 3.95-3.96 (m, 1H), 4.10-4.13 (m, 1H), 4.31-4.38 (m, 2H), 4.57-4.59 (m, 1H), 5.37- 5.40 (m, 2H), 9.23 (s, 1H); C26H38N10O6S; HPLC 92.4%; Mass 619.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((2-amino-2- oxoethylamino)methyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 438

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.97 (m, 1H), 2.12-2.17 (m, 3H), 2.64 (m, 3H), 3.00-3.07 (m, 3H), 3.27-3.31 (m, 2H), 3.42-3.43 (m, 2H), 3.65-3.70 (m, 3H), 4.01 (m, 1H), 4.11-4.13 (m, 1H), 4.28-4.30 (m, 1H), 4.37-4.40 (m, 1H), 4.53- 4.57 (m, 1H), 5.40 (d, 2H), 9.25 (s, 1H); C25H35N9O5S; HPLC 92.6%; Mass 574.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 439

¹HNMR (D₂O)-1.17 (d, 3H), 1.30- 1.32 (d, 3H), 1.75-1.77 (m, 2H), 2.11-2.16 (m, 3H), 3.22-3.23 (m, 3H), 3.30-3.36 (m, 2H), 3.40-3.44 (m, 3H), 3.53-3.55 (m, 2H), 3.79- 3.89 (m, 3H), 4.09-4.10 (m, 1H), 4.22-4.27 (m, 1H), 4.37-4.40 (m, 2H), 5.40 (m, 2H), 9.24 (s, 1H); C25H35N9O5S; HPLC 97.4%; Mass 574.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 440

¹HNMR (D₂O)-1.16-1.18 (d, 3H), 1.31-1.32 (d, 3H), 2.24-2.28 (m, 1H), 2.42-2.49 (m, 1H), 2.98 (m, 1H), 3.38 (m, 2H), 3.62-3.65 (m, 4H), 3.76-3.77 (m, 2H), 3.87-3.89 (m, 2H), 3.92 (m, 1H), 4.11-4.17 (m, 2H), 4.37-4.40 (m, 2H), 5.39 (s, 2H), 9.24 (s, 1H); C23H33N9O6S; HPLC 94.6%; Mass 564.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5- ((2S,4R)-4-amino-2-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)- 4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 441

¹HNMR (D₂O)-1.17-1.19 (d, 3H), 1.31-1.33 (d, 3H), 1.99-2.02 (m, 2H), 2.62-2.68 (m, 1H), 2.92-2.97 (m, 2H), 3.09-3.33 (m, 4H), 3.52-3.62 (m, 3H), 3.92 (m, 2H), 4.11-4.13 (m, 2H), 4.28 (m, 1H), 4.37-4.41 (m, 3H), 4.98 (m, 1H), 5.40 (s, 2H), 9.25 (s, 1H); C24H36N10O7S2; HPLC 91.2%; Mass 641.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-4- amino-2-(methylsulfonamido-methyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 442

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((S)-3-amino-2- hydroxypropyl)piperazioe-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.28 (d, 3H), 1.33 (d, 3H), 2.55-2.58 (m, 6H), 2.60-2.63 (m, 2H), 2.93-2.96 (m, 3H), 3.14- 3.15 (m, 1H), 3.15-3.18 (m, 3H), 3.51-3.55 (m, 2H), 3.56-3.58 (m, 2H), 3.95 (m, 1H), 4.12-4.15 (m, 1H), 4.39-4.42 (m, 1H), 4.7 (m, 1H), 5.40-5.42 (m, 2H), 9.26 (s, 1H); C25H38H10O6S; HPLC 96.9% Mass 607.20 (M + 1) 443

¹HNMR (D₂O)-1.19 (m, 3H), 1.33 (d, 3H), 1.93 (m, 1H), 2.3 (m, 2H), 2.79 (m, 2H), 2.8)1 (m, 2H), 2.96 (m, 3H), 3.10 (m, 1H), 3.21-3.22 (m, 2H), 3.58-3.61 (m, 3H), 3.81-3.84 (m, 3H), 4.0 (m, 1H), 4.2 (m, 1H), 4.26-4.28 (m, 2H), 4.40-4.42 (m, 2H), 5.39-5.43 (m, 2H), 9.27 (s, 1H); C26H40N10O5S; HPLC 90.2% Mass 605.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((2- aminoethylamino)methyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 444

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 2.23 (m, 1H), 2.40-2.43 (m, 2H), 2.86 (m, 1H), 3.19-3.27 (m, 4H), 3.50-3.56 (m, 2H), 3.76 (m, 1H), 3.95 (m, 2H), 4.07-4.13 (m, 2H), 4.35-4.42 (m, 2H), 4.55 (m, 1H), 5.40-5.44 (m, 2H), 9.2 (s, 1H); C23H34N10O5S; HPLC 90.0%; Mass 563.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4R)-4-amino-2- (aminoethyl)pyrrolidine-1-carbooyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 445

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.90 (m, 1H), 2.59 (m, 4H), 2.60 (m, 2H), 3.01-3.05 (m, 4H), 3.36- 3.38 (m, 2H), 3.56-3.57 (m, 5H), 3.71 (m, 3H), 4.01-4.05 (m, 1H), 4.11-4.13 (m, 1H), 4.39 (m, 1H), 5.39-5.40 (m, 2H), 9.25 (s, 1H); C25H38N10O5S; HPLC 96.4%; Mass 591.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(3- aminopropyl)piperazine-1-carbooyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 446

¹HNMR (D₂O)-1.16 (d, 3H), 1.31 (d, 3H), 1.78-1.84 (m, 1H), 2.94-2.95 (m, 1H), 3.28-3.34 (m, 2H), 3.53- 3.58 (m, 5H), 3.62-3.68 (m, 4H), 3.95 (m, 1H), 4.09-4.11 (m, 2H), 4.23 (m, 2H), 4.30-4.38 (m, 1H), 4.58 (m, 1H), 5.39-5.43 (m, 2H), 9.24 (s, 1H); C25H36N12O6S HPLC 93.6%; Mass 633.6 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2- guanidinoacetyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 447

¹HNMR (D₂O)-1.08 (d, 3H), 1.21 (d, 3H), 2.25 (m, 2H), 2.35-2.44 (m, 2H), 2.87 (m, 1H), 3.14 (m, 1H), 3.22-3.26 (m, 2H), 3.29-3.30 (m, 2H), 3.43-3.46 (m, 1H), 3.50-3.59 (m, 2H), 3.78 (m, 1H), 3.80-3.86 (m, 3H), 3.93-3.95 (m, 1H), 4.00-4.02 (m, 2H), 4.27-4.29 (m, 2H), 4.82- 4.86 (m, 1H), 5.32-5.34 (m, 2H), 9.14 (s, 1H); C27H39N11O6S HPLC 93.0%; Mass 646.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4R)-4-amino-2-((R)-3- aminopyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 448

¹HNMR (D₂O)-1.17-1.19 (d, 3H), 1.31-1.33 (d, 3H), 2.00-2.07 (m, 2H), 2.28-2.31 (m, 2H), 3.11-3.14 (m, 2H), 3.31 (m, 1H), 3.45-3.48 (m, 2H), 3.55-3.58 (m, 1H), 3.70-3.80 (m, 1H), 3.85-3.95 (m, 1H), 4.05 (m, 1H), 4.12-4.14 (m, 1H), 4.38-4.42 (m, 2H), 4.79-4.91 (m, 3H), 5.39- 5.40 (s, 2H); 7.78 (s, 2H), 9.24 (s, 1H); C25H33N11O5S; HPLC 97.4%; Mass 600.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2H-1,2,3-triazol-2- yl)piperidine-1-carbooyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 449

¹HNMR (D₂O)-1.20 (d, 3H), 1.27 (d, 3H), 2.3-2.5 (m, 1H), 3.32-3.41 (m, 3H), 3.56-3.60 (m, 2H), 3.63-3.88 (m, 2H), 3.90-3.96 (m, 3H), 4.11- 4.15 (m, 1H), 4.38-4.42 (m, 1H), 5.40-5.41 (d, 2H), 9.25 (s, 1H); C19H26N8O5S; HPLC 95.3%; Mass 479.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((S)-1-(2- aminoacetyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 450

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (m, 3H), 1.89 (m, 2H), 2.54-2.59 (m, 4H), 2.60-2.62 (m, 2H), 2.90-2.92 (d, 2H), 3.13-3.14 (m, 1H), 3.3 (m, 2H), 3.54-3.57 (m, 4H), 3.59 (m, 1H), 4.1- 4.13 (m, 1H), 4.14 (m, 2H), 4.39 (m, 1H), 4.7 (m, 1H), 5.39-5.40 (m, 2H), 9.25 (s, 1H); C25H38N10O6S; HPLC 90.1%; Mass 607.2 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((R)-3-amino- 2-hydroxypropyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 451

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.92 (m, 1H), 2.68-2.76 (m, 6H), 2.82 (m, 4H), 3.01 (m, 3H), 3.28-3.33 (m, 6H), 3.57-3.59 (m, 6H), 4.00-4.16 (m, 2H), 4.39-4.43 (m, 2H), 5.41-5.42 (m, 2H), 9.27 (s, 1H); C28H43N11O5S; HPLC 92.9%; Mass 646.6 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-methyl-7-oxo-3-((3S,5S)-5- (4-(2-(piperazin-1-yl)ethyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

The following examples 452-601 were prepared adopting the procedure for synthesizing example 2982

Ex- am- ple Structure Analytical Data 452

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.77-1.89 (m, 4H), 2.80-2.84 (m, 2H), 2.97-2.99 (m, 1H), 3.11-3.14 (m, 2H), 3.30-3.34 (m, 3H), 3.43 (m, 1H), 3.49-3.54 (m, 1H), 3.68-3.71 (m, 1H), 3.77-3.89 (m, 4H), 4.11- 4.15 (m, 1H), 4.24- 4.26 (m, 1H), 4.37-4.39 (m, 1H), 5.42-5.44 (d, 2H), 9.24 (s, 1H) C25H35N9O5S HPLC 95.3% Mass (M + 1) 574.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,4-b]pyridine-6-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 453

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 2.06-2.08 (m, 1H), 2.30- 2.34 (m, 1H), 2.59-2.61 (m, 2H), 3.03-3.05 (m, 1H), 3.31-3.33 (m, 1H), 3.43-3.48 (m, 1H), 3.55-3.57 (m, 1H), 3.72-3.77 (m, 2H), 3.94- 4.02 (m, 2H), 4.12-4.14 (m, 1H), 4.37-4.43 (m, 2H), 4.47-4.49 (m, 1H), 5.40-5.44 (d, 2H), 9.24 (s, 1H) C23H31N9O7S 25 HPLC 94.8%, Mass (M + 1) 578.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4R)-4- amino-2-carboxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 454

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.89-1.96 (m, 1H), 2.59-2.76 (m, 2H), 2.78 (m, 1H), 3.11-3.14 (m, 1H), 3.22-3.29 (m, 2H), 3.41-3.46 (m, 2H), 3.48-3.49 (m, 1H), 3.54- 3.55 (m, 2H), 3.75 (m, 2H), 3.94- 4.12 (m, 2H) 4.29-4.37 (m, 2H), 5.40-5.44 (d, 2H), 9.23 (s, 1H) C23H35N11O7S2 HPLC 90.1%, Mass (M+ 1) 642.6 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-4- amino-2-((sulfamoylamino)-methyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 455

¹HNMR (D₂O) 1.17 (d, 3H), 1.30 (d, 3H), 1.88 (m, 1H), 2.22 (m, 1H), 2.33 (m, 1H), 2.42 (m, 1H), 2.89 (m, 1H), 3.18 (m, 1H), 3.20-3.25 (m, 1H), 3.30-3.34 (m, 1H), 3.53-3.54 (d, 2H), 3.70-3.77 (m, 2H), 3.86-3.89 (m, 2H) 4.10-4.11 (m, 2H), 4.28-4.38 (m, 2H), 5.41-5.43 (d, 2H), 9.20 (s, 1H) C23H35N11O7S2 HPLC 90.2%, Mass (M + 1) 642.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4R)-4- amino-2-((sulfamoylamino)methyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 456

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.91 (m, 1H), 2.88-2.91 (m, 2H), 3.32-3.33 (m, 2H), 3.55-3.57 (m, 2H), 3.61-3.65 (m, 4H), 3.71- 3.74 (m, 4H), 3.80-3.82 (m, 1H), 3,96 (m, 1H), 4.11-4.13(m, 2H), 4.37-4.41 (m, 2H), 5.42-5.45 (d, 2H), 9.27 (s, 1H) C25H37N11O6S HPLC 90.2%, Mass (M + 1) 621.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((S)-2,3- diaminopropanoyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 457

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.82-1.86 (m, 1H), 1.89 (m, 2H), 2.72-2.77 (m, 3H), 2.94-2.97 (m, 1H), 3.07-3.10 (m, 1H), 3.23- 3.33 (m, 3H), 3.54-3.56 (m, 3H), 3.70-3.75 (m, 2H), 3.95 (m, 1H), 4.11-4.13 (m, 1H), 4.37-4.41 (m, 2H), 4.60-4.80 (m, 2H), 5.35-5.45 (m, 2H), 8.43 (m, 1H), 9.23 (s, 1H), C25H39N11O5S HPLC 90.9%, Mass 606.6 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((R)-2,3- diaminopropyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 458

¹HNMR (D₂O)-1.22 (d, 3H), 1.28 (d, 3H), 1.34 (m, 1H), 1.57 (m, 1H), 1.82 (m, 1H), 2.08 (d, 1H), 2.30 (m, 1H), 2.32 (m, 1H), 2.99 (s, 3H), 3.12 (d, 3H), 3.23-3.24 (d, 2H), 3.32-3.46 (m, 3H), 3.60-3.81 (m, 2H), 4.00 (d, 2H), 4.42 (m, 2H), 4.59 (m, 1H), 4.72 (m, 1H), 5.25 (m, 1H) C23H35N5O5S HPLC 90.9%, Mass (M + 1) 494.6 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-6-((R)-1-(2-(pyrrolidin-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0)hept- 2-eoe-2-carboxylic acid 459

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.81-1.91 (m, 4H), 2.88 (m, 2H), 3.16 (m, 1H), 3.20-3.28 (m, 2H), 3.36-3.39 (m, 3H), 3.57-3.59 (m, 2H), 3.72-3.77 (m, 2H), 3.83- 3.87 (m, 1H), 3.90-3.92 (m, 2H), 4.12-4.14 (m, 1H), 4.25-4.29 (m, 1H), 4.39-4.42 (m, 1H), 5.41-5.42 (m, 2H), 9.27 (s, 1H) C25H35N9O5S HPLC 96.7%, Mass 574.4 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,4-b]pyridine-6-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-eoe-2-carboxylic acid 460

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.89 (m, 1H), 2.72-2.77 (m, 3H), 2.94-2.97 (m, 1H), 3.07-3.10 (m, 1H), 3.23-3.33 (m, 2H), 3.54- 3.56 (m, 2H), 3.70-3.75 (m, 2H), 3.95 (m, 1H), 4.11-4.13 (m, 1H), 4.37-4.41 (m, 2H), 4.60-4.80 (m, 2H), 5.35-5.45 (m, 2H), 8.43 (m, 1H), 9.23 (s, 1H) C23H33N9O6S HPLC 90%, Mass (M + 1) 564.1 (4R,5S,5R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-2- (aminomethyl)morpholine-4-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 461

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.87 (m, 1 H), 2.68-2.73 (m, 3H), 2.90-2.94 (m, 1H), 3.02-3.08 (m, 1H), 3.28-3.42 (m, 2H), 3.58- 3.62 (m, 2H), 3.72-3.78 (m, 2H), 4.01 (m, 1H), 4.14-4.18 (m, 1H), 4.40-4.44 (m, 2H), 4.72-4.94 (m, 2H), 5.44-5.48 (m, 2H), 8.52 (m, 1H), 9.26 (s, 1H) C23H33N9O6S HPLC 95.1%, Mass (M + 1) 564.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((S)-2- (aminomethyl)morpholine-4-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 462

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 2.58-2.62 (m, 3H), 2.66-2.70 (m, 4H), 2.82-2.87 (m, 2H), 2.93- 2.99 (m, 1H), 3.25-3.29 (m, 3H), 3.35-3.39 (m, 3H), 3.55-3.60 (m, 1H), 3.72-3.99 (m, 1H), 4.0-4.13 (m, 1H), 4.33-4.65 (m, 1H), 4.67-4.80 (m, 1H), 5.1 (m, 1H), 5.3 (m, 1H), 5.4 (m, 2H), 9.25 (s, 1H) C25H37FN10O5S HPLC 95.6%, Mass 609.5 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-((S)-3-amino-2- fluoropropyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 463

¹HNMR (D₂O)-1.27 (d, 3H), 1.33 (d, 3H), 1.65-1.80 (m, 1H), 2.44-2.48 (m, 1H), 3.13-3.14 (m, 1H), 3.30- 3.36 (m, 1H), 3.52-3.58 (m, 3H), 3.62-3.65 (m, 3H), 3.71-3.77 (m, 3H), 3.99 (m, 2H), 4.13-4.15 (m, 3H), 4.31-4.39 (m, 2H), 4.40-4.69 (m, 1H), 4.79 (m, 1H), 5.30-5.46 (m, 2H), 9.25 (s, 1H) C25H37N9O6S HPLC 90%, Mass 591.7 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(aminomethyl)-4- (hydroxymethyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 464

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.89-1.96 (m, 1H), 2.42-2.44 (m, 2H) 2.59-2.76 (m, 1H), 2.78 (m, 1H), 3.11-3.14 (m, 1H), 3.22-3.29 (m, 2H), 3.41-3.46 (m, 2H), 3.48- 3.49 (m, 1H), 3.54-3.55 (m, 2H), 3.75 (m, 2H), 3.94-4.12 (m, 2H) 4.29-4.37 (m, 2H), 5.40-5.44 (d, 2H), 9.23 (s, 1H) C23H33N9O5S HPLC 90%, Mass (M + 1) 548.2 (4R,5S,6R)-6-((R)-1-(2-(1-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((S)-2- (aminomethyl)pyrrolidine-1-carbooyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 465

¹HNMR (D₂O)-1.17 (d, 3H), 1.30 (d, 3H), 1.92 (m, 1H), 2.43-2.46 (m, 2H) 2.60-2.74 (m, 1H), 2.80-2,82 (m, 1H), 3.14-3.16 (m, 1H), 3.28-3.32 (m, 2H), 3.42-3.45 (m, 2H), 3.49- 3.51 (m, LH), 3.56-3.58 (m, 2H), 3.72-3.78 (m, 2H), 3.90-4.10 (m, 2H) 4.31-4.38 (m, 2H), 5.41-5.43 (d, 2H), 9.23 (s, 1H) C23H33N9O5S HPLC 95.1%, Mass (M + 1) 548.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-2- (aminomethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 466

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydropyrrolo[3,4-b]pyrrole-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.18 (d, 3H), 1.3 (d, 3H), 1.92 (m, 1H), 2.01-2.02 (m, 1H), 2.24-2.27 (m, 1H), 3.18-3.20 (m, 2H), 3.23-3.30 (m, 2H), 3.34- 3.36 (m, 2H), 3.46-3.48 (m, 3H), 3.65-3.70 (m, 2H), 3.78-3.81 (m, 1H), 3.94-3.96 (m, 1H) 4.12-4.15 (m, 1H), 4.38-4.40 (m, 1H), 4.45-4.49 (m, 1H), 4.68-4.71 (m, 1H), 5.44- 5.46 (d, 2H), 9.25 (s, 1H) C24H33N9O5S HPLC 97.9%, Mass (M + 1) 560.2 467

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydropyrrolo[3,4-b]pyrrole-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.94-1.95 (m, 1H), 1.97-1.99 (m, 1H), 2.22-2.26 (m, 1H), 3.17- 3.19 (m, 2H), 3.21-3.29 (m, 2H), 3.30-3.31 (m, 2H), 3.43-3.47 (m, 3H), 3.64-3.69 (m, 2H), 3.77 (m, 1H), 3.95 (m, 1H) 4.11-4.14 (m, 1H), 4.37-4.39 (m, 1H), 4.41-4.49 (m, 1H), 4.65-4.66 (m, 1H), 5.42-5.44 (d, 2H), 9.25 (s, 1H) C24H33N9O5S HPLC 92.7%, Mass (M +1) 560.2 468

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.64-1.68 (m, 2H), 1.81-1.91 (m, 2H), 2.23-2.27 (m, 2H), 2.46- 2.49 (m, 1H), 2.91-3.01 (m, 1H), 3.15-3.18 (m, 1H), 3.23-3.28 (m, 1H), 3.31-3.48 (m, 2H), 3.58-3.65 (m, 3H), 3.89-3.96 (m, 3H), 4.12- 4.15 (m, 1H), 4.29-4.43 (m, 3H), 5.42-5.44 (d, 2H), 9.27 (s, 1H) C25H35N9O5S HPLC 94.6%, Mass (M + 1) 574.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 469

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.70-1.93 (m, 4H), 2.14-2.17 (m, 1H), 2.37-2.47 (m, 2H), 2.98 (m, 1H), 3.21 (m, 1H), 3.32-3.35 (m, 2H), 3.57-3.58 (m, 2H), 3.72-3.79 (m, 2H), 3.94-3.98 (m, 2H), 4.13- 4.15 (m, 2H), 4.32-4.44 (m, 3H), 5.42-5.44 (d, 2H), 9.27 (s, 1H) C25H35N9O5S HPLC 90%, Mass (M + 1) 574.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 470

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 2.03-2.07 (m, 1H), 2.42-2.46 (m, 1H), 2.95-3.00 (m, 1H), 3.33- 3.39 (m, 4H), 3.54-3.58 (m, 3H), 3.74-3.77 (m, 2H), 3.81-3.99 (m, 1H), 4.14-4.16 (m, 1H), 4.33-4.48 (m, 3H), 4.58 (m, 1H), 5.44-5.46 (m, 2H), 9.27 (s, 1H) C23H33N9O6S HPLC 92.4%, Mass (M + 1) 564.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-2- (aminomethyl)-4-hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 471

¹HNMR (D₂O)-1.20 (d, 3H), 1.33 (d, 3H), 1.81-1.84 (m, 1H), 2.86-2.92 (m, 1H), 3.31-3.34 (m, 2H), 3.37- 3.40 (m, 1H), 3.47-3.53 (m, 4H), 3.55-3.62 (m, 3H), 3.94 (m, 1H), 4.02-4.04 (m, 1H), 4.12-4.14 (m, 1H), 4.31-4.38 (m, 2H), 4.40-4.42 (m, 1H), 4.56-4.57 (m, 1H), 5.02- 5.04 (m, 1H), 5.44-5.46 (m, 2H), 9.26 (s, 1H) C23H33N9O6S HPLC 90.3%, Mass (M + 1) 564.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- ((4aR,7aS)-octahydropyrrolo[3,4-b][1,4]oxazine-4-carbonyl)pyrrolidin-3-ylthio)-7-oxo- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 472

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.82-1.85 (m, 2H), 2.16-2.30 (m, 1H), 2.4-2.6 (m, 1H), 2.93 (m, 1H), 3.10-3.13 (m, 2H), 3.32-3.33 (m, 2H), 3.56-3.57 (m, 2H), 3.63- 3.65 (m, 1H), 3.71-3.79 (m, 2H), 3.96 (m, 1H), 4.12-4.14 (d, 2H), 4.40- 4.42 (m, 2H), 5.43-5.44 (d, 2H), 9.26 (s, 1H) C23H33N9O5S HPLC 90.9%, Mass 548.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((S)-3- (aminomethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 473

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.78-1.80 (m, 1H), 2.42-2.44 (m, 1H), 2.80-2.84 (m, 1H), 3.15- 3.18 (m, 2H), 3.30-3.36 (m, 3H), 3.54-3.56 (m, 2H), 3.70-3.77 (m, 1H), 3.84-3.94 (m, 3H), 4.11-4.12 (m, 1H), 4.23 (m, 1H), 4.30-4.39 (m, 2H), 5.43-5.45 (d, 2H), 9.25 (s, 1H) C23H34N10O5S HPLC 90.0%, Mass (M + 1) 563.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2R,4R)-4-amino-2- (aminomethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 474

¹HNMR (D₂O) 1.19 (d, 3H), 1.32 (d, 3H), 2.4 (m, 1H), 2.78 (m, 1H), 2.88 (m, 1H), 3.22-3.25 (m, 2H), 3.31- 3.33 (m, 1H), 3.4 (m, 2H), 3.54-3.56 (m, 2H), 4.0 (m, 2H), 4.3-4.39 (m, 2H), 4.40-4.79 (m, 3H), 5.3-5.4 (m, 3H), 9.23 (s, 1H) C23H33N9O6S, HPLC 90.5%, Mass 564.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2R,4R)-4-amino-2- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 475

¹HNMR (D₂O)-1.18 (d, 3H), 1.31 (d, 3H), 3.30-3.45 (m, 5H), 3.50-3.79 (m, 5H), 4.10-4.18 (m, 4H), 4.30- 4.38 (m, 4H), 5.30-5.41 (m, 4H), 9.24 (s, 1H) C24H35N9O6S HPLC 94%, Mass 578.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-amino-4- (hydroxymethyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 476

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.68-1.81 (m, 8H), 1.96-2.0 (m, 1H), 2.98-3.05 (m, 3H), 3.21- 3.26 (m, 3H), 3.28-3.30 (m, 2H), 3.41 (m, 2H), 3.48 (m, 2H), 3.55- 3.57 (m, 2H), 4.12-4.15 (m, 2H), 4.40 (m, 1H), 5.40-5.41 (3, 2H), 9.26 (s, 1H) C27H39N9O5S HPLC 93.2%, Mass (M + 1) 602.2 (4R,5S,6R)-3-((3S,5S)-5-(1,9-diazaspiro[5.5]undecane1-carbonyl)pyrrolidin-3-ylthio)-6-((R)- 1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 477

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.63-1.67 (m, 2H), 1.70-1.73 (m, 2H), 1.81-1.84 (m, 2H), 1.98- 2.02 (m, 1H), 3.04-3.12 (m, 3H), 3.24-3.28 (m, 3H), 3.30-3.36 (m, 2H), 3.44-3.46 (m, 2H), 3.49-3.51 (m, 2H), 3.57-3.59 (m, 2H), 4.11- 4.13 (m, 2H), 4.37-4.40 (m, 1H), 5.42-5.44 (3, 2H), 9.26 (s, 1H) C26H37N9O5S HPLC 95.1%, Mass (M + 1) 588.6 (4R,5S,6R)-3-((3S,5S)-5-(1,8-diazaspiro[4.5]decane-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 478

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 2.42-2.46 (m, 1H), 2.93 (m, 1H), 3.10-3.13 (m, 2H), 3.32-3.33 (m, 2H), 3.56-3.57 (m, 2H), 3.63- 3.65 (m, 1H), 3.71-379 (m, 2H), 3.96 (m, 1H), 4.12-4.14 (d, 2H), 4.40-4.42 (m, 2H), 5.43-5.44 (d, 2H), 9.26 (s, 1H) C22H30FN9O5S HPLC 97.9%, Mass (M + 1) 552.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-4- fluoropyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 479

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 2.38-2.42 (m, 1H), 2.78-2.89 (m, 1H), 3.12-3.15 (m, 2H), 3.34- 3.36 (m, 2H), 3.62-3.64 (m, 2H), 3.66-3.68 (m, 1H), 3.74-3.82 (m, 2H), 3.95-3.97 (m, 1H), 4.11-4.13 (d, 2H), 4.42-4.44 (m, 2H), 5.45-5.46 (d, 2H), 9.26 (s, 1H)C22H30FN9O5S HPLC 97.9%, Mass (M + 1) 552.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-4- fluoropyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 480

¹HNMR (D₂O)-1.18 (d, 3H), 1.34 (d, 3H), 1.63-1.67 (m, 2H), 1.70-1.73 (m, 1H), 1.81-1.84 (m, 2H), 1.91 (m, 4H), 2.81-2.84 (m, 1H), 3.03-3.07 (m, 3H), 3.19-3.21 (m, 1H), 3.30- 3.32 (m, 1H), 3.42-3.46 (m, 1H), 3.71-3.73 (m, 1H), 3.75-3.85 (m, 2H), 4.03-4.04 (m, 1H), 4.12-4.15 (m, 1H), 4.33-4.42 (m, 2H), 5.41- 5.42 (m, 2H), 9.27 (s, 1H) C25H37N9O5S HPLC 95.1%, Mass 576.3 (M + 1) (4R,5R,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(2-aminoethyl)piperidine- 1-carbonyl)pyrrolidin-3-ylthio)-4,6-dimethyl-7-oxo-1-azabicycl 481

¹HNMR (D₂O)-1.17 (d, 3H), 1.33 (d, 3H), 1.92 (m, 1H), 2.85-3.02 (m, 1H), 3.27-3.35 (m, 2H), 3.55-3.57 (m, 2H), 3.90-4.01 (m, 4H), 4.11- 4.13 (m, 1H), 4.38-4.42 (m, 1H), 4.61 (m, 1H), 4.75 (m, 2H), 4.92- 4.93 (m, 1H), 5.39-5.42 (m, 2H), 6.71 (s, 1H), 9.25 (s, 1H) C24H31N11O5S HPLC 90.1%, Mass 586.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-5,6,7,8- tetrahydroimidazo[1,5-a]pyrazine-7-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 482

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.65-1.91 (m, 5H), 2.23 (m, 2H), 2.91-2.98 (m, 1H), 3.17 (m, 3H), 3.30 (m, 3H), 3.51-3.53 (m, 2H), 3.55-3.57 (m, 1H), 3.71-3.83 (m, 2H), 3.96 (m, 1H), 4.12-4.14 (m, 2H), 4.39-4.42 (m, 1H), 4.54-4.62 (m, 1H), 5.42-5.44 (d, 2H), 9.27 (s, 1H) C26H37N9O5S HPLC 92.3%, Mass 588.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(decahydro-1,6- naphthyridine-6-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 483

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 2.45 (m, 1H), 2.98 (m, 1H), 3.28 (m, 2H), 3.30-3.34 (m, 2H), 3.41 (m, 1H), 3.54-3.57 (m, 2H), 3.77-3.79 (m, 2H), 3.98 (m, 1H), 4.00 (m, 2H), 4.12-4.13 (m, 2H), 4.29 (m, 1H), 4.38-4.42 (m, 1H), 5.41-5.42 (d, 2H), 7.32-7.33 (m, 1H), 7.55-7.56 (m, 2H), 7.67 (s, 1H), 9.26 (s, 1H) C29H36N10O6S HPLC 94.0%, Mass (M + 1) 653.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-(3- (piperazine-1-carbonyl)phenylcarbamoyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0] 484

¹HNMR (D₂O)-1.19(d, 3H), 1.33 (d, 3H), 2.45 (m, 1H), 2.90-2.93 (m, 1H), 3.26-3.39 (m, 1H), 3.55-3.57 (m, 1H), 3.61-3.65 (m, 1H), 3.72- 3.77 (m, 1H), 3.96 (m, 1H), 4.11- 4.18 (m, 1H), 4.23 (s, 1H), 4.33-4.42 (m, 3H), 5.43-5.44 (d, 2H), 7.47-7.49 (d, 2H), 7.54-7.56 (d, 2H), 9.27 (s, 1H) C25H31N9O5S HPLC 91.2%, Mass (M + 1) 570.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(aminomethyl)phenyl- carbamoyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 485

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 2.45 (m, 1H), 2.95-2.98 (m, 2H), 3.00 (m, 2H), 3.10-3.18 (m, 1H), 3.31-3.35 (m, 3H), 3.56-3.58 (d, 2H), 3.71-3.78 (m, 2H), 3.96 (m, 1H), 4.12-4.15 (m, 2H), 4.24 (m, 1H), 4.41 (m, 2H), 5.41-5.42 (d, 2H), 9.27 (s, 1H) C23H34N10O5S HPLC 92.4%, Mass (M + 1) 563.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((S)-3- (aminomethyl)piperazine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 486

  (4R,5S,6R)-6-((R)-1-(2,2-difluoroacetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.20 (d, 3H), 1.33 (d, 3H), 1.80-1.87 (m, 2H), 2.12-2.18 (m, 2H), 2.25 (m, 1H), 2.45 (m, 1H), 2.64-2.65 (m, 1H), 2.93-2.96 (m, 1H), 3.31-3.37 (m, 3H), 3.40-3.41 (m, 1H), 3.48 (m, 1H), 3.50-3.51 (m, 1H), 3.53-3.59 (m, 1H), 3.70-3.72 (m, 1H), 3.93-3.95 (m, 1H), 4.14- 4.16 (m, 2H), 4.29 (m, 1H), 4.31- 4.38 (m, 1H), 4.43-4.46 (m, 1H), 6.02-6.29 (t, 1H) C24H33F2N5O5S HPLC 92% Mass (M + 1) 542.4 487

¹HNMR (D₂O)-1.20 (d, 3H), 1.32 (d, 3H), 1.65-1.68 (m, 3H) 1.80-1.87 (m, 2H), 2.20-2.22 (m, 2H), 2.94- 2.97 (m, 1H), 3.12-3.17 (m, 3H), 3.28-3.30 (m, 3H), 3.52-3.54 (m, 2H), 3.56-3.58 (m, 1H), 3.80-3.89 (m, 2H), 3.94-3.98 (m, 1H), 4.14- 4.16 (m, 2H), 4.42-4.44 (m, 1H), 4.60-4.64 (m, 1H), 5.43-5.45 (d, 2H), 9.27 (s, 1H) C26H37N9O5S HPLC 97.9%, Mass (M + 1) 588.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamidin)ethyl)-3-((3S,5S)-5-(decahydro-1,6- naphthyridine-6-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 488

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.94-1.95 (m, 2H), 1.97-1.99 (m, 2H), 2.22-2.26 (m, 1H), 3.17- 3.19 (m, 2H), 3.21-3.29 (m, 2H), 3.30-3.31 (in, 2H), 3.43-3.47 (m, 1H), 3.64-3.69 (m, 2H), 3.77 (m, 2H), 3.95 (m, 2H) 4.11-4.14 (m, 1H), 4.37-4.39 (m, 1H), 4.41-4.49 (m, 1H), 4.65-4.66 (m, 1H), 5.42-5.44 (d, 2H), 9.25 (s, 1H) C25H35N9O5S HPLC 90% Mass (M + 1) 574.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,7- diazaspiro[4.4]nonane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 489

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5-(2- aminoethyl)octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.63-1.67 (m, 2H), 1.70-1.73 (m, 2H), 1.81-1.84 (m, 3H), 1.98- 2.02 (m, 2H), 3.04-3.12 (m, 3H), 3.24-3.28 (m, 3H), 3.30-3.36 (m, 2H), 3.44-3.46 (m, 2H), 3.49-3.51 (m, 2H), 3.57-3.59 (m, 2H), 4.11- 4.13 (m, 2H), 4.37-4.40 (m, 1H), 5.42-5.44 (d, 2H), 9.26 (s, 1H) C27H40N10O5S HPLC 95.1% Mass (M + 1) 617.4 490

¹HNMR (D₂O)-1.20 (d, 3H), 1.33 (d, 3H), 1.80-1.87 (m, 2H), 2.12-2.18 (m, 2H), 2.25 (m, 1H), 2.45 (m, 1H), 2.64-2.65 (m, 1H), 2.93-2.96 (m, 1H), 3.31-3.37 (m, 3H), 3.40-3.41 (m, 1H), 3.48 (m, 1H), 3.50-3.51 (m, 1H), 3.53-3.59 (m, 1H), 3.70-3.72 (m, 1H), 3.90 (s, 3H), 3.98-4.03 (m, 3H), 4.14-4.16 (m, 2H), 4.29 (m, 1H), 4.31-4.38 (m, 1H), 4.43-4.46 (m, 1H) C25H38N6O5S HPLC 97.9% Mass (M + 1) 535.1 (4R,5S,6R)-4-methyl-6-((R)-1-(2-(methylamino)acetamido)ethyl)-3-((3S,5S)-5-(octahydro- 1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthin)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 491

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.82-1.85 (m, 1H), 2.16-2.23 (m, 1H), 2.4-2.6 (m, 1H), 2.93 (m, 1H), 3.10-3.13 (m, 2H), 3.32-3.33 (m, 2H), 3.56-3.57 (m, 2H), 3.63- 3.65 (m, 1H), 3.71-379 (m, 2H), 3.96 (m, 1H), 4.12-4.14 (d, 2H), 4.40- 4.42 (m, 2H), 5.43-5.44 (d, 2H), 9.26 (s, 1H) C23H32FN9O5S HPLC 97.9% Mass (M + 1) 566.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-4-amino-2- (fluoromethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-eoe-2-carboxylic acid 492

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.80-1.83 (m, 2H), 2.20-2.23 (m, 1H), 2.66-2.69 (m, 2H), 2.81- 2.98 (m, 1H), 3.24-3.29 (m, 3H), 3.33-3.37 (m, 1H), 3.41-3.48 (m, 1H), 3.52-3.61 (m, 3H), 3.72-3.78 (m, 2H), 3.91-3.93 (m, 1H), 4.13- 4.15 (m, 1H), 4.28 (m, 1H), 4.38- 4.41 (m, 2H), 5.41-5.42 (m, 2H), 9.29 (s, 1H) C25H36N10O6S HPLC 97% Mass (M + 1) 605.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-(3- aminopropanamido)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 493

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.76-1.77 (m, 1H), 1.93-2.04 (m, 4H), 2.86 (m, 1H), 3.20-3.27 (m, 4H), 3.34-3.37 (m, 3H), 3.40-3.43 (m, 3H), 3.45-3.48 (m, 1H), 3.51- 3.58 (m, 1H), 3.85-3.88 (m, 1H), 4.02-4.04 (m, 1H), 4.27-4.33 (m, 2H), 5.30-5.31 (m, 2H), 9.26 (s, 1H) C25H35N9O5S HPLC 97.9% Mass 574.3 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl]-3-((3S,5S)-5-(2,7- diazaspiro[4.4]nonane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 494

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4S)-3-amino-4- methoxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid ¹HNMR (D₂O)-1.19 (d, 3H), 1.30 (d, 3H), 2.20-2.23 (m, 1H), 2.95 (m, 2H), 3.20-3.27 (m, 2H), 3.28-3.31 (m, 2H), 3.38-3.40 (m, 2H), 3.43 (s, 3H), 3.44-3.47 (m, 1H), 3.54-3.91 (m, 3H), 3.97 (m, 1H), 4.13-4.15 (m, 2H), 4.39-4.42 (m, 1H), 4.50-4.52 (m, 1H), 5.42-5.44 (d, 2H), 9.26 (s, 1H) C25H35N9O5S HPLC 96.2% Mass (M+l) 574.2 495

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.77-1.80 (m, 2H), 2.14-2.20 (m, 2H), 2.65 (m, 1H), 2.98-3.08 (m, 1H), 3.29-3.33 (m, 2H), 3.36-3.37 (m, 1H), 3.39-3.49 (m, 2H), 3.52 (m, 1H), 3.58-3.69 (m, 2H), 3.71 (m, 2H), 3.88 (m, 1H), 3.99-4.05 (m, 3H), 4.12-4.15 (d, 1H), 4.38-4.40 (m, 1H), 5.40-5.41 (d, 2H), 9.26 (s, 1H) C25H35N9O5S HPLC 95.8% Mass (M + 1) 574.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-(octahydro-1H- pyrrolo[2,3-c]pyridine-6-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 496

¹HNMR (D₂O)-1.09 (d, 3H), 1.18 (d, 3H), 2.01-2.24 (m, 2H), 2.98 (m, 1H), 3.20-3.23 (m, 2H), 3.46-3.47 (m, 2H), 3.50-3.51 (m, 2H), 3.58- 3.65 (m, 3H), 3.68-3.73 (m, 2H), 3.86 (m, 1H), 4.02-4.04 (m, 1H), 4.28-4.32 (m, 2H), 5.30-5.31 (d, 2H), 9.26 (s, 1H) C23H33N9O6S HCPLC 99% Mass (M + 1) 564.6 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-3- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 497

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 2.21-2.25 (m, 2H), 2.96-2.98 (m, 1H), 3.22-3,25 (m, 2H), 3.47- 3.49 (m, 2H), 3.51-3.54 (m, 2H), 3.59-3.65 (m, 3H), 3.71-3.76 (m, 2H), 3.92-3.96 (m, 1H), 4.04-4.06 (m, 1H)6 4.30-4.34 (m, 2H), 5.32- 5.33 (d, 2H), 9.25 (s, 1H) C23H33N9O6S HPLC 90.3% Mass (M + 1) 564.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-3- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 498

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.81 (m, 1H), 2.89-2.92 (m, 2H), 3.23-3.28 (m, 2H), 3.29 (m, 2H), 3.46-3.48 (m, 2H), 3.51-3.53 (m, 2H), 3.83-3.89 (m, 3H), 4.02- 4.04 (m, 1H), 4.28-4.32 (m, 1H), 5.30-5.31 (d, 2H), 9.16 (s, 1H) C22H30FN9O5S HPLC 99% Mass (M + 1) 552.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)-3-amino-4- fluoropyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 499

¹HNMR (D₂O)-1.19 (d, 3H), 1.34 (d, 3H), 1.85-1.97 (m, 5H), 2.03-2.04 (m, 3H), 2.91-2.97 (m, 1H), 3.27- 3.37 (m, 6H), 3.42-3.46 (m, 1H), 3.51-3.58 (m, 4H), 3.72 (m, 1H), 4.13-4.15 (m, 1H), 4.40-4.41 (m, 2H), 5.42-5.47 (d, 2H), 9.27 (s, 1H) C26H37N9O5S HPLC 98.8% Mass (M + 1) 588.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,8-diazaspiro[4.5]decane- 2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 500

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (m, 9H), 2.21-2.25 (m, 2H), 2.96- 2.98 (m, 1H), 3.22-3.25 (m, 2H), 3.47-3.49 (m, 2H), 3.51-3.54 (m, 2H), 3.59-3.65 (m, 3H), 3.71-3.76 (m, 1H), 3.92-3.96 (m, 1H), 4.04- 4.06 (m, 1H) 4.30-4.34 (m, 2H), 5.32-5.33 (d, 2H), 9.25 (s, 1H) C25H37N9O5S HPLC 97.9% Mass (M + 1) 576.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-(2-aminopropan-2- yl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 501

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.76-1.77 (m, 1H), 1.93-2.04 (m, 2H), 2.86 (m, 1H), 3.20-3.27 (m, 4H), 3.34-3.37 (m, 3H), 3.40-3.43 (m, 3H), 3.45-3.48 (m, 1H), 3.51- 3.58 (m, 1H), 3.85-3.88 (m, 1H), 4.02-4.04 (m, 1H), 4.27-4.33 (m, 2H), 5.30-5.31 (d, 2H), 9.26 (s, 1H) C24H33N9O5S HPLC 97.9% Mass (M+l) 560.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,6- diazaspiro[3,4]octane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 502

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.88 (m, 1H), 2.02-2.04 (m, 2H), 2.84-2.86 (m, 1H), 3.22-3.29 (m, 4H), 3.35-3.38 (m, 3H), 3.41- 3.44 (m, 3H), 3.46-3.49 (m, 1H), 3.52-3.59 (m, 1H), 3.86-3.89 (m, 1H), 4.03-4.05 (m, 1H), 4.28+.34 (m, 2H), 5.31-5.32 (d, 2H)} 9.26 (s, 1H) C24H33N905S HPLC 90% Mass (M+l) 560.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2,6- diazaspiro[3.4]octane-6-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 503

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.90-1.95 (m, 5H), 2.01-2.03 (m, 3H), 2.89-2.92 (m, 1H), 3.29- 3.34 (m, 6H), 3.41-3.47 (m, 1H), 3.52-3.55 (m, 4H), 3.69-3.72 (m, 1H), 4.11-4.14 (m, 1H), 4.39-4.40 (m, 2H), 5.41-5.45 (d, 2H), 9.27 (s, 1H) C26H37N9O5S HPLC 95.1% Mass (M + 1) 588.2 (4R,5S,6R)-3-((3S,5S)-5-(1,7-diazaspiro[4.5]decane-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 504

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.92-1.97 (m, 5H), 2.02-2.04 (m, 3H), 2.91-2.94 (m, 1H), 3.30- 3.35 (m, 6H), 3.42-3.48 (m, 1H), 3.53-3.56 (m, 4H), 3.72-3.75 (m, 1H), 4.12-4.15 (m, 1H), 4.40-4.41 (m, 2H), 5.42-5.46 (d, 2H), 9.27 (s, 1H) C26H37N9O5S HPLC 97.9% Mass (M + 1) 588.2 (4R,5S,6R)-3-((3S,5S)-5-(1,7-diazaspiro[4.5]decane-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 505

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.82-1.87 (m, 2H), 1.92-2.01 (m, 2H), 2.33-2.39 (m, 2H), 2.94- 2.98 (m, 2H), 3.28-3.34 (m, 2H), 3.44-3.47 (m, 3H), 3.50-3.52 (m, 1H), 3.72-3.77 (m, 1H), 3.89-3.93 (m, 2H), 4.13-4.15 (m, 1H), 4.40- 4.43 (m, 2H), 5.43-5.47 (d, 2H), 9.27 (s, 1H) C24H33N9O5S HPLC 93.1% Mass (M + 1) 560.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 506

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.85-1.91 (m, 2H), 2.01-2.03 (m, 2H), 2.35-2.41 (m, 2H), 2.98- 3.01 (m, 2H), 3.30-3.36 (m, 2H), 3.46-3.49 (m, 3H), 3.52-3.54 (m, 1H), 3.74-3.79 (m, 1H), 3.91-3.95 (m, 2H), 4.14-4.16 (m, 1H), 4.42- 4.45 (m, 2H), 5.44-5.48 (d, 2H), 9.27 (s, 1H) C24H33N9O5S HPLC 90% Mass (M + 1) 560.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 507

¹HNMR (D₂O)-1.20 (d, 3H), 1.32 (d, 3H), 1.92-1.95 (m, 1H), 1.97-2.00 (m, 1H), 2.19-2.32 (m, 1H), 2.46- 2.50 (m, 1H), 2.94-2.96 (m, 1H), 3.30-3.37 (m, 2H), 3.51-3.56 (m, 1H), 3.58-3.59 (m, 2H), 3.61-3.64 (m, 2H), 3.72-3.77 (m, 1H), 3.88- 3.96 (m, 2H), 4.07-4.12 (m, 2H), 4.35-4.39 (m, 2H), 6.96-7.23 (t, 1H) C22H31F2N5O5S2 HPLC 90.7% Mass (M + 1) 548.1 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1- (2-(difluoromethylthio)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 508

  (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-6- ((R)-1-(2-(piperazin-1-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid ¹HNMR (D₂O)-1.27 (d, 3H), 1.37 (d, 3H), 1.91-1.96 (m, 2H), 2.31- 2.33 (m, 1H), 2.59-2.60 (m, 1H), 2.94-3.26 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.21.3.22 (m, 1H), 3.40-3.45 (m, 2H), 3.47-3.49 (m, 4H), 3.57-3.58 (m, 2H), 3.73-3.77 (m, 2H), 3.91 (m, 1H), 4.13-4.15 (m, 1H), 4.43-4.47 (m, 2H) C23H36N6O5S HPLC 97.9% Mass (M + 1) 509.3 509

  (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-6-((R)-1-(2-((S)-pyrrolidin-2-yl)acetamido)ethyl)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid ¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.80-1.85 (m, 1H), 2.08-2.13 (m, 1H), 2.19-2.32 (m, 1H), 2.44- 2.48 (m, 3H), 2.70-3.00 (m, 3H), 2.94-2.96 (m, 1H), 3.19 (d, 3H), 3.29-3.37 (m, 3H), ), 3.40-3.45 (m, 2H), 3.47-3.49 (m, 4H), 3.54-3.78 (m, 2H), 4.14 (d, 1H), 4.38-4.42 (m, 1H), C25H38N6O5S HPLC 97.9% Mass (M + 1) 535.1 510

¹HNMR (D₂O)-1.18 (d, 3H), 1.34 (d, 3H), 1.82-1.85 (m, 2H), 2.18-2.32 (m, 1H), 2.42-2.56 (m, 1H), 2.88- 2.93 (m, 1H), 3.11-3.14 (m, 1H), 3.33-3.34 (m, 2H), 3.57-3.58 (m, 2H), 3.64-3.66 (m, 1H), 3.72-.38 (m, 2H), 3.98-3.99 (m, 1H), 4.13-4.15 (d, 2H), 4.41- 4.43 (m, 2H), 5.44-5.45 (d, 2H), 9.27 (s, 1H) C23H33N9O6S HPLC 90% Mass (M + 1) 564.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-(aminomethyl)-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 511

¹HNMR (D₂O)-1.16(d, 3H), 1.30 (d, 3H), 1.84-1.87 (m, 2H), 2.16-2.30 (m, 1H), 2.40-2.54 (m, 1H), 2.86- 2.91 (m, 1H), 3.09-3.12 (m, 1H), 3.31-3.32 (m, 2H), 3.52-3.53 (m, 2H), 3.62-3.64 (m, 1H), 3.70-.36 (m, 2H), 3.95-3.96 (m, 1H), 4.11-4.13 (d, 2H), 4.38-4.40 (m, 2H), 5.41-5.42 (d, 2H), 9.27 (s, 1H) C23H33N9O6S HPLC 95.1% Mass (M + 1) 564.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-(aminomethyl)-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 512

  (4R,5S,6R)-6-((R)-1-(2-(3,3-difluoropyrrolidin-1-yl)acetamido)ethyl)-3-((3S,5S)-5- (dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid ¹HNMR (D₂O)-1.20 (d, 3H), 1.33 (d, 3H), 1.8-1.86 (m, 2H), 1.91-1.96 (m, 2H), 2.14-2.20 (m, 2H), 2.31- 2.33 (m, 1H), 2.59-2.60 (m, 1H), 2.95-296 (m, 1H), 2.99 (s, 3H), 3.07 (s, 3H), 3.21.3.22 (m, 1H), 3.40-3.45 (m, 2H), 3.73-3.77 (m, 2H), 3.91 (m, 1H), 4.13-4.15 (m, 1H), 4.43-4.47 (m, 2H) C23H33F2N5O5S HPLC 97.9% Mass 530.1 (M + 1) 513

¹HNMR (D₂O)-1.18 (d, 3H), 1.32 (d, 3H), 1.85-1.88 (m, 2H), 2.18-2.32 (m, 1H), 2.42-2.46 (m, 1H), 2.89- 2.93 (m, 1H), 3.12-3.15 (m, 2H), 3.33-3.34 (m, 2H), 3.57-3.58 (m, 2H), 3.63-3.65 (m, 1H), 3.71-.379 (m, 2H), 3.96 (m, 1H), 4.12-4.14 (d, 2H), 4.40-4.42 (m, 2H), 5.43-5.44 (d, 2H), 9.26 (s, 1H) C23H33N9O5S HPLC 97.9% Mass (M + 1) 548.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-((3S,5S)-5-((R)- pyrrolidin-3-ylmethylcarbamoyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 514

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 9H), 1.79-1.82 (m, 1H), 2.08-2.11 (m, 1H), 2.35-2.38 (m, 1H), 3.33- 3.40 (m, 1H), 3.67-3.71 (m, 1H), 3.73 (m, 1H), 3.78 (d, 2H), 3.90 (m, 1H), 4.12-4.14 (m, 2H), 4.14-4.15 (m, 2H), 4.16 (d, 1H), 4.41 (d, 1H), 4.60 (d, 1H), 4.84 (d, 1H), 8.54 (s, 1H), C28H38N8O8S2 HPLC 90% Mass (M + 1) 679.1 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-((Z)-2-(2- aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)ethyl)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 515

¹HNMR (D₂O)-1.28 (d, 3H), 1.34 (d, 3H), 2.86 (m, 1H), 3.02-3.06 (m, 1H), 3.44-3.48 (m, 1H), 3.57-3.60 (m, 1H), 3.73-3.77 (m, 1H), 4.05 (m, 2H), 4.27-4.33 (m, 2H), 5.42 (d, 2H), 9.27 (s, 1H) C17H23N9O4S HPLC 95.1% Mass (M + 1) 450.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(1- carbamimidoylazetidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 516

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.85-1.92 (m, 1H), 2.94-3.26 (m, 4H), 3.46-3.49 (m, 4H), 3.57- 3.58 (m, 2H), 3.62-3.72 (m, 1H), 3.73-3.76 (m, 1H), 3.80-3.84 (m, 2H), 3.87-3.92 (m, 1H), 3.94-4.13 (m, 1H), 4.30 (d, 1H), 4.43-4.49 (m, 1H), 4.51-4.53 (m, 1H), 5.47 (m, 2H), 9.27 (s, 1H) C23H33N9O5S HPLC 97.9% Mass (M + 1) 548.1 (4R,5S,6R)-3-((3S,5S)-5-(1,4-diazepane-1-carbonyl)pyrrolidin-3-ylthio)-6-((R)-1-(2-(1H- tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 517

¹HNMR (D₂O) 1.20 (d, 3H), 1.34 (d, 3H), 1.88-1.95 (m, 1H), 3.12-3.34 (m, 4H), 3.48-3.51 (m, 4H), 3.59- 3.60 (m, 2H), 3.64-3.74 (m, 1H), 3.75-3.78 (m, 1H), 3.82-3.86 (m, 2H), 3.88-3.93 (m, 1H), 4.12-4.15 (m, 1H), 4.38 (d, 1H), 4.48-4.52 (m, 1H), 4.58-4.60 (m, 1H), 5.48 (m, 2H), 9.27 (s, 1H) C24H35N11O5S HPLC 97.9% Mass (M + 1) 590.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-carbamimidoyl-1,4- diazepane-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabocyclo[3.2.0]hept-2-ene-2- carboxylic acid 518

¹HNMR (D₂O)-1.21 (d, 3H), 1.29 (d, 3H), 1.94-2.0 (m, 1H), 3.00 (s, 3H), 3.03 (s, 3H), 3.28 (s, 3H), 3.35- 3.37 (m, 1H), 3.41 (s, 3H), 3.57-3.58 (m, 1H), 3.60-3.62 (m, 2H), 3.72- 3.73 (m, 3H), 3.90-3.91 (m, 2H), 4.03-4.04 (m, 1H), 4.14-4.16 (m, 1H), 4.44-4.47 (m, 1H) C22H35N5O6S HPLC 95.3% Mass (M + 1) 498.2 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-(2-(2- methoxyethylamino)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 519

  (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-6-((1R)-1-(2- (octahydro-1H-pyrrolo[3,2-c]pyridin-1-yl)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.21 (d, 3H), 1.31 (d, 3H), 1.57-1.65 (m, 1H), 1.92-2.00 (m, 2H), 2.08-2.10 (m, 2H), 2.55- 2.59 (m, 1H), 2.95 (m, 1H), 3.00 (s, 3H), 3.04 (m, 1H), 3.07 (s, 3H), 3.11- 3.19 (m, 2H), 3.23-3.26 (m, 2H), 3.34-3.39 (m, 3H), 3.40-3.43 (m, 2H), 3.48 (m, 1H), 3.68-3.70 (m, 2H), 4.02-4.09 (m, 1H), 4.19-4.21 (m, 1H), 4.33 (m, 1H), 4.72-4.74 (m, 1H) C26H40N6O5S HPLC 97.5% Mass (M + 1) 549.1 520

¹HNMR (D₂O)-1.09 (d, 3H), 1.19 (d, 3H), 1.54-1.57 (m, 1H), 1.63-1.67 (m, 1H), 1.88 (m, 2H), 1.98-2.01 (m, 1H), 2.36-2.40 (m, 1H), 2.62 (s, 3H), 2.87 (m, 1H), 2.94 (s, 3H), 3.01 (m, 1H), 3.03 (s, 3H), 3.09 (m, 1H), 3.13 (m, 2H), 3.24 (m, 1H), 3.34 (m, 3H), 3.46 (m, 2H), 3.75-3.85 (m, 1H), 4.03-4.05 (m, 1H), 4.29-4.33 (m, 1H), 4.49 (m, 1H) C25H40N6O5S HPLC 93.1% Mass (M + 1) 537.2 (4R,5S,6R)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-4-methyl-6- ((R)-1-(2-((S)-2-((methylamino)methyl)pyrrolidin-1-yl)acetamido)ethyl)-7-oxo- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 521

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5-((S)-3-amino-2- hydroxypropyl)octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.09 (d, 3H), 1.22 (d, 3H), 1.71-1.79 (m, 2H), 1.92-1.98 (m, 2H), 2.11 (m, 2H), 2.50 (m, 2H), 2.72 (m, 1H), 2.79-2.81 (m, 1H), 2.84-2.86 (m, 2H), 2.97 (m, 1H), 3.03-3.06 (m, 2H), 3.20-3.22 (m, 3H), 3.44-3.54 (m, 3H), 3.65 (m, 1H), 3.73-3.78 (m, 1H), 3.85 (m, 1H), 4.00-4.03 (m, 1H), 4.16 (m, 1H), 4.27-4.30 (m, 1H), 5.30-5.34 (d, 2H), 9.15 (s, 1H) C28H42N10O6S HPLC 99.8% Mass (M + 1) 647.3 522

¹HNMR (D₂O)-1.09 (d, 3H), 1.22 (d, 3H), 1.82-1.86 (m, 1H), 2.03-2.08 (m, 1H), 2.31-2.33 (m, 1H), 2.46- 2.48 (m, 1H), 2.77-2.82 (m, 1H), 3.18-3.23 (m, 2H), 3.38-3.39 (m, 2H), 3.58-3.61 (m, 1H), 3.65-3.68 (m, 2H), 3.82-3.87 (m, 2H), 4.00- 4.02 (m, 1H), 4.11 (m, 1H), 4.28- 4.29 (m, 2H), 5.26-5.28 (d, 2H), 9.13 (s, 1H) C23H33N9O6S HPLC 91.7% Mass (M + 1) 564.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,3R)-3-amino- 2-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 523

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,3R)-3-amino- 2-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.06 (d, 3H), 1.20 (d, 3H), 1.74-1.78 (m, 1H), 2.05-2.08 (m, 1H), 2.44-2.49 (m, 1H), 2.75- 2.78 (m, 1H), 3.08-3.19 (m, 1H), 3.20-3.23 (m, 1H), 3.31-3.35 (m, 1H), 3.43-3.44 (m, 1H), 3.55-3.59 (m, 1H), 3.63-3.69 (m, 2H), 3.72- 3.79 (m, 1H), 3.85 (m, 1H), 3.99 (m, 1H), 4.01 (m, 1H), 4.13 (m, 1H), 4.26-4.29 (m, 2H), 5.28-5.29 (d, 2H), 9.13 (s, 1H) C23H33N9O6S HPLC 90.5% Mass (M + 1) 564.2 524

¹HNMR (D₂O)-1.06 (d, 3H), 1.20 (d, 3H), 1.78 (m, 1H), 2.74 (m, 1H), 2.86 (m, 1H), 3.11-3.19 (m, 3H), 3.21-3.29 (m, 2H), 3.37-3.39 (m, 3H), 3.50 (m, 2H), 3.53-3.56 (m, 2H), 3.62 (m, 1H), 3.71-3.77 (m, 2H), 3.99-4.01 (m, 1H), 4.19-4.29 (m, 2H), 5.28-5.33 (d, 2H), 9.26 (s, 1H) C25H35N9O6S HPLC 92.2% Mass (M + 1) 590.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,6aR)-3a- (hydroxymethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 525

¹HNMR (D₂O)-1.09 (d, 3H), 1.27 (d, 3H), 1.80 (m, 1H), 2.76 (m, 1H), 2.88 (m, 1H), 3.18-3.26 (m, 3H), 3.26-3.34 (m, 2H), 3.39-3.41 (m, 3H), 3.52 (m, 2H), 3.55-3.58 (m, 2H), 3.64 (m, 1H), 3.74-3.80 (m, 2H), 4.02-4.03 (m, 1H), 4.22-4.32 (m, 2H), 5.30-5.35 (d, 2H), 9.27 (s, 1H) C25H35N9O6S HPLC 97.9% Mass (M + 1) 589.67 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aS,6aS)-3a- (hydroxymethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 526

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aS,5S,6aS)-5-amino-3a- (hydroxymethyl)octahydrocyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.69-1.79 (m, 2H), 1.93- 1.95 (m, 2H), 2.11-2.16 (m, 1H), 2.59-2.82 (m, 2H), 3.16-3.19 (m, 3H), 3.20-3.27 (m, 1H), 3.32-3.48 (m, 3H), 3.52-3.59 (m, 2H), 3.72 (m, 2H), 3.82 (m, 1H), 4.00-4.02 (m, 1H), 4.25-4.28 (m, 2H), 5.29-5.30 (m, 2H), 9.14 (s, 1H) C26H37N9O6S HPLC 92.1% Mass (M + 1) 604.2 527

¹HNMR (D₂O)-1.06 (d, 3H), 1.22 (d, 3H), 1.41-1.48 (m, 1H), 1.63-1.72 (m, 1H), 1.89 (m, 1H), 2.50-2.56 (m, 2H), 2.91-2.97 (m, 2H), 3.02-3.07 (m, 2H), 3.21 (m, 2H), 3.32-3.35 (m, 2H), 3.41-3.42 (m, 1H), 3.45-3.46 (m, 2H), 3.67-3.71 (m, 1H), 3.87 (m, 1H), 3.98-4.00 (m, 1H), 4.26-4.29 (m, 1H), 5.29-5.33 (d, 2H), 9.13 (s, 1H) C24H33N9O6S HPLC 100% Mass 574.1 (M + 1) (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-octahydro- 1H-pyrrolo[3,4-c]pyridine-2-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 528

¹HNMR (D₂O)-1.07 (d, 3H), 1.23 (d, 3H), 1.67 (m, 1H), 1.89 (m, 1H), 2.51-2.69 (m, 2H), 2.86 (m, 1H), 3.05-3.07 (m, 2H), 3.21-3.24 (m, 1H), 3.31-3.39 (m, 3H), 3.46 (m, 1H), 3.54-3.55 (m, 2H), 3.68-3.71 (m, 2H), 3.86 (m, 1H), 4.01-4.03 (m, 1H), 4.29-4.34 (m, 2H), 5.30-5.34 (d, 2H), 9.15 (s, 1H) C25H35N9O5S HPLC 99.8% Mass (M + 1) 574.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-(octahydro- 1H-pyrrolo[3,4-c]pyridine-2-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 529

¹HNMR (D₂O)-11.06 (d, 3H), 1.20 (d, 3H), 1.72-1.78 (m, 2H), 1.94 (m, 2H), 2.11 (m, 1H), 2.56-2.83 (m, 3H), 3.19-3.27 (m, 3H), 3.30-3.47 (m, 3H), 3.57 (m, 3H), 3.73 (m, 1H), 3.83 (m, 2H), 4.01 (m, 1H), 4.29 (m, 1H), 5.28 (d, 2H), 9.13 (s, 1H) C26H37N9O6S HPLC 98.6% Mass (M + 1) 604.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,5R,6aR)-5-amino- 3a-(hydroxymethyl)octahydrocyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 530

¹HNMR (D₂O)-1.20 (d, 3H) 1.33 (d, 3H), 2.36-2.39 (m, 1H), 2.79-2.85 (m, 2H), 3.28-3.35 (m, 2H), 3.57- 3.58 (m, 2H), 3.95 (m, 1H), 4.05- 4.07 (m, 2H), 4.13-4.17 (m, 3H), 4.27 (m, 2H), 4.30-4.32 (m, 2H), 4.38-4.39 (m, 2H), 5.41-5.42 (3, 2H), 9.27 (s, 1H) C24H33N9O6S HPLC 97.3% Mass (M + 1) 576.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(7-amino-5-oxa-2- azaspiro[3,4]octane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.1]hept-2- ene-2-carboxylic acid 531

¹HNMR (D₂O)-1.21 (d, 3H), 1.34 (d, 3H), 2.38-2.41 (m, 1H), 2.81-2.87 (m, 2H), 3.30-3.37 (m, 2H), 3.59- 3.60 (m, 2H), 3.97-3.99 (m, 1H), 4.07-4.09 (m, 2H), 4.15-4.19 (m, 3H), 4.29 (m, 2H), 4.32-4.34 (m, 2H), 4.40-4.41 (m, 2H), 5.43-5.44 (3, 2H), 9.27 (s, 1H) C24H33N9O6S HPLC 99.3% Mass (M + 1) 576.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(7-amino-5-oxa-2- azaspiro[3.4]octane-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 532

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.80-1.82 (m, 3H), 2.11-2.23 (m, 3H), 2.62-2.92 (m, 3H), 2.97- 3.17 (m, 3H), 3.20-3.33 (m, 3H), 3.35-3.42 (m, 2H), 3.52-3.58 (m, 3H), 3.72 (m, 2H), 3.99 (m, 1H), 4.13-4.15 (m, 2H), 4.32-4.43 (m, 2H), 5.42-5.43 (m, 2H), 9.27 (s, 1H) C28H42N10O6S HPLC 95.2% Mass (M + 1) 647.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5-((S)-3-amino-2- hydroxypropyl)octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 533

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.92-1.94 (m, 3H), 2.69 (m, 3H), 3.09-3.16 (m, 3H), 3.24-3.32 (m, 3H), 3.42-3.45 (m, 3H), 3.50- 3.58 (m, 2H), 3.70-3.75 (m, 2H), 4.00 (m, 1H), 4.14-4.16 (m, 1H), 4.39-4.43 (m, 1H), 5.42-5.43 (d, 2H), 9.27 (s, 1H) C25H35N9O5S HPLC 92.6% Mass (M + 1) 574.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5-(octahydro- 1H-pyrrolo[3,4-c]pyridine-5-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 534

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.92-1.95 (m, 2H), 2.67 (m, 3H), 2.98-3.07 (m, 2H), 3.23-3.26 (m, 2H), 3.32-3.29 (m, 3H), 3.51- 3.59 (m, 3H), 3.62-3.66 (m, 2H), 3.71 (m, 2H), 3.90 (m, 1H), 4.13- 4.15 (m, 1H), 4.41-4.43 (m, 1H), 5.41-5.42 (m, 2H), 9.27 (s, 1H) C25H35N9O5S HPLC 98.9% Mass (M + 1) 574.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)-ethyl)-3-((3S,5S)-5-(3a- (hydroxymethyl)octahydro-1H-pyrrolo[3,4-c]pyridine-5-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 535

¹HNMR (D₂O)-1.20 (d, 3H), 1.34 (d, 3H), 1.76-1.86 (m, 2H), 2.00 (m, 1H), 2.97-2.99 (m, 3H), 3.15-3.21 (m, 3H), 3.34-3.49 (m, 5H), 3.52- 3.73 (m, 6H), 3.98 (m, 1H), 4.13- 4.15 (m, 1H), 4.40-4.41 (m, 1H), 5.42-5.43 (m, 2H), 9.27 (s, 1H) C26H37N9O6S HPLC 97.8% Mass (M + 1) 604.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)-ethyl)-3-((3S,5S)-5-(3a- (hydroxymethyl)octahydro-1H-pyrrolo[3,4-c]pyridine-5-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 536

¹HNMR (D₂O)-1.20 (d, 3H), 1.34(d, 3H), 1.81 (m, 1H), 2.09-2.12 (m, 1H), 2.47 (m, 2H), 2.81 (m, 2H), 3.05 (m, 2H), 3.37-3.40 (m, 2H), 3.60-3.77 (m, 3H), 3.95 (m, 2H), 4.04-4.09 (m, 2H), 4.13 (m, 1H), 4.41 (m, 1H), 5.42-5.43 (m, 2H), 9.27 (s, 1H) C23H33N9O5S HPLC 90.2% Mass (M + 1) 548.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)-ethyl)-3-((3S,5R)-5-(2-((R)-3- aminopyrrolidin-1-yl)-2-oxoethyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 537

¹HNMR (D₂O)-1.19 (d, 3H), 1.33 (d, 3H), 1.74-1.84 (m, 2H), 1.98 (m, 1H), 2.95-2.97 (m, 3H), 3.13-3.19 (m, 3H), 3.33-3.47 (m, 5H), 3.50- 3.71 (m, 6H), 3.96 (m, 1H), 4.11- 4.13 (m, 1H), 4.38-4.39 (m, 1H), 5.40-5.41 (m, 2H), 9.25 (s, 1H) C26H37N9O6S HPLC 90.3% Mass (M + 1) 604.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydro-1H-pyrrolo[3,4-c]pyridine-5-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 538

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.74-1.80 (m, 2H), 1.96 (m, 2H), 2.13 (m, 1H), 2.58-2.85 (m, 3H), 3.21-3.29 (m, 3H), 3.32-3.49 (m, 3H), 3.59 (m, 3H), 3.75 (m, 1H), 3.85 (m, 2H), 4.03 (m, 1H), 4.31 (m, 1H), 5.30 (d, 2H), 9.15 (s, 1H) C26H38N10O5S HPLC 90% Mass (M + 1) 603.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,5S,6aS)-5-amino-3a- (aminomethyl)octahydro-cyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 539

¹HNMR (D₂O)-1.18 (d, 3H), 1.31 (d, 3H), 1.73-1.83 (m, 2H), 1.87 (m, 1H), 2.94-2.96 (m, 3H), 3.12-3.18 (m, 3H), 3.31-3.46 (m, 5H), 3.49- 3.70 (m, 6H), 3.95 (m, 1H), 4.10- 4.12 (m, 1H), 4.37-4.38 (m, 1H), 5.39-5.40 (m, 2H), 9.24 (s, 1H) C26H37N9O6S HPLC 95.1% Mass (M + 1) 604.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3a- (hydroxymethyl)octahydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 540

¹HNMR (D₂O)-1.05 (d, 3H), 1.19 (d, 3H), 1.76 (m, 1H), 2.72 (m, 1H), 2.84 (m, 1H), 3.09-3.17 (m, 3H), 3.19-3.27 (m, 2H), 3.35-3.37 (m, 3H), 3.48 (m, 2H), 3.51-3.54 (m, 2H), 3.60 (m, 1H), 3.69-3.75 (m, 2H), 3.97-3.99 (m, 1H), 4.17-4.27 (m, 2H), 5.26-5.31 (d, 2H), 9.24 (s, 1H) C24H33N9O5S HPLC 97.9% Mass 574.3 (M + 1) 560.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-((3S,5S)-5- (octahydropyrrolo-[3,4-c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 541

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((1R,7S)-3,8-Diaza- tricyclo[5.2.1.01,5]decane-3-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.74 (m, 1H), 1.81 (m, 4H), 2.46 (m, 1H), 2.86 (m, 1H), 3.15- 3.18 (m, 1H), 3.25-3.32 (m, 4H), 3.48 (m, 3H), 3.75-3.78 (m, 1H), 3.87 (m, 2H), 4.02-4.04 (m, 1H), 4.13 (m, 1H), 4.30 (m, 1H), 4.41 (m, 1H), 5.31-5.34 (m, 2H), 9.16 (s, 1H) C26H35N9O5S HPLC 98.4% Mass (M + 1) 586.2 542

¹HNMR (D₂O)-1.08 (d, 3H), 1.20 (d, 3H), 1.64-1.80 (m, 1H), 1.97-1.99 (m, 2H) 2.37-2.44 (m, 2H), 2.73 (m, 2H), 3.04-3.09 (m, 1H), 3.13-3.22 (m, 2H), 3.34 (m, 3H), 3.49 (m, 3H), 3.61 (m, 3H), 3.78-3.81 (m, 1H), 4.00-4.02 (m, 1H), 4.18 (m, 1H), 4.30-4.34 (m, 1H), 5.31-5.35 (m, 2H), 9.24 (s, 1H) C26H37N9O6S HPLC 97.4% Mass (M + 1) 604.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3a- (hydroxymethyl)octahydro-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-eoe-2-carboxylic acid 543

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5- aminooctahydrocyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.08 (d, 3H), 1.22 (d, 3H), 1.33-1.38 (m, 2H), 1.70-1.73 (m, 2H), 2.33-2.34 (m, 2H), 2.69- 2.77 (m, 3H), 3.18-3.23 (m, 2H), 3.34-3.36 (m, 2H), 3.40-3.46 (m, 2H), 3.50-3.56 (m, 2H), 3.63-3.67 (m, 1H), 3.83 (m, 1H), 4.01-4.03 (m, 1H), 4.29-4.31 (m, 1H), 5.30-5.31 (m, 2H), 9.15 (s, 1H) C25H35N9O5S HPLC 90.3% Mass (M + 1) 574.3 544

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.92 (m, 1H), 2.93-2.97 (m, 2H), 3.21-3.22 (m, 2H), 3.35-3.37 (m, 1H), 3.49-3.54 (m, 2H), 3.64- 3.73 (m, 2H), 3.83-3.97 (m, 2H), 4.04-4.05 (m, 2H), 4.29-4.37 (m, 2H), 5.29-5.31 (m, 2H), 9.16 (s, 1H) C23H33N11O6S HPLC 98.2% Mass (M + 1) 592.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4R)-3-guanidino-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 545

¹HNMR (D₂O)-1.10 (d, 3H), 1.24 (d, 3H), 1.93 (m, 1H), 2.95-2.99 (m, 2H), 3.24-3.26 (m, 2H), 3.37-3.39 (m, 1H), 3.51-3.56 (m, 2H), 3.66- 3.75 (m, 2H), 3.85-3.99 (m, 2H), 4.06-4.07 (m, 2H), 4.31-4.39 (m, 2H), 5.31-5.33 (m, 2H), 9.18 (s, 1H) C23H33N11O6S HPLC 98.2% Mass (M + 1) 592.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4S)-3-guanidino-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0)hept-2-ene-2- carboxylic acid 546

¹HNMR (D₂O)-1.08 (d, 3H), 1.21 (d, 3H), 1.88-1.89 (m, 1H), 2.91-2.95 (m, 2H), 3.19-3.21 (m, 2H), 3.33- 3.35 (m, 1H), 3.47-3.52 (m, 2H), 3.62-3.71 (m, 2H), 3.81-3.95 (m, 2H), 4.02-4.03 (m, 2H), 4.27-4.35 (m, 2H), 5.27-5.29 (m, 2H), 9.14 (s, 1H) C23H33N11O6S HPLC 92.6% Mass (M + 1) 592.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)-3-guanidino-4- hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 547

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aS,5R,6S)-5-amino-6- hydroxy-3a-(hydroxymethyl)octahydro-cyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl- 7-oxo-1-azabicyclo-[3.2.0]-hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.20 (d, 3H), 1.21 (d, 3H), 1.80 (m, 1H), 1.86-1.96 (m, 2H), 2.08 (m, 2H), 2.48-2.54 (m, 2H), 2.87-2.93 (m, 2H), 3.21-3.28 (m, 3H), 3.38 (m, 2H), 3.47 (m, 1H), 3.52-3.57 (m, 1H), 3.82-3.88 (m, 1H), 4.01-4.03 (m, 1H), 4.08 (m, 1H), 4.28-4.29 (m, 1H), 4.31 (m, 1H), 5.30-5.31 (m, 2H), 9.15 (s, 1H) C26H37N9O7S HPLC 90.9% Mass (M + 1) 620.6 548

¹HNMR (D₂O)-1.18 (d, 3H), 1.23 (d, 3H), 1.89-1.93 (m, 1H), 2.93-2.96 (m, 1H), 3.21-3.25 (m, 1H), 3.31- 3.34 (m, 2H), 3.47-3.48 (m, 2H), 3.51 (m, 2H), 3.57-3.59 (m, 1H), 3.61-3.69 (m, 1H), 3.73-3.88 (m, 2H), 4.03-4.08 (m, 2H), 4.29 (m, 1H), 4.32-4.39 (m, 1H), 5.31 (m, 2H), 9.16 (s, 1H) C23H33N9O7S HPLC 97.9% Mass (M + 1) 580.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,3R,4R)-3-amino- 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 549

¹HNMR (D₂O)-1.16 (d, 3H), 1.21 (d, 3H), 1.88-1.92 (m, 1H), 2.95-2.98 (m, 1H), 3.23-3.27 (m, 1H), 3.33- 3.36 (m, 2H), 3.49-3.50 (m, 2H), 3.53 (m, 2H), 3.59-3.61 (m, 1H), 3.63-3.71 (m, 1H), 3.75-3.90 (m, 2H), 4.05-4.10 (m, 2H), 4.31 (m, 1H), 4.34-4.41 (m, 1H), 5.33 (m, 2H), 9.17 (s, 1H) C23H33N9O7S HPLC 99% Mass (M + 1) 580.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2R,3R,4S)-4-amino- 3-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 550

¹HNMR (D₂O)-1.09 (d, 3H), 1.24 (d, 3H), 1.81 (m, 1H), 2.19 (m, 1H), 2.43 (m, 1H), 2.76-2.80 (m, 2H), 3.24-3.28 (m, 1H), 3.44-3.46 (m, 3H), 3.55-3.64 (m, 3H), 3.84 (m, 2H), 4.01-4.03 (m, 1H), 4.28-4.32 (m, 2H), 5.31-5.32 (m, 2H), 9.16 (s, 1H) C22H32N10O4S HPLC 94.7% Mass (M + 1) 533.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,6aR)-3a- (hydroxymethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 551

¹HNMR (D₂O)-1.09 (d, 3H), 1.24 (d, 3H), 1.99-2.03 (m, 3H), 2.86-2.87 (m, 3H), 3.25-3.35 (m, 4H), 3.46- 3.48 (m, 3H), 3.61-3.64 (m, 2H), 3.74-3.87 (m, 3H), 4.03-4.05 (m, 1H), 4.29-4.32 (m, 1H), 4.40-4.42 (m, 1H), 5.31-5.32 (m, 2H), 9.16 (s, 1H) C25H35N9O6S HPLC 97% Mass (M + 1) 590.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(2- (hydroxymethyl)octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic 552

¹HNMR (D₂O)-1.10 (d, 3H), 1.25 (d, 3H), 2.01-2.05 (m, 3H), 2.88-2.89 (m, 3H), 3.27-3.37 (m, 4H), 3.48- 3.50 (m, 3H), 3.63-3.66 (m, 2H), 3.76-3.89 (m, 3H), 4.05-4.07 (m, 1H), 4.31-4.34 (m, 1H), 4.42-4.44 (m, 1H), 5.33-5.34 (m, 2H), 9.17 (s, 1H) C25H35N9O6S HPLC 93.2% Mass (M + 1) 590.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(3S,5S)-5-((2S,3aS,6aS)-2- (hydroxymethyl)octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 553

¹HNMR (D₂O)-1.16 (d, 3H), 1.24 (d, 3H), 1.50-1.56 (m, 1H), 1.75-1.78 (m, 2H), 2.03-2.06 (m, 1H), 2.81- 2.87 (m, 2H), 2.96-2.99 (m, 1H), 3.15-3.23 (m, 3H), 3.41-3.48 (m, 2H), 3.74 (m, 2H), 3.87 (m, 1H), 4.02-4.05 (m, 1H), 4.29 (m, 1H), 4.31-4.32 (m, 1H), 5.31-5.32 (m, 2H), 9.16 (s, 1H) C23H33N9O6S HPLC 98.4% Mass (M + 1) 564.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4R)-4-amino-3- hydroxypiperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 554

¹HNMR (D₂O)-1.17 (d, 3H), 1.25 (d, 3H), 1.52-1.58 (m, 1H), 1.77-1.80 (m, 2H), 2.05-2.08 (m, 1H), 2.83- 2.89 (m, 2H), 2.98-3.01 (m, 1H), 3.17-3.25 (m, 3H), 3.43-3.50 (m, 2H), 3.76 (m, 2H), 3.89 (m, 1H), 4.04-4.07 (m, 1H), 4.31 (m, 1H), 4.33-4.34 (m, 1H), 5.33-5.34 (m, 2H), 9.18 (s, 1H) C23H33N9O6S HPLC 98.4% Mass (M + 1) 564.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4S)-4-amino-3- hydroxypiperidine-1-carbonyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 555

¹HNMR (D₂O)-1.09 (d, 3H), 1.24 (d, 3H), 1.82-1.90 (m, 5H), 2.30-2.33 (m, 1H), 2.88-2.91 (m, 2H), 3.22- 3.38 (m, 2H), 3.41-3.49 (m, 3H), 3.58-3.65 (m, 2H), 3.78-3.79 (m, 3H), 3.92-3.98 (m, 2H), 4.04-4.06 (m, 1H), 5.32-5.3 (d, 2H), 9.17 (s, 1H) C25H35N9O6S HPLC 97.5% Mass (M + 1) 590.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(6a- (hydroxymethyl)octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 556

¹HNMR (D₂O)-1.16 (d, 3H), 1.3 (d, 3H), 1.88-1.96 (m, 5H), 2.34-2.37 (m, 1H), 2.92-2.95 (m, 2H), 3.26- 3.42 (m. 2H), 3.44-3.53 (m, 3H), 3.62-3.69 (m, 2H), 3.82-3.83 (m, 3H), 4.01-4.07 (m, 2H), 4.12-4.14 (m, 1H), 5.38-5.36(d, 2H), 9.25 (s, 1H) C25H35N9O6S HPLC 97.9% Mass (M + 1) 590.6 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(6a- (hydroxymethyl)octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 557

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.89 (m, 1H), 2.22-2.26 (m, 1H), 2.56-2.62 (m, 1H), 3.15-3.18 (m, 1H), 3.45-3.47 (m, 1H), 3.77- 3.84 (m, 2H), 4.01-4.03 (m, 1H), 4.08-4.09 (m, 1H), 4.17-4.32 (m, 2H), 4.17-4.32 (m, 2H), 5.26-5.36 (d, 2H), 9.16 (s, 1H) C19H25N7O5S HPLC 90.3% Mass (M + 1) 464.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(5-oxa-2- azaspiro[3.4]octan-7-ylthio)-4-methyl-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene- 2-carboxylic acid 558

¹HNMR (D₂O)-1.11 (d, 3H), 1.25 (d, 3H), 1.91 (m, 1H), 2.24-2.28 (m, 1H), 2.58-2.64 (m, 1H), 3.17-3.20 (m, 1H), 3.47-3.49 (m, 1H), 3.79- 3.86 (m, 2H), 4.03-4.05 (m, 1H), 4.10-4.11 (m, 1H), 4.19-4.34 (m, 2H), 4.19-4.34 (m, 2H), 5.28-5.38 (d, 2H), 9.18 (s, 1H) C19H25N7O5S HPLC 90% Mass (M + 1) 464.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(5-oxa-2- azaspiro[3.4]octan-7-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 559

¹HNMR (D₂O)-1.19 (d, 3H), 1.21 (d, 3H), 1.68-1.69 (m, 1H), 1.83-1.87 (m, 3H), 2.02-2.09 (m, 4H), 2.48- 2.52 (m, 1H), 2.89-2.90 (m, 1H), 3.01-3.17 (m, 2H), 3.20-3.29 (m, 1H), 3.44-3.70 (m, 3H), 3.71-3.90 (m, 1H), 4.00-4.02 (m, 1H), 4.21- 4.30 (m, 3H), 4.47-4.70 (m, 1H), 5.29-5.33 (m, 2H), 9.14 (s, 1H) C26H37N11O5S HPLC 98.7% Mass (M + 1) 616.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5-carbamimidoyloctahydro- 1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 560

¹HNMR (D₂O)-1.20 (d, 3H), 1.23 (d, 3H), 1.72-1.73 (m, 1H), 1.87-1.71 (m, 3H), 2.06-2.13 (m, 4H), 2.52- 2.56 (m, 1H, 2.93-2.94 (m, 1H), 3.05-3.21 (m, 2H), 3.24-3.33 (m, 1H), 3.48-3.74 (m, 3H), 3.76-3.95 (m, 1H), 4.04-4.06 (m, 1H), 4.25- 4.34 (m, 3H), 4.51-4.74 (m, 1H), 5.33-5.37 (m, 2H), 9.15 (s, 1H) C26H37N11O5S HPLC 98.7% Mass (M + 1) 616.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(5-carbamimidnyloctahydro- 1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 561

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.69-1.81 (m, 3H), 2.19-2.20 (m, 1H), 2.81-2.82 (m, 1H), 2.99- 3.01 (m, 1H), 3.09-3.22 (m, 3H), 3.37-3.52 (m, 4H), 3.62-3.66 (m, 4H), 3.81-3.82 (m, 1H), 3.93-3.96 (m, 2H), 4.28-4.29 (m, 1H), 5.30- 5.31 (d, 2H), 9.14 (s, 1H) C25H35N9O6S HPLC 90.4% Mass (M + 1) 590.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(6a- (hydroxymethyl)octahydropyrrolo[3,4-b]-pyrrole-1-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 562

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.37-1.38 (m, 1H), 1.60-1.61 (m, 1H), 1.81-2.09 (m, 4H), 3.11- 3.35 (m, 4H), 3.44-3.47 (m, 2H), 3.52-3.57 (m, 3H), 3.60-3.66 (m, 2H), 3.84-3.88 (m, 1H), 3.91-4.03 (m, 1H), 4.87-5.29 (m, 2H), 5.30- 5.46 (m, 2H), 9.14 (s, 1H) C26H35N9O7S HPLC 94.7% Mass (M + 1) 618.3 5-((2S,4S)-4-((4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-2-carboxy-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl-thio)pyrrolidine-2-carbonyl)octahydro-1H- pyrrolo[3,4-c]pyridine-3a-carboxylic acid 563

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.41-1.42 (m, 1H), 1.64-1.65 (m, 1H), 1.85-2.13 (m, 4H), 3.15- 3.39(m, 4H), 3.48-3.51 (m, 2H), 3.56-3.61 (m, 3H), 3.64-3.70 (m, 2H), 3.88-3.92 (m, 1H), 3.95-4.07 (m, 1H), 4.91-5.33 (m, 2H), 5.34- 5.50 (m, 2H), 9.15 (s, 1H) C26H35N9O7S HPLC 94.7% Mass (M + 1) 618.3 5-((2S,4S)-4-((4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-2-carboxy-4-methyl- 7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl-thio)pyrrolidine-2-carbonyl)octahydro-1H- pyrrolo[3,4-c]pyridine-3a-carboxylic acid 564

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.71-1.79 (m, 3H), 1.85-2.05 (m, 2H), 2.33-2.45 (m, 1H), 2.82- 2.84 (m, 1H), 2.98-3.01 (m, 1H), 3.12-3.27 (m, 3H), 3.38-3.44 (m, 2H), 3.61-3.66 (m, 1H), 3.73-3.75 (m, 2H), 3.81-3.89 (m, 1H), 4.00- 4.02 (m, 1H), 4.10-4.20 (m, 2H), 4.30-4.47 (m, 2H), 5.25-5.34 (d, 2H), 9.13 (s, 1H) C26H35N9O5S HPLC 97.9% Mass (M + 1) 586.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((1S,7R)-3,8-Diaza- tricyclo[5.2.1.01,5]decane-3-carbonyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carbnxylic acid 565

¹HNMR (D₂O)-1.09 (d, 3H), 1.24 (d, 3H), 1.81-1.89 (m, 2H), 2.86-2.88 (m, 1H), 3.24-3.30 (m, 2H), 3.36- 3.48 (m, 3H), 3.55-3.68 (m, 3H), 3.70-3.75 (m, 1H), 3.80-3.89 (m, 1H), 4.03-4.05 (m, 1H), 4.15-4.70 (m, 2H), 5.27-5.36 (d, 2H), 9.16 (s, 1H) C23H34N12O5S HPLC 96.9% Mass (M + 1) 591.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)-3-amino-4- guanidinopyrrolidine-1-carbonyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 566

¹HNMR (D₂O)-1.07 (d, 3H), 1.22 (d, 3H), 1.79-1.88 (m, 2H), 2.70-2.72 (m, 1H), 3.12-3.20 (m, 2H), 3.30- 3.46 (m, 2H), 3.80-3.92 (m, 2H), 4.00-4.02 (m, 1H), 4.13-4.29 (m, 2H), 4.42-4.54 (m, 3H), 5.30-5.35 (d, 2H), 9.15 (s, 1H) C22H31N11O5S HPLC 97.2% Mass (M + 1) 562.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-guanidinoazetidine-1- carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 567

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.78-1.87 (m, 3H), 1.96-1.98 (m, 1H), 2.09-2.16 (m, 2H), 2.81- 2.83 (m, 1H), 3.19-3.25 (m, 2H), 3.46-3.48 (m, 3H), 3.60-3.63 (m, 1H), 3.83-3.87 (m, 3H), 4.01-4.02 (m, 1H), 4.21-4.32 (m, 2H), 5.24- 5.33 (d, 2H), 9.14 (s, 1H) C25H36N12O6S HPLC 98.1% Mass (M + 1) 633.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((R)-3-(2- guanidinoacetamido)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 568

¹HNMR (D₂O)-1.18 (d, 3H), 1.22 (d, 3H), 1.73-1.78 (m, 1H), 1.88-2.20 (m, 2H), 2.41-2.44 (m, 2H), 2.54- 2.66 (m, 3H), 2.79-2.82 (m, 2H), 3.11-3.14 (m, 1H), 3.26-3.37 (m, 3H), 3.53-3.68 (m, 2H), 3.70-3.74 (m, 3H), 3.81-3.84 (m, 3H), 3.90- 3.95 (m, 1H), 3.97-4.04 (m, 1H), C24H36N6O5S HPLC 94.3% Mass (M + 1) 521.2 (4R,5S,6R)-3-((3S,5S)-5-((R)-3-aminopyrrolidine-1-carbonyl)pyrroldin-3-ylthio)-6-((R)-1-(2- (azetidin-3-yl)acetamido)ethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 569

¹HNMR (D₂O)-1.06 (d, 3H), 1.20 (d, 3H), 1.78-1.79 (m, 1H), 1.86-1.87 (m, 2H), 2.87-2.89 (m, 1H), 3.19- 3.27 (m, 4H), 3.43-3.49 (m, 4H), 3.59-3.65 (m, 1H), 3.72-3.77 (m, 2H), 3.87-3.88 (m, 1H), 3.99-4.01 (m, 1H), 4.25-4.29 (m, 1H). 4.37- 4.43 (m, 2H), 5.28-5.32 (d, 2H), 9.13 (s, 1H) C25H35N11O5S HPLC 91.1% Mass (M + 1) 602.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(1- Carbamimidoyloctahydro-pyrrolo[3,4-b]-pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7- oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 570

¹HNMR (D₂O)-1.08 (d, 3H), 1.22 (d, 3H), 1.82-1.83 (m, 1H), 1.90-1.91 (m, 2H), 2.91-2.93 (m, 1H), 3.23- 3.31 (m, 4H), 3.47-3.53 (m, 4H), 3.63-3.69 (m, 1H), 3.76-3.81 (m, 2H), 3.91-3.92 (m, 1H), 4.03-4.05 (m, 1H), 4.29-4.33 (m, 1H), 4.41- 4.47 (m, 2H), 5.32-5.36 (d, 2H), 9.13 (s, 1H) C25H35N11O5S HPLC 96.9% Mass (M + 1) 602.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(1-carbamimidoyl- octahydropyrrolo[3,4-b]-pyrrole-5-carbonyl)pyrrolidin-3-yl-thio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 571

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.67-1.79 (m, 4H), 1.93-1.98 (m, 1H), 2.39-2.40 (m, 1H), 2.77- 2.78 (m, 1H), 2.89-2.95 (m, 1H), 3.14-3.15 (m, 1H), 3.22-3.23 (m, 1H), 3.29-3.37 (m, 3H), 3.43-3.45 (m, 2H), 3.51-3.57 (m, 1H), 3.60- 3.67 (m, 1H), 3.80-3.81 (m, 1H), 4.00-4.02 (m, 1H), 4.14-4.17 (m, 1H), 4.27-4.33 (m, 2H), 5.25-5.34 (m, 2H), 9.14 (s, 1H) C26H35N9O5S HPLC 97.9% Mass (M + 1) 586.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((1R,7R)-3,8-Diaza- tricyclo[5.2.1.01,5]decane-8-carbonyl)-pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 572

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(3-amino-2- hydroxypropylcarbamoyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo- 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.15 (d, 3H), 1.22 (d, 3H), 1.45-1.52 (m, 2H), 1.67-1.69 (m, 1H), 1.78-1.87 (m, 3H), 2.52- 2.53 (m, 1H), 2.74.-2.80 (m, 3H), 2.99-3.02 (m, 1H), 3.02-3.22 (m, 3H), 3.35-3.36 (m, 1H), 3.38-3.44 (m, 1H), 3.60-3.64 (m, 1H), 3.74- 3.77 (m, 1H), 3.84-3.85 (m, 2H), 4.00-4.02 (m, 1H), 4.21-4.70 (m, 3H), 5.25-5.34 (m, 2H), 9.13 (s, 1H) C27H40N10O7S HPLC 96.5% Mass (M + 1) 649.2 573

¹HNMR (D₂O)-1.17 (d, 3H), 1.24 (d, 3H), 1.48-1.55 (m, 2H), 1.70-1.72 (m, 1H), 1.81-1.90 (m, 3H), 2.55-2.56 (m, 1H), 2.77-2.83 (m, 3H), 3.02-3.05 (m, 1H), 3.05-3.25 (m, 3H), 3.38-3.39 (m, 1H), 3.41-3.47 (m, 1H), 3.63-3.67 (m, 1H), 3.77-3.81 (m, 1H), 3.87-3.88 (m, 2H), 4.03-4.05 (m, 1H), 4.24-4.73 (m, 3H), 5.28-5.37 (m, 2H), 9.15 (s, 1H) C27H40N10O7S HPLC 97.9% Mass (M + 1) 648.73 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(4-(3-amino-2- hydroxypropylcarbamoyl)piperidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 574

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.64-1.69 (m, 2H), 1.70-1.78 (m, 2H), 1.84-1.95 (m, 1H), 2.09-2.10 (m, 1H), 2.33-2.35 (m, 1H), 2.42-2.46 (m 1H), 2.76-2.77 (m, 1H), 3.08-3.09 (m, 1H), 3.18-3.19 (m, 1H), 3.20-3.22 (m, 2H), 3.27-3.30 (m, 1H), 3.43-3.46 (m, 1H), 3.44-3.50 (m, 2H), 3.60-3.66 (m, 1H), 3.91-3.99 (m, 2H), 5.27-5.29 (m, 2H), 9.14 (s, 1H) C25H36N10O5S HPLC 91.8% Mass (M + 1) 589.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aS,5S,6aR)-3a,5- diaminooctahydrocyclo-penta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 575

¹HNMR (D₂O)-1.05 (d, 3H), 1.20 (d, 3H), 1.73 (m, 1H), 1.94 (m, 2H), 2.04 (m, 1H), 2.32 (m, 2H), 2.49 (m, 1H), 3.24 (m, 2H), 3.44-3.55 (m, 3H), 3.59 (m, 1H), 3.82 (m, 1H), 4.01-4.03 (m, 1H), 4.19-4.28 (m, 1H), 4.34 (m, 1H), 5.28-5.29 (d, 2H), 9.13 (s, 1H) C23H33N11O5S HPLC 97.1% Mass (M + 1) 576.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(((R)-3-aminopyrrolidin-1-yl) (imino)-methylcarbamoyl)-pyrrolidin-3-yl-thio)-4-methyl-7-oxo-1-azabicyclo-[3.2.0]-hept-2-ene-2- carboxylic acid 576

¹HNMR (D₂O)-1.03 (d, 3H), 1.17 (d, 3H), 1.80-1.83 (m, 2H), 2.36-2.43 (m, 1H), 2.74-2.82 (m, 1H), 3.14-3.18 (m, 2H), 3.24-3.26 (m, 1H), 3.41-3.45 (m, 2H), 3.52-3.58 (m, 1H), 3.75-3.79 (m, 2H), 3.80-3.87 (m, 1H), 3.96-3.98 (m, 1H), 4.03-4.08 (m, 2H), 4.22-4.26 (m, 1H), 4.33-4.35 (m, 1H), 5.25-5.30 (d, 2H), 9.10 (s, 1H) C24H35N11O6S HPLC 99.1% Mass (M + 1) 606.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((2S,4S)-4-guanidino-2- (hydroxymethyl)-pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylic acid 577

¹HNMR (D₂O)-1.07 (d, 3H), 1.21 (d, 3H), 1.51 (m, 1H), 1.86 (m, 1H), 2.27 (m, 1H), 2.74-2.90 (m, 3H), 3.01-3.14 (m, 3H), 3.22 (m, 4H), 3.34-3.55 (m, 4H), 3.68 (m, 2H), 3.72 (m, 1H), 3.84 (m, 1H), 3.99-4.02 (m, 1H), 4.28-4.30 (m, 2H), 5.29 (d, 2H), 9.14 (s, 1H) C26H38N10O5S HPLC 97.9% Mass (M + 1) 603.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(1-(2- aminoethyl) octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 578

¹HNMR (D₂O)-1.09 (d, 3H), 1.23 (d, 3H), 1.53 (m, 1H), 1.88 (m, 1H), 2.29 (m, 1H), 2.76-2.92 (m, 3H), 3.03-3.16 (m, 3H), 3.24 (m, 4H), 3.36-3.57 (m, 4H), 3.70 (m, 2H), 3.74 (m, 1H), 3.86 (m, 1H), 4.01-4.04 (m, 1H), 4.30-4.32 (m, 2H), 5.31 (d, 2H), 9.16 (s, 1H) C26H38N10O58 HPLC 91.6% Mass (M + 1) 603.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(1-(2-aminoethyl) octahydropyrrolo[3,4-b]pyrrole-5-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 579

¹HNMR (D₂O)-0.93 (d, 3H), 1.21 (d, 3H), 1.86 (m, 1H), 2.70-2.77 (m, 1H), 2.97-3.03 (m, 1H), 3.23-3.28 (m, 1H), 3.30-3.36 (m, 1H), 3.40-3.42 (m, 1H), 3.95-3.98 (m, 1H), 4.26-4.31 (m, 1H), 5.31-5.33 (m, 2H), 9.14 (s, 1H) C16H23N9O4S HPLC 94.4% Mass (M + 1) 438.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(2- guanidinoethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-carboxylic acid 580

¹HNMR (D₂O)-1.05 (d, 3H), 1.31 (d, 3H), 1.71-1.79 (m, 1H), 1.88-1.97 (m, 1H), 2.14-2.43 (m, 1H), 2.89-3.01 (m, 1H), 3.20-3.36 (m, 2H), 3.42-3.49 (m, 1H), 3.53-3.55 (m, 2H), 3.61-3.68 (m, 1H), 3.76-3.79 (m, 1H), 3.82-3.85 (m, 2H), 3.85-3.86 (m, 1H), 3.99-4.03 (m, 1H), 4.09-4.11 (m, 1H), 5.34-5.43 (m, 2H), 9.26 (s, 11H) C23H31N11O5S HPLC 90.3% Mass (M + 1) 574.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,6aS)-2- iminooctahydropyrrolo[3,4-d]imidazole-5-carbonyl)pyrrolidin-3-ylthio)-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 581

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-yl)acetamido)ethyl)-3-((3S,5S)-5-(5- guanidinooctahydroyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid ¹HNMR (D₂O)-1.08 (d, 3H), 1.22 (d, 3H), 1.51-1.52 (m, 1H), 1.61-1.62 (m, 1H), 1.69-1.70 (m, 1H), 1.81-1.82 (m, 1H), 2.20-2.30 (m, 1H), 2.62-2.69 (m, 2H), 2.89-2.90 (m, 1H), 2.91-2.96 (m, 1H), 3.06-3.08 (m, 1H), 3.10-3.11 (m, 1H), 3.23-3.24 (m, 1H) 3.33-3.36(m, 1H), 3.43-3.47 (m, 2H), 3.52-3.58 (m, 2H), 3.62-3.69 (m, 1H), 3.80-3.82 (m, 1H), 3.90-4.03 (m, 1H), 4.29-4.47 (m, 1H), 5.30-5.33 (d, 2H), 9.15 (s, 1H) C26H37H11O5S HPLC 93.8% Mass (M + 1) 616.2 582

¹HNMR (D₂O)-1.09 (d, 3H), 1.22 (d, 3H), 2.23-2.27 (m, 2H), 2.86-2.92 (m, 1H), 3.21-3.22 (m, 1H), 3.26-3.29 (m, 1H), 3.30-3.39 (m, 1H), 3.45-3.46 (m, 2H), 3.50-3.58 (m, 3H), 3.60-3.67 (m, 1H), 3.74-3.78 (m, 1H), 3.78-3.88 (m, 1H), 3.90-4.03 (m, 1H), 4.13-4.18 (m, 1H), 4.27-4.30 (m, 1H), 5.30-5.34 (d, 2H), 9.15 (s, 1H) C23H33N11O5S HPLC 97.5% Mass (M + 1) 576.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)-ethyl)-3-((3S,5S)-5-((S)-3-guanidino- pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-ene-2- carboxylic acid 583

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.82-1.83 (m, 1H), 1.97-1.98 (m, 1H), 2.50-2.57 (m, 1H), 2.88-2.89 (m, 1H), 3.23-3.32 (m, 2H), 3.32-3.38 (m, 2H), 3.41-3.44 (m, 1H), 3.54-3.55 (m, 1H), 3.67-3.78 (m, 2H), 3.90-3.92 (m, 2H), 4.03-4.07 (m, 2H), 4.32-4.38 (m, 2H), 5.35-5.44 (m, 2H), 9.24 (s, 1H) C24H35N11O6S HPLC 94.5% Mass (M + 1) 606.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)-3-guanidino-4- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept- 2-ene-2-carboxylic acid 584

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.89-1.97 (m, 2H), 2.61-2.71 (m, 2.99-3.00 (m, 2H), 3.28-3.43 (m, 2H), 3.44-3.46 (m, 1H), 3.54-3.67 (m, 4H), 3.70-3.78 (m, 3H), 3.81-3.88 (m, 1H), 3.91-3.96 (m, 1H), 3.99-4.06 (m, 1H), 5.34-5.43 (d, 2H), 9.25 (s, 1H) C23H33N9O6S HPLC 94% Mass (M + 1) 564.4 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3S,4R)-3-amino- 4-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 585

¹HNMR (D₂O)-1.22 (d, 3H), 1.31 (d, 3H), 1.37-1.38 (m, 1H), 1.50-1.54 (m, 1H), 1.97-1.98 (m, 4H), 2.19-2.20 (m, 1H), 2.74-2.89 (m, 2H), 3.22-3.38 (m, 3H), 3.470-3.49 (m, 4H), 3.55-4.12 (m, 5H), 4.61 (m, 1H), 5.38-5.54 (d, 2H), 9.25 (s, 1H)C27H39N11O6S HPLC 95.8% Mass (M + 1) 646.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3aR,5R)-5-guanidino-3a- (hydroxymethyl)octahydrocyclopenta[c]pyrrole-2-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 586

¹HNMR (D₂O)-1.17 (d, 3H), 1.31 (d, 3H), 1.82-1.96 (m, 1H), 2.74-2.95 (m, 2H), 3.27-3.33 (m, 2H), 3.41-3.44 (m, 3H), 3.51-3.53 (m, 2H), 3.66-3.77 (m, 4H), 3.83-3.86 (m, 2H), 4.38-4.80 (m, 2H), 5.34-5.43 (d, 2H), 9.23 (s, 1H) C23H33N9O6S HPLC 94.5% Mass (M + 1) 564.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-4- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 587

¹HNMR (D₂O)-1.18 (d, 3H), 1.33 (d, 3H), 1.84-1.98 (m, 1H), 2.76-2.97 (m, 2H), 3.29-3.35 (m, 2H), 3.43-3.46 (m, 3H), 3.53-3.55 (m, 2H), 3.68-3.79 (m, 4H), 3.85-3.88 (m, 2H), 4.40-4.82 (m, 2H), 5.36-5.45 (d, 2H), 9.25 (s, 1H) C23H33N9O6S HPLC 98.2% Mass (M + 1) 564.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3-amino-4- (hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 588

¹HNMR (D₂O)-1.07 (d, 3H), 1.15 (d, 3H), 1.79-1.86 (m, 1H), 2.63 (s, 3H), 3.24-3.25 (m, 2H), 3.25-3.47 (m, 4H), 3.49-3.51 (m, 1H), 3.53-3.55 (m, 2H), 3.75-3.76 (m, 2H), 3.80-3.87 (m, 2H), 4.00-4.03 (m, 2H), 4.31-4.39 (m, 2H) C23H36N8O6S HPLC 95.6% Mass (M + 1) 553.2 (4R,5S,6R)-3-((3S,5S)-5-((3R,4R)-3-guanidino-4-hydroxypyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)- 4-methyl-6-((R)-1-(2-(methylamino)acetamido)ethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 589

¹HNMR (D₂O)-1.28 (d, 3H), 1.34 (d, 3H), 1.97-1.99 (m, 1H), 2.99 (m, 1H), 3.00 (m, 2H), 3.04 (m, 1H), 3.31-3.36 (m, 1H), 3.44-3.48 (m, 1H), 3.57-3.60 (m, 1H), 3.73-3.77 (m, 1H), 4.05 (m, 1H), 4.13-3.16 (m, 1H), 4.40-4.43 (m, 1H), 5.42 (d, 2H), 9.27 (s, 1H) C19H28N10O4S HPLC 89.8% Mass (M + 1) 493.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5- (guanidinomethyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene- 2-carboxylic acid 590

¹HNMR (D₂O)-1.26 (d, 3H), 1.31 (d, 3H), 1.79-1.97 (m, 2H), 2.84-2.85 (m, 1H), 3.20-3.22 (m, 1H), 3.33-3.41 (m, 1H), 3.48-3.53 (m, 1H), 3.73-3.74 (m, 2H), 3.90-3.91 (m, 1H), 3.97-3.98 (m, 2H), 3.99-4.00 (m, 1H), 4.110-4.12 (m, 1H), 4.18-4.26 (m, 2H), 4.36-4.46 (m, 2H), 5.03-5.10 (m, 1H), 5.30-5.44 (s, 2H), 9.25 (s, 1H) C23H31N9O5S HPLC 96.1% Mass (M + 1) 546.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3,6- diazabicyclo[3.2.0]heptane-3-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-axo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 591

¹HNMR (D₂O)-1.28(d, 3H), 1.33 (d, 3H), 1.81-1.99 (m, 2H), 2.86-2.87 (m, 1H), 3.22-3.24 (m, 1H), 3.35-3.43 (m, 1H), 3.50-3.55 (m, 1H), 3.75-3.76 (m, 2H), 3.92-3.93 (m, 1H), 3.99-4.00 (m, 2H), 4.01-4.02 (m, 1H), 4.12-4.14 (m, 1H), 4.20-4.28 (m, 2H), 4.38-4.48 (m, 2H), 5.05-5.12 (m, 1H), 5.32-5.46 (d, 2H), 9.25 (s, 1H) C23H31N9O5S HPLC 96.1% Mass (M + 1) 546.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(3,6- diazabicyclo[3.2.0]heptane-3-carbonyl)pyrrolidin-3-ylthio)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 592

¹HNMR (D₂O)-1.17 (d, 3H), 1.32 (d, 3H), 1.83-1.97 (m, 1H), 2.75-2.96 (m, 2H), 3.28-3.34 (m, 2H), 3.42-3.45 (m, 3H), 3.52-3.54 (m, 2H), 3.67-3.78 (m, 4H), 3.84-3.87 (m, 2H), 4.39-4.81 (m, 2H), 5.35-5.44 (d, 2H), 9.24 (s, 1H) C24H35N11O6S 27 HPLC 90% Mass (M + 1) 606.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-((3R,4S)-3-guanidino- 4-diazabicyclo[3.2.0]heptane-3-(hydroxymethyl)pyrrolidine-1-carbonyl)pyrrolidin-3-ylthio)-4- methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 593

¹HNMR (D₂O)-1.97 (d, 3H), 1.29 (d, 3H), 1.78-1.80 1H), 1.94-1.98 (m, 2H), 2.14-2.22 (m, 1H), 2.86-2.96 (m, 2H), 3.05-3.10 (m, 1H), 3.34-3.44 (m, 2H), 3.96-3.99 (m, 1H), 4.31-4.33 (m, 3H), 5.36-5.40 (m, 2H), 7.70-7.73 (m, 1H), 7.93-7.97 (m, 1H), 9.23 (s, 1H) C21H27N9O4S HPLC 91.35% Mass (M + 1) 502.3 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-(1-((R)- pyrrolidin-3-ylmethyl)-1H-pyrazol-4-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2- carboxylic acid 594

¹HNMR (D₂O)-1.13 (d, 3H), 1.28 (d, 3H), 2.20-2.29 (m, 3H), 2.97 (m, 2H), 3.87-3.88 (m, 2H), 3.47-3.48 (m, 3H), 3.87-3.88 (m, 3H), 3.99-4.15 (m, 2H), 4.30 (m, 2H), 5.36 (d, 2H), 7.43-7.44 (m, 2H), 7.54-7.56 (m, 2H), 7.93 (s, 1H), 8.04 (s, 1H), 9.22 (s, 1H) C25H36N10O4S HPLC 91.4% Mass (M + 1) 573.1 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(1-((1-(2-aminoethyl)-1-methylpiperidinium- 4-yl)methyl)-1H-pyrazol-4-ylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 595

¹HNMR (D₂O)-0.86-0.88 (d, 3H), 1.68 (d, 3H), 2.18-2.19 (m, 2H), 3.02- 3.06 (m, 2H), 3.31-3.32 (m, 2H), 3.47- 3.48 (m, 2H), 3.86-3.87 (m, 1H), 4.11- 4.13 (m, 2H), 4.23-4.24 (m, 1H), 5.27- 5.28 (m, 2H), 7.63 (m, 2H), 7.84 (m, 2H), 8.39 (s, 1H), 8.43 (s, 1H) 9.14 (s, 1H) C26H31N9O4S HPLC 94.4% Mass (M + 1) 566.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(4-(1-(3-aminopropyl)-1H-pyrazol- yl)benzylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid 596

¹HNMR (D₂O)-1.00 (d, 3H), 1.18 (d, 3H), 2.22-2.23 (d, 2H), 3.00-3.01 (m, 2H), 3.31-3.33 (m, 1H), 3.69-3.71 (m, 2H), 3.91-3.92 (m, 1H), 3.99-4.01 (m, 1H), 4.07 (s, 3H), 4.20-4.21 (m, 1H), 4.47-4.49 (m, 1H), 5.25-5.26 (m, 2H), 7.35-7.37 (m, 2H), 7.43-7.47 (m, 2H), 8.44 (s, 1H), 8.50 (s, 1H), 9.12 (s, 1H) C27H33N9O4S HPLC 96.7% (M + 1) 580.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(4-(1-(3-aminopropyl)-2-methyl-1H- pyrazol-2-ium-4-yl)benzylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 597

¹HNMR (D₂O)-0.89-0.91 (d, 3H), 1.20 (d, 3H), 1.79-1.80 (m, 1H), 2.15- 2.16 (m, 1H), 2.76-2.77 (m, 1H), 2.99- 3.06 (m, 2H), 3.41-3.42 (m, 2H), 3.50- 3.51 (m, 1H), 3.92-3.94 (m, 1H), 3.99- 4.00 (m, 1H), 4.05 (s, 3H), 4.10-4.11 (m, 1H), 4.44-4.45 (m, 1H), 5.24-5.25 (m, 2H), 8.45 (s, 1H), 8.55 (s, 1H), 9.13 (s, 1H) C22H29N9O4S HPLC 90% (M + 1) 516.2 (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-3-(2-methyl-1- ((R)-pyrrolidin-3-ylmethyl)-1H-pyrazol-2-ium-4-ylthio)-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylate 598

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(4-(1-(3-aminopropyl)-2-methyl-1H- pyrazol-2-ium-4-yl)benzylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate ¹HNMR (D₂O)-1.06 (d, 3H), 1.20 (d, 3H), 1.70-1.71 (m, 2H), 1.78-1.79 (m, 2H), 1.86-1.87 (m, 1H), 2.06-2.07 (m, 2H), 2.22-2.23 (m, 1H), 2.59-2.60 (m, 2H), 2.83-2.86 (m, 1H), 3.02 (s, 3H), 3.06 (s, 3H), 3.19 (m, 2H), 3.40-3.43 (m, 2H), 3.53-3.54 (m, 2H), 3.63-3.64 (m, 1H), 3.85-3.86 (m, 2H), 4.27-4.38 (m, 1H), 5.29-5.30 (d, 2H), 9.14 (s, 1H) C27H39N9O5S HPLC 94.7% (M + 1) 602.1 599

  (4R,5S,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(4-(1-(3-aminopropyl)-2-methyl-1H- pyrazol-2-ium-4-yl)benzylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate ¹HNMR (D₂O)-1.08 (d, 3H), 1.22 (d, 3H), 1.72-1.73 (m, 2H), 1.80-1.81 (m, 2H), 1.88-1.89 (m, 1H), 2.08-2.09 (m, 2H), 2.24-2.25 (m, 1H), 2.61-2.62 (m, 2H), 2.85-2.87 (m, 1H), 3.03 (s, 3H), 3.07 (s, 3H), 3.21 (m, 2H), 3.42-3.45 (m, 2H), 3.55-3.56 (m, 2H), 3.64-3.65 (m, 1H), 3.87-3.88 (m, 2H), 4.29-4.40 (m, 1H), 5.31-5.32 (d, 2H), 9.15 (s, 1H) C27H39N9O5S HPLC 90% (M + 1) 602.1 600

¹HNMR (D₂O)-1.16 (d, 3H), 1.26 (d, 3H), 3.19-3.21 (m, 2H), 3.23 (m, 1H), 3.47 (m, 1H), 3.51 (m, 1H), 3.84-3.86 (m, 1H), 3.98-4.05 (m, 1H), 4.12-4.16 (m, 2H), 4.22 (m, 2H), 4.49 (m, 1H), 5.30-5.46 (m, 2H), 9.25 (s, 1H) C19H28N10O5 HPLC 90% Mass (M + 1) 477.1 (4S,5R,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(((3S,4S)- 3-guanidino-4-hydroxypyrrolidin-1-yl)methyl)-4-methyl-7-oxo-1- azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Example 600: Synthesis of (4S,5R,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(((3S,4S)-3-guanidino-4-hydroxypyrrolidin-1-yl)methyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Preparation 28: (4S,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((isobutoxycarbonyloxy)methyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(R)-4-Nitrobenzyl 4-((2R,3R)-3-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-oxoazetidin-2-yl)-2-diazo-3-oxopentanoate (10 g, 20 mmol) was dissolved in 200 mL of acetone under N₂ atmosphere. To this solution was added rhodium octanoate (750 mg, 0.96 mmoles) and heated to 60° C. for 2.5 hours. After the completion of the reaction, the reaction mixture was then cooled to −40° C. and triflic anhydride (4.6 mL, 28 mmoles), diisopropylethylamine (8.8 mL, 50.9 mmol) and catalytic amount of dimethylaminopyridine (750 mg, 6.14 mmol) was added successively. The reaction mixture was then stirred for 1 hour at −40° C. The reaction mixture was quenched with addition of 0.1M phosphate buffer (pH=7) The aqueous layer was extracted with dichloromethane and the organic layer evaporated under vacuum at room temperature to obtain crude. Partial purification of the crude was done by column chromatography to yield (4R,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-(trifluoromethylsulfonyloxy)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (2.7 g, 47%). A mixture containing (4R,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(H-tetrazol-1-yl)acetamido)ethyl)-4-methyl-7-oxo-3-(trifluoromethylsulfonyloxy)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (2.6 g), tri-n-butylstannylmethanol (5.48 g, 17.1 mmol) and hexamethylphosphoramide (degassed) was stirred for 30 minutes. To the above a separately prepared solution containing tris(2-furyl)phosphine (0.32 g, 1:38 mmol), Pd(dba)₃ (0.513 g, 0.56 mmol) and zinc chloride (0.513 g, 3.77 mmol) in 10 mL of hexamethylphosphoramide (degassed) was added and heated to 70° C. for 1 hour in a sealed tube. Reaction mixture was diluted with diethyl ether and water. The organic layer was separated and concentrated to obtain the crude. Column chromatographic purification of the crude was done to obtain 1 g of (4S,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(hydroxymethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate. ¹H NMR CDCl₃ 1.17 (d, 3H), 1.39 (d, 3H), 3.22-3.24 (m, 1H), 3.41-3.43 (m, 1H), 4.09-4.12 (d, 1H), 4.34-4.37 (m, 1H), 4.38-4.39 (m, 1H), 4.58-4.62 (m, 1H), 5.12-5.13 (d, 2H), 5.26-5.29 (dd, 1H), 5.49-5.52 (dd, 1H), 6.13 (br s, 1H), 7.64-7.66 (m, 2H), 8.22-8.24 (d, 2H), 8.93 (s, 1H).

A mixture of N,N-diisopropylethylamine (1.36 mL, 7.85 mmol) and dimethylaminopyridine (0.015 g, 0.13 mmol) in tetrahydrofuran (30 mL) was cooled to 0° C. and isobutyl-chloroformate (0.5 mL, 3.84 mmol) was added and stirred for 5 minutes. To the above, a solution of (4 S,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(hydroxymethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (0.6 g, 1.24 mmol) dissolved in tetrahydrofuran (10 mL) was added at 0° C. and continued stirring at room temperature for 24 h. Reaction mixture was concentrated under vacuo and purified the crude by column chromatography to obtain the titled compound, 0.4 g. ¹H NMR CDCl₃ −0.94-0.96 (d, 61H), 1.18. (d, 3H), 1.38 (d, 3H), 1.94-2.01 (m, 1H), 3.10-3.11 (m, 1H), 3.30-3.34 (m, 1H), 3.93-3.94 (d, 2H), 4.10-4.12 (d, 1H), 4.38-4.42 (m, 1H), 4.78-4.82 (m, 1H), 5.17 (d, 2H), 5.25-5.29 (m, 1H), 5.47-5.51 (m, 2H), 6.67-6.68 (br s, 1H), 7.63-7.65 (m, 2H), 8.23-8.25 (d, 2H), 8.87 (s, 1H).

Preparation 29: (4S,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(((3S,4S)-3-((E)-2,3-bis((4-nitrobenzyloxy)carbonyl)guanidino)-4-hydroxypyrrolidin-1-yl)methyl)-4-methyl-7-oxo-i-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

Pd(dba)₃CHCl₃ (0.026 g, 0.025 mmol), triethylphosphite (0.18 ml, 0.104 mmol) and a mixture of 10 mL of tetrahydrofuran-toluene (degassed, 1:9) was stirred for 30 minutes. To the above, a solution containing mixture of 4-nitrobenzyl ((3S,4S)-4-hydroxypyrrolidin-3-ylamino)((4-nitrobenzyloxy)carbonylamino)methylenecarbamate, trifluoroacetate salt (0.085 g, 0.102 mmol, neutralized with diisopropylethylamine) and (4S,5R,6R)-4-nitrobenzyl 6-((R)-1-(2-(1H-tetrazol-yl)acetamido)ethyl)-3-((isobutoxycarbonyloxy)methyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (0.1 g, 0.17 mmol) in 5 mL of tetrahydrofuran-toluene (degassed 1:9) was added and stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate and 0.1M phosphate buffer 7.0. Organic layer was separated and washed with water and brine. After drying over sodium sulphate, organic layer was concentrated to obtain crude. The crude was purified by column chromatography to obtain the titled compound (0.06 g). ¹H NMR CDCl₃ 1.14 (d, 3H), 1.38 (d, 3H), 1.98-1.99 (m, 1H), 2.52-2.24 (m, 1H), 3.08 (m, 1H), 3.34 (m, 1H), 3.41 (m, 1H), 4.06 (m, 0.1H), 4.11-4.13 (m, 1H), 4.43 (m, 1H), 4.91-4.94 (m, 2H), 5.11-5.21 (m, 4H), 5.24-5.30 (m, 4H), 5.43-5.49 (m, 2H), 6.65 (br s, 1H), 7.51-7.56 (m, 6H), 8.19-8.24 (m, 6H), 8.87 (s, 1H)

The above compound was hydrogenated similar to Step 4 of example 298 to obtain the required compound (4S,5R,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-(((3S,4S)-3-guanidino-4-hydroxypyrrolidin-1-yl)methyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid. ¹H NMR (D₂O) −1.16 (d, 3H), 1.26 (d, 3H), 3.19-3.21 (m, 2H), 3.23 (m, 1H), 3.47 (m, 1H), 3.51 (m, 1H), 3.84-3.86 (m, 1H), 3.98-4.05 (m, 1H), 4.12-4.16 (m, 2H), 4.22 (m, 2H), 4.49 (m, 1H), 5.30-5.46 (m, 2H), 9.25 (s, 1H) C19H28N10O5 HPLC 90% Mass (M+1) 477.1

601

¹HNMR (D₂O)-1.32 (d, 3H), 1.68- 1.69 (m, 1H), 1.83-1.87 (m, 2H), 1.97 (m, 1H), 2.12-2.17 (m, 3H), 2.48-2.52 (m, 1H), 2.64 (m, 3H), 3.00-3.07 (m, 3H), 3.27-3.31 (m, 2H), 3.42-3.43 (d, 3H), 3.65-3.70 (m, 3H), 4.01 (m, 1H), 4.11-4.13 (d, 1H), 4.28-4.30 (m, 1H), 4.37-4.40 (m, 1H), 4.53-4.57 (m, 1H), 5.40 (d, 2H), 9.25 (s, 1H) C25H37N9O6S HPLC 90% Mass 592.2 (M + 1)

Example 601: Synthesis of (5R,6R)-6-((R)-1-(2-(1H-tetrazol-1-yl)acetamido)ethyl)-3-((3S,5S)-5-(octahydro-1H-pyrrolo[3,2-c]pyridine-1-carbonyl)pyrrolidin-3-ylthio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Preparation 30: 2-((2R)-3-((R)-1-(tert-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)acetic acid

To a solution of (S)-4-phenyl-3-acetyl-2-oxazolidinone (42.8 g, 0.21 mol) in dichloromethane (250 mL), TiCl₄ (50 g, 0.26 mol) was added dropwise in 30 min at −20 to −25° C. After stirring the mixture for 30 min at −20 to −25° C., diisopropyl ethylamine (56 g, 0.24 mol) was added dropwise, and stirring continued for 1 h at same temperature. To the above, (3R,4R)-4-acetoxy-3-[(R)-1-((tertbutyldimethylsilyl)oxy)ethyl]-2-azetidinone (50 g, 0.17 mol) dissolved in dichloromethane (100 mL) was added at −15 to −10° C. over a period of 20 minutes. Then the mixture was stirred at room temperature for 3 h. Reaction mixture was diluted with dichloromethane (300 mL) and washed with water and brine. After drying over sodium sulphate, the organic layer was concentrated under vacuum to obtain a residue. The residue was purified by column chromatography (Eluant −15% acetone in hexane) to obtain (4S)-3-(2-((2R)-3-((R)-1-(tert-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)acetyl)-4-phenyloxazolidin-2-one (28.5 g). This compound (28.5 g) was dissolved in 300 mL of mixture of acetone and water (2:1) and cooled to 0° C. Cooled hydrogen peroxide (30%, 22 mL) was added followed by dropwise addition of 1N sodium hydroxide solution (200 mL) at 0° C. in 30 minutes. After stirring for 15 minutes at the same temperature, the reaction was diluted with water (1 L). The aqueous layer was washed with ethyl acetate (500 mL×2) The aqueous layer was cooled to 0° C. and the pH was adjusted with 6 N HCl to 8. The aqueous layer was washed with ethyl acetate (500 mL×2) The aqueous layer was acidified to pH 3 with dil HCl and extracted with ethyl acetate (400 mL×2) After drying over sodium sulphate the organic layer was evaporated to obtain 2-((2R)-3-((R)-1-(tert-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)acetic acid, 11.5 g ¹H NMR-CDCl₃ −0.05 (d, 6H), 0.8 (s, 9H), 1.21 (d, 3H), 2.53-2.62 (m, 1H), 2.76-2.78 (m, 1H), 2.82-2.84 (d, 1H), 3.96-3.98 (d, 1H), 4.12-4.14 (m, 1H), 6.68 (br s, NH)

Scheme 1 was followed for preparing the below compound by using the starting material obtained above (2-((2R)-3-((R)-1-(tert-butyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl)acetic acid)

¹H NMR (D₂O) −1.32 (d, 3H), 1.68-1.69 (m, 1H), 1.83-1.87 (m, 2H), 1.97 (m, 1H), 2.12-2.17 (m, 3H), 2.48-2.52 (m, 1H), 2.64 (m, 31H), 3.00-3.07 (m, 3H), 3.27-3.31 (m, 2H), 3.42-3.43 (d, 3H), 3.65-3.70 (m, 3H), 4.01 (m, 1H), 4.11-4.13 (d, 1H₁), 4.28-4.30 (m, 1H), 4.37-4.40 (m, 1H), 4.53-4.57 (m, 1H), 5.40 (d, 2H), 9.25 (s, 1H), C25H37N9O6S, HPLC 90% Mass 592.2 (M+1)

Antibacterial Activity:

Compounds were evaluated for their antibacterial activity against Gram positive and Gram negative bacterial strains. These strains include methicillin-sensitive Staphylococcus aureus, carbapenem sensitive Escherichia coli, extended spectrum β lactamase (ESBL) SHV18 producing Klebsiella pneumoniae, carbapenemase producing K. pneumoniae, Enterobacter spp; Morganello spp; Citrobacter spp; Serratia spp; Acinetobacter and carbapenem sensitive Pseudomonas aeruginosa.

Experimental

Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC) of these compounds by broth micro-dilution method (CLSI guidelines, M7-A7/January 2006, M100-S18/January 2008) Two-fold serial dilutions of the test compounds in Mueller-Hinton broth were prepared in 96 well micro-titre plates. To these dilutions, equal amount of Mueller-Hinton broth containing bacterial suspensions were added to obtain a 5×10⁵ colony forming units per mL. MIC of the test compounds was determined after incubating micro-titre plates at 35° C. for 22 hours. The minimum concentration of the compound that inhibited visible growth of bacteria is defined as MIC.

Results:

MIC of test compounds is presented in table 1.

TABLE 1 MIC of test compounds Pheno type- Organism ESBL +ve Meropenem MSSA (SHV-18) KPC-2 ESBL −ve suscept1ble S. aureus K. pneumoniae K. pneumoniae E. coli P. aeruginosa ATCC29213 ATCC700603 ATCC BAA-1705 ATCC25922 ATCC27853 Example MIC DATA (μg/mL) 1  8-16 −0.5-1   −2-4  0.25-1   32-64 5 8 >128 >128 8 >128 7 2-8 2-4 2-4 0.5 32-64 9 8 >128 >128 128 >128 10 16 2 4 1 >128 11 8 64 32 4 >128 12 8 128 32 4 >128 13 4 8 4 1 64 14 4 4 4 0.5 128 15 2 16 16 1 128 16 4 64 16 4 >128 17 4 >128 32 16 128 18 8 64 8 4 32 19 1 8 >128 1 128 20 2 8 16 1 128 21 2 4  4-16 2 >128 22 2  64-128 32 8 >128 23 16 1 8 0.5  32-128 24 16 1 4 0.5 32-64 25 4 8 8 1 128 26 4 4-8 8 1 128 27 16 1 4 0.5  64-128 28 8 2 4-8 2 4-8 29 4 8 >128 1 128 30 2 8 8 1 128 31 16 16 4 4 >128 32 1 1 1 0.5 32 33 4 32 16 4 >128 34 4 8 8 1 128 35 1 4 2-4 1 >128 36 1 16 16 2 128 37 16 1 16 1 >128 38 0.25 1 2-4 1 32-64 39 16 16 16 4 16 40 4 8 4-8 1 >128 41 2 16 16 1 >128 42 2 1 8 1 128 43 2 4 8 1 64 44 32 4 8 4 16 45 1 4 16 1 4 46 1 4 8 1 16 47 2 128 64 2 >128 48 16 1 64 0.5 8 49 2 2 >128 1 >128 50 1  8-16 2-4 1-2 16-32 51 8 32 32 4 >128 52 1 128 >128 8 >128 54 1 >128 >128 8 >128 56 64 16 16 8 64 57 32 16 128 4 >128 58 32 >128 >128 16 >128 59 32 16 >128 2 32 60 32 32 64 16 >128 61 1 16 16 1 >128 63  8-16 16-32  8-16 1-2 >128 64 2 8 8 1-2 64 66 8 8 4-8 2 >128 67 4 >128 >128 8 >128 68 32 8 >128 4 32-64 70 16 8 16 4 >128 71 8 128 64 16 >128 72 32 >128 >128 32 >128 73 4 4 8 1-2  4-16 74  8-16 1-2 4 1-2 8 75 4 8 16 1 >128 76 2 8 8 1 >128 77 4-8 1 4 0.5-1   32-64 78 8 2 >128 1 128 79 4 >128 >128 32 >128 80 4 32 64 4 >128 81 1 8 8 1 64 82 8 2 8 1 128 83 2 >128 >128 64 >128 84 4 4 16 1 128 85 1 2 2 0.5 64 86 2 8 8 1 128 87 2 8 8 1 64 88 0.25 >128 >128 128 >128 89 0.5 8 4 0.5 128 90 1 32 4 1 128 91 16 32 32 4 >128 92 1 4 4 0.5 32 93 16 >128 >128 128 >128 94 0.25 >128 >128 64 >128 95 32 2 2 1 2 96 1 64 32 4 >128 97 1 128 64 8 >128 98 32 32 32 8 >128 99 128 16 64 64 16 100 16 8 4 1 32 101 2 1 4 0.5 64 102 2 8 8 2 64 103 0.5 4 8 0.5 8 104 4 1 4 0.5 128 105 8 8 8 1 128 106 4 4 4 1 4 107 4 4 4 1 16 108 2 4 16 1 128 109 8 4 16 4 4 110 4 2 4 0.5 32 111 4 16 16 1 >128 112 64 4 4 2 8 113 16 32 16 4 >128 114 8 2 4 0.5 >128 115 8 2 8 0.5 >128 116 8 2 4 0.5 >128 117 2 2 4 0.5 >128 118 4 2 8 0.5 64 119 2 1 8 0.5 16 120 2 4 4 0.5 4 121 1 4 4 0.5 8 122 1 4 4 1 16 123 2 2 4 0.5 64 124 2 4 4 1 4 125 2 32 16 2 128 126 2 8 8 2 16 127 2 8 16 2 32 128 16 8 8 4 64 129 32 32 8 4 8 130 2 8 4 1 32 131 4 2 8 0.5 16 132 2 4 4 1 4 133 4 4 8 1 8 134 2 4 4 1 16 135 2 4 4 1 8 136 >128 16 16 4 32 137 4 8 8 1 >128 138 32 32 64 4 >128 139 32 4 4 1 32 140 2 1 2 0.5 32 141 4-8 4-8 4-8 1 64 142 4-8 8 8 1 16-32 143 2 8 8 1 32-64 145 0.5  8-16 8 2 32 146 1-4 1-2 2 1 64 147 2 2 4-8 1  64-128 148 1-2 1 2-4 0.5 32-64 149 2 8 8 1 4 150 4 64 16 4 64 151 4 16 8 2 32 153 8 2 8 1 64 154 4 2 8 1 64 155 2 8 8 1 32 156 32 16 32 8 >128 157 2 8 4 1 4 158 2 4 4 1 8 159 2 4 4 1 8 160 4 8 8 1 16 161 0.5 8 4 0.5 8 162 1 4 4 0.5 16 163 1 4 4 1 8 164 1 1 4 0.25 32 165 64 4 2 2 32 166 64 8 8 4 32 167 2 4 4 4 32 168 16 2 2 1 2 169 8 16 2 1 4 170 2 4 8 1 32 171 2 128 128 4 >128 172 4 8 8 1 64 173 4 16 8 2 16 174 4 16 8 2 32 175 2 2 4 1 16 176 2 4 8 1 8 177 8 2 2 2 32 178 32 4 4 2 4 179 128 16 8 2 16 180 128 32 32 4 16 181 >128 >128 64 8 128 182 128 16 16 8 8 183 8 32 16 2 64 184 2 4 8 0.5 4 185 2 64 16 2 64 186 4 4 4 0.5 8 187 4 8 64 2 128 188 128 16 8 8 16 189 >128 32 8 4 16 190 64 16 4 2 4 191 64 32 8 8 32 192 64 2 2 1 4 193 64 8 4 4 8 194 8 8 16 2 16 195 2 1 4 0.5 8 196 2 4 8 1 32 197 16 16 16 4 32 198 2 1 4 0.25 32 199 32 4 2 1 4 200 128 8 4 2 4 201 16 16 64 2 16 202 64 64 16 4 8 203 16 1 4 0.5 128 204 32 >128 >128 8 >128 205 32 2 4 1 8 206 64 4 4 4 4 207 2 8 8 2 >128 208 64 8 8 4 >128 209 2 2 2 0.5 64 210 2 4 4 1 64 211 2 4 4 1 16 212 1 2 4 0.5 8 213 1 2 4 0.5 8 214 32 32 16 4 >128 215 8 32 8 2 >128 216 32 16 4 1 4 217 16 1 1 0.5 2 218 16 2 2 1 2 219 2 4 4 1 4 220 32 2 2 1 2 221 32 2 2 2 4 222 64 8 4 2 8 225 16 32 2 1 64 226 32 32 8 1 64 227 64 8 4 2 32 228 64 4 8 1 64 229 128 64 64 16 32 230 32 8 4 1 8 231 32 4 2 1 16 232 2 8 8 2 >128 233 4 4 4 1 >128 234 0.5 4 4 0.5 >128 235 2 — 16 2 >128 236 2 — 4 2 128 237 1 — 4 2 128 238 16 — NT 16 >128 241 16 — 2 2 32 242 16 — 2 2 8 243 32 — 32 16 >128 244 1 — 4 1 64 245 8 — 4 2 4 246 32 — 128 8 >128 247 32 — 32 4 >128 248 1 — 4 1 >128 251 0.5 — 0.5 0.25 32 252 16 — 4 2 16 253 32 — 16 16 16 254 64 — 16 8 128 255 8 — 8 4 32 256 4 — 2 1 32 257 >128 — 16 4 128 258 1 — 16 4 128 259 2 — 16 4 >128 260 1 — 8 4 32 261 2 — 16 2 64 262 32 — 16 4 64 263 0.25 — 2 0.25 128 264 16 — 4 2 8 265 2 — 8 2 >128 266 64 — 8 2 128 267 0.5 — 2 1 >128 268 8 — 4 2 32 269 16 — 4 4 128 270 4 — 4 1 64 271 2 — 4 1 8 272 128 — 64 64 >128 273 128 — 32 16 128 274 32 — 16 16 >128 275 64 — 64 16 >128 276 32 — 4 2 8 277 64 — 4 2 16 278 16 — 2 2 4 279 >128 — 16 4 >128 280 64 — 8 8 16 281 32 — 16 8 64 282 32 — 2 1 32 283 16 — 0.5 0.25 8 284 1 — 4 1 64 285 64 — 8 4 128 287 128 — 8 4 16 288 128 — 16 4 >128 289 8 — 16 8 >128 290 32 — 4 2 8 291 32 — 2 2 8 292 128 — 8 4 16 293 128 — 128 32 >128 294 1 — 1 0.06 16 295 16 — 16 2 64 296 4 — 2 0.5 64 297 16 — 2 1 4 298 1 — 1 0.125 1 299 16 — 8 4 16 300 16 — 4 1 128 301 16 — 64 4 >128 302 2 — 16 1 128 303 2 — 64 4 >128 304 8 — 4 1 >128 305 2 — 1 0.25 8 306 2 — 1 0.25 4 307 1 — 4 0.25 128 309 16 — 4 1 32 310 32 — 4 1 64 311 32 — 32 8 >128 312 16 — 4 1 64 313 4 — 16 1 >128 314 4 — 2 0.25 4 315 4 — 2 0.125 64 316 4 — 16 0.25 16 317 2 — 8 0.5 128 318 16 — 128 2 >128 319 2 — 1 0.25 32 320 2 — 4 1 128 321 2 — 8 1 >128 322 16 — 16 2 >128 323 16 — 8 2 >128 324 4 — 4 0.5 4 325 8 — 64 4 >128 326 2 — 16 1 64 327 1 — 32 2 64 328 4 — 4 2 32 329 8 — 2 0.25 8 330 8 — 2 0.25 64 331 4 — 4 0.25 8 332 8 — 4 1 8 333 8 — 4 0.5 4 334 4 — 32 0.5 128 335 4 — 64 1 >128 336 4 — 4 1 8 337 2 — 1 0.5 32 338 8 — 32 2 128 339 8 — 32 1 32 340 8 — 4 1 4 341 4 — 4 1 8 342 16 — 8 2 8 343 16 — 8 2 8 344 16 — 16 1 16 345 64 — 32 8 128 346 16 — 8 1 16 347 4 — 16 0.5 >128 348 8 — 16 1 >128 349 4 — 4 0.25 32 350 2 — 1 0.25 128 351 16 — 4 1 >128 352 4 — 2 0.25 2 353 16 — 2 0.25 16 354 2 — 1 0.125 32 355 4 — 16 1 128 356 4 — 16 1 >128 357 2 — 32 1 >128 358 1 — 32 1 >128 359 8 — 2 0.5 16 360 8 — 2 0.5 1 361 8 4 2 1 2 362 8 4 4 0.25 4 363 4 2 0.25 1 364 4 2 0.25 1 365 4 2 0.25 2 366 4 2 0.25 2 367 2 2 0.25 1 368 2 2 0.25 1 369 2 — 8 0.25 16 370 8 — 64 4 >128 371 16 — 4 1 64 372 4 — 8 0.5 64 373 4 — >128 32 >128 374 8 — >128 32 >128 375 16 — 8 2 4 376 8 — 16 0.25 >128 377 4 — 2 0.25 8 378 4 — 2 0.25 128 379 16 — 16 0.5 >128 380 32 — 8 1 32 381 16 — 4 1 >128 382 16 — 4 1 128 383 4 — 4 0.25 >128 384 4 — 4 0.5 64 385 4 — 2 0.25 64 386 2 — 8 0.125 8 387 8 — 8 0.25 32 388 8 — 8 2 >128 389 8 — 4 1 >128 390 4 — 16 1 128 391 1 — 0.5 0.5 4 392 4 — 4 1 64 393 4 — 1 0.125 8 394 8 — 32 2 128 395 2 — 1 0.125 1 396 4 — 1 0.125 4 397 2 — 1 0.25 2 398 4 — 1 0.25 2 399 2 — 2 0.125 8 400 4 — 1 0.125 1 401 8 — 2 0.5 2 402 1 — 1 0.06 32 403 4 — 8 0.5 16 404 1 — 0.5 0.25 1 405 4 — 2 0.125 4 406 4 — 2 0.25 16 407 2 — 1 0.5 8 408 4 — 2 1 2 409 4 — 2 1 4 410 2 — 4 0.5 4 411 2 — 1 0.25 1 412 2 — 2 0.25 1 413 2 — 2 0.25 2 414 4 — 2 0.5 4 415 4 — 1 2 16 416 4 — 2 0.5 8 417 8 — 2 0.5 16 418 8 — 4 1 8 419 4 — 1 0.25 1 420 4 — 1 0.25 2 421 4 — 2 0.125 32 422 4 — 2 0.25 4 423 8 — 2 0.5 32 424 16 — 2 0.25 16 425 4 — 2 0.25 2 426 4 — 1 0.25 2 427 2 — 1 0.25 2 428 4 — 4 0.5 2 429 4 — 2 0.25 2 430 4 — 2 0.5 4 431 2 — 0.5 0.25 1 432 2 — 1 0.25 1 433 2 — 1 0.25 1 434 2 — 2 0.5 2 435 2 — 1 0.25 1 436 8 — 1 0.25 8 437 2 — 1 0.25 2 438 2 — 1 0.25 2 439 2 — 1 0.25 1 440 2 — 1 0.25 1 441 4 — 2 0.25 8 442 2 — 1 0.125 0.5 443 4 — 2 0.5 1 444 2 — 2 0.5 2 445 2 — 1 0.25 1 446 2 — 1 0.25 4 447 16 — 4 0.5 16 448 4 — 8 0.5 >128 449 4 — 4 0.5 64 450 8 — 1 0.25 1 451 8 — 1 0.25 2 452 2 — 1 0.25 2 453 16 — 2 0.125 8 454 8 — 4 0.5 4 455 4 — 2 0.5 4 456 2 — 2 0.5 2 457 2 — 1 0.25 1 458 16 — 1 0.5 16 459 1 — 1 0.125 2 460 4 — 2 0.5 4 461 4 — 2 0.5 4 462 4 — 1 0.25 2 463 4 — 1 0.5 2 464 4 — 4 1 16 465 4 — 2 0.5 16 466 4 — 2 0.5 4 467 8 — 2 1 8 468 4 — 2 0.5 8 469 4 — 2 0.5 4 470 4 — 2 0.5 4 471 2 — 2 0.5 4 472 4 — 2 0.5 2 473 4 — 2 0.5 4 474 4 — 2 0.25 2 475 4 — 2 0.5 2 476 2 — 2 1 32 477 2 — 2 0.5 64 478 8 — 1 0.125 8 479 8 — 2 0.25 16 480 2 — 1 0.25 2 481 2 — 2 0.125 2 482 4 — 4 0.25 4 483 4 — 4 0.5 128 484 2 — 4 1 32 485 8 — 4 0.5 4 486 2 — 8 0.5 64 487 2 — 1 0.25 8 488 4 — 1 0.25 2 489 4 — 1 0.5 16 490 32 — 2 2 32 491 4 — 2 0.25 8 492 4 — 2 0.5 2 493 2 — 1 0.125 0.5 494 8 — 4 0.25 16 495 2 — 1 0.25 1 496 2 — 2 0.25 2 497 4 — 2 0.25 4 498 2 — 2 0.125 8 499 2 — 1 0.25 1 500 2 — 2 0.25 2 501 4 — 1 0.25 1 502 4 — 1 0.25 2 503 2 — 1 0.5 16 504 2 — 4 0.5 32 505 2 — 1 0.25 1 506 4 — 1 0.25 1 507 2 — 8 1 64 508 16 — 8 2 128 509 32 — 4 4 32 510 4 — 4 0.25 1 511 4 — 2 0.25 1 512 8 — 64 2 >128 513 4 — 1 0.25 16 514 16 — 16 0.5 32 515 2 — 1 0.25 16 516 2 — 2 0.25 2 517 4 — 2 0.5 4 518 8 — 4 1 128 519 16 — 16 2 >128 520 16 — 16 2 >128 521 2 — 0.5 0.5 2 522 4 — 2 0.25 1 523 2 — 1 0.125 1 524 4 — 2 0.25 1 525 4 — 2 0.25 0.5 526 4 — 2 0.25 1 527 4 — 1 0.125 1 528 4 — 1 0.25 1 529 4 — 2 0.25 1 530 2 — 1 0.25 0.5 531 4 — 2 0.125 1 532 4 — 2 0.25 2 533 4 — 2 0.25 2 534 2 — 1 0.125 1 535 2 — 2 0.25 1 536 2 — 2 0.25 4 537 4 — 2 0.25 2 538 4 — 2 0.25 1 539 4 — 1 0.25 2 540 4 — 2 0.25 1 541 2 — 1 0.25 1 542 4 — 2 0.25 2 543 2 — 1 0.5 2 544 1 — 0.5 0.25 1 545 1 — 0.5 0.125 1 546 1 — 1 0.25 2 547 4 — 2 0.5 2 548 8 — 1 0.25 4 549 4 — 1 0.125 1 550 1 — 2 0.25 8 551 4 — 2 0.25 2 552 4 — 2 0.25 2 553 2 — 1 0.25 2 554 4 — 2 0.5 2 555 4 — 1 0.25 2 556 2 — 1 0.125 4 557 4 — 4 0.125 16 558 16 — 2 0.5 128 559 1 — 1 0.25 4 560 1 — 0.5 0.125 1 561 4 — 2 0.5 8 562 16 — 2 0.5 2 563 16 — 2 0.25 2 564 2 — 1 0.125 1 565 2 — 2 0.25 1 566 0.5 — 0.5 0.06 0.25 567 1 — 0.5 0.125 1 568 16 — 2 1 4 569 2 — 1 0.25 2 570 1 — 1 0.125 2 571 1 — 0.5 0.06 1 572 4 — 2 0.25 4 573 4 — 2 0.125 1 574 8 — 4 0.5 2 575 16 — 0.5 0.125 >128 576 1 — 0.5 0.125 0.25 577 4 — 2 0.25 4 578 2 — 1 0.25 4 579 4 — 1 0.25 16 580 2 — 1 0.25 0.5 581 8 — 8 0.5 64 582 2 — 2 0.25 0.5 583 1 — 1 0.03 0.5 584 2 — 1 0.25 1 585 2 — 1 0.125 4 586 4 — 1 0.25 2 587 4 — 2 0.25 2 588 32 — 4 4 4 589 4 — 2 0.5 16 590 4 — 1 0.25 1 591 2 — 1 0.25 1 592 2 — 0.5 0.125 0.5 593 16 — 32 1 128 594 1 — >128 32 >128 595 8 — >128 4 >128 596 2 — 16 1 32 597 4 — 32 4 32 598 8 — 2 1 16 599 4 — 2 1 4 600 0.5 — 4 0.5 16 601 2 — 64 2 128 

We claim:
 1. A compound of formula (I)

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof: wherein: A represents —NR⁰R or —OR^(z); Z represents —H or —CH₃; X represents —S— or —CH₂—; R^(z) represents isoxazolyl; R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy; R is: 1) —(CH₂)_(n)C(═O)R², 2) —(CH₂)_(n)C(═S)R², 3) —(CH₂)_(n)SO₂R², 4) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or 5) —CH(═NH), or R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S; n is an integer selected from 0, 1, 2, 3, 4, 5 and 6; R¹ is: 1) —(CH₂)₀₋₆-AryC, 2) —(CH₂)₀₋₆-HetC, 3) —(CH₂)₁₋₆NH(C═NH)NH₂, or 4) C₂₋₆aminoalkyl optionally substituted with a) —C(═O)C₁₋₆alkoxy, b) —C(═O)-pyrrolidinyl substituted with —NR^(x)R^(y), c) —CR^(x)═NR^(x), or d) —COO-phenyl; R² is: 1) H, 2) C₁₋₆alkyl optionally substituted with 1, 2 or 3 substitutents independently selected from halogen, —OH, —CN, C₃₋₈cycloalkyl, —(CH₂)₀₋₁C(═O)NR^(x)R^(y), —NR^(a)R^(b), C₁₋₆alkoxy, —OC(═O)C₁₋₆alkyl, —P(═O)(C₁₋₆alkoxy)₂, —COOH, —COOC₁₋₆alkyl, —SO₂C₁₋₆alkyl, —S(═O)C₁₋₆haloalkyl, —SCHF₂, Het A, AryA, —S-AryA; azetidine and azetidinone optionally substituted with C₁₋₆hydroxyalkyl, 3) C₃₋₈cycloalkyl substituted with C₁₋₆ haloalkyl or —NR^(x)R^(y), 4) —(CH₂)₀₋₃—CR^(k) ═NOC₁₋₆alkyl optionally substituted with —COOR^(x), 5) —C(═O)NR^(x)R^(y), 6) —C(═O)C₁₋₆alkoxy, 7) —NR^(x)R^(y), 8) —OH, 9) —COOH, 10) C₁₋₆alkoxy, 11) C₁₋₆haloalkyl, 12) C₁₋₆haloalkoxy, 13) AryA, or 14) HetA; R⁴ is —COO⁻ or —COOR⁵; R⁵ is hydrogen, a carboxylic acid protecting group or an ester prodrug moiety; AryA is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, or 2) a substituted or unsubstituted 9- or 10-membered bicyclic aromatic ring with 1, 2, 3, 4, 5 or 6 heteroatom ring atoms independently selected from N, O and S; HetA is a substituted or unsubstituted 5- to 10-membered saturated ring with 1, 2, 3 or 4 heteroatom-ring atoms independently selected from N, O and S, wherein any S atom in the ring is optionally oxidized; AryC is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms independently selected from N, O and S, wherein the N atom is optionally quaternized with —CH₃, or 2) a substituted or unsubstituted 7- to 10-membered bicyclic aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms selected from N, S, and O; HetC is a substituted or unsubstituted 4- to 8-membered saturated ring with 1 or 2 heteroatom ring atoms selected from N, O or S; R^(a) is hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, —CR^(x)(═NR^(x)), —C(═NR^(x))N(R^(x))₂, —CH₂C(═O)N(R^(x))₂, —(CH₂)₁₋₆ OR^(x) or —SO₂C₁₋₆alkyl; R^(b) is hydrogen or C₁₋₃alkyl; R^(c) is 1) H, 2) —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j), —CN or —OH, 3) —(CH₂)₁₋₃C(═O)NR^(x)R^(y), 4) —(CH₂)₁₋₃C(═O)NHCH₂CH₂OH, 5) —(CH₂)₁₋₃C(═O)NHOCH₃, 6) —(CH₂)₁₋₃C(═O)NHOBn, 7) —C₁₋₆alkoxy, 8) pyridinyl; 9) —(CH₂)₁₋₃-pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y), 10) tetrahydro-2H-pyran-4-yl, 11) —(CH₂)₁₋₃C(═O)-diazepanyl, 12) —(CH₂)₁₋₃ C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y), 13) —C(═NH)-pyrrolidin-1-yl optionally substituted with NR^(x)R^(y), 14) —(CH₂)₁₋₃-pyranyl optionally substituted with 1 or 2 substituents selected from oxo and methoxy, 15) —(CH₂)₁₋₃-pyridinyl optionally substituted with one or more groups selected from —CH₃, —OH, and oxo, 16) -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y), 17) -phenyl-C(═O)-piperazinyl, or 18) -phenyl-(CH₂)₁₋₃—NR^(x)R^(y); R^(d) is hydrogen, C₁₋₃alkyl, C₁₋₃hydroxyalkyl or C₁₋₃cyanoalkyl, or R^(c) and R^(d) are taken together, with the N to which they are attached, to form a substituted or unsubstituted 4- to 12-membered heterocyclic ring or ring system with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S, Wherein the rings in the heterocyclic ring system can be bridged, fused, spiro-linked or any combination of two thereof; wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; and wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from 1) —(CH₂)₀₋₃halogen, 2) oxo, 3) ═NH, 4) —(CH₂)₀₋₃OH, 5) —C₁₋₆alkyl optionally substituted with halogen, —CN and —OH, 6) —OC₁₋₆alkyl, 7) —CH₂CH(OH)CH₂NH₂, 8) —CH₂CH(F)CH₂NH₂, 9) —C(═O)OH, 10) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with 1 or 2 of —CH₃, —NH₂ or halogen, 11) —NHCH₂CN, 12) —NHCH═NH, 13) —NHC(═O)R^(i), 14) —NHC(═O)CH₂NHC(═NH)NH₂, 15) —C(═NH)NH₂, 16) —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH, 17) —(CH₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j) optionally substituted with —NH₂ or —OH, 18) —(CH₂)₀₋₂C(═O)CH(NH₂)(CH₂)₀₋₂OH, 19) —C(═O)NH(CH₂)₁₋₃NH₂ optionally substituted with —OH, 20) —C(═O)(CH₂)₁₋₃NH₂ optionally substituted with —NH₂, 21) —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂, 22) —(CH₂)₀₋₁NHCH₂CH₂NR^(h)R^(j), 23) —(CH₂)₀₋₃NHC(═NH)NH₂, 24) —(CH₂)₀₋₁NH(CH₂)₀₋₁C(═O)(CH₂)₀₋₁NR^(h)R^(j), 25) —(CH₂)₀₋₁NHSO₂(CH₂)₀₋₂NR^(h)R^(j), 26) —(CH₂)₀₋₂NHSO₂CH₃, 27) —ONH₂, 28) —ONHC(═O)CH₂NHCH₃, 29) —C(═O)NH-pyridinyl, 30) —C(═O)-diazepinyl optionally substituted with —C(═N)NH₂, 31) —C(═O)-piperazinyl, 32) —(CH₂)₀₋₁C(═O)-pyrrolidinyl optionally substituted with —NH₂, 33) —NHCH₂-pyridinyl optionally substituted with one or more groups selected from oxo, —CH₃ and —OH, 34) —NH-pyrimidinyl, 35) —(CH₂)₀₋₁-phenyl, 36) —(CH₂)₀₋₂-piperazinyl, 37) —(CH₂)₀₋₂azetidinyl optionally substituted with —CH₂NH₂, —NH₂, or —OH, 38) —(CH₂)₀₋₂pyrrolidinyl optionally substituted with —NH₂, 39) —(CH₂)₀₋₂triazolyl optionally substituted with —CH₂NH₂, and 40) —(CH₂)₀₋₂tetrazolyl; R^(f) is H, —C(═O)N(C₁₋₆alkyl)₂, —SO₂C₁₋₆alkyl, —SO₂N(R^(x))₂, —C(═O)-cyclopentyl-N(R^(x))₂, —C(═O)-pyridinyl optionally substituted with one or more groups selected from oxo, —C₁₋₃alkyl and —OH, —C(═O)-pyrrolidinyl substituted with —NR^(a)R^(b) or halogen, —C(═O)-thiazolidinyl, —SO₂-piperazine, or SO₂-pyrrolidinyl-N(R^(x))₂; R^(g) is hydrogen or C₁₋₃alkyl, or R^(f) and R^(g) are taken together, with the N to which they are attached, to form morpholinyl; piperazinyl; pyrrolidinyl optionally substituted with —CH₃; piperidinyl or thiomorpholinyl optionally substituted with —C₁₋₆alkyl or —N(R^(x))₂; or triazolyl substituted with —CH₂NH₂; R^(h) and R^(j) is independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl; R^(i) is —C₁₋₅ amino alkyl, —OC₁₋₆alkyl, —C₁₋₃cyanoalkyl, or —C₁₋₆haloalkyl optionally substituted with —NR^(x)R^(y); R^(k) is C₁₋₆alkyl, or thiazole substituted with —NH₂; each R^(x) and R^(y) is independently hydrogen or C₁₋₃alkyl; and wherein when HetA, AryA, AryC, HetC, or the rings formed by combining R and R⁰ are substituted, the substituents are 1 to 4 members selected from 1) halogen, 2) —OH, 3) oxo, 4) —COOH, 5) —COOC₁₋₆alkyl, 6) C₁₋₆alkyl, 7) C₁₋₆alkoxy, 8) —(CH₂)₀₋₃—C₁₋₃alkyl, 9) C₁₋₆haloalkyl, 10) C₁₋₆hydroxyalkyl, 11) C₃-C₈cycloalkyl, 12) —C(═O)C₁₋₆alkyl, 13) —C(═O)C₁₋₆aminoalkyl, 14) —C(═O)NR^(c)R^(d); 15) —(CH₂)₀₋₁NR^(x)R^(y), 16) —(CH₂)₀₋₃NR^(f)R^(g), 17) —(CH₂)₁₋₃—C(═O)NR^(x)R^(y), 18) —NHCH₂CN, 19) —NHC(═O)R^(i), 20) —(CH₂)₀₋₁NHSO₂NR^(x)R^(y), 21) —SO₂NR^(c)R^(d), 22) —CH═NH, 23) —(CH₂)₀₋₃C(═NH)NH₂, 24) —(CH₂)₀₋₃NHC(═NH)NH₂, 25) —(CH₂)₀₋₂-thienyl, 26) —(CH₂)₀₋₂-tetrazolyl, 27) —(CH₂)₀₋₂-thiazolyl, 28) —(CH₂)₀₋₂-pyridinyl optionally substituted with —CH₃ or quaternized with —CH₃ or CH₂CONH₂, 29) —(CH₂)₀₋₂-triazolyl, 30) —(CH₂)₀₋₂-piperidinyl optionally substituted with —CH₃ or quaternized with —CH₃ or —(CH₂)₀₋₃NH₂, 31) —(CH₂)₀₋₂-pyrazolyl optionally substituted with one or more of —(CH₂)₀₋₃NH₂ and further optionally quaternized with —CH₃, 32) —(CH₂)₁₋₃—C(═O)-pyrolidinyl optionally substituted with —NR^(x)R^(y), 33) —(CH₂)₀₋₂-pyrolidinyl optionally substituted with —NR^(x)R^(y), 34) —C(═NH)-pyrolidinyl optionally substituted with —NR^(x)R^(y), and 35) 4,5-dihydrothiazol-2-yl.
 2. The compound of claim 1 of formula (Ib)

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof: wherein: A represents —NR⁰R or —OR^(z); R^(z) represents isoxazolyl; R⁰ is hydrogen or C₁₋₆alkyl which is optionally substituted with one or two substituents selected from halogen, hydroxyl, cyano, carbamoyl, —SO₂NH₂ and C₁₋₆alkoxy; R is: 1) —(CH₂)_(n)C(═O)R², 2) —(CH₂)_(n)C(═S)R², 3) —(CH₂)_(n)SO₂R², 4) —C₁₋₆alkyl optionally substituted with —C₃₋₆cycloalkyl, or 5) —CH(═NH), or R and R⁰ together with the N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S; n is an integer selected from 0, 1, 2, 3, 4, 5 and 6; R¹ is: 1) —(CH₂)₀₋₆-AryC, 2) —(CH₂)₀₋₆-HetC, or 3) C₂₋₆aminoalkyl optionally substituted with a) —C(═O) C₁₋₆alkoxy, b) —C(═O)-pyrrolidinyl substituted with —NR^(x)R^(y), c) —CR^(x)═NR^(x), or d) —COO-phenyl; R² is: 1) H, 2) C₁₋₆alkyl optionally substituted with 1, 2 or 3 substitutents independently selected from halogen, —OH, —CN, C₃₋₈cycloalkyl, —(CH₂)₀₋₁C(═O)NR^(x)R^(y), —NR^(a)R^(b), C₁₋₆alkoxy, —OC(═O)C₁₋₆alkyl, —P(═O)(C₁₋₆alkoxy)₂, —COOH, —COOC₁₋₆alkyl, —SO₂C₁₋₆alkyl, —S(═O)C₁₋₆haloalkyl, AryA, —S-AryA and azetidinone optionally substituted with C₁₋₆hydroxyalkyl, 3) C₃₋₈ cycloalkyl substituted with C₁₋₆haloalkyl or —NR^(x)R^(y), 4) —CR^(k)═NOC₁₋₆alkyl optionally substituted with —COOR^(x), 5) —C(═O)NR^(x)R^(y), 6) —C(═O)C₁₋₆alkoxy, 7) —NR^(x)R^(y), 8) —OH, 9) —COOH, 10) C₁₋₆alkoxy, 11) C₁₋₆haloalkyl, 12) C₁₋₆haloalkoxy, 13) AryA, or 14) HetA; R⁴ is —COO⁻, or —COOR⁵; R⁵ is hydrogen, a carboxylic acid protecting group or an ester prodrug moiety; AryA is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, or 2) a substituted or unsubstituted 9- or 10-membered bicyclic aromatic ring with 1, 2, 3, 4, 5 or 6 heteroatom ring atoms independently selected from N, O and S; HetA is a substituted or unsubstituted 5- to 10-membered saturated ring with 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, wherein any S atom in the ring is optionally oxidized; AryC is 1) a substituted or unsubstituted 5- or 6-membered aromatic ring with 1, 2 or 3 heteroatom ring atoms independently selected from N, O and S, or 2) a substituted or unsubstituted 7- to 10-membered bicyclic aromatic ring with 0, 1, 2 or 3 heteroatom ring atoms selected from N, S, and O; HetC is a substituted or unsubstituted 4- to 6-membered saturated ring with 1 or 2 heteroatom ring atoms selected from N, O or S; R^(a) is hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, —CR^(x)(═NR^(x)), —C(═NR^(x))N(R^(x))₂, —CH₂C(═O)N(R^(x))₂, or —SO₂C₁₋₆alkyl; R^(b) is hydrogen, or C₁₋₃alkyl; R^(c) is 1) H, 2) —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j), —CN or —OH; —(CH₂)₁₋₃C(═O)NR^(x)R^(y), 3) —(CH₂)₁₋₃C(═O)NHCH₂CH₂OH, 4) —(CH₂)₁₋₃C(═O)NHOCH₃, —(CH₂)₁₋₃C(═O)NHOBn, 5) —C₁₋₆alkoxy, pyridinyl, 6) pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y), 7) tetrahydro-2H-pyran-4-yl, 8) —(CH₂)₁₋₃C(═O)-diazepanyl, —(CH₂)₁₋₃C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y), 9) —(CH₂)₁₋₃-pyranyl optionally substituted with 1 or 2 substituents selected from oxo and methoxy, —(CH₂)₁₋₃-pyridinyl optionally substituted with one or more groups selected from —CH₃, —OH, and oxo, or 10) -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y); R^(d) is hydrogen, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, or C₁₋₃ cyanoalkyl, or R^(c) and R^(d) are taken together, with the N to which they are attached, to form a substituted or unsubstituted 4- to 12-membered heterocyclic ring or ring system with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S; wherein the rings in the heterocyclic ring system can be bridged, fused, spiro-linked or any combination of two thereof; wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; and wherein the heterocyclic ring or ring system is optionally substituted with 1, 2, 3 or 4 substituents independently selected from 1) halogen, 2) oxo, 3) —OH, 4) —C₁₋₆alkyl optionally substituted with —OH, halogen, or cyano, 5) —CH₂CH(OH)CH₂NH₂, 6) —C(═O)OH, 7) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or halogen, 8) —NHCH₂CN, 9) —NHCH═NH, 10) —NHC(═O)R^(i), 11) —NHC(═O)CH₂NHC(═NH)NH₂, 12) —C(═N)N H₂, 13) —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH, 14) —(CH₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j), 15) —(CH₂)₀₋₂C(═O)CH(NH₂)(CH₂)₀₋₂OH, 16) —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂, 17) —(CH₂)₀₋₁NHCH₂CH₂NR^(h)R^(j), 18) —(CH₂)₀₋₃NHC(═NH)NH₂, 19) —(CH₂)₀₋₁NH(CH₂)₀₋₁ C(═O)(CH₂)₀₋₁NR^(h)R^(j), 20) —(CH₂)₀₋₁ NHSO₂(CH₂)₀₋₂NR^(h)R^(j), 21) —(CH₂)₀₋₂NHSO₂CH₃, 22) —ONH₂, 23) —ONHC(═O)CH₂NHCH₃, 24) —C(═O)NH-pyridinyl, 25) —C(═O)-piperazinyl, 26) —C(═O)-pyrrolidinyl optionally substituted with —NH₂, 27) —NHCH₂-pyridinyl optionally substituted with one or more groups selected from —CH₃, —OH, and oxo, 28) —NH-pyrimidinyl, 29) —(CH₂)₀₋₁-phenyl, 30) —(CH₂)₀₋₂-piperazinyl, 31) —(CH₂)₀₋₂azetidinyl optionally substituted with —NH₂, —CH₂NH₂, or —OH, 32) —(CH₂)₀₋₂pyrrolidinyl optionally substituted with —NH₂, 33) —(CH₂)₀₋₂triazolyl optionally substituted with —CH₂NH₂, and 34) —(CH₂)₀₋₂tetrazolyl; R^(f) is 1) H, 2) —C(═O)N(C₁₋₆alkyl)₂, 3) —SO₂C₁₋₆alkyl, 4) —SO₂N(R^(x))₂, 5) —C(═O)-cyclopentyl-N(R^(x))₂, 6) —C(═O)-pyridinyl optionally substituted with one or more groups selected from oxo, —C₁₋₃alkyl and —OH, 7) —C(═O)-pyrrolidinyl substituted with —NR^(a)R^(b) or halogen, 8) —C(═O)-thiazolidinyl; —SO₂-piperazine, or 9) —SO₂-pyrrolidinyl-N(R^(x))₂; R^(g) is hydrogen, or C₁₋₃alkyl; or R^(f) and R^(g) are taken together, with the N to which they are attached, to form morpholinyl; piperazinyl; pyrrolidinyl optionally substituted with —CH₃; piperidinyl or thiomorpholinyl optionally substituted with —C₁₋₆alkyl, or —N(R^(x))₂, or triazolyl substituted with —CH₂NH₂; R^(h) and R^(j) is independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl; R^(i) is —C₁₋₅ amino alkyl, —OC₁₋₆alkyl, —C₁₋₃cyanoalkyl, or —C₁₋₆haloalkyl optionally substituted with —NR^(x)R^(y); R^(k) is C₁₋₆alkyl, or thiazole substituted with —NH₂; each R^(x) and R^(y) is independently hydrogen, or C₁₋₃alkyl; wherein when HetA, AryA, AryC, HetC or the rings formed by combining R and R⁰ are substituted, the substituents are 1 to 4 members selected from 1) halogen; 2) —OH; 3) oxo; 4) —COOH; 5) —COOC₁₋₆alkyl; 6) C₁₋₆alkyl optionally substituted with —NR^(f)R^(g); 7) C₁₋₆alkoxy; 8) —(CH₂)₀₋₃O—C₁₋₃alkyl; 9) C₁₋₆haloalkyl; 10) C₁₋₆hydroxyalkyl; 11) C₃-C₈cycloalkyl; 12) —C(═O)C₁₋₆alkyl; 13) —C(═O)C₁₋₆aminoalkyl; 14) —C(═O)NR^(c)R^(d); 15) —(CH₂)₀₋₃NR^(f)R^(g); 16) —NHCH₂CN; 17) —NHC(═O)R^(i); —(CH₂)₀₋₁NHSO₂NR^(x)R^(y); 18) SO₂NR^(c)R^(d); —CH═NH; 19) —(CH₂)₀₋₂-thienyl; 20) —(CH₂)₀₋₂tetrazolyl; 21) —(CH₂)₀₋₂-thiazolyl; —(CH₄)₀₋₂-pyridinyl optionally substituted with —CH₃ or quaternized with —CH₃; 22) —(CH₂)₀₋₂-triazolyl; and 23) 4,5-dihydrothiazol-2-yl.
 3. The compound of claims 1 or 2, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein A represents —NR⁰R.
 4. The compound of claims 1, 2 or 3, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R⁰ is hydrogen, or methyl; R is 1) —(CH₂)_(n)C(═O)R², or 2) —(CH₂)_(n)SO₂R², or R and R⁰ together with the N to which they are attached form 1) [1,2,3-]triazolyl substituted with C₁₋₆alkyl, wherein the C₁₋₆alkyl is substituted with halo, —NR^(a)R^(b), —OH, or C₁₋₃alkoxy, or 2) tetrazolyl optionally substituted with —NR^(a)R^(b).
 5. The compound of any one of claims 1 to 4, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein n is 0 or
 1. 6. The compound of claim 5, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein n is
 0. 7. The compound of any one of claims 1 to 6, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is: —(CH₂)₀₋₂-AryC, or —(CH₂)₀₋₁-HetC.
 8. The compound of any one of claims 1 to 7, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein AryA is 1) a 5- to 6-membered aromatic ring with 0, 1, 2, 3 or 4 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, —(CH₂)₀₋₁NR^(x)R^(y), C₃-C₈cycloalkyl, —COOH, —COOC₁₋₆ alkyl, C₁₋₆alkoxy, thienyl, and tetrazolyl, or 2) a 9- to 10-membered bicyclic aromatic ring with 1 to 6 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents selected from halogen, C₁₋₆alkyl, and C₁₋₆haloalkyl; HetA is a 5- to 10-membered saturated ring with 1 or 2 heteroatom ring atoms independently selected from N, O and S, optionally substituted with 1 or 2 substituents independently selected from halogen, —NR^(x)R^(y), —CH₂NR^(x)R^(y), —OH, and oxo; AryC is 1) a 5- or 6-membered aromatic ring with 0, 1 or 2 heteroatom ring atoms independently selected from N and S, optionally quaternized with CH₃ and optionally substituted 1 to 3 substituents independently selected from —CH₂NR^(x)R^(y), —CH₂-pyrrolidinyl, —OH, oxo, pyridinyl which is optionally quaternized with methyl or —CH₂CONH₂, or 2) a 7- to 10-membered bicyclic aromatic ring With 3 heteroatom ring atoms selected from N; and HetC is a 4- to 8-membered saturated ring with 1 or 2 N or O ring atoms, optionally substituted with 1 or 2 substituents independently selected from halogen, —OH, —C₁₋₆alkyl, —(CH₂)₀₋₃NR^(f)R^(g), —CH═NH, —C(═O)C₁₋₆alkyl, —C(═NH) —NH₂, —CH₂—(C═O)-pyrrolidinyl optionally substituted with —NR^(x)R^(y), —NH—C(═NH) —NH₂, —CH₂—NH—C(═NH) —NH₂, —C(═O)C₁₋₆aminoalkyl, —C(═O)NR^(c)R^(d), —NR^(x)R^(y), —NHSO₂NR^(x)R^(y), —SO₂NR^(c)R^(d), thiazolyl, and 4,5-dihydrothiazol-2-yl.
 9. The compound of any one of claims 1 to 8, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R^(c) is 1) H, 2) —CH₂CN, 3) —C₁₋₆alkyl optionally substituted with —NR^(h)R^(j), pyrrolidinyl or —OH, 4) —CH₂CH₂C(═O)NR^(x)R^(y), 5) —CH₂CH₂C(═O)NHCH₂CH₂OH, 6) —CH₂CH₂C(═O)NHOCH₃, 7) —CH₂CH₂C(═O)NHOBn, 8) —C₁₋₆alkoxy, 9) pyridinyl, 10) pyrrolidinyl optionally substituted with —C(═O)NR^(x)R^(y), 11) —C(═NH)-pyrrolidin-1-yl optionally substituted with NR^(x)R^(y), 12) tetrahydro-2H-pyran-4-yl, 13) —CH₂CH₂C(═O)-diazepanyl, 14) —CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NR^(x)R^(y), 15) —CH₂-pyranyl optionally substituted with 1 or 2 substituents selected from oxo and methoxy, 16) —CH₂-pyridinyl optionally substituted with —CH₃, —OH, and oxo, 17) -phenyl-C(═O)-piperazinyl, 18) -phenyl-CH₂—NR^(x)R^(y), or 19) -phenyl-C(═O)-pyrrolidinyl-NR^(x)R^(y); R^(d) is hydrogen, or C₁₋₃alkyl; or R^(c) and R^(d) are taken together, with the N to which they are attached, to form a) a 4- to 8-membered heterocyclic ring with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S, or b) a 6- to 12-membered heterocyclic bi- or tricyclic ring with 0, 1, or 2 additional heteroatom ring atoms independently selected from N, O, and S, wherein the bicyclic ring is optionally bridged, fused, spirocyclic or any combination of two thereof, and wherein any nitrogen ring atom of the heterocyclic ring or heterocyclic bicyclic ring is optionally quadricovalent; and wherein the heterocyclic ring or heterocyclic bicyclic ring is optionally substituted with 1, 2 or 3 substituents independently selected from 38) halogen, 39) —C₁₋₆alkyl optionally substituted with 1 or 2 substituents selected from halogen, —CN and —OH, 40) —C(═NH)NH₂, 41) —(CH₂)₀₋₂C(═O)(CH₂)₀₋₂NR^(h)R^(j) optionally substituted with —NH₂ or —OH, 42) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or halogens, 43) —C(═O)C₁₋₆aminoalkyl optionally substituted with —OH, 44) —C(═O)OH, 45) —C(═O)(CH₂)₀₋₃NHC(═NH)NH₂, 46) —(CH₂)₀₋₁NHCH₂CH₂NR^(h)R^(j), 47) —(CH₂)₀₋₃NHC(═NH)NH₂, 48) —(CH₂)₀₋₁NH(CH₂)₀₋₁ C(═O)(CH₂)₀₋₁NR^(h)R^(j), 49) —(CH₂)₀₋₁NHSO₂NH₂, 50) —(CH₂)₀₋₁NHSO₂(CH₂)₀₋₂NH₂, 51) —(CH₂)₀₋₂NHSO₂CH₃, 52) —NR^(h)R^(j), 53) —NHCH₂CN, 54) —NHCH═NH, 55) —NHC(═O)R^(i); 56) —NHSO₂N(CH₃)₂, 57) —NHC(═O)(CH₂)₀₋₂NH(═NH)NH₂, 58) —OH, 59) —OC₁₋₆alkyl, 60) —ONH₂, 61) —ONHC(═O)CH₂NHCH₃, 62) oxo, 63) ═NH, 64) —(CH)₀₋₁-phenyl, 65) —(CH₂)₀₋₂-piperazinyl, 66) —C(═O)NH-pyridinyl, 67) —C(═O)-piperazinyl, 68) —C(═O-pyrrolidinyl optionally substituted with —NH₂, 69) azetidinyl optionally substituted with —CH₂NH₂, —NH₂, or —OH, 70) pyrrolidinyl optionally substituted with —NH₂, 71) —NHCH₂-pyridinyl substituted with oxo, —CH₃, and —OH, 72) —NH-pyrimidinyl, 73) triazolyl optionally substituted with —CH₂NH₂, and 74) tetrazolyl.
 10. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R⁰ is hydrogen and R is: 1) —C(═O)CHF₂, 2) —C(═O)CF₃, 3) —C(═O)CH₂CF₃, 4) —C(═O)CF₂CF₃, 5) —C(═O)CF₂—C₁₋₆alkyl, 6) —C(═O)CHFCH₃, 7) —C(═O)CF₂CH₂NH₂, 8) —C(═O)CF₂CH₂OH, 9) —C(═O)CH₂OH, 10) —C(═O)CH₂OCOCH₃, 11) —C(═O)CH₂CN, 12) —C(═O)CH₂SO₂C₁₋₆alkyl, 13) —C(═O)CH₂SCHF₂, 14) —C(═O)CH₂S(═O)CHF₂, 15) —C(═O)CH₂P(═O)(OCH₃)₂, 16) —C(═O)CH₂S-tetrazole optionally substituted with —CH₃, 17) —C(═O)CH₂-thienyl, 18) —C(═O)CH(NH₂)CH₂-tetrazole, 19) —C(═O)CH(NH₂)CH₂-pyrazole, 20) —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃, —CF₃, —CHF₂, —CH₃, NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂, or —COOEt, 21) —C(═O)CH₂-triazole optionally substituted with —CH₂NR^(a)R^(b), or —CH₃ and —CF₃, or —CF₃ and —NH₂, 22) —C(═O)CH₂-oxadiazole-CH₂NR^(a)R^(b), 23) —C(═O)C(CH₃)₂-tetrazole, 24) —C(═O)CH₂-azetidine, 25) —C(═O)CH(CH₃)-azetidine optionally substituted with oxo, hydroxyethyl, or both, 26) —C(═O)CH₂-pyrrolidinyl optionally substituted with one or more —F or —CH₂NHCH₃, 27) —C(═O)CF₂-thienyl, 28) —C(═O)—C₁₋₆alkyl-NR^(a)R^(b), 29) —C(═O)-pyrrolidinyl optionally substituted with F or NH₂, 30) —C(═O)-tetrahydrofuran, 31) —C(═O)—(CH₂)₀₋₁piperazine, 32) —C(═O)-pyrazine, 33) —C(═O)-thiazolidine optionally substituted with one or more oxo, 34) —C(═O)-pyrazole optionally substituted with CH₃ and CF₃, 35) —C(═O)CH(NH₂)C₁₋₆alkyl optionally substituted with —OH or phenyl, 36) —C(═O)CHFC₁₋₆alkyl, 37) —C(═O)CH(OH)C₁₋₆alkyl, 38) —C(═O)CR^(k)═NOC(CH₃)₂COOH, 39) —C(═O)CR^(k)═NOCH₃; 40) —C(═S)OC₁₋₆alkyl, 41) —C(═O)C(═O)OH, 42) —C(═O)C(═O)NR^(a)R^(b), 43) —C(═O)(CH₂)₁₋₆C(═O)NR^(a)R^(b), 44) —C(═O)C(═O)ONR^(a)R^(b), 45) —C(═O)C(═O)OC₁₋₆alkyl, 46) —(CH₂)₀₋₆ C(═O)OH, 47) —(CH₂)₀₋₆C(═O)OC₁₋₆alky, 48) —(CH₂)₀₋₆C(═O)(CH₂)₁₋₆OH, 49) —(CH₂)₀₋₆C(═O)(CH₂)₁₋₆OC₁₋₆alkyl, 50) —C(═O)OCH₂CHF₂, 51) —C(═O)OCH₂CF₃, 52) —C(═O)—C₃₋₆cycloalkyl substituted with CF₃ or NH₂, 53) —C₁₋₆alkyl-NR^(a)R^(b), 54) —C₁₋₆alkyl-C₃₋₆cycloalkyl, 55) —(CH₂)₀₋₆SO₂(CH₂)₀₋₄R^(c), 56) —CH(═NH), or 57) —C₁₋₆alkyl, or R and R⁰ together with the N to which they are attached form a [1,2,3-]triazole optionally substituted with —CH₂OH, —CH₂OCH₃, —CH₂F, —CH₂NH₂, —CH₂NHCH₃, —C(═O)OCH₃, or a tetrazole optionally substituted with —NH₂.
 11. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R⁰ is hydrogen and R is: 1) —C(═O)CHF₂, 2) —C(═O)CH₂NH₂, 3) —C(═O)CH₂NHCH₃, 4) —C(═O)CH₂NHC(═NH)NH₂, 5) —C(═O)CH₂-tetrazolyl, or 6) —SO₂CH₃, or R and R⁰ combine together to form -triazolyl optionally substituted with —CH₂—OH.
 12. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is: 1) pyrrolidinyl substituted with 1 or 2 of a) —CONR^(c)R^(d), b) —CON(CH₃)CH₂CH₂C(═O)-pyrrolidin-1-yl substituted with NH₂ or diazepanyl, c) —CH₂NR^(f)R^(g), d) —CH═NH, e) F, f) —(CH₂)₀₋₁NHC(═NH)NH₂, g) —CH₂NHSO₂-pyrrolidinyl-NH₂, h) —CH₂NH(C═O)-pyrrolidinyl substituted NH₂ or F, i) —CH₂NH(C═O)-pyridinyl substituted with oxo, CH₃ and OH, j) —CH₂NH(C═O)-cyclopentyl-NH₂, k) —CH₂NHSO₂-piperazine, l) —CH₃, or m) OH,

3) —CH₂-pyridinyl, 4) thiazole substituted with pyridinyl wherein the pyridinyl is optionally substituted with —CH₃ or —CH₂C(═O)NH₂, 5) azetidinyl substituted with —C(═N)NH₂, —SO₂NH₂, thiazolyl or 4,5-dihydrothiazol-2-yl, 6) —CH₂CH₂-pyridinyl substituted with oxo, CH₂NH₂ and OH, 7) —CH₂-pyrrolidinyl substituted with acetyl and —NH₂, or —NHSO₂NH₂, 8) —CH₂-piperazine, 9) —CH₂CH₂—NH(═NH)NH₂,

11) pyrazole optionally quaternized with —CH₃ and optionally substituted with —CH₂ pyrrolidine, or CH₂ piperidine optionally quaternized with —CH₃ and optionally substituted with —CH₂CH₂NH₂, 12) —CH₂-phenyl substituted with pyrazole optionally quaternized with —CH₃ and substituted with —(CH₂)₃NH₂, or 13) —CH₂CH₂NHCO₂-tert-butyl.
 13. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is pyrrolidinyl substituted with 1) —C(═O)NR^(c)R^(d); 2) —CH₂NHSO₂NH₂, or 3) —CH₂-pyrrolidinyl-NH₂, or 4) —CH₂—CO-pyrrolidinyl-NH₂; wherein R^(c) is —CH₃, R^(d) is —CH₃; R^(c) and R^(d) are taken together, with the N to which they are attached, to form 1) azetidinyl optionally substituted with —NHC(═NH)NH₂, 2) pyrrolidinyl substituted with a. one or two —NH₂, b. —NHCH₃, c. —C(Me)₂NH₂, d. one or two —OH, e. —CH₂NH₂, f. —NHC(═O)CH₂NH₂, g. —NHC(═O)CH₂CH₂NH₂, h. —NHC(═O)CH₂NH(═NH)NH₂, i. —NHCH═NH, j. —F and —NH₂, k. —NH₂ and —OH, l. —NH₂ and —CH₃, m. —NH₂ and —CH₂OH, n. —NH₂ and —CH₂NH₂, o. —NH₂ and —OMe, p. —OH and —CH₂NH₂, q. —CH₂OH and —CH₂NH₂, r. —NH₂ and —COOH, s. —NHC(═NH)NH₂, t. —NHC(═NH)NH₂ and —OH, u. —NHC(═NH)NH₂ and —CH₂OH, v. —NHC(═NH)NH₂ and —NH₂, w. —NH₂ and —CH₂NHSO₂NH₂, x. —CH₂F and NH₂, y. —OH, —NH₂ and —CH₂NH₂, z. —OH, —NH₂ and —CH₂OH, or aa. triazolyl substituted with —CH₂NH₂, 3) piperidinyl substituted with —(CH₂)₀₋₂NH₂, —CH₂NHCH₂C(═O)NH₂, —CH₂CH₂NH₂, —CH₃ and —NH₂, —CH₂OH and —CH₂NH₂, —F and —NH₂, —OH and —NH₂, —CONHCH₂CH(OH)CH₂NH₂, or azetidinyl substituted with —OH or piperazinyl, 4) piperazinyl optionally substituted with one or two —CH₃, —CH₂NH₂, —CH₂CH₂NH₂, —C(═NH)NH₂, —CH₂CH₂NHC(═NH)NH₂, —C(═O)(CH₂)₁₋₂NH₂, —C(═O)CH(NH₂)NH₂, —CH₂CH(NH₂)CH₂NH₂, —CH₂CH(F)CH₂NH₂, —C(═O)CH₂NHCH₃, —C(═O)CH(NH₂)CH₂OH, or —CH₃ and —CH₂C(═O)NH₂; 5) morpholinyl optionally substituted with —CH₂NH₂; 6) 1,4-diazepane optionally substituted with —C(═NH)NH₂; 7) octahydro-1H-pyrrolo[3,2-c]pyridine optionally substituted with —CH₂CH₂NH₂, —CH₂CH(OH)NH₂, or —C(═NH)NH₂, 8) octahydrocyclopenta[c]pyrrole optionally substituted with a. one or two —NH₂, b. —NH₂ and —CH₂OH, c. —NH₂ and —CH₂NH₂, d. —NH₂, e. —NHC(═NH)NH₂, f. —NHC(═NH)NH₂ and —CH₂OH, or g. s-OH, —NH₂ and —CH₂OH, 9) octahydro-1H-pyrrolo[2,3-c]pyridine, 10) octahydro-1H-pyrrolo[3,2-c]pyridine optionally substituted with —CH₂CH(OH) CH₂NH₂, 11) octahydro-1H-pyrrolo[3,4-b]pyridine optionally substituted with —CH₂OH, 12) octahydropyrrolo[3,4-b]pyrrole optionally substituted with —CH₂OH, —CH₂CH₂NH₂, or —C(═NH)NH₂; 13) octahydro-1H-pyrrolo[3,4-c]pyridine optionally substituted with —CH₂OH, or —COOH; 14) 5,5-dimethyloctahydro-1H-pyrrolo[3,2-c]pyridin-1-5-ium, 15) octahydropyrrolo[3,4-c]pyrrole optionally substituted with —CH₂OH, 16) octahydropyrrolo[3,4-d]imidazole optionally substituted with ═NH, 17) octahydro-1H-pyrrolo[3,2-b]pyridine, 18) octahydropyrrolo[3,4-b][1,4]oxazine, 19) 3,6-diazabicyclo[3.2.0]heptane, 20) 1,9-diazaspiro[5.5]undecane, 21) decahydro-1,6-naphthyridine, 22) 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazioe optionally substituted with —NH₂, 23) 2,7-diazaspiro[4.4]nonane, 24) 2,8-diazaspiro[4.5]decane, 25) 2,6-diazaspiro[3.4]octane, 26) 1,7-diazaspiro[3.5]nonane, 27) 2,7-diazaspiro[3.5]nonane, 28) 1,8-diazaspiro[4.5]decane, 29) 1,7-diazaspiro[4.5]decane, 30) 5-oxa-2-azaspiro[3.4]octane optionally substituted with —NH₂, 31) 3,8-diaza-tricyclo[5.2.1.01,5]decane, or 32) 8-azaspiro[bicyclo[3.2.1]octane-3,3′-pyrrolidine.
 14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound has a structure according to formula Ia:

wherein: A is NR⁰R or -triazolyl substituted with —CH₂OH; R is: 1) —C(═O)—C₁₋₆alkyl-NR^(a)R^(b); 2) —C(═O)CHF₂, 3) —C(═O)CH₂SCHF₂, 4) —C(═O)CH₂NH(CH₂)₂OMe, 5) —C(═O)CH₂pyrrolidin, 6) —C(═O)CH₂azetidine, 7) —C(═O)CH₂piperazine, 8) —C(═O)CH₂ pyrrolidine optionally substituted with 1 or 2 substituents selected from fluorine and —CH₂NHMe, 9) —C(═O)CH₂-tetrazole optionally substituted with —C(CH₃)₃, —CF₃, —CHF₂, —CH₃, —NH₂—COOC₁₋₆alkyl, thienyl, —CH₂NHCH₃, —NH₂, or —COOCH₂CH₃, or 10) —SO₂CH₃; R⁰ is H; R¹ is 1) pyrrolidinyl substituted with 1 or 2 of —CONR^(c)R^(d), 2) —CH₂NHSO₂NH₂, or 3) —CH₂-pyrrolidinyl optionally substituted with —NH₂; R^(a) and R^(b) are independently H, —C₁₋₆alkyl, —C₃₋₈cycloalkyl, —SO₂CH₃, —CH(═NH), —C(═NH)NH₂, or —CH₂C(═O)NH₂; R^(c) and R^(d) are independently H, C₁₋₃alkyl, —C(═NH)-pyrrolidinyl optionally substituted with —NH₂, or R^(c) and R^(d) are taken together, with the N to which they are attached, to form a 4- to 12-membered heterocyclic ring or ring system with 0, 1, 2 or 3 additional heteroatom ring atoms selected from N and O; wherein any nitrogen ring atom of the heterocyclic ring or ring system is optionally quadricovalent; the ring system is a bridged, fused or spiro ring system; and the 4- to 12-membered heterocyclic ring or ring system is optionally substituted with 1, 2 or 3 substituents selected from 1) ═NH, 2) —C(═O)(CH₂)₁₋₂NH₂, 3) —C(═O)CH₂NHCH₃, 4) —CH₂CH(NH₂)CH₂NH₂, 5) —C(═O)CH(NH₂)CH₂NH₂, 6) —C(═O)CH(F)CH₂NH₂, 7) —C(═O)CH(NH₂)CH₂OH, 8) —CH₂CH(OH)CH₂NH₂, 9) —C(═O)NH CH₂CH(OH)CH₂NH₂, 10) —C(═NH)NH₂, 11) —COOH, 12) —CH₃, 13) —CH₂C(═O)NH₂, 14) —CH₂NH CH₂C(═O)NH₂, 15) —CH₂NR^(h)R^(j), 16) —CH₂CH₂NH₂, 17) —CH₂CH₂NH—C(═NH)—NH₂, 18) —CH₂NHSO₂NH₂; 19) —CH₂OH, 20) —C(CH₃)₂NH₂, 21) —CH₂F; 22) —OH, 23) —OMe, 24) —F, 25) —NR^(h)R^(j), 26) —NHCH═NH, 27) —NH—C(═NH)—NH₂, 28) —NHCOCH₂—NH—C(═NH)—NH₂, 29) —NHCOCH₂NH₂; 30) —(CH₂)₀₋₃NR^(h)R^(j) optionally substituted with —NH₂ or halogens, 31) azetidinyl optionally substituted with —OH, 32) piperazinyl, and 33) triazolyl substituted with CH₂NH₂; and R^(h) and R^(j) are independently H, C₁₋₆alkyl, or C₃₋₈cycloalkyl.
 15. The compound of claim 2 which is selected from:

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof.
 16. The compound of claim 1 which is selected from:

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof.
 17. The compound of claim 2 which is selected from:

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof.
 18. The compound of claim 1 which is selected from:

or a stereoisomer, internal salt, N-oxide, prodrug, or pharmaceutically acceptable salt thereof.
 19. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R is —(CH₂)_(n)C(═O)R², —(CH₂)_(n)C(═S)R², (CH₂)_(n)SO₂R², or —CH(═NH); or R and R⁰ together with N to which they are attached form a substituted or unsubstituted 5-6 membered cyclic ring with 0, 1, 2, 3 or 4 additional heteroatom ring atoms independently selected from N, O and S; with the provisos that when R is —(CH₂)_(n)C(═O)R², n is 0 and R⁰ is H, then R² is not unsubstituted C₁₋₆alkyl; when R is —(CH₂)_(n)C(═O)R² and n is not 0, R² is not OH or NH₂; when R is —(CH₂)_(n)SO₂R² and n is not 0, R² is not OH; and when R and R⁰ combine together to form triazole then Z is not H.
 20. The compound of claim 1, or a stereoisomer, internal salt, N-oxide, or pharmaceutically acceptable salt thereof, wherein R¹ is C₂₋₆aminoalkyl optionally substituted with —CR^(x)═NR^(x).
 21. The compound of claim 1 wherein said pharmaceutically acceptable salt is selected from sodium, potassium, calcium, magnesium and ammonium salts.
 22. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
 23. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment (i) a therapeutically effective amount of a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof or (ii) a pharmaceutical composition according to claim
 19. 24. Use of a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection, or in the manufacture of a medicament for treating a bacterial infection.
 25. The method of claim 20 or the use of claim 21, wherein the bacterial infection is due to Pseudomonas spp., Klebsiella spp., Enterobacter spp, Escherichia spp., Morganella spp., Citrobacter spp., Serratia spp. or Acintetobacter spp. 